#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Reward Contingencies Improve Goal-Directed Behavior by Enhancing Posterior Brain Attentional Regions and Increasing Corticostriatal Connectivity in Cocaine Addicts
#Text=The dopaminergic system provides the basis for the interaction between motivation and cognition.
1-1	0-6	Reward	_	
1-2	7-20	Contingencies	_	
1-3	21-28	Improve	_	
1-4	29-42	Goal-Directed	_	
1-5	43-51	Behavior	_	
1-6	52-54	by	_	
1-7	55-64	Enhancing	_	
1-8	65-74	Posterior	_	
1-9	75-80	Brain	_	
1-10	81-92	Attentional	_	
1-11	93-100	Regions	_	
1-12	101-104	and	_	
1-13	105-115	Increasing	_	
1-14	116-131	Corticostriatal	_	
1-15	132-144	Connectivity	_	
1-16	145-147	in	_	
1-17	148-155	Cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]	
1-18	156-163	Addicts	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]	
1-19	164-167	The	_	
1-20	168-180	dopaminergic	_	
1-21	181-187	system	_	
1-22	188-196	provides	_	
1-23	197-200	the	_	
1-24	201-206	basis	_	
1-25	207-210	for	_	
1-26	211-214	the	_	
1-27	215-226	interaction	_	
1-28	227-234	between	_	
1-29	235-245	motivation	_	
1-30	246-249	and	_	
1-31	250-259	cognition	_	
1-32	259-260	.	_	

#Text=It is triggered by the possibility of obtaining rewards to initiate the neurobehavioral adaptations necessary to achieve them by directing the information from motivational circuits to cognitive and action circuits.
2-1	261-263	It	_	
2-2	264-266	is	_	
2-3	267-276	triggered	_	
2-4	277-279	by	_	
2-5	280-283	the	_	
2-6	284-295	possibility	_	
2-7	296-298	of	_	
2-8	299-308	obtaining	_	
2-9	309-316	rewards	_	
2-10	317-319	to	_	
2-11	320-328	initiate	_	
2-12	329-332	the	_	
2-13	333-348	neurobehavioral	_	
2-14	349-360	adaptations	_	
2-15	361-370	necessary	_	
2-16	371-373	to	_	
2-17	374-381	achieve	_	
2-18	382-386	them	_	
2-19	387-389	by	_	
2-20	390-399	directing	_	
2-21	400-403	the	_	
2-22	404-415	information	_	
2-23	416-420	from	_	
2-24	421-433	motivational	_	
2-25	434-442	circuits	_	
2-26	443-445	to	_	
2-27	446-455	cognitive	_	
2-28	456-459	and	_	
2-29	460-466	action	_	
2-30	467-475	circuits	_	
2-31	475-476	.	_	

#Text=In drug addiction, the altered dopamine (DA) modulation of the meso-cortico-limbic reward circuitry, such as the prefrontal cortex (PFC), underlies the disproportionate motivational value of drug use at the expense of other non-drug reinforcers and the user’s loss of control over his/her drug intake.
3-1	477-479	In	_	
3-2	480-484	drug	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[2]	
3-3	485-494	addiction	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[2]	
3-4	494-495	,	_	
3-5	496-499	the	_	
3-6	500-507	altered	_	
3-7	508-516	dopamine	_	
3-8	517-518	(	_	
3-9	518-520	DA	_	
3-10	520-521	)	_	
3-11	522-532	modulation	_	
3-12	533-535	of	_	
3-13	536-539	the	_	
3-14	540-559	meso-cortico-limbic	_	
3-15	560-566	reward	_	
3-16	567-576	circuitry	_	
3-17	576-577	,	_	
3-18	578-582	such	_	
3-19	583-585	as	_	
3-20	586-589	the	_	
3-21	590-600	prefrontal	_	
3-22	601-607	cortex	_	
3-23	608-609	(	_	
3-24	609-612	PFC	_	
3-25	612-613	)	_	
3-26	613-614	,	_	
3-27	615-624	underlies	_	
3-28	625-628	the	_	
3-29	629-645	disproportionate	_	
3-30	646-658	motivational	_	
3-31	659-664	value	_	
3-32	665-667	of	_	
3-33	668-672	drug	_	
3-34	673-676	use	_	
3-35	677-679	at	_	
3-36	680-683	the	_	
3-37	684-691	expense	_	
3-38	692-694	of	_	
3-39	695-700	other	_	
3-40	701-709	non-drug	_	
3-41	710-721	reinforcers	_	
3-42	722-725	and	_	
3-43	726-729	the	_	
3-44	730-734	user	_	
3-45	734-735	’	_	
3-46	735-736	s	_	
3-47	737-741	loss	_	
3-48	742-744	of	_	
3-49	745-752	control	_	
3-50	753-757	over	_	
3-51	758-761	his	_	
3-52	761-762	/	_	
3-53	762-765	her	_	
3-54	766-770	drug	_	
3-55	771-777	intake	_	
3-56	777-778	.	_	

#Text=We examine how the magnitude of the reward affects goal-directed processes in healthy control (HC) subjects and abstinent cocaine dependent (ACD) patients by using functional magnetic resonance imaging (fMRI) during a counting Stroop task with blocked levels of monetary incentives of different magnitudes (€0, €0.01, €0.5, €1 or €1.5).
4-1	779-781	We	_	
4-2	782-789	examine	_	
4-3	790-793	how	_	
4-4	794-797	the	_	
4-5	798-807	magnitude	_	
4-6	808-810	of	_	
4-7	811-814	the	_	
4-8	815-821	reward	_	
4-9	822-829	affects	_	
4-10	830-843	goal-directed	_	
4-11	844-853	processes	_	
4-12	854-856	in	_	
4-13	857-864	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
4-14	865-872	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
4-15	873-874	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
4-16	874-876	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
4-17	876-877	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
4-18	878-886	subjects	_	
4-19	887-890	and	_	
4-20	891-900	abstinent	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[4]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[5]	
4-21	901-908	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[4]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[5]	
4-22	909-918	dependent	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[4]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[5]	
4-23	919-920	(	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[4]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[5]	
4-24	920-923	ACD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[4]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[5]	
4-25	923-924	)	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[4]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[5]	
4-26	925-933	patients	_	
4-27	934-936	by	_	
4-28	937-942	using	_	
4-29	943-953	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
4-30	954-962	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
4-31	963-972	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
4-32	973-980	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
4-33	981-982	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
4-34	982-986	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
4-35	986-987	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
4-36	988-994	during	_	
4-37	995-996	a	_	
4-38	997-1005	counting	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[7]	
4-39	1006-1012	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[7]	
4-40	1013-1017	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[7]	
4-41	1018-1022	with	_	
4-42	1023-1030	blocked	_	
4-43	1031-1037	levels	_	
4-44	1038-1040	of	_	
4-45	1041-1049	monetary	_	
4-46	1050-1060	incentives	_	
4-47	1061-1063	of	_	
4-48	1064-1073	different	_	
4-49	1074-1084	magnitudes	_	
4-50	1085-1086	(	_	
4-51	1086-1088	€0	_	
4-52	1088-1089	,	_	
4-53	1090-1095	€0.01	_	
4-54	1095-1096	,	_	
4-55	1097-1101	€0.5	_	
4-56	1101-1102	,	_	
4-57	1103-1105	€1	_	
4-58	1106-1108	or	_	
4-59	1109-1113	€1.5	_	
4-60	1113-1114	)	_	
4-61	1114-1115	.	_	

#Text=Our results showed that increasing reward magnitude enhances (1) performance facilitation in both groups; (2) left dorsolateral prefrontal cortex (DLPFC) activity in HC and left superior occipital cortex activity in ACD; and (3) left DLPFC and left putamen connectivity in ACD compared to HC.
5-1	1116-1119	Our	_	
5-2	1120-1127	results	_	
5-3	1128-1134	showed	_	
5-4	1135-1139	that	_	
5-5	1140-1150	increasing	_	
5-6	1151-1157	reward	_	
5-7	1158-1167	magnitude	_	
5-8	1168-1176	enhances	_	
5-9	1177-1178	(	_	
5-10	1178-1179	1	_	
5-11	1179-1180	)	_	
5-12	1181-1192	performance	_	
5-13	1193-1205	facilitation	_	
5-14	1206-1208	in	_	
5-15	1209-1213	both	_	
5-16	1214-1220	groups	_	
5-17	1220-1221	;	_	
5-18	1222-1223	(	_	
5-19	1223-1224	2	_	
5-20	1224-1225	)	_	
5-21	1226-1230	left	_	
5-22	1231-1243	dorsolateral	_	
5-23	1244-1254	prefrontal	_	
5-24	1255-1261	cortex	_	
5-25	1262-1263	(	_	
5-26	1263-1268	DLPFC	_	
5-27	1268-1269	)	_	
5-28	1270-1278	activity	_	
5-29	1279-1281	in	_	
5-30	1282-1284	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
5-31	1285-1288	and	_	
5-32	1289-1293	left	_	
5-33	1294-1302	superior	_	
5-34	1303-1312	occipital	_	
5-35	1313-1319	cortex	_	
5-36	1320-1328	activity	_	
5-37	1329-1331	in	_	
5-38	1332-1335	ACD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[8]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[9]	
5-39	1335-1336	;	_	
5-40	1337-1340	and	_	
5-41	1341-1342	(	_	
5-42	1342-1343	3	_	
5-43	1343-1344	)	_	
5-44	1345-1349	left	_	
5-45	1350-1355	DLPFC	_	
5-46	1356-1359	and	_	
5-47	1360-1364	left	_	
5-48	1365-1372	putamen	_	
5-49	1373-1385	connectivity	_	
5-50	1386-1388	in	_	
5-51	1389-1392	ACD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[10]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[11]	
5-52	1393-1401	compared	_	
5-53	1402-1404	to	_	
5-54	1405-1407	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
5-55	1407-1408	.	_	

#Text=Moreover, we observed that (4) dorsal striatal and pallidum activity was associated with craving and addiction severity during the parametric increases in the monetary reward.
6-1	1409-1417	Moreover	_	
6-2	1417-1418	,	_	
6-3	1419-1421	we	_	
6-4	1422-1430	observed	_	
6-5	1431-1435	that	_	
6-6	1436-1437	(	_	
6-7	1437-1438	4	_	
6-8	1438-1439	)	_	
6-9	1440-1446	dorsal	_	
6-10	1447-1455	striatal	_	
6-11	1456-1459	and	_	
6-12	1460-1468	pallidum	_	
6-13	1469-1477	activity	_	
6-14	1478-1481	was	_	
6-15	1482-1492	associated	_	
6-16	1493-1497	with	_	
6-17	1498-1505	craving	_	
6-18	1506-1509	and	_	
6-19	1510-1519	addiction	_	
6-20	1520-1528	severity	_	
6-21	1529-1535	during	_	
6-22	1536-1539	the	_	
6-23	1540-1550	parametric	_	
6-24	1551-1560	increases	_	
6-25	1561-1563	in	_	
6-26	1564-1567	the	_	
6-27	1568-1576	monetary	_	
6-28	1577-1583	reward	_	
6-29	1583-1584	.	_	

#Text=In conclusion, the brain response to gradients in monetary value was different in HC and ACD, but both groups showed improved task performance due to the possibility of obtaining greater monetary rewards.
7-1	1585-1587	In	_	
7-2	1588-1598	conclusion	_	
7-3	1598-1599	,	_	
7-4	1600-1603	the	_	
7-5	1604-1609	brain	_	
7-6	1610-1618	response	_	
7-7	1619-1621	to	_	
7-8	1622-1631	gradients	_	
7-9	1632-1634	in	_	
7-10	1635-1643	monetary	_	
7-11	1644-1649	value	_	
7-12	1650-1653	was	_	
7-13	1654-1663	different	_	
7-14	1664-1666	in	_	
7-15	1667-1669	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
7-16	1670-1673	and	_	
7-17	1674-1677	ACD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[12]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[13]	
7-18	1677-1678	,	_	
7-19	1679-1682	but	_	
7-20	1683-1687	both	_	
7-21	1688-1694	groups	_	
7-22	1695-1701	showed	_	
7-23	1702-1710	improved	_	
7-24	1711-1715	task	_	
7-25	1716-1727	performance	_	
7-26	1728-1731	due	_	
7-27	1732-1734	to	_	
7-28	1735-1738	the	_	
7-29	1739-1750	possibility	_	
7-30	1751-1753	of	_	
7-31	1754-1763	obtaining	_	
7-32	1764-1771	greater	_	
7-33	1772-1780	monetary	_	
7-34	1781-1788	rewards	_	
7-35	1788-1789	.	_	

#Text=Introduction
#Text=Drug addiction is characterized by an enhanced and recurring motivational value of the drug, at the expense of other non-drug reinforcers, and an impaired ability to inhibit intentional actions associated with strong desires to take the drug that result in a pathological and compulsive pattern of drug-seeking and drug-taking.
8-1	1790-1802	Introduction	_	
8-2	1803-1807	Drug	_	
8-3	1808-1817	addiction	_	
8-4	1818-1820	is	_	
8-5	1821-1834	characterized	_	
8-6	1835-1837	by	_	
8-7	1838-1840	an	_	
8-8	1841-1849	enhanced	_	
8-9	1850-1853	and	_	
8-10	1854-1863	recurring	_	
8-11	1864-1876	motivational	_	
8-12	1877-1882	value	_	
8-13	1883-1885	of	_	
8-14	1886-1889	the	_	
8-15	1890-1894	drug	_	
8-16	1894-1895	,	_	
8-17	1896-1898	at	_	
8-18	1899-1902	the	_	
8-19	1903-1910	expense	_	
8-20	1911-1913	of	_	
8-21	1914-1919	other	_	
8-22	1920-1928	non-drug	_	
8-23	1929-1940	reinforcers	_	
8-24	1940-1941	,	_	
8-25	1942-1945	and	_	
8-26	1946-1948	an	_	
8-27	1949-1957	impaired	_	
8-28	1958-1965	ability	_	
8-29	1966-1968	to	_	
8-30	1969-1976	inhibit	_	
8-31	1977-1988	intentional	_	
8-32	1989-1996	actions	_	
8-33	1997-2007	associated	_	
8-34	2008-2012	with	_	
8-35	2013-2019	strong	_	
8-36	2020-2027	desires	_	
8-37	2028-2030	to	_	
8-38	2031-2035	take	_	
8-39	2036-2039	the	_	
8-40	2040-2044	drug	_	
8-41	2045-2049	that	_	
8-42	2050-2056	result	_	
8-43	2057-2059	in	_	
8-44	2060-2061	a	_	
8-45	2062-2074	pathological	_	
8-46	2075-2078	and	_	
8-47	2079-2089	compulsive	_	
8-48	2090-2097	pattern	_	
8-49	2098-2100	of	_	
8-50	2101-2113	drug-seeking	_	
8-51	2114-2117	and	_	
8-52	2118-2129	drug-taking	_	
8-53	2129-2130	.	_	

#Text=This process occupies an inordinate amount of an individual’s time and thoughts, and it persists despite adverse consequences.
9-1	2131-2135	This	_	
9-2	2136-2143	process	_	
9-3	2144-2152	occupies	_	
9-4	2153-2155	an	_	
9-5	2156-2166	inordinate	_	
9-6	2167-2173	amount	_	
9-7	2174-2176	of	_	
9-8	2177-2179	an	_	
9-9	2180-2190	individual	_	
9-10	2190-2191	’	_	
9-11	2191-2192	s	_	
9-12	2193-2197	time	_	
9-13	2198-2201	and	_	
9-14	2202-2210	thoughts	_	
9-15	2210-2211	,	_	
9-16	2212-2215	and	_	
9-17	2216-2218	it	_	
9-18	2219-2227	persists	_	
9-19	2228-2235	despite	_	
9-20	2236-2243	adverse	_	
9-21	2244-2256	consequences	_	
9-22	2256-2257	.	_	

#Text=During goal-directed behavior, changes in DA activity transform information about a reward into abstract cognitive decisions, which in turn are translated into specific actions taken to achieve the reward.
10-1	2258-2264	During	_	
10-2	2265-2278	goal-directed	_	
10-3	2279-2287	behavior	_	
10-4	2287-2288	,	_	
10-5	2289-2296	changes	_	
10-6	2297-2299	in	_	
10-7	2300-2302	DA	_	
10-8	2303-2311	activity	_	
10-9	2312-2321	transform	_	
10-10	2322-2333	information	_	
10-11	2334-2339	about	_	
10-12	2340-2341	a	_	
10-13	2342-2348	reward	_	
10-14	2349-2353	into	_	
10-15	2354-2362	abstract	_	
10-16	2363-2372	cognitive	_	
10-17	2373-2382	decisions	_	
10-18	2382-2383	,	_	
10-19	2384-2389	which	_	
10-20	2390-2392	in	_	
10-21	2393-2397	turn	_	
10-22	2398-2401	are	_	
10-23	2402-2412	translated	_	
10-24	2413-2417	into	_	
10-25	2418-2426	specific	_	
10-26	2427-2434	actions	_	
10-27	2435-2440	taken	_	
10-28	2441-2443	to	_	
10-29	2444-2451	achieve	_	
10-30	2452-2455	the	_	
10-31	2456-2462	reward	_	
10-32	2462-2463	.	_	

#Text=However, DA-mediated appetitive motivation drives behaviors that are not always under goal-directed control and can be maladaptive, as occurs in drug addiction.
11-1	2464-2471	However	_	
11-2	2471-2472	,	_	
11-3	2473-2484	DA-mediated	_	
11-4	2485-2495	appetitive	_	
11-5	2496-2506	motivation	_	
11-6	2507-2513	drives	_	
11-7	2514-2523	behaviors	_	
11-8	2524-2528	that	_	
11-9	2529-2532	are	_	
11-10	2533-2536	not	_	
11-11	2537-2543	always	_	
11-12	2544-2549	under	_	
11-13	2550-2563	goal-directed	_	
11-14	2564-2571	control	_	
11-15	2572-2575	and	_	
11-16	2576-2579	can	_	
11-17	2580-2582	be	_	
11-18	2583-2594	maladaptive	_	
11-19	2594-2595	,	_	
11-20	2596-2598	as	_	
11-21	2599-2605	occurs	_	
11-22	2606-2608	in	_	
11-23	2609-2613	drug	_	
11-24	2614-2623	addiction	_	
11-25	2623-2624	.	_	

#Text=Specifically, the improper DA modulation of the PFC via frontostriatal connections implies PFC dysfunction and the user’s loss of control over the drug craving.
12-1	2625-2637	Specifically	_	
12-2	2637-2638	,	_	
12-3	2639-2642	the	_	
12-4	2643-2651	improper	_	
12-5	2652-2654	DA	_	
12-6	2655-2665	modulation	_	
12-7	2666-2668	of	_	
12-8	2669-2672	the	_	
12-9	2673-2676	PFC	_	
12-10	2677-2680	via	_	
12-11	2681-2695	frontostriatal	_	
12-12	2696-2707	connections	_	
12-13	2708-2715	implies	_	
12-14	2716-2719	PFC	_	
12-15	2720-2731	dysfunction	_	
12-16	2732-2735	and	_	
12-17	2736-2739	the	_	
12-18	2740-2744	user	_	
12-19	2744-2745	’	_	
12-20	2745-2746	s	_	
12-21	2747-2751	loss	_	
12-22	2752-2754	of	_	
12-23	2755-2762	control	_	
12-24	2763-2767	over	_	
12-25	2768-2771	the	_	
12-26	2772-2776	drug	_	
12-27	2777-2784	craving	_	
12-28	2784-2785	.	_	

#Text=This craving is characterized by great salience and brain reactivity to cocaine-related stimuli at the expense of other appetitive stimuli, and it is considered a sign of addiction severity in drug users.
13-1	2786-2790	This	_	
13-2	2791-2798	craving	_	
13-3	2799-2801	is	_	
13-4	2802-2815	characterized	_	
13-5	2816-2818	by	_	
13-6	2819-2824	great	_	
13-7	2825-2833	salience	_	
13-8	2834-2837	and	_	
13-9	2838-2843	brain	_	
13-10	2844-2854	reactivity	_	
13-11	2855-2857	to	_	
13-12	2858-2873	cocaine-related	_	
13-13	2874-2881	stimuli	_	
13-14	2882-2884	at	_	
13-15	2885-2888	the	_	
13-16	2889-2896	expense	_	
13-17	2897-2899	of	_	
13-18	2900-2905	other	_	
13-19	2906-2916	appetitive	_	
13-20	2917-2924	stimuli	_	
13-21	2924-2925	,	_	
13-22	2926-2929	and	_	
13-23	2930-2932	it	_	
13-24	2933-2935	is	_	
13-25	2936-2946	considered	_	
13-26	2947-2948	a	_	
13-27	2949-2953	sign	_	
13-28	2954-2956	of	_	
13-29	2957-2966	addiction	_	
13-30	2967-2975	severity	_	
13-31	2976-2978	in	_	
13-32	2979-2983	drug	_	
13-33	2984-2989	users	_	
13-34	2989-2990	.	_	

#Text=Chronic cocaine users often perform poorly on goal-directed tasks.
14-1	2991-2998	Chronic	_	
14-2	2999-3006	cocaine	_	
14-3	3007-3012	users	_	
14-4	3013-3018	often	_	
14-5	3019-3026	perform	_	
14-6	3027-3033	poorly	_	
14-7	3034-3036	on	_	
14-8	3037-3050	goal-directed	_	
14-9	3051-3056	tasks	_	
14-10	3056-3057	.	_	

#Text=However, in spite of frontostriatal dysfunction, reward seems to behaviorally improve cognitive performance similarly in cocaine addicts and in HC by involving the compensatory activity of other brain regions, such as the occipital, parietal or temporal lobes.
15-1	3058-3065	However	_	
15-2	3065-3066	,	_	
15-3	3067-3069	in	_	
15-4	3070-3075	spite	_	
15-5	3076-3078	of	_	
15-6	3079-3093	frontostriatal	_	
15-7	3094-3105	dysfunction	_	
15-8	3105-3106	,	_	
15-9	3107-3113	reward	_	
15-10	3114-3119	seems	_	
15-11	3120-3122	to	_	
15-12	3123-3135	behaviorally	_	
15-13	3136-3143	improve	_	
15-14	3144-3153	cognitive	_	
15-15	3154-3165	performance	_	
15-16	3166-3175	similarly	_	
15-17	3176-3178	in	_	
15-18	3179-3186	cocaine	_	
15-19	3187-3194	addicts	_	
15-20	3195-3198	and	_	
15-21	3199-3201	in	_	
15-22	3202-3204	HC	_	
15-23	3205-3207	by	_	
15-24	3208-3217	involving	_	
15-25	3218-3221	the	_	
15-26	3222-3234	compensatory	_	
15-27	3235-3243	activity	_	
15-28	3244-3246	of	_	
15-29	3247-3252	other	_	
15-30	3253-3258	brain	_	
15-31	3259-3266	regions	_	
15-32	3266-3267	,	_	
15-33	3268-3272	such	_	
15-34	3273-3275	as	_	
15-35	3276-3279	the	_	
15-36	3280-3289	occipital	_	
15-37	3289-3290	,	_	
15-38	3291-3299	parietal	_	
15-39	3300-3302	or	_	
15-40	3303-3311	temporal	_	
15-41	3312-3317	lobes	_	
15-42	3317-3318	.	_	

#Text=Unlike controls, addicts show a disruption in the ability to perceive inner motivational drives because there is no relationship between reward induced improvement and self-reported interest in the reward value.
16-1	3319-3325	Unlike	_	
16-2	3326-3334	controls	_	
16-3	3334-3335	,	_	
16-4	3336-3343	addicts	_	
16-5	3344-3348	show	_	
16-6	3349-3350	a	_	
16-7	3351-3361	disruption	_	
16-8	3362-3364	in	_	
16-9	3365-3368	the	_	
16-10	3369-3376	ability	_	
16-11	3377-3379	to	_	
16-12	3380-3388	perceive	_	
16-13	3389-3394	inner	_	
16-14	3395-3407	motivational	_	
16-15	3408-3414	drives	_	
16-16	3415-3422	because	_	
16-17	3423-3428	there	_	
16-18	3429-3431	is	_	
16-19	3432-3434	no	_	
16-20	3435-3447	relationship	_	
16-21	3448-3455	between	_	
16-22	3456-3462	reward	_	
16-23	3463-3470	induced	_	
16-24	3471-3482	improvement	_	
16-25	3483-3486	and	_	
16-26	3487-3500	self-reported	_	
16-27	3501-3509	interest	_	
16-28	3510-3512	in	_	
16-29	3513-3516	the	_	
16-30	3517-3523	reward	_	
16-31	3524-3529	value	_	
16-32	3529-3530	.	_	

#Text=Therefore, the increase in awareness of inner motivational drives and the improvement in goal-directed behavior produced by reward contingencies via brain compensation may be two of the most important points to consider in dealing with drug addiction at the psychological and neurobiological levels.
17-1	3531-3540	Therefore	_	
17-2	3540-3541	,	_	
17-3	3542-3545	the	_	
17-4	3546-3554	increase	_	
17-5	3555-3557	in	_	
17-6	3558-3567	awareness	_	
17-7	3568-3570	of	_	
17-8	3571-3576	inner	_	
17-9	3577-3589	motivational	_	
17-10	3590-3596	drives	_	
17-11	3597-3600	and	_	
17-12	3601-3604	the	_	
17-13	3605-3616	improvement	_	
17-14	3617-3619	in	_	
17-15	3620-3633	goal-directed	_	
17-16	3634-3642	behavior	_	
17-17	3643-3651	produced	_	
17-18	3652-3654	by	_	
17-19	3655-3661	reward	_	
17-20	3662-3675	contingencies	_	
17-21	3676-3679	via	_	
17-22	3680-3685	brain	_	
17-23	3686-3698	compensation	_	
17-24	3699-3702	may	_	
17-25	3703-3705	be	_	
17-26	3706-3709	two	_	
17-27	3710-3712	of	_	
17-28	3713-3716	the	_	
17-29	3717-3721	most	_	
17-30	3722-3731	important	_	
17-31	3732-3738	points	_	
17-32	3739-3741	to	_	
17-33	3742-3750	consider	_	
17-34	3751-3753	in	_	
17-35	3754-3761	dealing	_	
17-36	3762-3766	with	_	
17-37	3767-3771	drug	_	
17-38	3772-3781	addiction	_	
17-39	3782-3784	at	_	
17-40	3785-3788	the	_	
17-41	3789-3802	psychological	_	
17-42	3803-3806	and	_	
17-43	3807-3822	neurobiological	_	
17-44	3823-3829	levels	_	
17-45	3829-3830	.	_	

#Text=In this study, HC and ACD performed a counting Stroop task using blocked levels of monetary incentives to analyze the effects of parametric increases in monetary rewards on performance and brain activation patterns.
18-1	3831-3833	In	_	
18-2	3834-3838	this	_	
18-3	3839-3844	study	_	
18-4	3844-3845	,	_	
18-5	3846-3848	HC	_	
18-6	3849-3852	and	_	
18-7	3853-3856	ACD	_	
18-8	3857-3866	performed	_	
18-9	3867-3868	a	_	
18-10	3869-3877	counting	_	
18-11	3878-3884	Stroop	_	
18-12	3885-3889	task	_	
18-13	3890-3895	using	_	
18-14	3896-3903	blocked	_	
18-15	3904-3910	levels	_	
18-16	3911-3913	of	_	
18-17	3914-3922	monetary	_	
18-18	3923-3933	incentives	_	
18-19	3934-3936	to	_	
18-20	3937-3944	analyze	_	
18-21	3945-3948	the	_	
18-22	3949-3956	effects	_	
18-23	3957-3959	of	_	
18-24	3960-3970	parametric	_	
18-25	3971-3980	increases	_	
18-26	3981-3983	in	_	
18-27	3984-3992	monetary	_	
18-28	3993-4000	rewards	_	
18-29	4001-4003	on	_	
18-30	4004-4015	performance	_	
18-31	4016-4019	and	_	
18-32	4020-4025	brain	_	
18-33	4026-4036	activation	_	
18-34	4037-4045	patterns	_	
18-35	4045-4046	.	_	

#Text=The aims of our study include comparing HC and ACD on how the parametric increses in the monetary reward magnitude modulates: (1) the performance during goal-directed behavior (e.g., reaction time, accuracy, and response variability) and the relationship between performance and self-reported interest in the reward value; (2) the brain activation in frontal and striatal regions generally involved in Stroop performance and posterior brain regions involved in the Stroop task in ACD; (3) the connectivity between the PFC and striatal regions; and (4) the way individual differences in clinical variables such as craving or severity dependence are related to the modulation of the reward magnitude on brain function.
19-1	4047-4050	The	_	
19-2	4051-4055	aims	_	
19-3	4056-4058	of	_	
19-4	4059-4062	our	_	
19-5	4063-4068	study	_	
19-6	4069-4076	include	_	
19-7	4077-4086	comparing	_	
19-8	4087-4089	HC	_	
19-9	4090-4093	and	_	
19-10	4094-4097	ACD	_	
19-11	4098-4100	on	_	
19-12	4101-4104	how	_	
19-13	4105-4108	the	_	
19-14	4109-4119	parametric	_	
19-15	4120-4128	increses	_	
19-16	4129-4131	in	_	
19-17	4132-4135	the	_	
19-18	4136-4144	monetary	_	
19-19	4145-4151	reward	_	
19-20	4152-4161	magnitude	_	
19-21	4162-4171	modulates	_	
19-22	4171-4172	:	_	
19-23	4173-4174	(	_	
19-24	4174-4175	1	_	
19-25	4175-4176	)	_	
19-26	4177-4180	the	_	
19-27	4181-4192	performance	_	
19-28	4193-4199	during	_	
19-29	4200-4213	goal-directed	_	
19-30	4214-4222	behavior	_	
19-31	4223-4224	(	_	
19-32	4224-4227	e.g	_	
19-33	4227-4228	.	_	
19-34	4228-4229	,	_	
19-35	4230-4238	reaction	_	
19-36	4239-4243	time	_	
19-37	4243-4244	,	_	
19-38	4245-4253	accuracy	_	
19-39	4253-4254	,	_	
19-40	4255-4258	and	_	
19-41	4259-4267	response	_	
19-42	4268-4279	variability	_	
19-43	4279-4280	)	_	
19-44	4281-4284	and	_	
19-45	4285-4288	the	_	
19-46	4289-4301	relationship	_	
19-47	4302-4309	between	_	
19-48	4310-4321	performance	_	
19-49	4322-4325	and	_	
19-50	4326-4339	self-reported	_	
19-51	4340-4348	interest	_	
19-52	4349-4351	in	_	
19-53	4352-4355	the	_	
19-54	4356-4362	reward	_	
19-55	4363-4368	value	_	
19-56	4368-4369	;	_	
19-57	4370-4371	(	_	
19-58	4371-4372	2	_	
19-59	4372-4373	)	_	
19-60	4374-4377	the	_	
19-61	4378-4383	brain	_	
19-62	4384-4394	activation	_	
19-63	4395-4397	in	_	
19-64	4398-4405	frontal	_	
19-65	4406-4409	and	_	
19-66	4410-4418	striatal	_	
19-67	4419-4426	regions	_	
19-68	4427-4436	generally	_	
19-69	4437-4445	involved	_	
19-70	4446-4448	in	_	
19-71	4449-4455	Stroop	_	
19-72	4456-4467	performance	_	
19-73	4468-4471	and	_	
19-74	4472-4481	posterior	_	
19-75	4482-4487	brain	_	
19-76	4488-4495	regions	_	
19-77	4496-4504	involved	_	
19-78	4505-4507	in	_	
19-79	4508-4511	the	_	
19-80	4512-4518	Stroop	_	
19-81	4519-4523	task	_	
19-82	4524-4526	in	_	
19-83	4527-4530	ACD	_	
19-84	4530-4531	;	_	
19-85	4532-4533	(	_	
19-86	4533-4534	3	_	
19-87	4534-4535	)	_	
19-88	4536-4539	the	_	
19-89	4540-4552	connectivity	_	
19-90	4553-4560	between	_	
19-91	4561-4564	the	_	
19-92	4565-4568	PFC	_	
19-93	4569-4572	and	_	
19-94	4573-4581	striatal	_	
19-95	4582-4589	regions	_	
19-96	4589-4590	;	_	
19-97	4591-4594	and	_	
19-98	4595-4596	(	_	
19-99	4596-4597	4	_	
19-100	4597-4598	)	_	
19-101	4599-4602	the	_	
19-102	4603-4606	way	_	
19-103	4607-4617	individual	_	
19-104	4618-4629	differences	_	
19-105	4630-4632	in	_	
19-106	4633-4641	clinical	_	
19-107	4642-4651	variables	_	
19-108	4652-4656	such	_	
19-109	4657-4659	as	_	
19-110	4660-4667	craving	_	
19-111	4668-4670	or	_	
19-112	4671-4679	severity	_	
19-113	4680-4690	dependence	_	
19-114	4691-4694	are	_	
19-115	4695-4702	related	_	
19-116	4703-4705	to	_	
19-117	4706-4709	the	_	
19-118	4710-4720	modulation	_	
19-119	4721-4723	of	_	
19-120	4724-4727	the	_	
19-121	4728-4734	reward	_	
19-122	4735-4744	magnitude	_	
19-123	4745-4747	on	_	
19-124	4748-4753	brain	_	
19-125	4754-4762	function	_	
19-126	4762-4763	.	_	

#Text=We hypothesized that as the size of the reward contingencies increases: (1) the task performance will improve in both experimental groups, but this improvement will be related to self-reported interest in the reward value only in HC; and (2) the activity of the prefrontal regions will be deficiently modulated in ACD compared to HC, but ACD will enhance the activation of other brain regions to counteract prefrontal impairment; moreover, (3) ACD prefrontal function will be related to a different pattern of frontostriatal connectivity compared to HC; and (4) higher scores on clinical variable scales will be related to activation of the frontal and striatal regions during the reward magnitude increases.
20-1	4764-4766	We	_	
20-2	4767-4779	hypothesized	_	
20-3	4780-4784	that	_	
20-4	4785-4787	as	_	
20-5	4788-4791	the	_	
20-6	4792-4796	size	_	
20-7	4797-4799	of	_	
20-8	4800-4803	the	_	
20-9	4804-4810	reward	_	
20-10	4811-4824	contingencies	_	
20-11	4825-4834	increases	_	
20-12	4834-4835	:	_	
20-13	4836-4837	(	_	
20-14	4837-4838	1	_	
20-15	4838-4839	)	_	
20-16	4840-4843	the	_	
20-17	4844-4848	task	_	
20-18	4849-4860	performance	_	
20-19	4861-4865	will	_	
20-20	4866-4873	improve	_	
20-21	4874-4876	in	_	
20-22	4877-4881	both	_	
20-23	4882-4894	experimental	_	
20-24	4895-4901	groups	_	
20-25	4901-4902	,	_	
20-26	4903-4906	but	_	
20-27	4907-4911	this	_	
20-28	4912-4923	improvement	_	
20-29	4924-4928	will	_	
20-30	4929-4931	be	_	
20-31	4932-4939	related	_	
20-32	4940-4942	to	_	
20-33	4943-4956	self-reported	_	
20-34	4957-4965	interest	_	
20-35	4966-4968	in	_	
20-36	4969-4972	the	_	
20-37	4973-4979	reward	_	
20-38	4980-4985	value	_	
20-39	4986-4990	only	_	
20-40	4991-4993	in	_	
20-41	4994-4996	HC	_	
20-42	4996-4997	;	_	
20-43	4998-5001	and	_	
20-44	5002-5003	(	_	
20-45	5003-5004	2	_	
20-46	5004-5005	)	_	
20-47	5006-5009	the	_	
20-48	5010-5018	activity	_	
20-49	5019-5021	of	_	
20-50	5022-5025	the	_	
20-51	5026-5036	prefrontal	_	
20-52	5037-5044	regions	_	
20-53	5045-5049	will	_	
20-54	5050-5052	be	_	
20-55	5053-5064	deficiently	_	
20-56	5065-5074	modulated	_	
20-57	5075-5077	in	_	
20-58	5078-5081	ACD	_	
20-59	5082-5090	compared	_	
20-60	5091-5093	to	_	
20-61	5094-5096	HC	_	
20-62	5096-5097	,	_	
20-63	5098-5101	but	_	
20-64	5102-5105	ACD	_	
20-65	5106-5110	will	_	
20-66	5111-5118	enhance	_	
20-67	5119-5122	the	_	
20-68	5123-5133	activation	_	
20-69	5134-5136	of	_	
20-70	5137-5142	other	_	
20-71	5143-5148	brain	_	
20-72	5149-5156	regions	_	
20-73	5157-5159	to	_	
20-74	5160-5170	counteract	_	
20-75	5171-5181	prefrontal	_	
20-76	5182-5192	impairment	_	
20-77	5192-5193	;	_	
20-78	5194-5202	moreover	_	
20-79	5202-5203	,	_	
20-80	5204-5205	(	_	
20-81	5205-5206	3	_	
20-82	5206-5207	)	_	
20-83	5208-5211	ACD	_	
20-84	5212-5222	prefrontal	_	
20-85	5223-5231	function	_	
20-86	5232-5236	will	_	
20-87	5237-5239	be	_	
20-88	5240-5247	related	_	
20-89	5248-5250	to	_	
20-90	5251-5252	a	_	
20-91	5253-5262	different	_	
20-92	5263-5270	pattern	_	
20-93	5271-5273	of	_	
20-94	5274-5288	frontostriatal	_	
20-95	5289-5301	connectivity	_	
20-96	5302-5310	compared	_	
20-97	5311-5313	to	_	
20-98	5314-5316	HC	_	
20-99	5316-5317	;	_	
20-100	5318-5321	and	_	
20-101	5322-5323	(	_	
20-102	5323-5324	4	_	
20-103	5324-5325	)	_	
20-104	5326-5332	higher	_	
20-105	5333-5339	scores	_	
20-106	5340-5342	on	_	
20-107	5343-5351	clinical	_	
20-108	5352-5360	variable	_	
20-109	5361-5367	scales	_	
20-110	5368-5372	will	_	
20-111	5373-5375	be	_	
20-112	5376-5383	related	_	
20-113	5384-5386	to	_	
20-114	5387-5397	activation	_	
20-115	5398-5400	of	_	
20-116	5401-5404	the	_	
20-117	5405-5412	frontal	_	
20-118	5413-5416	and	_	
20-119	5417-5425	striatal	_	
20-120	5426-5433	regions	_	
20-121	5434-5440	during	_	
20-122	5441-5444	the	_	
20-123	5445-5451	reward	_	
20-124	5452-5461	magnitude	_	
20-125	5462-5471	increases	_	
20-126	5471-5472	.	_	

#Text=Materials and Methods
#Text=Participants
#Text=Thirty-seven HC and thirty-four ACD, matched on age, sex, laterality, and educational level, participated in this study (see Table 1).
21-1	5473-5482	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[14]	
21-2	5483-5486	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[14]	
21-3	5487-5494	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[14]	
21-4	5495-5507	Participants	_	
21-5	5508-5520	Thirty-seven	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-6	5521-5523	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[16]	
21-7	5524-5527	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-8	5528-5539	thirty-four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-9	5540-5543	ACD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[17]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[18]	
21-10	5543-5544	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-11	5545-5552	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-12	5553-5555	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-13	5556-5559	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-14	5559-5560	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-15	5561-5564	sex	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-16	5564-5565	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-17	5566-5576	laterality	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-18	5576-5577	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-19	5578-5581	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-20	5582-5593	educational	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-21	5594-5599	level	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-22	5599-5600	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-23	5601-5613	participated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-24	5614-5616	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-25	5617-5621	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-26	5622-5627	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
21-27	5628-5629	(	_	
21-28	5629-5632	see	_	
21-29	5633-5638	Table	_	
21-30	5639-5640	1	_	
21-31	5640-5641	)	_	
21-32	5641-5642	.	_	

#Text=On the one hand, ACD patients were recruited from the Addictive Behaviors Unit in Castellón and Sagunto (Spain) from patients who regularly visit the clinic to manage their abstinence.
22-1	5643-5645	On	_	
22-2	5646-5649	the	_	
22-3	5650-5653	one	_	
22-4	5654-5658	hand	_	
22-5	5658-5659	,	_	
22-6	5660-5663	ACD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[20]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[21]	
22-7	5664-5672	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-8	5673-5677	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-9	5678-5687	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-10	5688-5692	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-11	5693-5696	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-12	5697-5706	Addictive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-13	5707-5716	Behaviors	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-14	5717-5721	Unit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-15	5722-5724	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-16	5725-5734	Castellón	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-17	5735-5738	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-18	5739-5746	Sagunto	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-19	5747-5748	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-20	5748-5753	Spain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-21	5753-5754	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-22	5755-5759	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-23	5760-5768	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-24	5769-5772	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-25	5773-5782	regularly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-26	5783-5788	visit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-27	5789-5792	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-28	5793-5799	clinic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-29	5800-5802	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-30	5803-5809	manage	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-31	5810-5815	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-32	5816-5826	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
22-33	5826-5827	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=In addition to behavioral and/or pharmacological treatment, patients were monitored for continued abstinence with urine toxicology testing or through clinical interviews with a psychiatrist who supervised treatment.
23-1	5828-5830	In	_	
23-2	5831-5839	addition	_	
23-3	5840-5842	to	_	
23-4	5843-5853	behavioral	_	
23-5	5854-5857	and	_	
23-6	5857-5858	/	_	
23-7	5858-5860	or	_	
23-8	5861-5876	pharmacological	_	
23-9	5877-5886	treatment	_	
23-10	5886-5887	,	_	
23-11	5888-5896	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-12	5897-5901	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-13	5902-5911	monitored	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-14	5912-5915	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-15	5916-5925	continued	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-16	5926-5936	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-17	5937-5941	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-18	5942-5947	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-19	5948-5958	toxicology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-20	5959-5966	testing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-21	5967-5969	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-22	5970-5977	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-23	5978-5986	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://www.case.edu/ProvCaRe/provcare#Questionnaire[23]	
23-24	5987-5997	interviews	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://www.case.edu/ProvCaRe/provcare#Questionnaire[23]	
23-25	5998-6002	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-26	6003-6004	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-27	6005-6017	psychiatrist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-28	6018-6021	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-29	6022-6032	supervised	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-30	6033-6042	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
23-31	6042-6043	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	

#Text=All 34 patients received the primary Axis I diagnosis of cocaine dependence according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).
24-1	6044-6047	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-2	6048-6050	34	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-3	6051-6059	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-4	6060-6068	received	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-5	6069-6072	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-6	6073-6080	primary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-7	6081-6085	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-8	6086-6087	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-9	6088-6097	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-10	6098-6100	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-11	6101-6108	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[25]	
24-12	6109-6119	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[25]	
24-13	6120-6129	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-14	6130-6132	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-15	6133-6136	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-16	6137-6147	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-17	6148-6151	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-18	6152-6163	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-19	6164-6170	Manual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-20	6171-6173	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-21	6174-6180	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-22	6181-6190	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-23	6190-6191	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-24	6192-6198	Fourth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-25	6199-6206	Edition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-26	6207-6208	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-27	6208-6214	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-28	6214-6215	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
24-29	6215-6216	.	_	

#Text=Due to the high rates of comorbidity with alcohol and other drug abuse in the patient population, patients were not excluded if they had abused other drugs or alcohol prior to the onset of their cocaine abstinence.
25-1	6217-6220	Due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-2	6221-6223	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-3	6224-6227	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-4	6228-6232	high	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-5	6233-6238	rates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-6	6239-6241	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-7	6242-6253	comorbidity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-8	6254-6258	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-9	6259-6266	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-10	6267-6270	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-11	6271-6276	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-12	6277-6281	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-13	6282-6287	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-14	6288-6290	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-15	6291-6294	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-16	6295-6302	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-17	6303-6313	population	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-18	6313-6314	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-19	6315-6323	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-20	6324-6328	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-21	6329-6332	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-22	6333-6341	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-23	6342-6344	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-24	6345-6349	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-25	6350-6353	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-26	6354-6360	abused	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-27	6361-6366	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-28	6367-6372	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-29	6373-6375	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-30	6376-6383	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-31	6384-6389	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-32	6390-6392	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-33	6393-6396	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-34	6397-6402	onset	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-35	6403-6405	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-36	6406-6411	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-37	6412-6419	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-38	6420-6430	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
25-39	6430-6431	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	

#Text=On the other hand, the HC group was recruited by placing posters in public places such as town halls and universities, and through word of mouth.
26-1	6432-6434	On	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-2	6435-6438	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-3	6439-6444	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-4	6445-6449	hand	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-5	6449-6450	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-6	6451-6454	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-7	6455-6457	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[28]	
26-8	6458-6463	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-9	6464-6467	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-10	6468-6477	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-11	6478-6480	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-12	6481-6488	placing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-13	6489-6496	posters	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-14	6497-6499	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-15	6500-6506	public	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-16	6507-6513	places	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-17	6514-6518	such	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-18	6519-6521	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-19	6522-6526	town	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-20	6527-6532	halls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-21	6533-6536	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-22	6537-6549	universities	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-23	6549-6550	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-24	6551-6554	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-25	6555-6562	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-26	6563-6567	word	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-27	6568-6570	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-28	6571-6576	mouth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
26-29	6576-6577	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	

#Text=A previous interview collected past and current drug use data and ensured that HC had no history of psychoactive substance dependence or abuse.
27-1	6578-6579	A	_	
27-2	6580-6588	previous	_	
27-3	6589-6598	interview	_	
27-4	6599-6608	collected	_	
27-5	6609-6613	past	_	
27-6	6614-6617	and	_	
27-7	6618-6625	current	_	
27-8	6626-6630	drug	_	
27-9	6631-6634	use	_	
27-10	6635-6639	data	_	
27-11	6640-6643	and	_	
27-12	6644-6651	ensured	_	
27-13	6652-6656	that	_	
27-14	6657-6659	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
27-15	6660-6663	had	_	
27-16	6664-6666	no	_	
27-17	6667-6674	history	_	
27-18	6675-6677	of	_	
27-19	6678-6690	psychoactive	_	
27-20	6691-6700	substance	_	
27-21	6701-6711	dependence	_	
27-22	6712-6714	or	_	
27-23	6715-6720	abuse	_	
27-24	6720-6721	.	_	

#Text=Exclusion criteria for HC and ACD were as follows: 1) Any major psychiatric illness; 2) Head trauma resulting in loss of consciousness for longer than 30 min; 3) Presence of any past or current brain pathology; 4) The presence of any contraindications to an MRI environment.
28-1	6722-6731	Exclusion	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-2	6732-6740	criteria	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-3	6741-6744	for	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-4	6745-6747	HC	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[30]	
28-5	6748-6751	and	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-6	6752-6755	ACD	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[31]	
28-7	6756-6760	were	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-8	6761-6763	as	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-9	6764-6771	follows	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-10	6771-6772	:	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-11	6773-6774	1	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-12	6774-6775	)	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-13	6776-6779	Any	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-14	6780-6785	major	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-15	6786-6797	psychiatric	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-16	6798-6805	illness	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-17	6805-6806	;	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-18	6807-6808	2	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-19	6808-6809	)	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-20	6810-6814	Head	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-21	6815-6821	trauma	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-22	6822-6831	resulting	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-23	6832-6834	in	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-24	6835-6839	loss	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-25	6840-6842	of	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-26	6843-6856	consciousness	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-27	6857-6860	for	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-28	6861-6867	longer	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-29	6868-6872	than	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-30	6873-6875	30	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-31	6876-6879	min	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-32	6879-6880	;	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-33	6881-6882	3	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-34	6882-6883	)	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-35	6884-6892	Presence	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-36	6893-6895	of	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-37	6896-6899	any	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-38	6900-6904	past	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-39	6905-6907	or	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-40	6908-6915	current	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-41	6916-6921	brain	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-42	6922-6931	pathology	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-43	6931-6932	;	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-44	6933-6934	4	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-45	6934-6935	)	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-46	6936-6939	The	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-47	6940-6948	presence	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-48	6949-6951	of	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-49	6952-6955	any	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-50	6956-6973	contraindications	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-51	6974-6976	to	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-52	6977-6979	an	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-53	6980-6983	MRI	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[32]	
28-54	6984-6995	environment	http://www.case.edu/ProvCaRe/provcare#StudyExclusionCriterion[29]	
28-55	6995-6996	.	_	

#Text=Before the scanning session, the ACD filled in two addiction severity-related scales: the Cocaine Selective Severity Assessment (CSSA,) and the Spanish version of the Severity Dependence Scale (SDS,).
29-1	6997-7003	Before	_	
29-2	7004-7007	the	_	
29-3	7008-7016	scanning	_	
29-4	7017-7024	session	_	
29-5	7024-7025	,	_	
29-6	7026-7029	the	_	
29-7	7030-7033	ACD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
29-8	7034-7040	filled	_	
29-9	7041-7043	in	_	
29-10	7044-7047	two	_	
29-11	7048-7057	addiction	_	
29-12	7058-7074	severity-related	_	
29-13	7075-7081	scales	_	
29-14	7081-7082	:	_	
29-15	7083-7086	the	_	
29-16	7087-7094	Cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineSelectiveSeverityAssessmentScale[33]	
29-17	7095-7104	Selective	http://maven.renci.org/NeuroBridge/neurobridge#CocaineSelectiveSeverityAssessmentScale[33]	
29-18	7105-7113	Severity	http://maven.renci.org/NeuroBridge/neurobridge#CocaineSelectiveSeverityAssessmentScale[33]	
29-19	7114-7124	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#CocaineSelectiveSeverityAssessmentScale[33]	
29-20	7125-7126	(	http://maven.renci.org/NeuroBridge/neurobridge#CocaineSelectiveSeverityAssessmentScale[33]	
29-21	7126-7130	CSSA	http://maven.renci.org/NeuroBridge/neurobridge#CocaineSelectiveSeverityAssessmentScale[33]	
29-22	7130-7131	,	http://maven.renci.org/NeuroBridge/neurobridge#CocaineSelectiveSeverityAssessmentScale[33]	
29-23	7131-7132	)	http://maven.renci.org/NeuroBridge/neurobridge#CocaineSelectiveSeverityAssessmentScale[33]	
29-24	7133-7136	and	_	
29-25	7137-7140	the	_	
29-26	7141-7148	Spanish	_	
29-27	7149-7156	version	_	
29-28	7157-7159	of	_	
29-29	7160-7163	the	_	
29-30	7164-7172	Severity	http://maven.renci.org/NeuroBridge/neurobridge#ScheduleforDeficitSyndrome[34]	
29-31	7173-7183	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#ScheduleforDeficitSyndrome[34]	
29-32	7184-7189	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScheduleforDeficitSyndrome[34]	
29-33	7190-7191	(	http://maven.renci.org/NeuroBridge/neurobridge#ScheduleforDeficitSyndrome[34]	
29-34	7191-7194	SDS	http://maven.renci.org/NeuroBridge/neurobridge#ScheduleforDeficitSyndrome[34]	
29-35	7194-7195	,	http://maven.renci.org/NeuroBridge/neurobridge#ScheduleforDeficitSyndrome[34]	
29-36	7195-7196	)	http://maven.renci.org/NeuroBridge/neurobridge#ScheduleforDeficitSyndrome[34]	
29-37	7196-7197	.	_	

#Text=Furthermore, patients were screened on their craving-related score, based on the 12-item Spanish version of the Cocaine Craving Questionnaire-General (SCCQ-G-12,) (see Table 1).
30-1	7198-7209	Furthermore	_	
30-2	7209-7210	,	_	
30-3	7211-7219	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
30-4	7220-7224	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
30-5	7225-7233	screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
30-6	7234-7236	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
30-7	7237-7242	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
30-8	7243-7258	craving-related	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
30-9	7259-7264	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
30-10	7264-7265	,	_	
30-11	7266-7271	based	_	
30-12	7272-7274	on	_	
30-13	7275-7278	the	_	
30-14	7279-7281	12	_	
30-15	7281-7282	-	_	
30-16	7282-7286	item	_	
30-17	7287-7294	Spanish	_	
30-18	7295-7302	version	_	
30-19	7303-7305	of	_	
30-20	7306-7309	the	_	
30-21	7310-7317	Cocaine	http://www.case.edu/ProvCaRe/provcare#Questionnaire[36]	
30-22	7318-7325	Craving	http://www.case.edu/ProvCaRe/provcare#Questionnaire[36]	
30-23	7326-7347	Questionnaire-General	http://www.case.edu/ProvCaRe/provcare#Questionnaire[36]	
30-24	7348-7349	(	http://www.case.edu/ProvCaRe/provcare#Questionnaire[36]	
30-25	7349-7355	SCCQ-G	http://www.case.edu/ProvCaRe/provcare#Questionnaire[36]	
30-26	7355-7356	-	http://www.case.edu/ProvCaRe/provcare#Questionnaire[36]	
30-27	7356-7358	12	http://www.case.edu/ProvCaRe/provcare#Questionnaire[36]	
30-28	7358-7359	,	http://www.case.edu/ProvCaRe/provcare#Questionnaire[36]	
30-29	7359-7360	)	http://www.case.edu/ProvCaRe/provcare#Questionnaire[36]	
30-30	7361-7362	(	_	
30-31	7362-7365	see	_	
30-32	7366-7371	Table	_	
30-33	7372-7373	1	_	
30-34	7373-7374	)	_	
30-35	7374-7375	.	_	

#Text=All the participants received information about the nature of the research, provided written informed consent prior to participating in the study, and received a monetary award for their participation depending on their performance on the task.
31-1	7376-7379	All	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-2	7380-7383	the	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-3	7384-7396	participants	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-4	7397-7405	received	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-5	7406-7417	information	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-6	7418-7423	about	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-7	7424-7427	the	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-8	7428-7434	nature	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-9	7435-7437	of	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-10	7438-7441	the	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-11	7442-7450	research	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-12	7450-7451	,	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-13	7452-7460	provided	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-14	7461-7468	written	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-15	7469-7477	informed	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-16	7478-7485	consent	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-17	7486-7491	prior	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-18	7492-7494	to	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-19	7495-7508	participating	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-20	7509-7511	in	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-21	7512-7515	the	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-22	7516-7521	study	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-23	7521-7522	,	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-24	7523-7526	and	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-25	7527-7535	received	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-26	7536-7537	a	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-27	7538-7546	monetary	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-28	7547-7552	award	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-29	7553-7556	for	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-30	7557-7562	their	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-31	7563-7576	participation	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-32	7577-7586	depending	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-33	7587-7589	on	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-34	7590-7595	their	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-35	7596-7607	performance	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-36	7608-7610	on	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-37	7611-7614	the	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-38	7615-7619	task	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	
31-39	7619-7620	.	http://www.case.edu/ProvCaRe/provcare#Questionnaire[37]	

#Text=The institutional Review Board of the Universitat Jaume I (Castellón, east Spain) approved this study.
32-1	7621-7624	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-2	7625-7638	institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-3	7639-7645	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-4	7646-7651	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-5	7652-7654	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-6	7655-7658	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-7	7659-7670	Universitat	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-8	7671-7676	Jaume	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-9	7677-7678	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-10	7679-7680	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-11	7680-7689	Castellón	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-12	7689-7690	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-13	7691-7695	east	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-14	7696-7701	Spain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-15	7701-7702	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-16	7703-7711	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-17	7712-7716	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-18	7717-7722	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
32-19	7722-7723	.	_	

#Text=Demographic variables for all study participants and clinical variables for ACD.
33-1	7724-7735	Demographic	_	
33-2	7736-7745	variables	_	
33-3	7746-7749	for	_	
33-4	7750-7753	all	_	
33-5	7754-7759	study	_	
33-6	7760-7772	participants	_	
33-7	7773-7776	and	_	
33-8	7777-7785	clinical	_	
33-9	7786-7795	variables	_	
33-10	7796-7799	for	_	
33-11	7800-7803	ACD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[39]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[40]	
33-12	7803-7804	.	_	

#Text=HC (N = 37)\tACD (N = 34)\t \tAge (years)\t36.89 (8.937)\t36.65 (7.118)\t \tSex: men/women\t31/6\t30/4\t \tLaterality: right/left-handed/ambidextrous\t37/0\t31/1/2\t \tEducation (years)\t11.95 (2.808)\t10.94 (3.829)\t \tDuration of current abstinence (months)\t\t10.16 (14.639); range (0–50)\t \tDuration of cocaine use (years)\t\t15.147 (6.387); range(3–30)\t \tAge of onset of cocaine use\t\t19.853 (4.781); range (14–34)\t \tCSSA\t\t44 (20.999); range (0–81)\t \tSDS\t\t9.765 (2.511); range (5–15)\t \tSCCQ-G-12\t\t2.628 (1.562); range (0.33–5.92)\t \tPsychotherapy: yes/no\t\t19/15\t \t
#Text=HC: Healthy Controls; ACD: Abstinent Cocaine Dependents; WAIS-III: Matrix Reasoning test; CSSA: Cocaine Selective Severity Assessment; SDS: Severity of Dependence Scale; SCCQ-N-10: CCQ-N-10 in its Spanish adaptation.
34-1	7806-7808	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
34-2	7809-7810	(	_	
34-3	7810-7811	N	_	
34-4	7812-7813	=	_	
34-5	7814-7816	37	_	
34-6	7816-7817	)	_	
34-7	7818-7821	ACD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
34-8	7822-7823	(	_	
34-9	7823-7824	N	_	
34-10	7825-7826	=	_	
34-11	7827-7829	34	_	
34-12	7829-7830	)	_	
34-13	7833-7836	Age	_	
34-14	7837-7838	(	_	
34-15	7838-7843	years	_	
34-16	7843-7844	)	_	
34-17	7845-7850	36.89	_	
34-18	7851-7852	(	_	
34-19	7852-7857	8.937	_	
34-20	7857-7858	)	_	
34-21	7859-7864	36.65	_	
34-22	7865-7866	(	_	
34-23	7866-7871	7.118	_	
34-24	7871-7872	)	_	
34-25	7875-7878	Sex	_	
34-26	7878-7879	:	_	
34-27	7880-7883	men	_	
34-28	7883-7884	/	_	
34-29	7884-7889	women	_	
34-30	7890-7892	31	_	
34-31	7892-7893	/	_	
34-32	7893-7894	6	_	
34-33	7895-7897	30	_	
34-34	7897-7898	/	_	
34-35	7898-7899	4	_	
34-36	7902-7912	Laterality	_	
34-37	7912-7913	:	_	
34-38	7914-7919	right	_	
34-39	7919-7920	/	_	
34-40	7920-7931	left-handed	_	
34-41	7931-7932	/	_	
34-42	7932-7944	ambidextrous	_	
34-43	7945-7947	37	_	
34-44	7947-7948	/	_	
34-45	7948-7949	0	_	
34-46	7950-7952	31	_	
34-47	7952-7953	/	_	
34-48	7953-7954	1	_	
34-49	7954-7955	/	_	
34-50	7955-7956	2	_	
34-51	7959-7968	Education	_	
34-52	7969-7970	(	_	
34-53	7970-7975	years	_	
34-54	7975-7976	)	_	
34-55	7977-7982	11.95	_	
34-56	7983-7984	(	_	
34-57	7984-7989	2.808	_	
34-58	7989-7990	)	_	
34-59	7991-7996	10.94	_	
34-60	7997-7998	(	_	
34-61	7998-8003	3.829	_	
34-62	8003-8004	)	_	
34-63	8007-8015	Duration	_	
34-64	8016-8018	of	_	
34-65	8019-8026	current	_	
34-66	8027-8037	abstinence	_	
34-67	8038-8039	(	_	
34-68	8039-8045	months	_	
34-69	8045-8046	)	_	
34-70	8048-8053	10.16	_	
34-71	8054-8055	(	_	
34-72	8055-8061	14.639	_	
34-73	8061-8062	)	_	
34-74	8062-8063	;	_	
34-75	8064-8069	range	_	
34-76	8070-8071	(	_	
34-77	8071-8072	0	_	
34-78	8072-8073	–	_	
34-79	8073-8075	50	_	
34-80	8075-8076	)	_	
34-81	8079-8087	Duration	_	
34-82	8088-8090	of	_	
34-83	8091-8098	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[41]	
34-84	8099-8102	use	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[41]	
34-85	8103-8104	(	_	
34-86	8104-8109	years	_	
34-87	8109-8110	)	_	
34-88	8112-8118	15.147	_	
34-89	8119-8120	(	_	
34-90	8120-8125	6.387	_	
34-91	8125-8126	)	_	
34-92	8126-8127	;	_	
34-93	8128-8133	range	_	
34-94	8133-8134	(	_	
34-95	8134-8135	3	_	
34-96	8135-8136	–	_	
34-97	8136-8138	30	_	
34-98	8138-8139	)	_	
34-99	8142-8145	Age	_	
34-100	8146-8148	of	_	
34-101	8149-8154	onset	_	
34-102	8155-8157	of	_	
34-103	8158-8165	cocaine	_	
34-104	8166-8169	use	_	
34-105	8171-8177	19.853	_	
34-106	8178-8179	(	_	
34-107	8179-8184	4.781	_	
34-108	8184-8185	)	_	
34-109	8185-8186	;	_	
34-110	8187-8192	range	_	
34-111	8193-8194	(	_	
34-112	8194-8196	14	_	
34-113	8196-8197	–	_	
34-114	8197-8199	34	_	
34-115	8199-8200	)	_	
34-116	8203-8207	CSSA	_	
34-117	8209-8211	44	_	
34-118	8212-8213	(	_	
34-119	8213-8219	20.999	_	
34-120	8219-8220	)	_	
34-121	8220-8221	;	_	
34-122	8222-8227	range	_	
34-123	8228-8229	(	_	
34-124	8229-8230	0	_	
34-125	8230-8231	–	_	
34-126	8231-8233	81	_	
34-127	8233-8234	)	_	
34-128	8237-8240	SDS	_	
34-129	8242-8247	9.765	_	
34-130	8248-8249	(	_	
34-131	8249-8254	2.511	_	
34-132	8254-8255	)	_	
34-133	8255-8256	;	_	
34-134	8257-8262	range	_	
34-135	8263-8264	(	_	
34-136	8264-8265	5	_	
34-137	8265-8266	–	_	
34-138	8266-8268	15	_	
34-139	8268-8269	)	_	
34-140	8272-8278	SCCQ-G	_	
34-141	8278-8279	-	_	
34-142	8279-8281	12	_	
34-143	8283-8288	2.628	_	
34-144	8289-8290	(	_	
34-145	8290-8295	1.562	_	
34-146	8295-8296	)	_	
34-147	8296-8297	;	_	
34-148	8298-8303	range	_	
34-149	8304-8305	(	_	
34-150	8305-8309	0.33	_	
34-151	8309-8310	–	_	
34-152	8310-8314	5.92	_	
34-153	8314-8315	)	_	
34-154	8318-8331	Psychotherapy	_	
34-155	8331-8332	:	_	
34-156	8333-8336	yes	_	
34-157	8336-8337	/	_	
34-158	8337-8339	no	_	
34-159	8341-8343	19	_	
34-160	8343-8344	/	_	
34-161	8344-8346	15	_	
34-162	8350-8352	HC	_	
34-163	8352-8353	:	_	
34-164	8354-8361	Healthy	_	
34-165	8362-8370	Controls	_	
34-166	8370-8371	;	_	
34-167	8372-8375	ACD	_	
34-168	8375-8376	:	_	
34-169	8377-8386	Abstinent	_	
34-170	8387-8394	Cocaine	_	
34-171	8395-8405	Dependents	_	
34-172	8405-8406	;	_	
34-173	8407-8415	WAIS-III	_	
34-174	8415-8416	:	_	
34-175	8417-8423	Matrix	_	
34-176	8424-8433	Reasoning	_	
34-177	8434-8438	test	_	
34-178	8438-8439	;	_	
34-179	8440-8444	CSSA	_	
34-180	8444-8445	:	_	
34-181	8446-8453	Cocaine	_	
34-182	8454-8463	Selective	_	
34-183	8464-8472	Severity	_	
34-184	8473-8483	Assessment	_	
34-185	8483-8484	;	_	
34-186	8485-8488	SDS	_	
34-187	8488-8489	:	_	
34-188	8490-8498	Severity	_	
34-189	8499-8501	of	_	
34-190	8502-8512	Dependence	_	
34-191	8513-8518	Scale	_	
34-192	8518-8519	;	_	
34-193	8520-8526	SCCQ-N	_	
34-194	8526-8527	-	_	
34-195	8527-8529	10	_	
34-196	8529-8530	:	_	
34-197	8531-8536	CCQ-N	_	
34-198	8536-8537	-	_	
34-199	8537-8539	10	_	
34-200	8540-8542	in	_	
34-201	8543-8546	its	_	
34-202	8547-8554	Spanish	_	
34-203	8555-8565	adaptation	_	
34-204	8565-8566	.	_	

#Text=Task design
#Text=We scanned all the participants while they performed a counting Stroop task with reward contingencies (see Fig 1).
35-1	8567-8571	Task	_	
35-2	8572-8578	design	_	
35-3	8579-8581	We	_	
35-4	8582-8589	scanned	_	
35-5	8590-8593	all	_	
35-6	8594-8597	the	_	
35-7	8598-8610	participants	_	
35-8	8611-8616	while	_	
35-9	8617-8621	they	_	
35-10	8622-8631	performed	_	
35-11	8632-8633	a	_	
35-12	8634-8642	counting	_	
35-13	8643-8649	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
35-14	8650-8654	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
35-15	8655-8659	with	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
35-16	8660-8666	reward	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
35-17	8667-8680	contingencies	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
35-18	8681-8682	(	_	
35-19	8682-8685	see	_	
35-20	8686-8689	Fig	_	
35-21	8690-8691	1	_	
35-22	8691-8692	)	_	
35-23	8692-8693	.	_	

#Text=The task was an adaptation from an earlier study.
36-1	8694-8697	The	_	
36-2	8698-8702	task	_	
36-3	8703-8706	was	_	
36-4	8707-8709	an	_	
36-5	8710-8720	adaptation	_	
36-6	8721-8725	from	_	
36-7	8726-8728	an	_	
36-8	8729-8736	earlier	_	
36-9	8737-8742	study	_	
36-10	8742-8743	.	_	

#Text=Participants viewed sets of one to four identical number words that appeared on the screen in each trial during the entire paradigm: “one”, “two”, “three” and “four” (“uno”, “dos”, “tres” “cuatro” in Spanish).
37-1	8744-8756	Participants	_	
37-2	8757-8763	viewed	_	
37-3	8764-8768	sets	_	
37-4	8769-8771	of	_	
37-5	8772-8775	one	_	
37-6	8776-8778	to	_	
37-7	8779-8783	four	_	
37-8	8784-8793	identical	_	
37-9	8794-8800	number	_	
37-10	8801-8806	words	_	
37-11	8807-8811	that	_	
37-12	8812-8820	appeared	_	
37-13	8821-8823	on	_	
37-14	8824-8827	the	_	
37-15	8828-8834	screen	_	
37-16	8835-8837	in	_	
37-17	8838-8842	each	_	
37-18	8843-8848	trial	_	
37-19	8849-8855	during	_	
37-20	8856-8859	the	_	
37-21	8860-8866	entire	_	
37-22	8867-8875	paradigm	_	
37-23	8875-8876	:	_	
37-24	8877-8878	“	_	
37-25	8878-8881	one	_	
37-26	8881-8882	”	_	
37-27	8882-8883	,	_	
37-28	8884-8885	“	_	
37-29	8885-8888	two	_	
37-30	8888-8889	”	_	
37-31	8889-8890	,	_	
37-32	8891-8892	“	_	
37-33	8892-8897	three	_	
37-34	8897-8898	”	_	
37-35	8899-8902	and	_	
37-36	8903-8904	“	_	
37-37	8904-8908	four	_	
37-38	8908-8909	”	_	
37-39	8910-8911	(	_	
37-40	8911-8912	“	_	
37-41	8912-8915	uno	_	
37-42	8915-8916	”	_	
37-43	8916-8917	,	_	
37-44	8918-8919	“	_	
37-45	8919-8922	dos	_	
37-46	8922-8923	”	_	
37-47	8923-8924	,	_	
37-48	8925-8926	“	_	
37-49	8926-8930	tres	_	
37-50	8930-8931	”	_	
37-51	8932-8933	“	_	
37-52	8933-8939	cuatro	_	
37-53	8939-8940	”	_	
37-54	8941-8943	in	_	
37-55	8944-8951	Spanish	_	
37-56	8951-8952	)	_	
37-57	8952-8953	.	_	

#Text=We instructed them to respond as quickly as possible by pressing a button on a keypad containing two buttons for each hand (Response Grips, NordicNeuroLab, Norway), coinciding with the number of words in each set.
38-1	8954-8956	We	_	
38-2	8957-8967	instructed	_	
38-3	8968-8972	them	_	
38-4	8973-8975	to	_	
38-5	8976-8983	respond	_	
38-6	8984-8986	as	_	
38-7	8987-8994	quickly	_	
38-8	8995-8997	as	_	
38-9	8998-9006	possible	_	
38-10	9007-9009	by	_	
38-11	9010-9018	pressing	_	
38-12	9019-9020	a	_	
38-13	9021-9027	button	_	
38-14	9028-9030	on	_	
38-15	9031-9032	a	_	
38-16	9033-9039	keypad	_	
38-17	9040-9050	containing	_	
38-18	9051-9054	two	_	
38-19	9055-9062	buttons	_	
38-20	9063-9066	for	_	
38-21	9067-9071	each	_	
38-22	9072-9076	hand	_	
38-23	9077-9078	(	_	
38-24	9078-9086	Response	_	
38-25	9087-9092	Grips	_	
38-26	9092-9093	,	_	
38-27	9094-9108	NordicNeuroLab	_	
38-28	9108-9109	,	_	
38-29	9110-9116	Norway	_	
38-30	9116-9117	)	_	
38-31	9117-9118	,	_	
38-32	9119-9129	coinciding	_	
38-33	9130-9134	with	_	
38-34	9135-9138	the	_	
38-35	9139-9145	number	_	
38-36	9146-9148	of	_	
38-37	9149-9154	words	_	
38-38	9155-9157	in	_	
38-39	9158-9162	each	_	
38-40	9163-9166	set	_	
38-41	9166-9167	.	_	

#Text=Inside the scanner, subjects performed 10 functional blocks consisting of 26 trials each, yielding a total of 260 trials.
39-1	9168-9174	Inside	_	
39-2	9175-9178	the	_	
39-3	9179-9186	scanner	_	
39-4	9186-9187	,	_	
39-5	9188-9196	subjects	_	
39-6	9197-9206	performed	_	
39-7	9207-9209	10	_	
39-8	9210-9220	functional	_	
39-9	9221-9227	blocks	_	
39-10	9228-9238	consisting	_	
39-11	9239-9241	of	_	
39-12	9242-9244	26	_	
39-13	9245-9251	trials	_	
39-14	9252-9256	each	_	
39-15	9256-9257	,	_	
39-16	9258-9266	yielding	_	
39-17	9267-9268	a	_	
39-18	9269-9274	total	_	
39-19	9275-9277	of	_	
39-20	9278-9281	260	_	
39-21	9282-9288	trials	_	
39-22	9288-9289	.	_	

#Text=Each block included 5 congruent trials (15%, n = 40), where the number of words agreed with the number word, (e.g., "two" "two", response: two).
40-1	9290-9294	Each	_	
40-2	9295-9300	block	_	
40-3	9301-9309	included	_	
40-4	9310-9311	5	_	
40-5	9312-9321	congruent	_	
40-6	9322-9328	trials	_	
40-7	9329-9330	(	_	
40-8	9330-9333	15%	_	
40-9	9333-9334	,	_	
40-10	9335-9336	n	_	
40-11	9337-9338	=	_	
40-12	9339-9341	40	_	
40-13	9341-9342	)	_	
40-14	9342-9343	,	_	
40-15	9344-9349	where	_	
40-16	9350-9353	the	_	
40-17	9354-9360	number	_	
40-18	9361-9363	of	_	
40-19	9364-9369	words	_	
40-20	9370-9376	agreed	_	
40-21	9377-9381	with	_	
40-22	9382-9385	the	_	
40-23	9386-9392	number	_	
40-24	9393-9397	word	_	
40-25	9397-9398	,	_	
40-26	9399-9400	(	_	
40-27	9400-9403	e.g	_	
40-28	9403-9404	.	_	
40-29	9404-9405	,	_	
40-30	9406-9407	"	_	
40-31	9407-9410	two	_	
40-32	9410-9411	"	_	
40-33	9412-9413	"	_	
40-34	9413-9416	two	_	
40-35	9416-9417	"	_	
40-36	9417-9418	,	_	
40-37	9419-9427	response	_	
40-38	9427-9428	:	_	
40-39	9429-9432	two	_	
40-40	9432-9433	)	_	
40-41	9433-9434	.	_	

#Text=On the incongruent trials (85%, n = 220, 21 in each block), the number of words was discordant with the number word, (e.g., "one" "one", response: two).
41-1	9435-9437	On	_	
41-2	9438-9441	the	_	
41-3	9442-9453	incongruent	_	
41-4	9454-9460	trials	_	
41-5	9461-9462	(	_	
41-6	9462-9465	85%	_	
41-7	9465-9466	,	_	
41-8	9467-9468	n	_	
41-9	9469-9470	=	_	
41-10	9471-9474	220	_	
41-11	9474-9475	,	_	
41-12	9476-9478	21	_	
41-13	9479-9481	in	_	
41-14	9482-9486	each	_	
41-15	9487-9492	block	_	
41-16	9492-9493	)	_	
41-17	9493-9494	,	_	
41-18	9495-9498	the	_	
41-19	9499-9505	number	_	
41-20	9506-9508	of	_	
41-21	9509-9514	words	_	
41-22	9515-9518	was	_	
41-23	9519-9529	discordant	_	
41-24	9530-9534	with	_	
41-25	9535-9538	the	_	
41-26	9539-9545	number	_	
41-27	9546-9550	word	_	
41-28	9550-9551	,	_	
41-29	9552-9553	(	_	
41-30	9553-9556	e.g	_	
41-31	9556-9557	.	_	
41-32	9557-9558	,	_	
41-33	9559-9560	"	_	
41-34	9560-9563	one	_	
41-35	9563-9564	"	_	
41-36	9565-9566	"	_	
41-37	9566-9569	one	_	
41-38	9569-9570	"	_	
41-39	9570-9571	,	_	
41-40	9572-9580	response	_	
41-41	9580-9581	:	_	
41-42	9582-9585	two	_	
41-43	9585-9586	)	_	
41-44	9586-9587	.	_	

#Text=Congruent trials were intermixed among the incongruent trials to minimize strategy effects and increase interference.
42-1	9588-9597	Congruent	_	
42-2	9598-9604	trials	_	
42-3	9605-9609	were	_	
42-4	9610-9620	intermixed	_	
42-5	9621-9626	among	_	
42-6	9627-9630	the	_	
42-7	9631-9642	incongruent	_	
42-8	9643-9649	trials	_	
42-9	9650-9652	to	_	
42-10	9653-9661	minimize	_	
42-11	9662-9670	strategy	_	
42-12	9671-9678	effects	_	
42-13	9679-9682	and	_	
42-14	9683-9691	increase	_	
42-15	9692-9704	interference	_	
42-16	9704-9705	.	_	

#Text=In addition, we applied a linear parametric approach with five “reward” conditions corresponding to the possibility of obtaining different monetary incomes (€0, €0.01, €0.5, 1€, €1.5) for correct task performance.
43-1	9706-9708	In	_	
43-2	9709-9717	addition	_	
43-3	9717-9718	,	_	
43-4	9719-9721	we	_	
43-5	9722-9729	applied	_	
43-6	9730-9731	a	_	
43-7	9732-9738	linear	_	
43-8	9739-9749	parametric	_	
43-9	9750-9758	approach	_	
43-10	9759-9763	with	_	
43-11	9764-9768	five	_	
43-12	9769-9770	“	_	
43-13	9770-9776	reward	_	
43-14	9776-9777	”	_	
43-15	9778-9788	conditions	_	
43-16	9789-9802	corresponding	_	
43-17	9803-9805	to	_	
43-18	9806-9809	the	_	
43-19	9810-9821	possibility	_	
43-20	9822-9824	of	_	
43-21	9825-9834	obtaining	_	
43-22	9835-9844	different	_	
43-23	9845-9853	monetary	_	
43-24	9854-9861	incomes	_	
43-25	9862-9863	(	_	
43-26	9863-9865	€0	_	
43-27	9865-9866	,	_	
43-28	9867-9872	€0.01	_	
43-29	9872-9873	,	_	
43-30	9874-9878	€0.5	_	
43-31	9878-9879	,	_	
43-32	9880-9881	1	_	
43-33	9881-9882	€	_	
43-34	9882-9883	,	_	
43-35	9884-9888	€1.5	_	
43-36	9888-9889	)	_	
43-37	9890-9893	for	_	
43-38	9894-9901	correct	_	
43-39	9902-9906	task	_	
43-40	9907-9918	performance	_	
43-41	9918-9919	.	_	

#Text=Participants repeated each condition in two random blocks within a single run.
44-1	9920-9932	Participants	_	
44-2	9933-9941	repeated	_	
44-3	9942-9946	each	_	
44-4	9947-9956	condition	_	
44-5	9957-9959	in	_	
44-6	9960-9963	two	_	
44-7	9964-9970	random	_	
44-8	9971-9977	blocks	_	
44-9	9978-9984	within	_	
44-10	9985-9986	a	_	
44-11	9987-9993	single	_	
44-12	9994-9997	run	_	
44-13	9997-9998	.	_	

#Text=Our goal was to analyze the effects of reward on goal-directed behavior and, to this end, we examined the effects of reward increases during the performance of a blocked interference condition rather than during a passive conditioning task.
45-1	9999-10002	Our	_	
45-2	10003-10007	goal	_	
45-3	10008-10011	was	_	
45-4	10012-10014	to	_	
45-5	10015-10022	analyze	_	
45-6	10023-10026	the	_	
45-7	10027-10034	effects	_	
45-8	10035-10037	of	_	
45-9	10038-10044	reward	_	
45-10	10045-10047	on	_	
45-11	10048-10061	goal-directed	_	
45-12	10062-10070	behavior	_	
45-13	10071-10074	and	_	
45-14	10074-10075	,	_	
45-15	10076-10078	to	_	
45-16	10079-10083	this	_	
45-17	10084-10087	end	_	
45-18	10087-10088	,	_	
45-19	10089-10091	we	_	
45-20	10092-10100	examined	_	
45-21	10101-10104	the	_	
45-22	10105-10112	effects	_	
45-23	10113-10115	of	_	
45-24	10116-10122	reward	_	
45-25	10123-10132	increases	_	
45-26	10133-10139	during	_	
45-27	10140-10143	the	_	
45-28	10144-10155	performance	_	
45-29	10156-10158	of	_	
45-30	10159-10160	a	_	
45-31	10161-10168	blocked	_	
45-32	10169-10181	interference	_	
45-33	10182-10191	condition	_	
45-34	10192-10198	rather	_	
45-35	10199-10203	than	_	
45-36	10204-10210	during	_	
45-37	10211-10212	a	_	
45-38	10213-10220	passive	_	
45-39	10221-10233	conditioning	_	
45-40	10234-10238	task	_	
45-41	10238-10239	.	_	

#Text=We applied a parametric design to avoid the shortcomings of using a neutral or congruent condition for cognitive subtraction.
46-1	10240-10242	We	_	
46-2	10243-10250	applied	_	
46-3	10251-10252	a	_	
46-4	10253-10263	parametric	_	
46-5	10264-10270	design	_	
46-6	10271-10273	to	_	
46-7	10274-10279	avoid	_	
46-8	10280-10283	the	_	
46-9	10284-10296	shortcomings	_	
46-10	10297-10299	of	_	
46-11	10300-10305	using	_	
46-12	10306-10307	a	_	
46-13	10308-10315	neutral	_	
46-14	10316-10318	or	_	
46-15	10319-10328	congruent	_	
46-16	10329-10338	condition	_	
46-17	10339-10342	for	_	
46-18	10343-10352	cognitive	_	
46-19	10353-10364	subtraction	_	
46-20	10364-10365	.	_	

#Text=Instead, we included a fixation point shown for 7200 milliseconds (msec.) between each task block as the baseline, which also precluded carryover effects.
47-1	10366-10373	Instead	_	
47-2	10373-10374	,	_	
47-3	10375-10377	we	_	
47-4	10378-10386	included	_	
47-5	10387-10388	a	_	
47-6	10389-10397	fixation	_	
47-7	10398-10403	point	_	
47-8	10404-10409	shown	_	
47-9	10410-10413	for	_	
47-10	10414-10418	7200	_	
47-11	10419-10431	milliseconds	_	
47-12	10432-10433	(	_	
47-13	10433-10437	msec	_	
47-14	10437-10438	.	_	
47-15	10438-10439	)	_	
47-16	10440-10447	between	_	
47-17	10448-10452	each	_	
47-18	10453-10457	task	_	
47-19	10458-10463	block	_	
47-20	10464-10466	as	_	
47-21	10467-10470	the	_	
47-22	10471-10479	baseline	_	
47-23	10479-10480	,	_	
47-24	10481-10486	which	_	
47-25	10487-10491	also	_	
47-26	10492-10501	precluded	_	
47-27	10502-10511	carryover	_	
47-28	10512-10519	effects	_	
47-29	10519-10520	.	_	

#Text=Schematic representation of the counting Stroop task in an fMRI block-design.
48-1	10521-10530	Schematic	_	
48-2	10531-10545	representation	_	
48-3	10546-10548	of	_	
48-4	10549-10552	the	_	
48-5	10553-10561	counting	_	
48-6	10562-10568	Stroop	_	
48-7	10569-10573	task	_	
48-8	10574-10576	in	_	
48-9	10577-10579	an	_	
48-10	10580-10584	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
48-11	10585-10597	block-design	_	
48-12	10597-10598	.	_	

#Text=“sec.”, seconds; €, euros.
49-1	10599-10600	“	_	
49-2	10600-10603	sec	_	
49-3	10603-10604	.	_	
49-4	10604-10605	”	_	
49-5	10605-10606	,	_	
49-6	10607-10614	seconds	_	
49-7	10614-10615	;	_	
49-8	10616-10617	€	_	
49-9	10617-10618	,	_	
49-10	10619-10624	euros	_	
49-11	10624-10625	.	_	

#Text=The figure represents two examples of trials (a no-conflict trial and a conflict trial) included in a €1 block, which is one of the ten randomized blocks.
50-1	10626-10629	The	_	
50-2	10630-10636	figure	_	
50-3	10637-10647	represents	_	
50-4	10648-10651	two	_	
50-5	10652-10660	examples	_	
50-6	10661-10663	of	_	
50-7	10664-10670	trials	_	
50-8	10671-10672	(	_	
50-9	10672-10673	a	_	
50-10	10674-10685	no-conflict	_	
50-11	10686-10691	trial	_	
50-12	10692-10695	and	_	
50-13	10696-10697	a	_	
50-14	10698-10706	conflict	_	
50-15	10707-10712	trial	_	
50-16	10712-10713	)	_	
50-17	10714-10722	included	_	
50-18	10723-10725	in	_	
50-19	10726-10727	a	_	
50-20	10728-10730	€1	_	
50-21	10731-10736	block	_	
50-22	10736-10737	,	_	
50-23	10738-10743	which	_	
50-24	10744-10746	is	_	
50-25	10747-10750	one	_	
50-26	10751-10753	of	_	
50-27	10754-10757	the	_	
50-28	10758-10761	ten	_	
50-29	10762-10772	randomized	_	
50-30	10773-10779	blocks	_	
50-31	10779-10780	.	_	

#Text=The fMRI paradigm started with a baseline block.
51-1	10781-10784	The	_	
51-2	10785-10789	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[43]	
51-3	10790-10798	paradigm	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[43]	
51-4	10799-10806	started	_	
51-5	10807-10811	with	_	
51-6	10812-10813	a	_	
51-7	10814-10822	baseline	_	
51-8	10823-10828	block	_	
51-9	10828-10829	.	_	

#Text=After this first baseline block and in the following ones, task blocks started with a cue (C) that appeared and lasted 2 seconds (sec.)
52-1	10830-10835	After	_	
52-2	10836-10840	this	_	
52-3	10841-10846	first	_	
52-4	10847-10855	baseline	_	
52-5	10856-10861	block	_	
52-6	10862-10865	and	_	
52-7	10866-10868	in	_	
52-8	10869-10872	the	_	
52-9	10873-10882	following	_	
52-10	10883-10887	ones	_	
52-11	10887-10888	,	_	
52-12	10889-10893	task	_	
52-13	10894-10900	blocks	_	
52-14	10901-10908	started	_	
52-15	10909-10913	with	_	
52-16	10914-10915	a	_	
52-17	10916-10919	cue	_	
52-18	10920-10921	(	_	
52-19	10921-10922	C	_	
52-20	10922-10923	)	_	
52-21	10924-10928	that	_	
52-22	10929-10937	appeared	_	
52-23	10938-10941	and	_	
52-24	10942-10948	lasted	_	
52-25	10949-10950	2	_	
52-26	10951-10958	seconds	_	
52-27	10959-10960	(	_	
52-28	10960-10963	sec	_	
52-29	10963-10964	.	_	
52-30	10964-10965	)	_	

#Text=The cue informed the participants about the amount of money (€0, €0.01, €0.5, €1 or €1.5) they could win for each correct response within each corresponding Stroop block.
53-1	10966-10969	The	_	
53-2	10970-10973	cue	_	
53-3	10974-10982	informed	_	
53-4	10983-10986	the	_	
53-5	10987-10999	participants	_	
53-6	11000-11005	about	_	
53-7	11006-11009	the	_	
53-8	11010-11016	amount	_	
53-9	11017-11019	of	_	
53-10	11020-11025	money	_	
53-11	11026-11027	(	_	
53-12	11027-11029	€0	_	
53-13	11029-11030	,	_	
53-14	11031-11036	€0.01	_	
53-15	11036-11037	,	_	
53-16	11038-11042	€0.5	_	
53-17	11042-11043	,	_	
53-18	11044-11046	€1	_	
53-19	11047-11049	or	_	
53-20	11050-11054	€1.5	_	
53-21	11054-11055	)	_	
53-22	11056-11060	they	_	
53-23	11061-11066	could	_	
53-24	11067-11070	win	_	
53-25	11071-11074	for	_	
53-26	11075-11079	each	_	
53-27	11080-11087	correct	_	
53-28	11088-11096	response	_	
53-29	11097-11103	within	_	
53-30	11104-11108	each	_	
53-31	11109-11122	corresponding	_	
53-32	11123-11129	Stroop	_	
53-33	11130-11135	block	_	
53-34	11135-11136	.	_	

#Text=After each cue, we displayed a fixation point for 500 msec. just to maintain participants’ attention.
54-1	11137-11142	After	_	
54-2	11143-11147	each	_	
54-3	11148-11151	cue	_	
54-4	11151-11152	,	_	
54-5	11153-11155	we	_	
54-6	11156-11165	displayed	_	
54-7	11166-11167	a	_	
54-8	11168-11176	fixation	_	
54-9	11177-11182	point	_	
54-10	11183-11186	for	_	
54-11	11187-11190	500	_	
54-12	11191-11195	msec	_	
54-13	11195-11196	.	_	
54-14	11197-11201	just	_	
54-15	11202-11204	to	_	
54-16	11205-11213	maintain	_	
54-17	11214-11226	participants	_	
54-18	11226-11227	’	_	
54-19	11228-11237	attention	_	
54-20	11237-11238	.	_	

#Text=Afterward, we presented 26 trials, each lasting 1000 msec. with an inter-trial interval of 400 msec.
55-1	11239-11248	Afterward	_	
55-2	11248-11249	,	_	
55-3	11250-11252	we	_	
55-4	11253-11262	presented	_	
55-5	11263-11265	26	_	
55-6	11266-11272	trials	_	
55-7	11272-11273	,	_	
55-8	11274-11278	each	_	
55-9	11279-11286	lasting	_	
55-10	11287-11291	1000	_	
55-11	11292-11296	msec	_	
55-12	11296-11297	.	_	
55-13	11298-11302	with	_	
55-14	11303-11305	an	_	
55-15	11306-11317	inter-trial	_	
55-16	11318-11326	interval	_	
55-17	11327-11329	of	_	
55-18	11330-11333	400	_	
55-19	11334-11338	msec	_	
55-20	11338-11339	.	_	

#Text=The duration of each Stroop block was 46.7 sec., whereas total task duration was 7 minutes and 41 sec.
56-1	11340-11343	The	_	
56-2	11344-11352	duration	_	
56-3	11353-11355	of	_	
56-4	11356-11360	each	_	
56-5	11361-11367	Stroop	_	
56-6	11368-11373	block	_	
56-7	11374-11377	was	_	
56-8	11378-11382	46.7	_	
56-9	11383-11386	sec	_	
56-10	11386-11387	.	_	
56-11	11387-11388	,	_	
56-12	11389-11396	whereas	_	
56-13	11397-11402	total	_	
56-14	11403-11407	task	_	
56-15	11408-11416	duration	_	
56-16	11417-11420	was	_	
56-17	11421-11422	7	_	
56-18	11423-11430	minutes	_	
56-19	11431-11434	and	_	
56-20	11435-11437	41	_	
56-21	11438-11441	sec	_	
56-22	11441-11442	.	_	

#Text=Participants did not receive feedback on their performance at any time during the task, only at the end.
57-1	11443-11455	Participants	_	
57-2	11456-11459	did	_	
57-3	11460-11463	not	_	
57-4	11464-11471	receive	_	
57-5	11472-11480	feedback	_	
57-6	11481-11483	on	_	
57-7	11484-11489	their	_	
57-8	11490-11501	performance	_	
57-9	11502-11504	at	_	
57-10	11505-11508	any	_	
57-11	11509-11513	time	_	
57-12	11514-11520	during	_	
57-13	11521-11524	the	_	
57-14	11525-11529	task	_	
57-15	11529-11530	,	_	
57-16	11531-11535	only	_	
57-17	11536-11538	at	_	
57-18	11539-11542	the	_	
57-19	11543-11546	end	_	
57-20	11546-11547	.	_	

#Text=The stimuli presented throughout all the trials were white on a black background (resolution of 800x600 pixels).
58-1	11548-11551	The	_	
58-2	11552-11559	stimuli	_	
58-3	11560-11569	presented	_	
58-4	11570-11580	throughout	_	
58-5	11581-11584	all	_	
58-6	11585-11588	the	_	
58-7	11589-11595	trials	_	
58-8	11596-11600	were	_	
58-9	11601-11606	white	_	
58-10	11607-11609	on	_	
58-11	11610-11611	a	_	
58-12	11612-11617	black	_	
58-13	11618-11628	background	_	
58-14	11629-11630	(	_	
58-15	11630-11640	resolution	_	
58-16	11641-11643	of	_	
58-17	11644-11651	800x600	_	
58-18	11652-11658	pixels	_	
58-19	11658-11659	)	_	
58-20	11659-11660	.	_	

#Text=We controlled the stimulus presentation with the Presentation software (http://www.neurobs.com).
59-1	11661-11663	We	_	
59-2	11664-11674	controlled	_	
59-3	11675-11678	the	_	
59-4	11679-11687	stimulus	_	
59-5	11688-11700	presentation	_	
59-6	11701-11705	with	_	
59-7	11706-11709	the	_	
59-8	11710-11722	Presentation	_	
59-9	11723-11731	software	_	
59-10	11732-11733	(	_	
59-11	11733-11737	http	_	
59-12	11737-11738	:	_	
59-13	11738-11739	/	_	
59-14	11739-11740	/	_	
59-15	11740-11755	www.neurobs.com	_	
59-16	11755-11756	)	_	
59-17	11756-11757	.	_	

#Text=Before they entered the scanner, we instructed all the participants about the task by reading identical instructions.
60-1	11758-11764	Before	_	
60-2	11765-11769	they	_	
60-3	11770-11777	entered	_	
60-4	11778-11781	the	_	
60-5	11782-11789	scanner	_	
60-6	11789-11790	,	_	
60-7	11791-11793	we	_	
60-8	11794-11804	instructed	_	
60-9	11805-11808	all	_	
60-10	11809-11812	the	_	
60-11	11813-11825	participants	_	
60-12	11826-11831	about	_	
60-13	11832-11835	the	_	
60-14	11836-11840	task	_	
60-15	11841-11843	by	_	
60-16	11844-11851	reading	_	
60-17	11852-11861	identical	_	
60-18	11862-11874	instructions	_	
60-19	11874-11875	.	_	

#Text=The instructions explained that the participants had to respond to the number of words that appeared on the screen, not to the number word.
61-1	11876-11879	The	_	
61-2	11880-11892	instructions	_	
61-3	11893-11902	explained	_	
61-4	11903-11907	that	_	
61-5	11908-11911	the	_	
61-6	11912-11924	participants	_	
61-7	11925-11928	had	_	
61-8	11929-11931	to	_	
61-9	11932-11939	respond	_	
61-10	11940-11942	to	_	
61-11	11943-11946	the	_	
61-12	11947-11953	number	_	
61-13	11954-11956	of	_	
61-14	11957-11962	words	_	
61-15	11963-11967	that	_	
61-16	11968-11976	appeared	_	
61-17	11977-11979	on	_	
61-18	11980-11983	the	_	
61-19	11984-11990	screen	_	
61-20	11990-11991	,	_	
61-21	11992-11995	not	_	
61-22	11996-11998	to	_	
61-23	11999-12002	the	_	
61-24	12003-12009	number	_	
61-25	12010-12014	word	_	
61-26	12014-12015	.	_	

#Text=We also told them that before each set of trials, they would see an informative cue that determined the amount of money they would receive for each correct response obtained in each set of trials (e.g., €0.50), and they would receive a monetary reward when participation ended, based on their task performance.
62-1	12016-12018	We	_	
62-2	12019-12023	also	_	
62-3	12024-12028	told	_	
62-4	12029-12033	them	_	
62-5	12034-12038	that	_	
62-6	12039-12045	before	_	
62-7	12046-12050	each	_	
62-8	12051-12054	set	_	
62-9	12055-12057	of	_	
62-10	12058-12064	trials	_	
62-11	12064-12065	,	_	
62-12	12066-12070	they	_	
62-13	12071-12076	would	_	
62-14	12077-12080	see	_	
62-15	12081-12083	an	_	
62-16	12084-12095	informative	_	
62-17	12096-12099	cue	_	
62-18	12100-12104	that	_	
62-19	12105-12115	determined	_	
62-20	12116-12119	the	_	
62-21	12120-12126	amount	_	
62-22	12127-12129	of	_	
62-23	12130-12135	money	_	
62-24	12136-12140	they	_	
62-25	12141-12146	would	_	
62-26	12147-12154	receive	_	
62-27	12155-12158	for	_	
62-28	12159-12163	each	_	
62-29	12164-12171	correct	_	
62-30	12172-12180	response	_	
62-31	12181-12189	obtained	_	
62-32	12190-12192	in	_	
62-33	12193-12197	each	_	
62-34	12198-12201	set	_	
62-35	12202-12204	of	_	
62-36	12205-12211	trials	_	
62-37	12212-12213	(	_	
62-38	12213-12216	e.g	_	
62-39	12216-12217	.	_	
62-40	12217-12218	,	_	
62-41	12219-12224	€0.50	_	
62-42	12224-12225	)	_	
62-43	12225-12226	,	_	
62-44	12227-12230	and	_	
62-45	12231-12235	they	_	
62-46	12236-12241	would	_	
62-47	12242-12249	receive	_	
62-48	12250-12251	a	_	
62-49	12252-12260	monetary	_	
62-50	12261-12267	reward	_	
62-51	12268-12272	when	_	
62-52	12273-12286	participation	_	
62-53	12287-12292	ended	_	
62-54	12292-12293	,	_	
62-55	12294-12299	based	_	
62-56	12300-12302	on	_	
62-57	12303-12308	their	_	
62-58	12309-12313	task	_	
62-59	12314-12325	performance	_	
62-60	12325-12326	.	_	

#Text=Thus, their main goal was to win as much money as possible.
63-1	12327-12331	Thus	_	
63-2	12331-12332	,	_	
63-3	12333-12338	their	_	
63-4	12339-12343	main	_	
63-5	12344-12348	goal	_	
63-6	12349-12352	was	_	
63-7	12353-12355	to	_	
63-8	12356-12359	win	_	
63-9	12360-12362	as	_	
63-10	12363-12367	much	_	
63-11	12368-12373	money	_	
63-12	12374-12376	as	_	
63-13	12377-12385	possible	_	
63-14	12385-12386	.	_	

#Text=After receiving the instructions, the participants completed a practice version with 90 trials to minimize practice effects and get used to matching responses to the button to press.
64-1	12387-12392	After	_	
64-2	12393-12402	receiving	_	
64-3	12403-12406	the	_	
64-4	12407-12419	instructions	_	
64-5	12419-12420	,	_	
64-6	12421-12424	the	_	
64-7	12425-12437	participants	_	
64-8	12438-12447	completed	_	
64-9	12448-12449	a	_	
64-10	12450-12458	practice	_	
64-11	12459-12466	version	_	
64-12	12467-12471	with	_	
64-13	12472-12474	90	_	
64-14	12475-12481	trials	_	
64-15	12482-12484	to	_	
64-16	12485-12493	minimize	_	
64-17	12494-12502	practice	_	
64-18	12503-12510	effects	_	
64-19	12511-12514	and	_	
64-20	12515-12518	get	_	
64-21	12519-12523	used	_	
64-22	12524-12526	to	_	
64-23	12527-12535	matching	_	
64-24	12536-12545	responses	_	
64-25	12546-12548	to	_	
64-26	12549-12552	the	_	
64-27	12553-12559	button	_	
64-28	12560-12562	to	_	
64-29	12563-12568	press	_	
64-30	12568-12569	.	_	

#Text=Upon task completion, we asked 67 subjects (34 HCs and 33 ACDs) to rate their self-reported interest in the reward value for the five monetary amounts on a visual analogue scale (range: 0 to 7, boring to interesting, respectively).
#Text=fMRI Acquisition
#Text=We acquired blood oxygenation level-dependent (BOLD) fMRI data in a 1.5-Teslas Siemens Avanto (Erlangen, Germany).
65-1	12570-12574	Upon	_	
65-2	12575-12579	task	_	
65-3	12580-12590	completion	_	
65-4	12590-12591	,	_	
65-5	12592-12594	we	_	
65-6	12595-12600	asked	_	
65-7	12601-12603	67	_	
65-8	12604-12612	subjects	_	
65-9	12613-12614	(	_	
65-10	12614-12616	34	_	
65-11	12617-12620	HCs	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
65-12	12621-12624	and	_	
65-13	12625-12627	33	_	
65-14	12628-12632	ACDs	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[44]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[45]	
65-15	12632-12633	)	_	
65-16	12634-12636	to	_	
65-17	12637-12641	rate	_	
65-18	12642-12647	their	_	
65-19	12648-12661	self-reported	_	
65-20	12662-12670	interest	_	
65-21	12671-12673	in	_	
65-22	12674-12677	the	_	
65-23	12678-12684	reward	_	
65-24	12685-12690	value	_	
65-25	12691-12694	for	_	
65-26	12695-12698	the	_	
65-27	12699-12703	five	_	
65-28	12704-12712	monetary	_	
65-29	12713-12720	amounts	_	
65-30	12721-12723	on	_	
65-31	12724-12725	a	_	
65-32	12726-12732	visual	_	
65-33	12733-12741	analogue	_	
65-34	12742-12747	scale	_	
65-35	12748-12749	(	_	
65-36	12749-12754	range	_	
65-37	12754-12755	:	_	
65-38	12756-12757	0	_	
65-39	12758-12760	to	_	
65-40	12761-12762	7	_	
65-41	12762-12763	,	_	
65-42	12764-12770	boring	_	
65-43	12771-12773	to	_	
65-44	12774-12785	interesting	_	
65-45	12785-12786	,	_	
65-46	12787-12799	respectively	_	
65-47	12799-12800	)	_	
65-48	12800-12801	.	_	
65-49	12802-12806	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
65-50	12807-12818	Acquisition	_	
65-51	12819-12821	We	_	
65-52	12822-12830	acquired	_	
65-53	12831-12836	blood	_	
65-54	12837-12848	oxygenation	_	
65-55	12849-12864	level-dependent	_	
65-56	12865-12866	(	_	
65-57	12866-12870	BOLD	_	
65-58	12870-12871	)	_	
65-59	12872-12876	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
65-60	12877-12881	data	_	
65-61	12882-12884	in	_	
65-62	12885-12886	a	_	
65-63	12887-12890	1.5	_	
65-64	12890-12891	-	_	
65-65	12891-12897	Teslas	_	
65-66	12898-12905	Siemens	_	
65-67	12906-12912	Avanto	_	
65-68	12913-12914	(	_	
65-69	12914-12922	Erlangen	_	
65-70	12922-12923	,	_	
65-71	12924-12931	Germany	_	
65-72	12931-12932	)	_	
65-73	12932-12933	.	_	

#Text=We helped subjects to enter the MRI scanner and lie in a supine position.
66-1	12934-12936	We	_	
66-2	12937-12943	helped	_	
66-3	12944-12952	subjects	_	
66-4	12953-12955	to	_	
66-5	12956-12961	enter	_	
66-6	12962-12965	the	_	
66-7	12966-12969	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument	
66-8	12970-12977	scanner	_	
66-9	12978-12981	and	_	
66-10	12982-12985	lie	_	
66-11	12986-12988	in	_	
66-12	12989-12990	a	_	
66-13	12991-12997	supine	_	
66-14	12998-13006	position	_	
66-15	13006-13007	.	_	

#Text=We immobilized their heads with cushions to reduce motion artifacts.
67-1	13008-13010	We	_	
67-2	13011-13022	immobilized	_	
67-3	13023-13028	their	_	
67-4	13029-13034	heads	_	
67-5	13035-13039	with	_	
67-6	13040-13048	cushions	_	
67-7	13049-13051	to	_	
67-8	13052-13058	reduce	_	
67-9	13059-13065	motion	_	
67-10	13066-13075	artifacts	_	
67-11	13075-13076	.	_	

#Text=We presented the stimuli via MRI-compatible goggles, and we used a response system to control performance during the scanning session (Response grips, NordicNeuroLab).
68-1	13077-13079	We	_	
68-2	13080-13089	presented	_	
68-3	13090-13093	the	_	
68-4	13094-13101	stimuli	_	
68-5	13102-13105	via	_	
68-6	13106-13120	MRI-compatible	_	
68-7	13121-13128	goggles	_	
68-8	13128-13129	,	_	
68-9	13130-13133	and	_	
68-10	13134-13136	we	_	
68-11	13137-13141	used	_	
68-12	13142-13143	a	_	
68-13	13144-13152	response	_	
68-14	13153-13159	system	_	
68-15	13160-13162	to	_	
68-16	13163-13170	control	_	
68-17	13171-13182	performance	_	
68-18	13183-13189	during	_	
68-19	13190-13193	the	_	
68-20	13194-13202	scanning	_	
68-21	13203-13210	session	_	
68-22	13211-13212	(	_	
68-23	13212-13220	Response	_	
68-24	13221-13226	grips	_	
68-25	13226-13227	,	_	
68-26	13228-13242	NordicNeuroLab	_	
68-27	13242-13243	)	_	
68-28	13243-13244	.	_	

#Text=We obtained functional scans using a gradient-echo T2*-weighted echo-planar MR sequence (TR = 2000ms; TE = 48 ms; matrix = 64 x 64, voxel size = 3.5 x 3.5 x 4 mm, flip angle = 90°, 4.5-mm thickness, slice gap of 0.5 mm).
69-1	13245-13247	We	_	
69-2	13248-13256	obtained	_	
69-3	13257-13267	functional	_	
69-4	13268-13273	scans	_	
69-5	13274-13279	using	_	
69-6	13280-13281	a	_	
69-7	13282-13295	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[46]	
69-8	13296-13298	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[46]	
69-9	13298-13299	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[46]	
69-10	13299-13300	-	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[46]	
69-11	13300-13308	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[46]	
69-12	13309-13320	echo-planar	_	
69-13	13321-13323	MR	_	
69-14	13324-13332	sequence	_	
69-15	13333-13334	(	_	
69-16	13334-13336	TR	_	
69-17	13337-13338	=	_	
69-18	13339-13345	2000ms	_	
69-19	13345-13346	;	_	
69-20	13347-13349	TE	_	
69-21	13350-13351	=	_	
69-22	13352-13354	48	_	
69-23	13355-13357	ms	_	
69-24	13357-13358	;	_	
69-25	13359-13365	matrix	_	
69-26	13366-13367	=	_	
69-27	13368-13370	64	_	
69-28	13371-13372	x	_	
69-29	13373-13375	64	_	
69-30	13375-13376	,	_	
69-31	13377-13382	voxel	_	
69-32	13383-13387	size	_	
69-33	13388-13389	=	_	
69-34	13390-13393	3.5	_	
69-35	13394-13395	x	_	
69-36	13396-13399	3.5	_	
69-37	13400-13401	x	_	
69-38	13402-13403	4	_	
69-39	13404-13406	mm	_	
69-40	13406-13407	,	_	
69-41	13408-13412	flip	_	
69-42	13413-13418	angle	_	
69-43	13419-13420	=	_	
69-44	13421-13423	90	_	
69-45	13423-13424	°	_	
69-46	13424-13425	,	_	
69-47	13426-13429	4.5	_	
69-48	13429-13430	-	_	
69-49	13430-13432	mm	_	
69-50	13433-13442	thickness	_	
69-51	13442-13443	,	_	
69-52	13444-13449	slice	_	
69-53	13450-13453	gap	_	
69-54	13454-13456	of	_	
69-55	13457-13460	0.5	_	
69-56	13461-13463	mm	_	
69-57	13463-13464	)	_	
69-58	13464-13465	.	_	

#Text=We acquired 24 interleaved axial slices parallel to the hippocampi and covering the entire brain.
70-1	13466-13468	We	_	
70-2	13469-13477	acquired	_	
70-3	13478-13480	24	_	
70-4	13481-13492	interleaved	_	
70-5	13493-13498	axial	_	
70-6	13499-13505	slices	_	
70-7	13506-13514	parallel	_	
70-8	13515-13517	to	_	
70-9	13518-13521	the	_	
70-10	13522-13532	hippocampi	_	
70-11	13533-13536	and	_	
70-12	13537-13545	covering	_	
70-13	13546-13549	the	_	
70-14	13550-13556	entire	_	
70-15	13557-13562	brain	_	
70-16	13562-13563	.	_	

#Text=Prior to the functional MRI sequences, we acquired structural images using a high-resolution T1-weighted sequence with TR / TE = 2200 / 3.849 ms, FOV = 224 mm, matrix = 256 x 256 x 160, voxel size = 1 x 1 x 1 mm, which facilitated the localization and co-registration of the functional data.
#Text=fMRI preprocessing
#Text=We preprocessed and analyzed the data with the SPM8 software package (Statistical Parametric Mapping 8; Wellcome Department of Imaging Neuroscience; http://www.fil.ion.ucl.ac.uk/spm), as implemented in MATLAB R2007a (Mathworks, Inc., Natick, MA, USA).
71-1	13564-13569	Prior	_	
71-2	13570-13572	to	_	
71-3	13573-13576	the	_	
71-4	13577-13587	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[47]	
71-5	13588-13591	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[47]	
71-6	13592-13601	sequences	_	
71-7	13601-13602	,	_	
71-8	13603-13605	we	_	
71-9	13606-13614	acquired	_	
71-10	13615-13625	structural	_	
71-11	13626-13632	images	_	
71-12	13633-13638	using	_	
71-13	13639-13640	a	_	
71-14	13641-13656	high-resolution	_	
71-15	13657-13659	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[48]	
71-16	13659-13660	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[48]	
71-17	13660-13668	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[48]	
71-18	13669-13677	sequence	_	
71-19	13678-13682	with	_	
71-20	13683-13685	TR	_	
71-21	13686-13687	/	_	
71-22	13688-13690	TE	_	
71-23	13691-13692	=	_	
71-24	13693-13697	2200	_	
71-25	13698-13699	/	_	
71-26	13700-13705	3.849	_	
71-27	13706-13708	ms	_	
71-28	13708-13709	,	_	
71-29	13710-13713	FOV	_	
71-30	13714-13715	=	_	
71-31	13716-13719	224	_	
71-32	13720-13722	mm	_	
71-33	13722-13723	,	_	
71-34	13724-13730	matrix	_	
71-35	13731-13732	=	_	
71-36	13733-13736	256	_	
71-37	13737-13738	x	_	
71-38	13739-13742	256	_	
71-39	13743-13744	x	_	
71-40	13745-13748	160	_	
71-41	13748-13749	,	_	
71-42	13750-13755	voxel	_	
71-43	13756-13760	size	_	
71-44	13761-13762	=	_	
71-45	13763-13764	1	_	
71-46	13765-13766	x	_	
71-47	13767-13768	1	_	
71-48	13769-13770	x	_	
71-49	13771-13772	1	_	
71-50	13773-13775	mm	_	
71-51	13775-13776	,	_	
71-52	13777-13782	which	_	
71-53	13783-13794	facilitated	_	
71-54	13795-13798	the	_	
71-55	13799-13811	localization	_	
71-56	13812-13815	and	_	
71-57	13816-13831	co-registration	_	
71-58	13832-13834	of	_	
71-59	13835-13838	the	_	
71-60	13839-13849	functional	_	
71-61	13850-13854	data	_	
71-62	13854-13855	.	_	
71-63	13856-13860	fMRI	_	
71-64	13861-13874	preprocessing	_	
71-65	13875-13877	We	_	
71-66	13878-13890	preprocessed	_	
71-67	13891-13894	and	_	
71-68	13895-13903	analyzed	_	
71-69	13904-13907	the	_	
71-70	13908-13912	data	_	
71-71	13913-13917	with	_	
71-72	13918-13921	the	_	
71-73	13922-13926	SPM8	_	
71-74	13927-13935	software	_	
71-75	13936-13943	package	_	
71-76	13944-13945	(	_	
71-77	13945-13956	Statistical	_	
71-78	13957-13967	Parametric	_	
71-79	13968-13975	Mapping	_	
71-80	13976-13977	8	_	
71-81	13977-13978	;	_	
71-82	13979-13987	Wellcome	_	
71-83	13988-13998	Department	_	
71-84	13999-14001	of	_	
71-85	14002-14009	Imaging	_	
71-86	14010-14022	Neuroscience	_	
71-87	14022-14023	;	_	
71-88	14024-14028	http	_	
71-89	14028-14029	:	_	
71-90	14029-14030	/	_	
71-91	14030-14031	/	_	
71-92	14031-14052	www.fil.ion.ucl.ac.uk	_	
71-93	14052-14053	/	_	
71-94	14053-14056	spm	_	
71-95	14056-14057	)	_	
71-96	14057-14058	,	_	
71-97	14059-14061	as	_	
71-98	14062-14073	implemented	_	
71-99	14074-14076	in	_	
71-100	14077-14083	MATLAB	_	
71-101	14084-14090	R2007a	_	
71-102	14091-14092	(	_	
71-103	14092-14101	Mathworks	_	
71-104	14101-14102	,	_	
71-105	14103-14106	Inc	_	
71-106	14106-14107	.	_	
71-107	14107-14108	,	_	
71-108	14109-14115	Natick	_	
71-109	14115-14116	,	_	
71-110	14117-14119	MA	_	
71-111	14119-14120	,	_	
71-112	14121-14124	USA	_	
71-113	14124-14125	)	_	
71-114	14125-14126	.	_	

#Text=Preprocessing first included the realignment of each scan per individual to the first scan to correct motion-related artefacts (movement parameters never exceeded 2 mm of translation or 2 degrees of rotation in any direction for any participant).
72-1	14127-14140	Preprocessing	_	
72-2	14141-14146	first	_	
72-3	14147-14155	included	_	
72-4	14156-14159	the	_	
72-5	14160-14171	realignment	_	
72-6	14172-14174	of	_	
72-7	14175-14179	each	_	
72-8	14180-14184	scan	_	
72-9	14185-14188	per	_	
72-10	14189-14199	individual	_	
72-11	14200-14202	to	_	
72-12	14203-14206	the	_	
72-13	14207-14212	first	_	
72-14	14213-14217	scan	_	
72-15	14218-14220	to	_	
72-16	14221-14228	correct	_	
72-17	14229-14243	motion-related	_	
72-18	14244-14253	artefacts	_	
72-19	14254-14255	(	_	
72-20	14255-14263	movement	_	
72-21	14264-14274	parameters	_	
72-22	14275-14280	never	_	
72-23	14281-14289	exceeded	_	
72-24	14290-14291	2	_	
72-25	14292-14294	mm	_	
72-26	14295-14297	of	_	
72-27	14298-14309	translation	_	
72-28	14310-14312	or	_	
72-29	14313-14314	2	_	
72-30	14315-14322	degrees	_	
72-31	14323-14325	of	_	
72-32	14326-14334	rotation	_	
72-33	14335-14337	in	_	
72-34	14338-14341	any	_	
72-35	14342-14351	direction	_	
72-36	14352-14355	for	_	
72-37	14356-14359	any	_	
72-38	14360-14371	participant	_	
72-39	14371-14372	)	_	
72-40	14372-14373	.	_	

#Text=Second, the normalization to a standard EPI template was carried out in accordance with the Montreal Neurological Institute (MNI) template by applying an affine transformation followed by nonlinear deformation, and using the basic functions defined in the SPM program.
73-1	14374-14380	Second	_	
73-2	14380-14381	,	_	
73-3	14382-14385	the	_	
73-4	14386-14399	normalization	_	
73-5	14400-14402	to	_	
73-6	14403-14404	a	_	
73-7	14405-14413	standard	_	
73-8	14414-14417	EPI	_	
73-9	14418-14426	template	_	
73-10	14427-14430	was	_	
73-11	14431-14438	carried	_	
73-12	14439-14442	out	_	
73-13	14443-14445	in	_	
73-14	14446-14456	accordance	_	
73-15	14457-14461	with	_	
73-16	14462-14465	the	_	
73-17	14466-14474	Montreal	_	
73-18	14475-14487	Neurological	_	
73-19	14488-14497	Institute	_	
73-20	14498-14499	(	_	
73-21	14499-14502	MNI	_	
73-22	14502-14503	)	_	
73-23	14504-14512	template	_	
73-24	14513-14515	by	_	
73-25	14516-14524	applying	_	
73-26	14525-14527	an	_	
73-27	14528-14534	affine	_	
73-28	14535-14549	transformation	_	
73-29	14550-14558	followed	_	
73-30	14559-14561	by	_	
73-31	14562-14571	nonlinear	_	
73-32	14572-14583	deformation	_	
73-33	14583-14584	,	_	
73-34	14585-14588	and	_	
73-35	14589-14594	using	_	
73-36	14595-14598	the	_	
73-37	14599-14604	basic	_	
73-38	14605-14614	functions	_	
73-39	14615-14622	defined	_	
73-40	14623-14625	in	_	
73-41	14626-14629	the	_	
73-42	14630-14633	SPM	_	
73-43	14634-14641	program	_	
73-44	14641-14642	.	_	

#Text=We applied the computed transformation parameters to all the functional images by interpolating them to a final voxel size of 3 x 3 x 3 mm.
74-1	14643-14645	We	_	
74-2	14646-14653	applied	_	
74-3	14654-14657	the	_	
74-4	14658-14666	computed	_	
74-5	14667-14681	transformation	_	
74-6	14682-14692	parameters	_	
74-7	14693-14695	to	_	
74-8	14696-14699	all	_	
74-9	14700-14703	the	_	
74-10	14704-14714	functional	_	
74-11	14715-14721	images	_	
74-12	14722-14724	by	_	
74-13	14725-14738	interpolating	_	
74-14	14739-14743	them	_	
74-15	14744-14746	to	_	
74-16	14747-14748	a	_	
74-17	14749-14754	final	_	
74-18	14755-14760	voxel	_	
74-19	14761-14765	size	_	
74-20	14766-14768	of	_	
74-21	14769-14770	3	_	
74-22	14771-14772	x	_	
74-23	14773-14774	3	_	
74-24	14775-14776	x	_	
74-25	14777-14778	3	_	
74-26	14779-14781	mm	_	
74-27	14781-14782	.	_	

#Text=Finally, we spatially smoothed the images with an 8 x 8 x 8 mm (Full Width at Half Maximum; FWHM) Gaussian kernel.
75-1	14783-14790	Finally	_	
75-2	14790-14791	,	_	
75-3	14792-14794	we	_	
75-4	14795-14804	spatially	_	
75-5	14805-14813	smoothed	_	
75-6	14814-14817	the	_	
75-7	14818-14824	images	_	
75-8	14825-14829	with	_	
75-9	14830-14832	an	_	
75-10	14833-14834	8	_	
75-11	14835-14836	x	_	
75-12	14837-14838	8	_	
75-13	14839-14840	x	_	
75-14	14841-14842	8	_	
75-15	14843-14845	mm	_	
75-16	14846-14847	(	_	
75-17	14847-14851	Full	_	
75-18	14852-14857	Width	_	
75-19	14858-14860	at	_	
75-20	14861-14865	Half	_	
75-21	14866-14873	Maximum	_	
75-22	14873-14874	;	_	
75-23	14875-14879	FWHM	_	
75-24	14879-14880	)	_	
75-25	14881-14889	Gaussian	_	
75-26	14890-14896	kernel	_	
75-27	14896-14897	.	_	

#Text=Statistical analyses
#Text=Behavioral analysis
#Text=Three variables related to task performance were analyzed: mean reaction time (RT) on correct responses, error rate (%), and RT variability.
76-1	14898-14909	Statistical	_	
76-2	14910-14918	analyses	_	
76-3	14919-14929	Behavioral	_	
76-4	14930-14938	analysis	_	
76-5	14939-14944	Three	_	
76-6	14945-14954	variables	_	
76-7	14955-14962	related	_	
76-8	14963-14965	to	_	
76-9	14966-14970	task	_	
76-10	14971-14982	performance	_	
76-11	14983-14987	were	_	
76-12	14988-14996	analyzed	_	
76-13	14996-14997	:	_	
76-14	14998-15002	mean	_	
76-15	15003-15011	reaction	_	
76-16	15012-15016	time	_	
76-17	15017-15018	(	_	
76-18	15018-15020	RT	_	
76-19	15020-15021	)	_	
76-20	15022-15024	on	_	
76-21	15025-15032	correct	_	
76-22	15033-15042	responses	_	
76-23	15042-15043	,	_	
76-24	15044-15049	error	_	
76-25	15050-15054	rate	_	
76-26	15055-15056	(	_	
76-27	15056-15057	%	_	
76-28	15057-15058	)	_	
76-29	15058-15059	,	_	
76-30	15060-15063	and	_	
76-31	15064-15066	RT	_	
76-32	15067-15078	variability	_	
76-33	15078-15079	.	_	

#Text=We measured RT variability as within-subject RT standard deviation (SDrt), as in previous studies.
77-1	15080-15082	We	_	
77-2	15083-15091	measured	_	
77-3	15092-15094	RT	_	
77-4	15095-15106	variability	_	
77-5	15107-15109	as	_	
77-6	15110-15124	within-subject	_	
77-7	15125-15127	RT	_	
77-8	15128-15136	standard	_	
77-9	15137-15146	deviation	_	
77-10	15147-15148	(	_	
77-11	15148-15152	SDrt	_	
77-12	15152-15153	)	_	
77-13	15153-15154	,	_	
77-14	15155-15157	as	_	
77-15	15158-15160	in	_	
77-16	15161-15169	previous	_	
77-17	15170-15177	studies	_	
77-18	15177-15178	.	_	

#Text=We did not consider the analysis of the congruency effect because the small number of these trials and their inclusion in blocks with a higher proportion of incongruent trials may lead to unreliable estimations of the congruency effect.
78-1	15179-15181	We	_	
78-2	15182-15185	did	_	
78-3	15186-15189	not	_	
78-4	15190-15198	consider	_	
78-5	15199-15202	the	_	
78-6	15203-15211	analysis	_	
78-7	15212-15214	of	_	
78-8	15215-15218	the	_	
78-9	15219-15229	congruency	_	
78-10	15230-15236	effect	_	
78-11	15237-15244	because	_	
78-12	15245-15248	the	_	
78-13	15249-15254	small	_	
78-14	15255-15261	number	_	
78-15	15262-15264	of	_	
78-16	15265-15270	these	_	
78-17	15271-15277	trials	_	
78-18	15278-15281	and	_	
78-19	15282-15287	their	_	
78-20	15288-15297	inclusion	_	
78-21	15298-15300	in	_	
78-22	15301-15307	blocks	_	
78-23	15308-15312	with	_	
78-24	15313-15314	a	_	
78-25	15315-15321	higher	_	
78-26	15322-15332	proportion	_	
78-27	15333-15335	of	_	
78-28	15336-15347	incongruent	_	
78-29	15348-15354	trials	_	
78-30	15355-15358	may	_	
78-31	15359-15363	lead	_	
78-32	15364-15366	to	_	
78-33	15367-15377	unreliable	_	
78-34	15378-15389	estimations	_	
78-35	15390-15392	of	_	
78-36	15393-15396	the	_	
78-37	15397-15407	congruency	_	
78-38	15408-15414	effect	_	
78-39	15414-15415	.	_	

#Text=Therefore, we focused on the incongruent trials.
79-1	15416-15425	Therefore	_	
79-2	15425-15426	,	_	
79-3	15427-15429	we	_	
79-4	15430-15437	focused	_	
79-5	15438-15440	on	_	
79-6	15441-15444	the	_	
79-7	15445-15456	incongruent	_	
79-8	15457-15463	trials	_	
79-9	15463-15464	.	_	

#Text=In order to compare HC and ACD on the effect of parametric increases in the monetary reward magnitude on RT, error rate and SDrt, we conducted three 5x2 mixed-design ANOVAs, including the within-subject factor Reward (€0, €0.01, €0.5, €1 or €1.5) and the between-subject factor Group (HC, ACD).
80-1	15465-15467	In	_	
80-2	15468-15473	order	_	
80-3	15474-15476	to	_	
80-4	15477-15484	compare	_	
80-5	15485-15487	HC	_	
80-6	15488-15491	and	_	
80-7	15492-15495	ACD	_	
80-8	15496-15498	on	_	
80-9	15499-15502	the	_	
80-10	15503-15509	effect	_	
80-11	15510-15512	of	_	
80-12	15513-15523	parametric	_	
80-13	15524-15533	increases	_	
80-14	15534-15536	in	_	
80-15	15537-15540	the	_	
80-16	15541-15549	monetary	_	
80-17	15550-15556	reward	_	
80-18	15557-15566	magnitude	_	
80-19	15567-15569	on	_	
80-20	15570-15572	RT	_	
80-21	15572-15573	,	_	
80-22	15574-15579	error	_	
80-23	15580-15584	rate	_	
80-24	15585-15588	and	_	
80-25	15589-15593	SDrt	_	
80-26	15593-15594	,	_	
80-27	15595-15597	we	_	
80-28	15598-15607	conducted	_	
80-29	15608-15613	three	_	
80-30	15614-15617	5x2	_	
80-31	15618-15630	mixed-design	_	
80-32	15631-15637	ANOVAs	_	
80-33	15637-15638	,	_	
80-34	15639-15648	including	_	
80-35	15649-15652	the	_	
80-36	15653-15667	within-subject	_	
80-37	15668-15674	factor	_	
80-38	15675-15681	Reward	_	
80-39	15682-15683	(	_	
80-40	15683-15685	€0	_	
80-41	15685-15686	,	_	
80-42	15687-15692	€0.01	_	
80-43	15692-15693	,	_	
80-44	15694-15698	€0.5	_	
80-45	15698-15699	,	_	
80-46	15700-15702	€1	_	
80-47	15703-15705	or	_	
80-48	15706-15710	€1.5	_	
80-49	15710-15711	)	_	
80-50	15712-15715	and	_	
80-51	15716-15719	the	_	
80-52	15720-15735	between-subject	_	
80-53	15736-15742	factor	_	
80-54	15743-15748	Group	_	
80-55	15749-15750	(	_	
80-56	15750-15752	HC	_	
80-57	15752-15753	,	_	
80-58	15754-15757	ACD	_	
80-59	15757-15758	)	_	
80-60	15758-15759	.	_	

#Text=Moreover, we analyzed the relationship between self-reported interest in the reward value and the performance variables, for HC and ACD separately, by correlating the self-reported interest in the reward value for each reward magnitude with the respective individual RT, error rate, and SDrt (e.g., self-reported interest in reward value for €1 correlated with RT for the €1 condition).
81-1	15760-15768	Moreover	_	
81-2	15768-15769	,	_	
81-3	15770-15772	we	_	
81-4	15773-15781	analyzed	_	
81-5	15782-15785	the	_	
81-6	15786-15798	relationship	_	
81-7	15799-15806	between	_	
81-8	15807-15820	self-reported	_	
81-9	15821-15829	interest	_	
81-10	15830-15832	in	_	
81-11	15833-15836	the	_	
81-12	15837-15843	reward	_	
81-13	15844-15849	value	_	
81-14	15850-15853	and	_	
81-15	15854-15857	the	_	
81-16	15858-15869	performance	_	
81-17	15870-15879	variables	_	
81-18	15879-15880	,	_	
81-19	15881-15884	for	_	
81-20	15885-15887	HC	_	
81-21	15888-15891	and	_	
81-22	15892-15895	ACD	_	
81-23	15896-15906	separately	_	
81-24	15906-15907	,	_	
81-25	15908-15910	by	_	
81-26	15911-15922	correlating	_	
81-27	15923-15926	the	_	
81-28	15927-15940	self-reported	_	
81-29	15941-15949	interest	_	
81-30	15950-15952	in	_	
81-31	15953-15956	the	_	
81-32	15957-15963	reward	_	
81-33	15964-15969	value	_	
81-34	15970-15973	for	_	
81-35	15974-15978	each	_	
81-36	15979-15985	reward	_	
81-37	15986-15995	magnitude	_	
81-38	15996-16000	with	_	
81-39	16001-16004	the	_	
81-40	16005-16015	respective	_	
81-41	16016-16026	individual	_	
81-42	16027-16029	RT	_	
81-43	16029-16030	,	_	
81-44	16031-16036	error	_	
81-45	16037-16041	rate	_	
81-46	16041-16042	,	_	
81-47	16043-16046	and	_	
81-48	16047-16051	SDrt	_	
81-49	16052-16053	(	_	
81-50	16053-16056	e.g	_	
81-51	16056-16057	.	_	
81-52	16057-16058	,	_	
81-53	16059-16072	self-reported	_	
81-54	16073-16081	interest	_	
81-55	16082-16084	in	_	
81-56	16085-16091	reward	_	
81-57	16092-16097	value	_	
81-58	16098-16101	for	_	
81-59	16102-16104	€1	_	
81-60	16105-16115	correlated	_	
81-61	16116-16120	with	_	
81-62	16121-16123	RT	_	
81-63	16124-16127	for	_	
81-64	16128-16131	the	_	
81-65	16132-16134	€1	_	
81-66	16135-16144	condition	_	
81-67	16144-16145	)	_	
81-68	16145-16146	.	_	

#Text=We also tested for between-group differences in these correlation coefficients by means of Fisher’s r-to-z transformation, applying the Bonferroni correction for multiple comparisons.
82-1	16147-16149	We	_	
82-2	16150-16154	also	_	
82-3	16155-16161	tested	_	
82-4	16162-16165	for	_	
82-5	16166-16179	between-group	_	
82-6	16180-16191	differences	_	
82-7	16192-16194	in	_	
82-8	16195-16200	these	_	
82-9	16201-16212	correlation	_	
82-10	16213-16225	coefficients	_	
82-11	16226-16228	by	_	
82-12	16229-16234	means	_	
82-13	16235-16237	of	_	
82-14	16238-16244	Fisher	_	
82-15	16244-16245	’	_	
82-16	16245-16246	s	_	
82-17	16247-16253	r-to-z	_	
82-18	16254-16268	transformation	_	
82-19	16268-16269	,	_	
82-20	16270-16278	applying	_	
82-21	16279-16282	the	_	
82-22	16283-16293	Bonferroni	_	
82-23	16294-16304	correction	_	
82-24	16305-16308	for	_	
82-25	16309-16317	multiple	_	
82-26	16318-16329	comparisons	_	
82-27	16329-16330	.	_	

#Text=Based on this method, we divided the a priori selected threshold of p < .05 by the number of within variables group comparisons (k = 5), which stabilized statistical levels as significant if less than .01.
83-1	16331-16336	Based	_	
83-2	16337-16339	on	_	
83-3	16340-16344	this	_	
83-4	16345-16351	method	_	
83-5	16351-16352	,	_	
83-6	16353-16355	we	_	
83-7	16356-16363	divided	_	
83-8	16364-16367	the	_	
83-9	16368-16369	a	_	
83-10	16370-16376	priori	_	
83-11	16377-16385	selected	_	
83-12	16386-16395	threshold	_	
83-13	16396-16398	of	_	
83-14	16399-16400	p	_	
83-15	16401-16402	<	_	
83-16	16403-16406	.05	_	
83-17	16407-16409	by	_	
83-18	16410-16413	the	_	
83-19	16414-16420	number	_	
83-20	16421-16423	of	_	
83-21	16424-16430	within	_	
83-22	16431-16440	variables	_	
83-23	16441-16446	group	_	
83-24	16447-16458	comparisons	_	
83-25	16459-16460	(	_	
83-26	16460-16461	k	_	
83-27	16462-16463	=	_	
83-28	16464-16465	5	_	
83-29	16465-16466	)	_	
83-30	16466-16467	,	_	
83-31	16468-16473	which	_	
83-32	16474-16484	stabilized	_	
83-33	16485-16496	statistical	_	
83-34	16497-16503	levels	_	
83-35	16504-16506	as	_	
83-36	16507-16518	significant	_	
83-37	16519-16521	if	_	
83-38	16522-16526	less	_	
83-39	16527-16531	than	_	
83-40	16532-16535	.01	_	
83-41	16535-16536	.	_	

#Text=We carried out these analyses using SPSS v.20 (Statistical Package for Social Sciences; SPSS Inc., Chicago, IL, USA).
84-1	16537-16539	We	_	
84-2	16540-16547	carried	_	
84-3	16548-16551	out	_	
84-4	16552-16557	these	_	
84-5	16558-16566	analyses	_	
84-6	16567-16572	using	_	
84-7	16573-16577	SPSS	_	
84-8	16578-16579	v	_	
84-9	16579-16582	.20	_	
84-10	16583-16584	(	_	
84-11	16584-16595	Statistical	_	
84-12	16596-16603	Package	_	
84-13	16604-16607	for	_	
84-14	16608-16614	Social	_	
84-15	16615-16623	Sciences	_	
84-16	16623-16624	;	_	
84-17	16625-16629	SPSS	_	
84-18	16630-16633	Inc	_	
84-19	16633-16634	.	_	
84-20	16634-16635	,	_	
84-21	16636-16643	Chicago	_	
84-22	16643-16644	,	_	
84-23	16645-16647	IL	_	
84-24	16647-16648	,	_	
84-25	16649-16652	USA	_	
84-26	16652-16653	)	_	
84-27	16653-16654	.	_	

#Text=FMRI data analysis
#Text=We performed statistical analyses following the General Lineal Model (GLM).
85-1	16655-16659	FMRI	_	
85-2	16660-16664	data	_	
85-3	16665-16673	analysis	_	
85-4	16674-16676	We	_	
85-5	16677-16686	performed	_	
85-6	16687-16698	statistical	_	
85-7	16699-16707	analyses	_	
85-8	16708-16717	following	_	
85-9	16718-16721	the	_	
85-10	16722-16729	General	_	
85-11	16730-16736	Lineal	_	
85-12	16737-16742	Model	_	
85-13	16743-16744	(	_	
85-14	16744-16747	GLM	_	
85-15	16747-16748	)	_	
85-16	16748-16749	.	_	

#Text=In a block design analysis, we modeled each participant’s preprocessed time series under different conditions, using a boxcar function convolved with the hemodynamic response function.
86-1	16750-16752	In	_	
86-2	16753-16754	a	_	
86-3	16755-16760	block	_	
86-4	16761-16767	design	_	
86-5	16768-16776	analysis	_	
86-6	16776-16777	,	_	
86-7	16778-16780	we	_	
86-8	16781-16788	modeled	_	
86-9	16789-16793	each	_	
86-10	16794-16805	participant	_	
86-11	16805-16806	’	_	
86-12	16806-16807	s	_	
86-13	16808-16820	preprocessed	_	
86-14	16821-16825	time	_	
86-15	16826-16832	series	_	
86-16	16833-16838	under	_	
86-17	16839-16848	different	_	
86-18	16849-16859	conditions	_	
86-19	16859-16860	,	_	
86-20	16861-16866	using	_	
86-21	16867-16868	a	_	
86-22	16869-16875	boxcar	_	
86-23	16876-16884	function	_	
86-24	16885-16894	convolved	_	
86-25	16895-16899	with	_	
86-26	16900-16903	the	_	
86-27	16904-16915	hemodynamic	_	
86-28	16916-16924	response	_	
86-29	16925-16933	function	_	
86-30	16933-16934	.	_	

#Text=The model included seven regressors: five regressors that modeled the Stroop blocks for each monetary condition separately (€0, €0.01, €0.5, €1 or €1.5), one regressor that modeled the baseline condition (“*” for 7200 msec.), and another regressor that modeled all the informative cues.
87-1	16935-16938	The	_	
87-2	16939-16944	model	_	
87-3	16945-16953	included	_	
87-4	16954-16959	seven	_	
87-5	16960-16970	regressors	_	
87-6	16970-16971	:	_	
87-7	16972-16976	five	_	
87-8	16977-16987	regressors	_	
87-9	16988-16992	that	_	
87-10	16993-17000	modeled	_	
87-11	17001-17004	the	_	
87-12	17005-17011	Stroop	_	
87-13	17012-17018	blocks	_	
87-14	17019-17022	for	_	
87-15	17023-17027	each	_	
87-16	17028-17036	monetary	_	
87-17	17037-17046	condition	_	
87-18	17047-17057	separately	_	
87-19	17058-17059	(	_	
87-20	17059-17061	€0	_	
87-21	17061-17062	,	_	
87-22	17063-17068	€0.01	_	
87-23	17068-17069	,	_	
87-24	17070-17074	€0.5	_	
87-25	17074-17075	,	_	
87-26	17076-17078	€1	_	
87-27	17079-17081	or	_	
87-28	17082-17086	€1.5	_	
87-29	17086-17087	)	_	
87-30	17087-17088	,	_	
87-31	17089-17092	one	_	
87-32	17093-17102	regressor	_	
87-33	17103-17107	that	_	
87-34	17108-17115	modeled	_	
87-35	17116-17119	the	_	
87-36	17120-17128	baseline	_	
87-37	17129-17138	condition	_	
87-38	17139-17140	(	_	
87-39	17140-17141	“	_	
87-40	17141-17142	*	_	
87-41	17142-17143	”	_	
87-42	17144-17147	for	_	
87-43	17148-17152	7200	_	
87-44	17153-17157	msec	_	
87-45	17157-17158	.	_	
87-46	17158-17159	)	_	
87-47	17159-17160	,	_	
87-48	17161-17164	and	_	
87-49	17165-17172	another	_	
87-50	17173-17182	regressor	_	
87-51	17183-17187	that	_	
87-52	17188-17195	modeled	_	
87-53	17196-17199	all	_	
87-54	17200-17203	the	_	
87-55	17204-17215	informative	_	
87-56	17216-17220	cues	_	
87-57	17220-17221	.	_	

#Text=We also removed intrinsic autocorrelations by using a high-pass filter with a cut-off frequency of 128 Hz, which eliminated low-frequency components.
88-1	17222-17224	We	_	
88-2	17225-17229	also	_	
88-3	17230-17237	removed	_	
88-4	17238-17247	intrinsic	_	
88-5	17248-17264	autocorrelations	_	
88-6	17265-17267	by	_	
88-7	17268-17273	using	_	
88-8	17274-17275	a	_	
88-9	17276-17285	high-pass	_	
88-10	17286-17292	filter	_	
88-11	17293-17297	with	_	
88-12	17298-17299	a	_	
88-13	17300-17307	cut-off	_	
88-14	17308-17317	frequency	_	
88-15	17318-17320	of	_	
88-16	17321-17324	128	_	
88-17	17325-17327	Hz	_	
88-18	17327-17328	,	_	
88-19	17329-17334	which	_	
88-20	17335-17345	eliminated	_	
88-21	17346-17359	low-frequency	_	
88-22	17360-17370	components	_	
88-23	17370-17371	.	_	

#Text=Finally, we included the motion parameters for each subject’s realignment correction in the model as “nuisance” variables.
89-1	17372-17379	Finally	_	
89-2	17379-17380	,	_	
89-3	17381-17383	we	_	
89-4	17384-17392	included	_	
89-5	17393-17396	the	_	
89-6	17397-17403	motion	_	
89-7	17404-17414	parameters	_	
89-8	17415-17418	for	_	
89-9	17419-17423	each	_	
89-10	17424-17431	subject	_	
89-11	17431-17432	’	_	
89-12	17432-17433	s	_	
89-13	17434-17445	realignment	_	
89-14	17446-17456	correction	_	
89-15	17457-17459	in	_	
89-16	17460-17463	the	_	
89-17	17464-17469	model	_	
89-18	17470-17472	as	_	
89-19	17473-17474	“	_	
89-20	17474-17482	nuisance	_	
89-21	17482-17483	”	_	
89-22	17484-17493	variables	_	
89-23	17493-17494	.	_	

#Text=We generated statistical contrast images to obtain neural regions sensitive to reward gradients while performing the Stroop task, by subtracting the €0 condition from the rest of the reward magnitudes (R1 = “€0.01 vs. 0€”; R2 = “€0.5 vs. €0”; R3 = “€1 vs. €0”; R4 = “€1.5 vs. €0”).
90-1	17495-17497	We	_	
90-2	17498-17507	generated	_	
90-3	17508-17519	statistical	_	
90-4	17520-17528	contrast	_	
90-5	17529-17535	images	_	
90-6	17536-17538	to	_	
90-7	17539-17545	obtain	_	
90-8	17546-17552	neural	_	
90-9	17553-17560	regions	_	
90-10	17561-17570	sensitive	_	
90-11	17571-17573	to	_	
90-12	17574-17580	reward	_	
90-13	17581-17590	gradients	_	
90-14	17591-17596	while	_	
90-15	17597-17607	performing	_	
90-16	17608-17611	the	_	
90-17	17612-17618	Stroop	_	
90-18	17619-17623	task	_	
90-19	17623-17624	,	_	
90-20	17625-17627	by	_	
90-21	17628-17639	subtracting	_	
90-22	17640-17643	the	_	
90-23	17644-17646	€0	_	
90-24	17647-17656	condition	_	
90-25	17657-17661	from	_	
90-26	17662-17665	the	_	
90-27	17666-17670	rest	_	
90-28	17671-17673	of	_	
90-29	17674-17677	the	_	
90-30	17678-17684	reward	_	
90-31	17685-17695	magnitudes	_	
90-32	17696-17697	(	_	
90-33	17697-17699	R1	_	
90-34	17700-17701	=	_	
90-35	17702-17703	“	_	
90-36	17703-17708	€0.01	_	
90-37	17709-17711	vs	_	
90-38	17711-17712	.	_	
90-39	17713-17714	0	_	
90-40	17714-17715	€	_	
90-41	17715-17716	”	_	
90-42	17716-17717	;	_	
90-43	17718-17720	R2	_	
90-44	17721-17722	=	_	
90-45	17723-17724	“	_	
90-46	17724-17728	€0.5	_	
90-47	17729-17731	vs	_	
90-48	17731-17732	.	_	
90-49	17733-17735	€0	_	
90-50	17735-17736	”	_	
90-51	17736-17737	;	_	
90-52	17738-17740	R3	_	
90-53	17741-17742	=	_	
90-54	17743-17744	“	_	
90-55	17744-17746	€1	_	
90-56	17747-17749	vs	_	
90-57	17749-17750	.	_	
90-58	17751-17753	€0	_	
90-59	17753-17754	”	_	
90-60	17754-17755	;	_	
90-61	17756-17758	R4	_	
90-62	17759-17760	=	_	
90-63	17761-17762	“	_	
90-64	17762-17766	€1.5	_	
90-65	17767-17769	vs	_	
90-66	17769-17770	.	_	
90-67	17771-17773	€0	_	
90-68	17773-17774	”	_	
90-69	17774-17775	)	_	
90-70	17775-17776	.	_	

#Text=For a second-level analysis (random effects), we calculated a 4x2 mixed-design ANOVA, including the within-subject factor Reward (R1, R2, R3, R4) and the between-subject factor Group (HC, ACD) to compare HC and ACD on how parametric increases in the size of the monetary reward modulate brain activity, using the parameter estimates for the four conditions.
91-1	17777-17780	For	_	
91-2	17781-17782	a	_	
91-3	17783-17795	second-level	_	
91-4	17796-17804	analysis	_	
91-5	17805-17806	(	_	
91-6	17806-17812	random	_	
91-7	17813-17820	effects	_	
91-8	17820-17821	)	_	
91-9	17821-17822	,	_	
91-10	17823-17825	we	_	
91-11	17826-17836	calculated	_	
91-12	17837-17838	a	_	
91-13	17839-17842	4x2	_	
91-14	17843-17855	mixed-design	_	
91-15	17856-17861	ANOVA	_	
91-16	17861-17862	,	_	
91-17	17863-17872	including	_	
91-18	17873-17876	the	_	
91-19	17877-17891	within-subject	_	
91-20	17892-17898	factor	_	
91-21	17899-17905	Reward	_	
91-22	17906-17907	(	_	
91-23	17907-17909	R1	_	
91-24	17909-17910	,	_	
91-25	17911-17913	R2	_	
91-26	17913-17914	,	_	
91-27	17915-17917	R3	_	
91-28	17917-17918	,	_	
91-29	17919-17921	R4	_	
91-30	17921-17922	)	_	
91-31	17923-17926	and	_	
91-32	17927-17930	the	_	
91-33	17931-17946	between-subject	_	
91-34	17947-17953	factor	_	
91-35	17954-17959	Group	_	
91-36	17960-17961	(	_	
91-37	17961-17963	HC	_	
91-38	17963-17964	,	_	
91-39	17965-17968	ACD	_	
91-40	17968-17969	)	_	
91-41	17970-17972	to	_	
91-42	17973-17980	compare	_	
91-43	17981-17983	HC	_	
91-44	17984-17987	and	_	
91-45	17988-17991	ACD	_	
91-46	17992-17994	on	_	
91-47	17995-17998	how	_	
91-48	17999-18009	parametric	_	
91-49	18010-18019	increases	_	
91-50	18020-18022	in	_	
91-51	18023-18026	the	_	
91-52	18027-18031	size	_	
91-53	18032-18034	of	_	
91-54	18035-18038	the	_	
91-55	18039-18047	monetary	_	
91-56	18048-18054	reward	_	
91-57	18055-18063	modulate	_	
91-58	18064-18069	brain	_	
91-59	18070-18078	activity	_	
91-60	18078-18079	,	_	
91-61	18080-18085	using	_	
91-62	18086-18089	the	_	
91-63	18090-18099	parameter	_	
91-64	18100-18109	estimates	_	
91-65	18110-18113	for	_	
91-66	18114-18117	the	_	
91-67	18118-18122	four	_	
91-68	18123-18133	conditions	_	
91-69	18133-18134	.	_	

#Text=For this parametric analysis of reward magnitudes, we fitted a parametric contrast from R1 to R4 [–2–1 1 2] as a linear signal increase from R1 to R4.
92-1	18135-18138	For	_	
92-2	18139-18143	this	_	
92-3	18144-18154	parametric	_	
92-4	18155-18163	analysis	_	
92-5	18164-18166	of	_	
92-6	18167-18173	reward	_	
92-7	18174-18184	magnitudes	_	
92-8	18184-18185	,	_	
92-9	18186-18188	we	_	
92-10	18189-18195	fitted	_	
92-11	18196-18197	a	_	
92-12	18198-18208	parametric	_	
92-13	18209-18217	contrast	_	
92-14	18218-18222	from	_	
92-15	18223-18225	R1	_	
92-16	18226-18228	to	_	
92-17	18229-18231	R4	_	
92-18	18232-18233	[	_	
92-19	18233-18234	–	_	
92-20	18234-18235	2	_	
92-21	18235-18236	–	_	
92-22	18236-18237	1	_	
92-23	18238-18239	1	_	
92-24	18240-18241	2	_	
92-25	18241-18242	]	_	
92-26	18243-18245	as	_	
92-27	18246-18247	a	_	
92-28	18248-18254	linear	_	
92-29	18255-18261	signal	_	
92-30	18262-18270	increase	_	
92-31	18271-18275	from	_	
92-32	18276-18278	R1	_	
92-33	18279-18281	to	_	
92-34	18282-18284	R4	_	
92-35	18284-18285	.	_	

#Text=Then, in order to evaluate the brain areas that showed a higher parametric modulation in HC than in ACD, we fitted the contrast [–2–1 1 2 2 1–1–2], taking into account that the first four levels pertain to the HC group, and the latter four to the ACD group.
93-1	18286-18290	Then	_	
93-2	18290-18291	,	_	
93-3	18292-18294	in	_	
93-4	18295-18300	order	_	
93-5	18301-18303	to	_	
93-6	18304-18312	evaluate	_	
93-7	18313-18316	the	_	
93-8	18317-18322	brain	_	
93-9	18323-18328	areas	_	
93-10	18329-18333	that	_	
93-11	18334-18340	showed	_	
93-12	18341-18342	a	_	
93-13	18343-18349	higher	_	
93-14	18350-18360	parametric	_	
93-15	18361-18371	modulation	_	
93-16	18372-18374	in	_	
93-17	18375-18377	HC	_	
93-18	18378-18382	than	_	
93-19	18383-18385	in	_	
93-20	18386-18389	ACD	_	
93-21	18389-18390	,	_	
93-22	18391-18393	we	_	
93-23	18394-18400	fitted	_	
93-24	18401-18404	the	_	
93-25	18405-18413	contrast	_	
93-26	18414-18415	[	_	
93-27	18415-18416	–	_	
93-28	18416-18417	2	_	
93-29	18417-18418	–	_	
93-30	18418-18419	1	_	
93-31	18420-18421	1	_	
93-32	18422-18423	2	_	
93-33	18424-18425	2	_	
93-34	18426-18427	1	_	
93-35	18427-18428	–	_	
93-36	18428-18429	1	_	
93-37	18429-18430	–	_	
93-38	18430-18431	2	_	
93-39	18431-18432	]	_	
93-40	18432-18433	,	_	
93-41	18434-18440	taking	_	
93-42	18441-18445	into	_	
93-43	18446-18453	account	_	
93-44	18454-18458	that	_	
93-45	18459-18462	the	_	
93-46	18463-18468	first	_	
93-47	18469-18473	four	_	
93-48	18474-18480	levels	_	
93-49	18481-18488	pertain	_	
93-50	18489-18491	to	_	
93-51	18492-18495	the	_	
93-52	18496-18498	HC	_	
93-53	18499-18504	group	_	
93-54	18504-18505	,	_	
93-55	18506-18509	and	_	
93-56	18510-18513	the	_	
93-57	18514-18520	latter	_	
93-58	18521-18525	four	_	
93-59	18526-18528	to	_	
93-60	18529-18532	the	_	
93-61	18533-18536	ACD	_	
93-62	18537-18542	group	_	
93-63	18542-18543	.	_	

#Text=By contrast, to test the brain areas where ACD showed a higher parametric modulation than HC, we fitted the contrast [2 1–1–2–2–1 1 2].
94-1	18544-18546	By	_	
94-2	18547-18555	contrast	_	
94-3	18555-18556	,	_	
94-4	18557-18559	to	_	
94-5	18560-18564	test	_	
94-6	18565-18568	the	_	
94-7	18569-18574	brain	_	
94-8	18575-18580	areas	_	
94-9	18581-18586	where	_	
94-10	18587-18590	ACD	_	
94-11	18591-18597	showed	_	
94-12	18598-18599	a	_	
94-13	18600-18606	higher	_	
94-14	18607-18617	parametric	_	
94-15	18618-18628	modulation	_	
94-16	18629-18633	than	_	
94-17	18634-18636	HC	_	
94-18	18636-18637	,	_	
94-19	18638-18640	we	_	
94-20	18641-18647	fitted	_	
94-21	18648-18651	the	_	
94-22	18652-18660	contrast	_	
94-23	18661-18662	[	_	
94-24	18662-18663	2	_	
94-25	18664-18665	1	_	
94-26	18665-18666	–	_	
94-27	18666-18667	1	_	
94-28	18667-18668	–	_	
94-29	18668-18669	2	_	
94-30	18669-18670	–	_	
94-31	18670-18671	2	_	
94-32	18671-18672	–	_	
94-33	18672-18673	1	_	
94-34	18674-18675	1	_	
94-35	18676-18677	2	_	
94-36	18677-18678	]	_	
94-37	18678-18679	.	_	

#Text=Psychophysiological interactions
#Text=The PPI analysis determines the regions whose time series of activation exhibit significant covariance with the seed.
95-1	18680-18699	Psychophysiological	_	
95-2	18700-18712	interactions	_	
95-3	18713-18716	The	_	
95-4	18717-18720	PPI	_	
95-5	18721-18729	analysis	_	
95-6	18730-18740	determines	_	
95-7	18741-18744	the	_	
95-8	18745-18752	regions	_	
95-9	18753-18758	whose	_	
95-10	18759-18763	time	_	
95-11	18764-18770	series	_	
95-12	18771-18773	of	_	
95-13	18774-18784	activation	_	
95-14	18785-18792	exhibit	_	
95-15	18793-18804	significant	_	
95-16	18805-18815	covariance	_	
95-17	18816-18820	with	_	
95-18	18821-18824	the	_	
95-19	18825-18829	seed	_	
95-20	18829-18830	.	_	

#Text=PPI is a context-dependent connectivity measure used to explain the regional activity of other brain regions in terms of the interaction between responses in a seed region and a cognitive process.
96-1	18831-18834	PPI	_	
96-2	18835-18837	is	_	
96-3	18838-18839	a	_	
96-4	18840-18857	context-dependent	_	
96-5	18858-18870	connectivity	_	
96-6	18871-18878	measure	_	
96-7	18879-18883	used	_	
96-8	18884-18886	to	_	
96-9	18887-18894	explain	_	
96-10	18895-18898	the	_	
96-11	18899-18907	regional	_	
96-12	18908-18916	activity	_	
96-13	18917-18919	of	_	
96-14	18920-18925	other	_	
96-15	18926-18931	brain	_	
96-16	18932-18939	regions	_	
96-17	18940-18942	in	_	
96-18	18943-18948	terms	_	
96-19	18949-18951	of	_	
96-20	18952-18955	the	_	
96-21	18956-18967	interaction	_	
96-22	18968-18975	between	_	
96-23	18976-18985	responses	_	
96-24	18986-18988	in	_	
96-25	18989-18990	a	_	
96-26	18991-18995	seed	_	
96-27	18996-19002	region	_	
96-28	19003-19006	and	_	
96-29	19007-19008	a	_	
96-30	19009-19018	cognitive	_	
96-31	19019-19026	process	_	
96-32	19026-19027	.	_	

#Text=We carried out a PPI analysis using the generalized PPI toolbox (gPPI; http://www.nitrc.org/projects/gppi;).
97-1	19028-19030	We	_	
97-2	19031-19038	carried	_	
97-3	19039-19042	out	_	
97-4	19043-19044	a	_	
97-5	19045-19048	PPI	_	
97-6	19049-19057	analysis	_	
97-7	19058-19063	using	_	
97-8	19064-19067	the	_	
97-9	19068-19079	generalized	_	
97-10	19080-19083	PPI	_	
97-11	19084-19091	toolbox	_	
97-12	19092-19093	(	_	
97-13	19093-19097	gPPI	_	
97-14	19097-19098	;	_	
97-15	19099-19103	http	_	
97-16	19103-19104	:	_	
97-17	19104-19105	/	_	
97-18	19105-19106	/	_	
97-19	19106-19119	www.nitrc.org	_	
97-20	19119-19120	/	_	
97-21	19120-19128	projects	_	
97-22	19128-19129	/	_	
97-23	19129-19133	gppi	_	
97-24	19133-19134	;	_	
97-25	19134-19135	)	_	
97-26	19135-19136	.	_	

#Text=For each participant and task condition (psychological variables) in the gPPI, we calculated an interaction term using the de-convolved activity of the seed region and the separate regressors that represented the task conditions.
98-1	19137-19140	For	_	
98-2	19141-19145	each	_	
98-3	19146-19157	participant	_	
98-4	19158-19161	and	_	
98-5	19162-19166	task	_	
98-6	19167-19176	condition	_	
98-7	19177-19178	(	_	
98-8	19178-19191	psychological	_	
98-9	19192-19201	variables	_	
98-10	19201-19202	)	_	
98-11	19203-19205	in	_	
98-12	19206-19209	the	_	
98-13	19210-19214	gPPI	_	
98-14	19214-19215	,	_	
98-15	19216-19218	we	_	
98-16	19219-19229	calculated	_	
98-17	19230-19232	an	_	
98-18	19233-19244	interaction	_	
98-19	19245-19249	term	_	
98-20	19250-19255	using	_	
98-21	19256-19259	the	_	
98-22	19260-19272	de-convolved	_	
98-23	19273-19281	activity	_	
98-24	19282-19284	of	_	
98-25	19285-19288	the	_	
98-26	19289-19293	seed	_	
98-27	19294-19300	region	_	
98-28	19301-19304	and	_	
98-29	19305-19308	the	_	
98-30	19309-19317	separate	_	
98-31	19318-19328	regressors	_	
98-32	19329-19333	that	_	
98-33	19334-19345	represented	_	
98-34	19346-19349	the	_	
98-35	19350-19354	task	_	
98-36	19355-19365	conditions	_	
98-37	19365-19366	.	_	

#Text=Then we re-convolved the calculated interaction terms with the hemodynamic response function and included them in a GLM model, along with the time course of the seed region, the regressors modeling the task conditions, and the motion parameters.
99-1	19367-19371	Then	_	
99-2	19372-19374	we	_	
99-3	19375-19387	re-convolved	_	
99-4	19388-19391	the	_	
99-5	19392-19402	calculated	_	
99-6	19403-19414	interaction	_	
99-7	19415-19420	terms	_	
99-8	19421-19425	with	_	
99-9	19426-19429	the	_	
99-10	19430-19441	hemodynamic	_	
99-11	19442-19450	response	_	
99-12	19451-19459	function	_	
99-13	19460-19463	and	_	
99-14	19464-19472	included	_	
99-15	19473-19477	them	_	
99-16	19478-19480	in	_	
99-17	19481-19482	a	_	
99-18	19483-19486	GLM	_	
99-19	19487-19492	model	_	
99-20	19492-19493	,	_	
99-21	19494-19499	along	_	
99-22	19500-19504	with	_	
99-23	19505-19508	the	_	
99-24	19509-19513	time	_	
99-25	19514-19520	course	_	
99-26	19521-19523	of	_	
99-27	19524-19527	the	_	
99-28	19528-19532	seed	_	
99-29	19533-19539	region	_	
99-30	19539-19540	,	_	
99-31	19541-19544	the	_	
99-32	19545-19555	regressors	_	
99-33	19556-19564	modeling	_	
99-34	19565-19568	the	_	
99-35	19569-19573	task	_	
99-36	19574-19584	conditions	_	
99-37	19584-19585	,	_	
99-38	19586-19589	and	_	
99-39	19590-19593	the	_	
99-40	19594-19600	motion	_	
99-41	19601-19611	parameters	_	
99-42	19611-19612	.	_	

#Text=In the present study, we planned to perform a gPPI for each brain area in the PFC that showed significant differences between groups in parametric modulation as a function of the reward magnitude (see the Results section).
100-1	19613-19615	In	_	
100-2	19616-19619	the	_	
100-3	19620-19627	present	_	
100-4	19628-19633	study	_	
100-5	19633-19634	,	_	
100-6	19635-19637	we	_	
100-7	19638-19645	planned	_	
100-8	19646-19648	to	_	
100-9	19649-19656	perform	_	
100-10	19657-19658	a	_	
100-11	19659-19663	gPPI	_	
100-12	19664-19667	for	_	
100-13	19668-19672	each	_	
100-14	19673-19678	brain	_	
100-15	19679-19683	area	_	
100-16	19684-19686	in	_	
100-17	19687-19690	the	_	
100-18	19691-19694	PFC	_	
100-19	19695-19699	that	_	
100-20	19700-19706	showed	_	
100-21	19707-19718	significant	_	
100-22	19719-19730	differences	_	
100-23	19731-19738	between	_	
100-24	19739-19745	groups	_	
100-25	19746-19748	in	_	
100-26	19749-19759	parametric	_	
100-27	19760-19770	modulation	_	
100-28	19771-19773	as	_	
100-29	19774-19775	a	_	
100-30	19776-19784	function	_	
100-31	19785-19787	of	_	
100-32	19788-19791	the	_	
100-33	19792-19798	reward	_	
100-34	19799-19808	magnitude	_	
100-35	19809-19810	(	_	
100-36	19810-19813	see	_	
100-37	19814-19817	the	_	
100-38	19818-19825	Results	_	
100-39	19826-19833	section	_	
100-40	19833-19834	)	_	
100-41	19834-19835	.	_	

#Text=After generating the model, we performed contrast images using the beta-weights for the interaction terms.
101-1	19836-19841	After	_	
101-2	19842-19852	generating	_	
101-3	19853-19856	the	_	
101-4	19857-19862	model	_	
101-5	19862-19863	,	_	
101-6	19864-19866	we	_	
101-7	19867-19876	performed	_	
101-8	19877-19885	contrast	_	
101-9	19886-19892	images	_	
101-10	19893-19898	using	_	
101-11	19899-19902	the	_	
101-12	19903-19915	beta-weights	_	
101-13	19916-19919	for	_	
101-14	19920-19923	the	_	
101-15	19924-19935	interaction	_	
101-16	19936-19941	terms	_	
101-17	19941-19942	.	_	

#Text=Specifically, we generated statistical contrast images by subtracting the €0 condition from the rest of the reward magnitudes (once again, R1, R2, R3, R4) to test which regions changed their task-related connectivity with the seed as a function of the monetary reward.
102-1	19943-19955	Specifically	_	
102-2	19955-19956	,	_	
102-3	19957-19959	we	_	
102-4	19960-19969	generated	_	
102-5	19970-19981	statistical	_	
102-6	19982-19990	contrast	_	
102-7	19991-19997	images	_	
102-8	19998-20000	by	_	
102-9	20001-20012	subtracting	_	
102-10	20013-20016	the	_	
102-11	20017-20019	€0	_	
102-12	20020-20029	condition	_	
102-13	20030-20034	from	_	
102-14	20035-20038	the	_	
102-15	20039-20043	rest	_	
102-16	20044-20046	of	_	
102-17	20047-20050	the	_	
102-18	20051-20057	reward	_	
102-19	20058-20068	magnitudes	_	
102-20	20069-20070	(	_	
102-21	20070-20074	once	_	
102-22	20075-20080	again	_	
102-23	20080-20081	,	_	
102-24	20082-20084	R1	_	
102-25	20084-20085	,	_	
102-26	20086-20088	R2	_	
102-27	20088-20089	,	_	
102-28	20090-20092	R3	_	
102-29	20092-20093	,	_	
102-30	20094-20096	R4	_	
102-31	20096-20097	)	_	
102-32	20098-20100	to	_	
102-33	20101-20105	test	_	
102-34	20106-20111	which	_	
102-35	20112-20119	regions	_	
102-36	20120-20127	changed	_	
102-37	20128-20133	their	_	
102-38	20134-20146	task-related	_	
102-39	20147-20159	connectivity	_	
102-40	20160-20164	with	_	
102-41	20165-20168	the	_	
102-42	20169-20173	seed	_	
102-43	20174-20176	as	_	
102-44	20177-20178	a	_	
102-45	20179-20187	function	_	
102-46	20188-20190	of	_	
102-47	20191-20194	the	_	
102-48	20195-20203	monetary	_	
102-49	20204-20210	reward	_	
102-50	20210-20211	.	_	

#Text=We performed a 4x2 mixed-design ANOVA, including the within-subject factor Reward (R1, R2, R3, R4) and the between-subject factor Group (HC, ACD) in order to compare HC and ACD on the way parametric increases in monetary reward magnitude modulate the connectivity between the prefrontal and striatal regions, and we fitted the same contrast as in the fMRI analysis to test between-group differences.
103-1	20212-20214	We	_	
103-2	20215-20224	performed	_	
103-3	20225-20226	a	_	
103-4	20227-20230	4x2	_	
103-5	20231-20243	mixed-design	_	
103-6	20244-20249	ANOVA	_	
103-7	20249-20250	,	_	
103-8	20251-20260	including	_	
103-9	20261-20264	the	_	
103-10	20265-20279	within-subject	_	
103-11	20280-20286	factor	_	
103-12	20287-20293	Reward	_	
103-13	20294-20295	(	_	
103-14	20295-20297	R1	_	
103-15	20297-20298	,	_	
103-16	20299-20301	R2	_	
103-17	20301-20302	,	_	
103-18	20303-20305	R3	_	
103-19	20305-20306	,	_	
103-20	20307-20309	R4	_	
103-21	20309-20310	)	_	
103-22	20311-20314	and	_	
103-23	20315-20318	the	_	
103-24	20319-20334	between-subject	_	
103-25	20335-20341	factor	_	
103-26	20342-20347	Group	_	
103-27	20348-20349	(	_	
103-28	20349-20351	HC	_	
103-29	20351-20352	,	_	
103-30	20353-20356	ACD	_	
103-31	20356-20357	)	_	
103-32	20358-20360	in	_	
103-33	20361-20366	order	_	
103-34	20367-20369	to	_	
103-35	20370-20377	compare	_	
103-36	20378-20380	HC	_	
103-37	20381-20384	and	_	
103-38	20385-20388	ACD	_	
103-39	20389-20391	on	_	
103-40	20392-20395	the	_	
103-41	20396-20399	way	_	
103-42	20400-20410	parametric	_	
103-43	20411-20420	increases	_	
103-44	20421-20423	in	_	
103-45	20424-20432	monetary	_	
103-46	20433-20439	reward	_	
103-47	20440-20449	magnitude	_	
103-48	20450-20458	modulate	_	
103-49	20459-20462	the	_	
103-50	20463-20475	connectivity	_	
103-51	20476-20483	between	_	
103-52	20484-20487	the	_	
103-53	20488-20498	prefrontal	_	
103-54	20499-20502	and	_	
103-55	20503-20511	striatal	_	
103-56	20512-20519	regions	_	
103-57	20519-20520	,	_	
103-58	20521-20524	and	_	
103-59	20525-20527	we	_	
103-60	20528-20534	fitted	_	
103-61	20535-20538	the	_	
103-62	20539-20543	same	_	
103-63	20544-20552	contrast	_	
103-64	20553-20555	as	_	
103-65	20556-20558	in	_	
103-66	20559-20562	the	_	
103-67	20563-20567	fMRI	_	
103-68	20568-20576	analysis	_	
103-69	20577-20579	to	_	
103-70	20580-20584	test	_	
103-71	20585-20598	between-group	_	
103-72	20599-20610	differences	_	
103-73	20610-20611	.	_	

#Text=Regression analysis
#Text=Regression analyses were utilized to investigate the relationship between individual scores on the CSSA, SDS and SCCQ-N-10 questionnaires and brain activation during reward magnitude increases.
104-1	20612-20622	Regression	_	
104-2	20623-20631	analysis	_	
104-3	20632-20642	Regression	_	
104-4	20643-20651	analyses	_	
104-5	20652-20656	were	_	
104-6	20657-20665	utilized	_	
104-7	20666-20668	to	_	
104-8	20669-20680	investigate	_	
104-9	20681-20684	the	_	
104-10	20685-20697	relationship	_	
104-11	20698-20705	between	_	
104-12	20706-20716	individual	_	
104-13	20717-20723	scores	_	
104-14	20724-20726	on	_	
104-15	20727-20730	the	_	
104-16	20731-20735	CSSA	_	
104-17	20735-20736	,	_	
104-18	20737-20740	SDS	_	
104-19	20741-20744	and	_	
104-20	20745-20751	SCCQ-N	_	
104-21	20751-20752	-	_	
104-22	20752-20754	10	_	
104-23	20755-20769	questionnaires	_	
104-24	20770-20773	and	_	
104-25	20774-20779	brain	_	
104-26	20780-20790	activation	_	
104-27	20791-20797	during	_	
104-28	20798-20804	reward	_	
104-29	20805-20814	magnitude	_	
104-30	20815-20824	increases	_	
104-31	20824-20825	.	_	

#Text=Region-of-interest analysis
#Text=We focused our analyses on regions of interest (ROIs) for two reasons: to analyze the brain regions previously associated with interference task performance in cocaine addiction, and to maximize statistical power.
105-1	20826-20844	Region-of-interest	_	
105-2	20845-20853	analysis	_	
105-3	20854-20856	We	_	
105-4	20857-20864	focused	_	
105-5	20865-20868	our	_	
105-6	20869-20877	analyses	_	
105-7	20878-20880	on	_	
105-8	20881-20888	regions	_	
105-9	20889-20891	of	_	
105-10	20892-20900	interest	_	
105-11	20901-20902	(	_	
105-12	20902-20906	ROIs	_	
105-13	20906-20907	)	_	
105-14	20908-20911	for	_	
105-15	20912-20915	two	_	
105-16	20916-20923	reasons	_	
105-17	20923-20924	:	_	
105-18	20925-20927	to	_	
105-19	20928-20935	analyze	_	
105-20	20936-20939	the	_	
105-21	20940-20945	brain	_	
105-22	20946-20953	regions	_	
105-23	20954-20964	previously	_	
105-24	20965-20975	associated	_	
105-25	20976-20980	with	_	
105-26	20981-20993	interference	_	
105-27	20994-20998	task	_	
105-28	20999-21010	performance	_	
105-29	21011-21013	in	_	
105-30	21014-21021	cocaine	_	
105-31	21022-21031	addiction	_	
105-32	21031-21032	,	_	
105-33	21033-21036	and	_	
105-34	21037-21039	to	_	
105-35	21040-21048	maximize	_	
105-36	21049-21060	statistical	_	
105-37	21061-21066	power	_	
105-38	21066-21067	.	_	

#Text=Following Moeller et al.,, we defined the bilateral dorsolateral prefrontal cortex (DLPFC) (x, y, z MNI coordinates x = 44, y = 22, z = 11/-44, 21, 11) and bilateral anterior cingulate cortex (6, 23, 39/-6, 23, 38), as in the Leung et al. study, which used the color-word task, the most widely employed Stroop task in studies evaluating the effects of cocaine addiction.
106-1	21068-21077	Following	_	
106-2	21078-21085	Moeller	_	
106-3	21086-21088	et	_	
106-4	21089-21091	al	_	
106-5	21091-21092	.	_	
106-6	21092-21093	,	_	
106-7	21093-21094	,	_	
106-8	21095-21097	we	_	
106-9	21098-21105	defined	_	
106-10	21106-21109	the	_	
106-11	21110-21119	bilateral	_	
106-12	21120-21132	dorsolateral	_	
106-13	21133-21143	prefrontal	_	
106-14	21144-21150	cortex	_	
106-15	21151-21152	(	_	
106-16	21152-21157	DLPFC	_	
106-17	21157-21158	)	_	
106-18	21159-21160	(	_	
106-19	21160-21161	x	_	
106-20	21161-21162	,	_	
106-21	21163-21164	y	_	
106-22	21164-21165	,	_	
106-23	21166-21167	z	_	
106-24	21168-21171	MNI	_	
106-25	21172-21183	coordinates	_	
106-26	21184-21185	x	_	
106-27	21186-21187	=	_	
106-28	21188-21190	44	_	
106-29	21190-21191	,	_	
106-30	21192-21193	y	_	
106-31	21194-21195	=	_	
106-32	21196-21198	22	_	
106-33	21198-21199	,	_	
106-34	21200-21201	z	_	
106-35	21202-21203	=	_	
106-36	21204-21206	11	_	
106-37	21206-21207	/	_	
106-38	21207-21208	-	_	
106-39	21208-21210	44	_	
106-40	21210-21211	,	_	
106-41	21212-21214	21	_	
106-42	21214-21215	,	_	
106-43	21216-21218	11	_	
106-44	21218-21219	)	_	
106-45	21220-21223	and	_	
106-46	21224-21233	bilateral	_	
106-47	21234-21242	anterior	_	
106-48	21243-21252	cingulate	_	
106-49	21253-21259	cortex	_	
106-50	21260-21261	(	_	
106-51	21261-21262	6	_	
106-52	21262-21263	,	_	
106-53	21264-21266	23	_	
106-54	21266-21267	,	_	
106-55	21268-21270	39	_	
106-56	21270-21271	/	_	
106-57	21271-21272	-	_	
106-58	21272-21273	6	_	
106-59	21273-21274	,	_	
106-60	21275-21277	23	_	
106-61	21277-21278	,	_	
106-62	21279-21281	38	_	
106-63	21281-21282	)	_	
106-64	21282-21283	,	_	
106-65	21284-21286	as	_	
106-66	21287-21289	in	_	
106-67	21290-21293	the	_	
106-68	21294-21299	Leung	_	
106-69	21300-21302	et	_	
106-70	21303-21305	al	_	
106-71	21305-21306	.	_	
106-72	21307-21312	study	_	
106-73	21312-21313	,	_	
106-74	21314-21319	which	_	
106-75	21320-21324	used	_	
106-76	21325-21328	the	_	
106-77	21329-21339	color-word	_	
106-78	21340-21344	task	_	
106-79	21344-21345	,	_	
106-80	21346-21349	the	_	
106-81	21350-21354	most	_	
106-82	21355-21361	widely	_	
106-83	21362-21370	employed	_	
106-84	21371-21377	Stroop	_	
106-85	21378-21382	task	_	
106-86	21383-21385	in	_	
106-87	21386-21393	studies	_	
106-88	21394-21404	evaluating	_	
106-89	21405-21408	the	_	
106-90	21409-21416	effects	_	
106-91	21417-21419	of	_	
106-92	21420-21427	cocaine	_	
106-93	21428-21437	addiction	_	
106-94	21437-21438	.	_	

#Text=On the other hand, the only previous study that evaluates interference resolution during a counting Stroop task found differences between HC and ACD in the right inferior frontal gyrus (45, 17,-8), right inferior parietal gyrus (53, -39, 38), and right superior temporal gyrus (53, -41, 2); thus, we also defined these areas as ROIs.
107-1	21439-21441	On	_	
107-2	21442-21445	the	_	
107-3	21446-21451	other	_	
107-4	21452-21456	hand	_	
107-5	21456-21457	,	_	
107-6	21458-21461	the	_	
107-7	21462-21466	only	_	
107-8	21467-21475	previous	_	
107-9	21476-21481	study	_	
107-10	21482-21486	that	_	
107-11	21487-21496	evaluates	_	
107-12	21497-21509	interference	_	
107-13	21510-21520	resolution	_	
107-14	21521-21527	during	_	
107-15	21528-21529	a	_	
107-16	21530-21538	counting	_	
107-17	21539-21545	Stroop	_	
107-18	21546-21550	task	_	
107-19	21551-21556	found	_	
107-20	21557-21568	differences	_	
107-21	21569-21576	between	_	
107-22	21577-21579	HC	_	
107-23	21580-21583	and	_	
107-24	21584-21587	ACD	_	
107-25	21588-21590	in	_	
107-26	21591-21594	the	_	
107-27	21595-21600	right	_	
107-28	21601-21609	inferior	_	
107-29	21610-21617	frontal	_	
107-30	21618-21623	gyrus	_	
107-31	21624-21625	(	_	
107-32	21625-21627	45	_	
107-33	21627-21628	,	_	
107-34	21629-21631	17	_	
107-35	21631-21632	,	_	
107-36	21632-21633	-	_	
107-37	21633-21634	8	_	
107-38	21634-21635	)	_	
107-39	21635-21636	,	_	
107-40	21637-21642	right	_	
107-41	21643-21651	inferior	_	
107-42	21652-21660	parietal	_	
107-43	21661-21666	gyrus	_	
107-44	21667-21668	(	_	
107-45	21668-21670	53	_	
107-46	21670-21671	,	_	
107-47	21672-21673	-	_	
107-48	21673-21675	39	_	
107-49	21675-21676	,	_	
107-50	21677-21679	38	_	
107-51	21679-21680	)	_	
107-52	21680-21681	,	_	
107-53	21682-21685	and	_	
107-54	21686-21691	right	_	
107-55	21692-21700	superior	_	
107-56	21701-21709	temporal	_	
107-57	21710-21715	gyrus	_	
107-58	21716-21717	(	_	
107-59	21717-21719	53	_	
107-60	21719-21720	,	_	
107-61	21721-21722	-	_	
107-62	21722-21724	41	_	
107-63	21724-21725	,	_	
107-64	21726-21727	2	_	
107-65	21727-21728	)	_	
107-66	21728-21729	;	_	
107-67	21730-21734	thus	_	
107-68	21734-21735	,	_	
107-69	21736-21738	we	_	
107-70	21739-21743	also	_	
107-71	21744-21751	defined	_	
107-72	21752-21757	these	_	
107-73	21758-21763	areas	_	
107-74	21764-21766	as	_	
107-75	21767-21771	ROIs	_	
107-76	21771-21772	.	_	

#Text=We also defined posterior brain regions such as the left superior occipital cortex (-42, -88, 30), left inferior parietal cortex (-28, -38, 54), and bilateral fusiform gyrus (46, -58, -30/-24, -2, -44), based on previous task interference related effects.
108-1	21773-21775	We	_	
108-2	21776-21780	also	_	
108-3	21781-21788	defined	_	
108-4	21789-21798	posterior	_	
108-5	21799-21804	brain	_	
108-6	21805-21812	regions	_	
108-7	21813-21817	such	_	
108-8	21818-21820	as	_	
108-9	21821-21824	the	_	
108-10	21825-21829	left	_	
108-11	21830-21838	superior	_	
108-12	21839-21848	occipital	_	
108-13	21849-21855	cortex	_	
108-14	21856-21857	(	_	
108-15	21857-21858	-	_	
108-16	21858-21860	42	_	
108-17	21860-21861	,	_	
108-18	21862-21863	-	_	
108-19	21863-21865	88	_	
108-20	21865-21866	,	_	
108-21	21867-21869	30	_	
108-22	21869-21870	)	_	
108-23	21870-21871	,	_	
108-24	21872-21876	left	_	
108-25	21877-21885	inferior	_	
108-26	21886-21894	parietal	_	
108-27	21895-21901	cortex	_	
108-28	21902-21903	(	_	
108-29	21903-21904	-	_	
108-30	21904-21906	28	_	
108-31	21906-21907	,	_	
108-32	21908-21909	-	_	
108-33	21909-21911	38	_	
108-34	21911-21912	,	_	
108-35	21913-21915	54	_	
108-36	21915-21916	)	_	
108-37	21916-21917	,	_	
108-38	21918-21921	and	_	
108-39	21922-21931	bilateral	_	
108-40	21932-21940	fusiform	_	
108-41	21941-21946	gyrus	_	
108-42	21947-21948	(	_	
108-43	21948-21950	46	_	
108-44	21950-21951	,	_	
108-45	21952-21953	-	_	
108-46	21953-21955	58	_	
108-47	21955-21956	,	_	
108-48	21957-21958	-	_	
108-49	21958-21960	30	_	
108-50	21960-21961	/	_	
108-51	21961-21962	-	_	
108-52	21962-21964	24	_	
108-53	21964-21965	,	_	
108-54	21966-21967	-	_	
108-55	21967-21968	2	_	
108-56	21968-21969	,	_	
108-57	21970-21971	-	_	
108-58	21971-21973	44	_	
108-59	21973-21974	)	_	
108-60	21974-21975	,	_	
108-61	21976-21981	based	_	
108-62	21982-21984	on	_	
108-63	21985-21993	previous	_	
108-64	21994-21998	task	_	
108-65	21999-22011	interference	_	
108-66	22012-22019	related	_	
108-67	22020-22027	effects	_	
108-68	22027-22028	.	_	

#Text=We drew the ROI masks according to the Automatic Atlas Labeling from the WFU-PickAtlas, using a 10-mm-radius sphere centered at the peak voxel of each cluster.
109-1	22029-22031	We	_	
109-2	22032-22036	drew	_	
109-3	22037-22040	the	_	
109-4	22041-22044	ROI	_	
109-5	22045-22050	masks	_	
109-6	22051-22060	according	_	
109-7	22061-22063	to	_	
109-8	22064-22067	the	_	
109-9	22068-22077	Automatic	_	
109-10	22078-22083	Atlas	_	
109-11	22084-22092	Labeling	_	
109-12	22093-22097	from	_	
109-13	22098-22101	the	_	
109-14	22102-22115	WFU-PickAtlas	_	
109-15	22115-22116	,	_	
109-16	22117-22122	using	_	
109-17	22123-22124	a	_	
109-18	22125-22127	10	_	
109-19	22127-22128	-	_	
109-20	22128-22137	mm-radius	_	
109-21	22138-22144	sphere	_	
109-22	22145-22153	centered	_	
109-23	22154-22156	at	_	
109-24	22157-22160	the	_	
109-25	22161-22165	peak	_	
109-26	22166-22171	voxel	_	
109-27	22172-22174	of	_	
109-28	22175-22179	each	_	
109-29	22180-22187	cluster	_	
109-30	22187-22188	.	_	

#Text=We also defined the bilateral caudate, putamen, and pallidum as ROIs, selected from pre-established regions of the Pickatlas toolbox, due to their involvement in the reward dopaminergic system, cognitive control and action, and cocaine addiction in association with prefrontal areas.
110-1	22189-22191	We	_	
110-2	22192-22196	also	_	
110-3	22197-22204	defined	_	
110-4	22205-22208	the	_	
110-5	22209-22218	bilateral	_	
110-6	22219-22226	caudate	_	
110-7	22226-22227	,	_	
110-8	22228-22235	putamen	_	
110-9	22235-22236	,	_	
110-10	22237-22240	and	_	
110-11	22241-22249	pallidum	_	
110-12	22250-22252	as	_	
110-13	22253-22257	ROIs	_	
110-14	22257-22258	,	_	
110-15	22259-22267	selected	_	
110-16	22268-22272	from	_	
110-17	22273-22288	pre-established	_	
110-18	22289-22296	regions	_	
110-19	22297-22299	of	_	
110-20	22300-22303	the	_	
110-21	22304-22313	Pickatlas	_	
110-22	22314-22321	toolbox	_	
110-23	22321-22322	,	_	
110-24	22323-22326	due	_	
110-25	22327-22329	to	_	
110-26	22330-22335	their	_	
110-27	22336-22347	involvement	_	
110-28	22348-22350	in	_	
110-29	22351-22354	the	_	
110-30	22355-22361	reward	_	
110-31	22362-22374	dopaminergic	_	
110-32	22375-22381	system	_	
110-33	22381-22382	,	_	
110-34	22383-22392	cognitive	_	
110-35	22393-22400	control	_	
110-36	22401-22404	and	_	
110-37	22405-22411	action	_	
110-38	22411-22412	,	_	
110-39	22413-22416	and	_	
110-40	22417-22424	cocaine	_	
110-41	22425-22434	addiction	_	
110-42	22435-22437	in	_	
110-43	22438-22449	association	_	
110-44	22450-22454	with	_	
110-45	22455-22465	prefrontal	_	
110-46	22466-22471	areas	_	
110-47	22471-22472	.	_	

#Text=All previous analyses, including parametric effects, psychophysiological interactions, and regression analyses, were based on previously defined ROIs, in which significant effects were corrected for multiple comparisons by applying a threshold at a voxel-wise corrected level (FWE at p < .05) for each ROI independently.
111-1	22473-22476	All	_	
111-2	22477-22485	previous	_	
111-3	22486-22494	analyses	_	
111-4	22494-22495	,	_	
111-5	22496-22505	including	_	
111-6	22506-22516	parametric	_	
111-7	22517-22524	effects	_	
111-8	22524-22525	,	_	
111-9	22526-22545	psychophysiological	_	
111-10	22546-22558	interactions	_	
111-11	22558-22559	,	_	
111-12	22560-22563	and	_	
111-13	22564-22574	regression	_	
111-14	22575-22583	analyses	_	
111-15	22583-22584	,	_	
111-16	22585-22589	were	_	
111-17	22590-22595	based	_	
111-18	22596-22598	on	_	
111-19	22599-22609	previously	_	
111-20	22610-22617	defined	_	
111-21	22618-22622	ROIs	_	
111-22	22622-22623	,	_	
111-23	22624-22626	in	_	
111-24	22627-22632	which	_	
111-25	22633-22644	significant	_	
111-26	22645-22652	effects	_	
111-27	22653-22657	were	_	
111-28	22658-22667	corrected	_	
111-29	22668-22671	for	_	
111-30	22672-22680	multiple	_	
111-31	22681-22692	comparisons	_	
111-32	22693-22695	by	_	
111-33	22696-22704	applying	_	
111-34	22705-22706	a	_	
111-35	22707-22716	threshold	_	
111-36	22717-22719	at	_	
111-37	22720-22721	a	_	
111-38	22722-22732	voxel-wise	_	
111-39	22733-22742	corrected	_	
111-40	22743-22748	level	_	
111-41	22749-22750	(	_	
111-42	22750-22753	FWE	_	
111-43	22754-22756	at	_	
111-44	22757-22758	p	_	
111-45	22759-22760	<	_	
111-46	22761-22764	.05	_	
111-47	22764-22765	)	_	
111-48	22766-22769	for	_	
111-49	22770-22774	each	_	
111-50	22775-22778	ROI	_	
111-51	22779-22792	independently	_	
111-52	22792-22793	.	_	

#Text=Furthermore, we ran post-hoc analyses to examine what drove the parametric effects in all previous analyses (e.g., functional parametric effects, psychophysiological interactions, and regression analyses), obtaining a more thorough picture of what was driving the effects.
112-1	22794-22805	Furthermore	_	
112-2	22805-22806	,	_	
112-3	22807-22809	we	_	
112-4	22810-22813	ran	_	
112-5	22814-22822	post-hoc	_	
112-6	22823-22831	analyses	_	
112-7	22832-22834	to	_	
112-8	22835-22842	examine	_	
112-9	22843-22847	what	_	
112-10	22848-22853	drove	_	
112-11	22854-22857	the	_	
112-12	22858-22868	parametric	_	
112-13	22869-22876	effects	_	
112-14	22877-22879	in	_	
112-15	22880-22883	all	_	
112-16	22884-22892	previous	_	
112-17	22893-22901	analyses	_	
112-18	22902-22903	(	_	
112-19	22903-22906	e.g	_	
112-20	22906-22907	.	_	
112-21	22907-22908	,	_	
112-22	22909-22919	functional	_	
112-23	22920-22930	parametric	_	
112-24	22931-22938	effects	_	
112-25	22938-22939	,	_	
112-26	22940-22959	psychophysiological	_	
112-27	22960-22972	interactions	_	
112-28	22972-22973	,	_	
112-29	22974-22977	and	_	
112-30	22978-22988	regression	_	
112-31	22989-22997	analyses	_	
112-32	22997-22998	)	_	
112-33	22998-22999	,	_	
112-34	23000-23009	obtaining	_	
112-35	23010-23011	a	_	
112-36	23012-23016	more	_	
112-37	23017-23025	thorough	_	
112-38	23026-23033	picture	_	
112-39	23034-23036	of	_	
112-40	23037-23041	what	_	
112-41	23042-23045	was	_	
112-42	23046-23053	driving	_	
112-43	23054-23057	the	_	
112-44	23058-23065	effects	_	
112-45	23065-23066	.	_	

#Text=However, these analyses should not be considered for statistical inference as they were biased estimates of the effect because the ROIs were non-independent but based on the parametric contrast.
113-1	23067-23074	However	_	
113-2	23074-23075	,	_	
113-3	23076-23081	these	_	
113-4	23082-23090	analyses	_	
113-5	23091-23097	should	_	
113-6	23098-23101	not	_	
113-7	23102-23104	be	_	
113-8	23105-23115	considered	_	
113-9	23116-23119	for	_	
113-10	23120-23131	statistical	_	
113-11	23132-23141	inference	_	
113-12	23142-23144	as	_	
113-13	23145-23149	they	_	
113-14	23150-23154	were	_	
113-15	23155-23161	biased	_	
113-16	23162-23171	estimates	_	
113-17	23172-23174	of	_	
113-18	23175-23178	the	_	
113-19	23179-23185	effect	_	
113-20	23186-23193	because	_	
113-21	23194-23197	the	_	
113-22	23198-23202	ROIs	_	
113-23	23203-23207	were	_	
113-24	23208-23223	non-independent	_	
113-25	23224-23227	but	_	
113-26	23228-23233	based	_	
113-27	23234-23236	on	_	
113-28	23237-23240	the	_	
113-29	23241-23251	parametric	_	
113-30	23252-23260	contrast	_	
113-31	23260-23261	.	_	

#Text=In order to perform these ROI analyses, we extracted the signal from within the ROIs.
114-1	23262-23264	In	_	
114-2	23265-23270	order	_	
114-3	23271-23273	to	_	
114-4	23274-23281	perform	_	
114-5	23282-23287	these	_	
114-6	23288-23291	ROI	_	
114-7	23292-23300	analyses	_	
114-8	23300-23301	,	_	
114-9	23302-23304	we	_	
114-10	23305-23314	extracted	_	
114-11	23315-23318	the	_	
114-12	23319-23325	signal	_	
114-13	23326-23330	from	_	
114-14	23331-23337	within	_	
114-15	23338-23341	the	_	
114-16	23342-23346	ROIs	_	
114-17	23346-23347	.	_	

#Text=Thus, we extracted the eigenvariate values from the ROIs, as implemented in SPM8.
115-1	23348-23352	Thus	_	
115-2	23352-23353	,	_	
115-3	23354-23356	we	_	
115-4	23357-23366	extracted	_	
115-5	23367-23370	the	_	
115-6	23371-23383	eigenvariate	_	
115-7	23384-23390	values	_	
115-8	23391-23395	from	_	
115-9	23396-23399	the	_	
115-10	23400-23404	ROIs	_	
115-11	23404-23405	,	_	
115-12	23406-23408	as	_	
115-13	23409-23420	implemented	_	
115-14	23421-23423	in	_	
115-15	23424-23428	SPM8	_	
115-16	23428-23429	.	_	

#Text=It should be noted that eigenvariate values are not the same as mean values.
116-1	23430-23432	It	_	
116-2	23433-23439	should	_	
116-3	23440-23442	be	_	
116-4	23443-23448	noted	_	
116-5	23449-23453	that	_	
116-6	23454-23466	eigenvariate	_	
116-7	23467-23473	values	_	
116-8	23474-23477	are	_	
116-9	23478-23481	not	_	
116-10	23482-23485	the	_	
116-11	23486-23490	same	_	
116-12	23491-23493	as	_	
116-13	23494-23498	mean	_	
116-14	23499-23505	values	_	
116-15	23505-23506	.	_	

#Text=For the sake of reducing response heterogeneity within the cluster, eigenvariate values provide an eigenvector that downweights atypical voxels within the voxels that pass the original threshold, flexibly combining functional (e.g., statistical contrast) and anatomical (e.g., ROI coordinates) constraints.
117-1	23507-23510	For	_	
117-2	23511-23514	the	_	
117-3	23515-23519	sake	_	
117-4	23520-23522	of	_	
117-5	23523-23531	reducing	_	
117-6	23532-23540	response	_	
117-7	23541-23554	heterogeneity	_	
117-8	23555-23561	within	_	
117-9	23562-23565	the	_	
117-10	23566-23573	cluster	_	
117-11	23573-23574	,	_	
117-12	23575-23587	eigenvariate	_	
117-13	23588-23594	values	_	
117-14	23595-23602	provide	_	
117-15	23603-23605	an	_	
117-16	23606-23617	eigenvector	_	
117-17	23618-23622	that	_	
117-18	23623-23634	downweights	_	
117-19	23635-23643	atypical	_	
117-20	23644-23650	voxels	_	
117-21	23651-23657	within	_	
117-22	23658-23661	the	_	
117-23	23662-23668	voxels	_	
117-24	23669-23673	that	_	
117-25	23674-23678	pass	_	
117-26	23679-23682	the	_	
117-27	23683-23691	original	_	
117-28	23692-23701	threshold	_	
117-29	23701-23702	,	_	
117-30	23703-23711	flexibly	_	
117-31	23712-23721	combining	_	
117-32	23722-23732	functional	_	
117-33	23733-23734	(	_	
117-34	23734-23737	e.g	_	
117-35	23737-23738	.	_	
117-36	23738-23739	,	_	
117-37	23740-23751	statistical	_	
117-38	23752-23760	contrast	_	
117-39	23760-23761	)	_	
117-40	23762-23765	and	_	
117-41	23766-23776	anatomical	_	
117-42	23777-23778	(	_	
117-43	23778-23781	e.g	_	
117-44	23781-23782	.	_	
117-45	23782-23783	,	_	
117-46	23784-23787	ROI	_	
117-47	23788-23799	coordinates	_	
117-48	23799-23800	)	_	
117-49	23801-23812	constraints	_	
117-50	23812-23813	.	_	

#Text=Results
#Text=Behavioral results
#Text=The first goal of the current study was to test whether the magnitude of the reward contingencies increased task performance similarly in HC and ACD.
118-1	23814-23821	Results	_	
118-2	23822-23832	Behavioral	_	
118-3	23833-23840	results	_	
118-4	23841-23844	The	_	
118-5	23845-23850	first	_	
118-6	23851-23855	goal	_	
118-7	23856-23858	of	_	
118-8	23859-23862	the	_	
118-9	23863-23870	current	_	
118-10	23871-23876	study	_	
118-11	23877-23880	was	_	
118-12	23881-23883	to	_	
118-13	23884-23888	test	_	
118-14	23889-23896	whether	_	
118-15	23897-23900	the	_	
118-16	23901-23910	magnitude	_	
118-17	23911-23913	of	_	
118-18	23914-23917	the	_	
118-19	23918-23924	reward	_	
118-20	23925-23938	contingencies	_	
118-21	23939-23948	increased	_	
118-22	23949-23953	task	_	
118-23	23954-23965	performance	_	
118-24	23966-23975	similarly	_	
118-25	23976-23978	in	_	
118-26	23979-23981	HC	_	
118-27	23982-23985	and	_	
118-28	23986-23989	ACD	_	
118-29	23989-23990	.	_	

#Text=Table 2 and Fig 2 summarize the behavioral results.
119-1	23991-23996	Table	_	
119-2	23997-23998	2	_	
119-3	23999-24002	and	_	
119-4	24003-24006	Fig	_	
119-5	24007-24008	2	_	
119-6	24009-24018	summarize	_	
119-7	24019-24022	the	_	
119-8	24023-24033	behavioral	_	
119-9	24034-24041	results	_	
119-10	24041-24042	.	_	

#Text=The ANOVAs showed a main effect of reward on RT (F(4,66) = 14.991; p < .001) and error rate (F(4,66) = 4.977; p = .001) and a trend toward significance for SDrt (F(4,66) = 2.213; p = .077), with no group effect or interaction (p>0.1).
120-1	24043-24046	The	_	
120-2	24047-24053	ANOVAs	_	
120-3	24054-24060	showed	_	
120-4	24061-24062	a	_	
120-5	24063-24067	main	_	
120-6	24068-24074	effect	_	
120-7	24075-24077	of	_	
120-8	24078-24084	reward	_	
120-9	24085-24087	on	_	
120-10	24088-24090	RT	_	
120-11	24091-24092	(	_	
120-12	24092-24093	F	_	
120-13	24093-24094	(	_	
120-14	24094-24098	4,66	_	
120-15	24098-24099	)	_	
120-16	24100-24101	=	_	
120-17	24102-24108	14.991	_	
120-18	24108-24109	;	_	
120-19	24110-24111	p	_	
120-20	24112-24113	<	_	
120-21	24114-24118	.001	_	
120-22	24118-24119	)	_	
120-23	24120-24123	and	_	
120-24	24124-24129	error	_	
120-25	24130-24134	rate	_	
120-26	24135-24136	(	_	
120-27	24136-24137	F	_	
120-28	24137-24138	(	_	
120-29	24138-24142	4,66	_	
120-30	24142-24143	)	_	
120-31	24144-24145	=	_	
120-32	24146-24151	4.977	_	
120-33	24151-24152	;	_	
120-34	24153-24154	p	_	
120-35	24155-24156	=	_	
120-36	24157-24161	.001	_	
120-37	24161-24162	)	_	
120-38	24163-24166	and	_	
120-39	24167-24168	a	_	
120-40	24169-24174	trend	_	
120-41	24175-24181	toward	_	
120-42	24182-24194	significance	_	
120-43	24195-24198	for	_	
120-44	24199-24203	SDrt	_	
120-45	24204-24205	(	_	
120-46	24205-24206	F	_	
120-47	24206-24207	(	_	
120-48	24207-24211	4,66	_	
120-49	24211-24212	)	_	
120-50	24213-24214	=	_	
120-51	24215-24220	2.213	_	
120-52	24220-24221	;	_	
120-53	24222-24223	p	_	
120-54	24224-24225	=	_	
120-55	24226-24230	.077	_	
120-56	24230-24231	)	_	
120-57	24231-24232	,	_	
120-58	24233-24237	with	_	
120-59	24238-24240	no	_	
120-60	24241-24246	group	_	
120-61	24247-24253	effect	_	
120-62	24254-24256	or	_	
120-63	24257-24268	interaction	_	
120-64	24269-24270	(	_	
120-65	24270-24271	p	_	
120-66	24271-24272	>	_	
120-67	24272-24275	0.1	_	
120-68	24275-24276	)	_	
120-69	24276-24277	.	_	

#Text=In spite of the lack of behavioral differences between the groups, Table 2 and Fig 2 revealed that the error rate did not behave exactly the same way for HC and ACD.
121-1	24278-24280	In	_	
121-2	24281-24286	spite	_	
121-3	24287-24289	of	_	
121-4	24290-24293	the	_	
121-5	24294-24298	lack	_	
121-6	24299-24301	of	_	
121-7	24302-24312	behavioral	_	
121-8	24313-24324	differences	_	
121-9	24325-24332	between	_	
121-10	24333-24336	the	_	
121-11	24337-24343	groups	_	
121-12	24343-24344	,	_	
121-13	24345-24350	Table	_	
121-14	24351-24352	2	_	
121-15	24353-24356	and	_	
121-16	24357-24360	Fig	_	
121-17	24361-24362	2	_	
121-18	24363-24371	revealed	_	
121-19	24372-24376	that	_	
121-20	24377-24380	the	_	
121-21	24381-24386	error	_	
121-22	24387-24391	rate	_	
121-23	24392-24395	did	_	
121-24	24396-24399	not	_	
121-25	24400-24406	behave	_	
121-26	24407-24414	exactly	_	
121-27	24415-24418	the	_	
121-28	24419-24423	same	_	
121-29	24424-24427	way	_	
121-30	24428-24431	for	_	
121-31	24432-24434	HC	_	
121-32	24435-24438	and	_	
121-33	24439-24442	ACD	_	
121-34	24442-24443	.	_	

#Text=In order to explore these results, we performed a post-hoc analysis by making pairwise comparisons between groups for the monetary differentials (e.g., €0 vs €0.01).
122-1	24444-24446	In	_	
122-2	24447-24452	order	_	
122-3	24453-24455	to	_	
122-4	24456-24463	explore	_	
122-5	24464-24469	these	_	
122-6	24470-24477	results	_	
122-7	24477-24478	,	_	
122-8	24479-24481	we	_	
122-9	24482-24491	performed	_	
122-10	24492-24493	a	_	
122-11	24494-24502	post-hoc	_	
122-12	24503-24511	analysis	_	
122-13	24512-24514	by	_	
122-14	24515-24521	making	_	
122-15	24522-24530	pairwise	_	
122-16	24531-24542	comparisons	_	
122-17	24543-24550	between	_	
122-18	24551-24557	groups	_	
122-19	24558-24561	for	_	
122-20	24562-24565	the	_	
122-21	24566-24574	monetary	_	
122-22	24575-24588	differentials	_	
122-23	24589-24590	(	_	
122-24	24590-24593	e.g	_	
122-25	24593-24594	.	_	
122-26	24594-24595	,	_	
122-27	24596-24598	€0	_	
122-28	24599-24601	vs	_	
122-29	24602-24607	€0.01	_	
122-30	24607-24608	)	_	
122-31	24608-24609	.	_	

#Text=The results showed significant differences between groups for the monetary differentials €0 vs €0.01 (t(69) = -2.038; p = .045) and €0 vs €0.05 (t(69) = -2.036; p = .046).
123-1	24610-24613	The	_	
123-2	24614-24621	results	_	
123-3	24622-24628	showed	_	
123-4	24629-24640	significant	_	
123-5	24641-24652	differences	_	
123-6	24653-24660	between	_	
123-7	24661-24667	groups	_	
123-8	24668-24671	for	_	
123-9	24672-24675	the	_	
123-10	24676-24684	monetary	_	
123-11	24685-24698	differentials	_	
123-12	24699-24701	€0	_	
123-13	24702-24704	vs	_	
123-14	24705-24710	€0.01	_	
123-15	24711-24712	(	_	
123-16	24712-24713	t	_	
123-17	24713-24714	(	_	
123-18	24714-24716	69	_	
123-19	24716-24717	)	_	
123-20	24718-24719	=	_	
123-21	24720-24721	-	_	
123-22	24721-24726	2.038	_	
123-23	24726-24727	;	_	
123-24	24728-24729	p	_	
123-25	24730-24731	=	_	
123-26	24732-24736	.045	_	
123-27	24736-24737	)	_	
123-28	24738-24741	and	_	
123-29	24742-24744	€0	_	
123-30	24745-24747	vs	_	
123-31	24748-24753	€0.05	_	
123-32	24754-24755	(	_	
123-33	24755-24756	t	_	
123-34	24756-24757	(	_	
123-35	24757-24759	69	_	
123-36	24759-24760	)	_	
123-37	24761-24762	=	_	
123-38	24763-24764	-	_	
123-39	24764-24769	2.036	_	
123-40	24769-24770	;	_	
123-41	24771-24772	p	_	
123-42	24773-24774	=	_	
123-43	24775-24779	.046	_	
123-44	24779-24780	)	_	
123-45	24780-24781	.	_	

#Text=Graphical representation of performance on the different behavioral variables; and below, pairwise comparisons between reward magnitudes within each group.
124-1	24782-24791	Graphical	_	
124-2	24792-24806	representation	_	
124-3	24807-24809	of	_	
124-4	24810-24821	performance	_	
124-5	24822-24824	on	_	
124-6	24825-24828	the	_	
124-7	24829-24838	different	_	
124-8	24839-24849	behavioral	_	
124-9	24850-24859	variables	_	
124-10	24859-24860	;	_	
124-11	24861-24864	and	_	
124-12	24865-24870	below	_	
124-13	24870-24871	,	_	
124-14	24872-24880	pairwise	_	
124-15	24881-24892	comparisons	_	
124-16	24893-24900	between	_	
124-17	24901-24907	reward	_	
124-18	24908-24918	magnitudes	_	
124-19	24919-24925	within	_	
124-20	24926-24930	each	_	
124-21	24931-24936	group	_	
124-22	24936-24937	.	_	

#Text=The results in the tables under the scatterplots show the pairwise comparison t values (* = p < .05 and ** = p < .01). msec., milliseconds; SDrt, reaction time Standard Deviation; RT, reaction time; HC, Healthy Control; ACD, Abstinent Cocaine Dependent; €, euro.
125-1	24938-24941	The	_	
125-2	24942-24949	results	_	
125-3	24950-24952	in	_	
125-4	24953-24956	the	_	
125-5	24957-24963	tables	_	
125-6	24964-24969	under	_	
125-7	24970-24973	the	_	
125-8	24974-24986	scatterplots	_	
125-9	24987-24991	show	_	
125-10	24992-24995	the	_	
125-11	24996-25004	pairwise	_	
125-12	25005-25015	comparison	_	
125-13	25016-25017	t	_	
125-14	25018-25024	values	_	
125-15	25025-25026	(	_	
125-16	25026-25027	*	_	
125-17	25028-25029	=	_	
125-18	25030-25031	p	_	
125-19	25032-25033	<	_	
125-20	25034-25037	.05	_	
125-21	25038-25041	and	_	
125-22	25042-25043	*	_	
125-23	25043-25044	*	_	
125-24	25045-25046	=	_	
125-25	25047-25048	p	_	
125-26	25049-25050	<	_	
125-27	25051-25054	.01	_	
125-28	25054-25055	)	_	
125-29	25055-25056	.	_	
125-30	25057-25061	msec	_	
125-31	25061-25062	.	_	
125-32	25062-25063	,	_	
125-33	25064-25076	milliseconds	_	
125-34	25076-25077	;	_	
125-35	25078-25082	SDrt	_	
125-36	25082-25083	,	_	
125-37	25084-25092	reaction	_	
125-38	25093-25097	time	_	
125-39	25098-25106	Standard	_	
125-40	25107-25116	Deviation	_	
125-41	25116-25117	;	_	
125-42	25118-25120	RT	_	
125-43	25120-25121	,	_	
125-44	25122-25130	reaction	_	
125-45	25131-25135	time	_	
125-46	25135-25136	;	_	
125-47	25137-25139	HC	_	
125-48	25139-25140	,	_	
125-49	25141-25148	Healthy	_	
125-50	25149-25156	Control	_	
125-51	25156-25157	;	_	
125-52	25158-25161	ACD	_	
125-53	25161-25162	,	_	
125-54	25163-25172	Abstinent	_	
125-55	25173-25180	Cocaine	_	
125-56	25181-25190	Dependent	_	
125-57	25190-25191	;	_	
125-58	25192-25193	€	_	
125-59	25193-25194	,	_	
125-60	25195-25199	euro	_	
125-61	25199-25200	.	_	

#Text=Incongruent trial means (standard deviations) of behavioral variables of interest for each reward magnitude in each experimental group.
126-1	25201-25212	Incongruent	_	
126-2	25213-25218	trial	_	
126-3	25219-25224	means	_	
126-4	25225-25226	(	_	
126-5	25226-25234	standard	_	
126-6	25235-25245	deviations	_	
126-7	25245-25246	)	_	
126-8	25247-25249	of	_	
126-9	25250-25260	behavioral	_	
126-10	25261-25270	variables	_	
126-11	25271-25273	of	_	
126-12	25274-25282	interest	_	
126-13	25283-25286	for	_	
126-14	25287-25291	each	_	
126-15	25292-25298	reward	_	
126-16	25299-25308	magnitude	_	
126-17	25309-25311	in	_	
126-18	25312-25316	each	_	
126-19	25317-25329	experimental	_	
126-20	25330-25335	group	_	
126-21	25335-25336	.	_	

#Text=Experimental group\t€0\t€0.01\t€0.5\t€1\t€1.5\t \tRT(msec.)
127-1	25338-25350	Experimental	_	
127-2	25351-25356	group	_	
127-3	25357-25359	€0	_	
127-4	25360-25365	€0.01	_	
127-5	25366-25370	€0.5	_	
127-6	25371-25373	€1	_	
127-7	25374-25378	€1.5	_	
127-8	25381-25383	RT	_	
127-9	25383-25384	(	_	
127-10	25384-25388	msec	_	
127-11	25388-25389	.	_	
127-12	25389-25390	)	_	

#Text=HC\t688\t672\t659\t650\t658\t \t(88)\t(85)\t(84)\t(79)\t(78)\t \t\tACD\t698\t694\t674\t675\t684\t \t(65)\t(67)\t(61)\t(59)\t(66)\t \tError rate (%)\tHC\t9.073\t6.821\t5.084\t5.663\t5.985\t \t(6.915)\t(7.321)\t(5.388)\t(6.258)\t(6.138)\t \t\tACD\t7.563\t8.894\t6.723\t5.532\t7.213\t \t(6.873)\t(6.349)\t(5.757)\t(4.007)\t(5.059)\t \tSDrt (msec.)
128-1	25391-25393	HC	_	
128-2	25394-25397	688	_	
128-3	25398-25401	672	_	
128-4	25402-25405	659	_	
128-5	25406-25409	650	_	
128-6	25410-25413	658	_	
128-7	25416-25417	(	_	
128-8	25417-25419	88	_	
128-9	25419-25420	)	_	
128-10	25421-25422	(	_	
128-11	25422-25424	85	_	
128-12	25424-25425	)	_	
128-13	25426-25427	(	_	
128-14	25427-25429	84	_	
128-15	25429-25430	)	_	
128-16	25431-25432	(	_	
128-17	25432-25434	79	_	
128-18	25434-25435	)	_	
128-19	25436-25437	(	_	
128-20	25437-25439	78	_	
128-21	25439-25440	)	_	
128-22	25444-25447	ACD	_	
128-23	25448-25451	698	_	
128-24	25452-25455	694	_	
128-25	25456-25459	674	_	
128-26	25460-25463	675	_	
128-27	25464-25467	684	_	
128-28	25470-25471	(	_	
128-29	25471-25473	65	_	
128-30	25473-25474	)	_	
128-31	25475-25476	(	_	
128-32	25476-25478	67	_	
128-33	25478-25479	)	_	
128-34	25480-25481	(	_	
128-35	25481-25483	61	_	
128-36	25483-25484	)	_	
128-37	25485-25486	(	_	
128-38	25486-25488	59	_	
128-39	25488-25489	)	_	
128-40	25490-25491	(	_	
128-41	25491-25493	66	_	
128-42	25493-25494	)	_	
128-43	25497-25502	Error	_	
128-44	25503-25507	rate	_	
128-45	25508-25509	(	_	
128-46	25509-25510	%	_	
128-47	25510-25511	)	_	
128-48	25512-25514	HC	_	
128-49	25515-25520	9.073	_	
128-50	25521-25526	6.821	_	
128-51	25527-25532	5.084	_	
128-52	25533-25538	5.663	_	
128-53	25539-25544	5.985	_	
128-54	25547-25548	(	_	
128-55	25548-25553	6.915	_	
128-56	25553-25554	)	_	
128-57	25555-25556	(	_	
128-58	25556-25561	7.321	_	
128-59	25561-25562	)	_	
128-60	25563-25564	(	_	
128-61	25564-25569	5.388	_	
128-62	25569-25570	)	_	
128-63	25571-25572	(	_	
128-64	25572-25577	6.258	_	
128-65	25577-25578	)	_	
128-66	25579-25580	(	_	
128-67	25580-25585	6.138	_	
128-68	25585-25586	)	_	
128-69	25590-25593	ACD	_	
128-70	25594-25599	7.563	_	
128-71	25600-25605	8.894	_	
128-72	25606-25611	6.723	_	
128-73	25612-25617	5.532	_	
128-74	25618-25623	7.213	_	
128-75	25626-25627	(	_	
128-76	25627-25632	6.873	_	
128-77	25632-25633	)	_	
128-78	25634-25635	(	_	
128-79	25635-25640	6.349	_	
128-80	25640-25641	)	_	
128-81	25642-25643	(	_	
128-82	25643-25648	5.757	_	
128-83	25648-25649	)	_	
128-84	25650-25651	(	_	
128-85	25651-25656	4.007	_	
128-86	25656-25657	)	_	
128-87	25658-25659	(	_	
128-88	25659-25664	5.059	_	
128-89	25664-25665	)	_	
128-90	25668-25672	SDrt	_	
128-91	25673-25674	(	_	
128-92	25674-25678	msec	_	
128-93	25678-25679	.	_	
128-94	25679-25680	)	_	

#Text=HC\t137\t131\t127\t124\t129\t \t(26)\t(26)\t(28)\t(24)\t(26)\t \t\tACD\t142\t134\t134\t138\t136\t \t(26)\t(27)\t(27)\t(25)*\t(27)\t \tSelf-reported interest in reward value\tHC\t.618\t1.177\t3.147\t4.088\t4.559\t \t(1.577)\t(1.977)\t(2.35)\t(2.778)\t(2.894)\t \t\tACD\t1.333\t1.788\t3.273\t3.546\t3.818\t \t(2.483)\t(2.522)\t(2.415)\t(2.526)\t(2.675)\t \t
#Text=*p<0.05 for significant differences between groups
#Text=RT, Reaction Time; msec., milliseconds, SDrt, reaction time Standard Deviation; €, euro; HC, Healthy Control; ACD, Abstinent Cocaine Dependent.
129-1	25681-25683	HC	_	
129-2	25684-25687	137	_	
129-3	25688-25691	131	_	
129-4	25692-25695	127	_	
129-5	25696-25699	124	_	
129-6	25700-25703	129	_	
129-7	25706-25707	(	_	
129-8	25707-25709	26	_	
129-9	25709-25710	)	_	
129-10	25711-25712	(	_	
129-11	25712-25714	26	_	
129-12	25714-25715	)	_	
129-13	25716-25717	(	_	
129-14	25717-25719	28	_	
129-15	25719-25720	)	_	
129-16	25721-25722	(	_	
129-17	25722-25724	24	_	
129-18	25724-25725	)	_	
129-19	25726-25727	(	_	
129-20	25727-25729	26	_	
129-21	25729-25730	)	_	
129-22	25734-25737	ACD	_	
129-23	25738-25741	142	_	
129-24	25742-25745	134	_	
129-25	25746-25749	134	_	
129-26	25750-25753	138	_	
129-27	25754-25757	136	_	
129-28	25760-25761	(	_	
129-29	25761-25763	26	_	
129-30	25763-25764	)	_	
129-31	25765-25766	(	_	
129-32	25766-25768	27	_	
129-33	25768-25769	)	_	
129-34	25770-25771	(	_	
129-35	25771-25773	27	_	
129-36	25773-25774	)	_	
129-37	25775-25776	(	_	
129-38	25776-25778	25	_	
129-39	25778-25779	)	_	
129-40	25779-25780	*	_	
129-41	25781-25782	(	_	
129-42	25782-25784	27	_	
129-43	25784-25785	)	_	
129-44	25788-25801	Self-reported	_	
129-45	25802-25810	interest	_	
129-46	25811-25813	in	_	
129-47	25814-25820	reward	_	
129-48	25821-25826	value	_	
129-49	25827-25829	HC	_	
129-50	25830-25834	.618	_	
129-51	25835-25840	1.177	_	
129-52	25841-25846	3.147	_	
129-53	25847-25852	4.088	_	
129-54	25853-25858	4.559	_	
129-55	25861-25862	(	_	
129-56	25862-25867	1.577	_	
129-57	25867-25868	)	_	
129-58	25869-25870	(	_	
129-59	25870-25875	1.977	_	
129-60	25875-25876	)	_	
129-61	25877-25878	(	_	
129-62	25878-25882	2.35	_	
129-63	25882-25883	)	_	
129-64	25884-25885	(	_	
129-65	25885-25890	2.778	_	
129-66	25890-25891	)	_	
129-67	25892-25893	(	_	
129-68	25893-25898	2.894	_	
129-69	25898-25899	)	_	
129-70	25903-25906	ACD	_	
129-71	25907-25912	1.333	_	
129-72	25913-25918	1.788	_	
129-73	25919-25924	3.273	_	
129-74	25925-25930	3.546	_	
129-75	25931-25936	3.818	_	
129-76	25939-25940	(	_	
129-77	25940-25945	2.483	_	
129-78	25945-25946	)	_	
129-79	25947-25948	(	_	
129-80	25948-25953	2.522	_	
129-81	25953-25954	)	_	
129-82	25955-25956	(	_	
129-83	25956-25961	2.415	_	
129-84	25961-25962	)	_	
129-85	25963-25964	(	_	
129-86	25964-25969	2.526	_	
129-87	25969-25970	)	_	
129-88	25971-25972	(	_	
129-89	25972-25977	2.675	_	
129-90	25977-25978	)	_	
129-91	25982-25983	*	_	
129-92	25983-25984	p	_	
129-93	25984-25985	<	_	
129-94	25985-25989	0.05	_	
129-95	25990-25993	for	_	
129-96	25994-26005	significant	_	
129-97	26006-26017	differences	_	
129-98	26018-26025	between	_	
129-99	26026-26032	groups	_	
129-100	26033-26035	RT	_	
129-101	26035-26036	,	_	
129-102	26037-26045	Reaction	_	
129-103	26046-26050	Time	_	
129-104	26050-26051	;	_	
129-105	26052-26056	msec	_	
129-106	26056-26057	.	_	
129-107	26057-26058	,	_	
129-108	26059-26071	milliseconds	_	
129-109	26071-26072	,	_	
129-110	26073-26077	SDrt	_	
129-111	26077-26078	,	_	
129-112	26079-26087	reaction	_	
129-113	26088-26092	time	_	
129-114	26093-26101	Standard	_	
129-115	26102-26111	Deviation	_	
129-116	26111-26112	;	_	
129-117	26113-26114	€	_	
129-118	26114-26115	,	_	
129-119	26116-26120	euro	_	
129-120	26120-26121	;	_	
129-121	26122-26124	HC	_	
129-122	26124-26125	,	_	
129-123	26126-26133	Healthy	_	
129-124	26134-26141	Control	_	
129-125	26141-26142	;	_	
129-126	26143-26146	ACD	_	
129-127	26146-26147	,	_	
129-128	26148-26157	Abstinent	_	
129-129	26158-26165	Cocaine	_	
129-130	26166-26175	Dependent	_	
129-131	26175-26176	.	_	

#Text=The first goal of our study also included assessing whether performance improvement and self-reported interest in the reward value were related in HC but not in ACD.
130-1	26177-26180	The	_	
130-2	26181-26186	first	_	
130-3	26187-26191	goal	_	
130-4	26192-26194	of	_	
130-5	26195-26198	our	_	
130-6	26199-26204	study	_	
130-7	26205-26209	also	_	
130-8	26210-26218	included	_	
130-9	26219-26228	assessing	_	
130-10	26229-26236	whether	_	
130-11	26237-26248	performance	_	
130-12	26249-26260	improvement	_	
130-13	26261-26264	and	_	
130-14	26265-26278	self-reported	_	
130-15	26279-26287	interest	_	
130-16	26288-26290	in	_	
130-17	26291-26294	the	_	
130-18	26295-26301	reward	_	
130-19	26302-26307	value	_	
130-20	26308-26312	were	_	
130-21	26313-26320	related	_	
130-22	26321-26323	in	_	
130-23	26324-26326	HC	_	
130-24	26327-26330	but	_	
130-25	26331-26334	not	_	
130-26	26335-26337	in	_	
130-27	26338-26341	ACD	_	
130-28	26341-26342	.	_	

#Text=Self-reported interest in the reward value (34 HCs and 33 ACDs) was similar for both groups (we observed a main effect of reward condition (F(4,62) = 17.259; p < .001), without group effects (F(4,62) = 2.349; p>.05, or interactions (p>0.1)).
131-1	26343-26356	Self-reported	_	
131-2	26357-26365	interest	_	
131-3	26366-26368	in	_	
131-4	26369-26372	the	_	
131-5	26373-26379	reward	_	
131-6	26380-26385	value	_	
131-7	26386-26387	(	_	
131-8	26387-26389	34	_	
131-9	26390-26393	HCs	_	
131-10	26394-26397	and	_	
131-11	26398-26400	33	_	
131-12	26401-26405	ACDs	_	
131-13	26405-26406	)	_	
131-14	26407-26410	was	_	
131-15	26411-26418	similar	_	
131-16	26419-26422	for	_	
131-17	26423-26427	both	_	
131-18	26428-26434	groups	_	
131-19	26435-26436	(	_	
131-20	26436-26438	we	_	
131-21	26439-26447	observed	_	
131-22	26448-26449	a	_	
131-23	26450-26454	main	_	
131-24	26455-26461	effect	_	
131-25	26462-26464	of	_	
131-26	26465-26471	reward	_	
131-27	26472-26481	condition	_	
131-28	26482-26483	(	_	
131-29	26483-26484	F	_	
131-30	26484-26485	(	_	
131-31	26485-26489	4,62	_	
131-32	26489-26490	)	_	
131-33	26491-26492	=	_	
131-34	26493-26499	17.259	_	
131-35	26499-26500	;	_	
131-36	26501-26502	p	_	
131-37	26503-26504	<	_	
131-38	26505-26509	.001	_	
131-39	26509-26510	)	_	
131-40	26510-26511	,	_	
131-41	26512-26519	without	_	
131-42	26520-26525	group	_	
131-43	26526-26533	effects	_	
131-44	26534-26535	(	_	
131-45	26535-26536	F	_	
131-46	26536-26537	(	_	
131-47	26537-26541	4,62	_	
131-48	26541-26542	)	_	
131-49	26543-26544	=	_	
131-50	26545-26550	2.349	_	
131-51	26550-26551	;	_	
131-52	26552-26553	p	_	
131-53	26553-26554	>	_	
131-54	26554-26557	.05	_	
131-55	26557-26558	,	_	
131-56	26559-26561	or	_	
131-57	26562-26574	interactions	_	
131-58	26575-26576	(	_	
131-59	26576-26577	p	_	
131-60	26577-26578	>	_	
131-61	26578-26581	0.1	_	
131-62	26581-26582	)	_	
131-63	26582-26583	)	_	
131-64	26583-26584	.	_	

#Text=As Fig 3 shows, RT and SDrt associations with self-reported interest were negative for HC, but positive for ACD.
132-1	26585-26587	As	_	
132-2	26588-26591	Fig	_	
132-3	26592-26593	3	_	
132-4	26594-26599	shows	_	
132-5	26599-26600	,	_	
132-6	26601-26603	RT	_	
132-7	26604-26607	and	_	
132-8	26608-26612	SDrt	_	
132-9	26613-26625	associations	_	
132-10	26626-26630	with	_	
132-11	26631-26644	self-reported	_	
132-12	26645-26653	interest	_	
132-13	26654-26658	were	_	
132-14	26659-26667	negative	_	
132-15	26668-26671	for	_	
132-16	26672-26674	HC	_	
132-17	26674-26675	,	_	
132-18	26676-26679	but	_	
132-19	26680-26688	positive	_	
132-20	26689-26692	for	_	
132-21	26693-26696	ACD	_	
132-22	26696-26697	.	_	

#Text=In order to explore whether this difference was statistically significant, we performed post-hoc between-group comparisons in correlation coefficients using Fisher´s Z transformation, applying the Bonferroni correction for multiple comparisons.
133-1	26698-26700	In	_	
133-2	26701-26706	order	_	
133-3	26707-26709	to	_	
133-4	26710-26717	explore	_	
133-5	26718-26725	whether	_	
133-6	26726-26730	this	_	
133-7	26731-26741	difference	_	
133-8	26742-26745	was	_	
133-9	26746-26759	statistically	_	
133-10	26760-26771	significant	_	
133-11	26771-26772	,	_	
133-12	26773-26775	we	_	
133-13	26776-26785	performed	_	
133-14	26786-26794	post-hoc	_	
133-15	26795-26808	between-group	_	
133-16	26809-26820	comparisons	_	
133-17	26821-26823	in	_	
133-18	26824-26835	correlation	_	
133-19	26836-26848	coefficients	_	
133-20	26849-26854	using	_	
133-21	26855-26861	Fisher	_	
133-22	26861-26862	´	_	
133-23	26862-26863	s	_	
133-24	26864-26865	Z	_	
133-25	26866-26880	transformation	_	
133-26	26880-26881	,	_	
133-27	26882-26890	applying	_	
133-28	26891-26894	the	_	
133-29	26895-26905	Bonferroni	_	
133-30	26906-26916	correction	_	
133-31	26917-26920	for	_	
133-32	26921-26929	multiple	_	
133-33	26930-26941	comparisons	_	
133-34	26941-26942	.	_	

#Text=Fig 3 shows that the correlation coefficients between groups were different (p < .05) for all the reward conditions, except €0.01, related to RT, and the €0.01 and €0.5 reward conditions, related to SDrt (see Supplementary Material S1 Fig for raw RT and SDrt data).
134-1	26943-26946	Fig	_	
134-2	26947-26948	3	_	
134-3	26949-26954	shows	_	
134-4	26955-26959	that	_	
134-5	26960-26963	the	_	
134-6	26964-26975	correlation	_	
134-7	26976-26988	coefficients	_	
134-8	26989-26996	between	_	
134-9	26997-27003	groups	_	
134-10	27004-27008	were	_	
134-11	27009-27018	different	_	
134-12	27019-27020	(	_	
134-13	27020-27021	p	_	
134-14	27022-27023	<	_	
134-15	27024-27027	.05	_	
134-16	27027-27028	)	_	
134-17	27029-27032	for	_	
134-18	27033-27036	all	_	
134-19	27037-27040	the	_	
134-20	27041-27047	reward	_	
134-21	27048-27058	conditions	_	
134-22	27058-27059	,	_	
134-23	27060-27066	except	_	
134-24	27067-27072	€0.01	_	
134-25	27072-27073	,	_	
134-26	27074-27081	related	_	
134-27	27082-27084	to	_	
134-28	27085-27087	RT	_	
134-29	27087-27088	,	_	
134-30	27089-27092	and	_	
134-31	27093-27096	the	_	
134-32	27097-27102	€0.01	_	
134-33	27103-27106	and	_	
134-34	27107-27111	€0.5	_	
134-35	27112-27118	reward	_	
134-36	27119-27129	conditions	_	
134-37	27129-27130	,	_	
134-38	27131-27138	related	_	
134-39	27139-27141	to	_	
134-40	27142-27146	SDrt	_	
134-41	27147-27148	(	_	
134-42	27148-27151	see	_	
134-43	27152-27165	Supplementary	_	
134-44	27166-27174	Material	_	
134-45	27175-27177	S1	_	
134-46	27178-27181	Fig	_	
134-47	27182-27185	for	_	
134-48	27186-27189	raw	_	
134-49	27190-27192	RT	_	
134-50	27193-27196	and	_	
134-51	27197-27201	SDrt	_	
134-52	27202-27206	data	_	
134-53	27206-27207	)	_	
134-54	27207-27208	.	_	

#Text=Graphical representation of associations between self-reported interest in reward value and performance, and between-group differences in these associations.
135-1	27209-27218	Graphical	_	
135-2	27219-27233	representation	_	
135-3	27234-27236	of	_	
135-4	27237-27249	associations	_	
135-5	27250-27257	between	_	
135-6	27258-27271	self-reported	_	
135-7	27272-27280	interest	_	
135-8	27281-27283	in	_	
135-9	27284-27290	reward	_	
135-10	27291-27296	value	_	
135-11	27297-27300	and	_	
135-12	27301-27312	performance	_	
135-13	27312-27313	,	_	
135-14	27314-27317	and	_	
135-15	27318-27331	between-group	_	
135-16	27332-27343	differences	_	
135-17	27344-27346	in	_	
135-18	27347-27352	these	_	
135-19	27353-27365	associations	_	
135-20	27365-27366	.	_	

#Text=The results in the left-hand table under the scatterplot shows the pairwise comparison t values (* = p < .05 and ** = p < .01) between conditions within groups.
136-1	27367-27370	The	_	
136-2	27371-27378	results	_	
136-3	27379-27381	in	_	
136-4	27382-27385	the	_	
136-5	27386-27395	left-hand	_	
136-6	27396-27401	table	_	
136-7	27402-27407	under	_	
136-8	27408-27411	the	_	
136-9	27412-27423	scatterplot	_	
136-10	27424-27429	shows	_	
136-11	27430-27433	the	_	
136-12	27434-27442	pairwise	_	
136-13	27443-27453	comparison	_	
136-14	27454-27455	t	_	
136-15	27456-27462	values	_	
136-16	27463-27464	(	_	
136-17	27464-27465	*	_	
136-18	27466-27467	=	_	
136-19	27468-27469	p	_	
136-20	27470-27471	<	_	
136-21	27472-27475	.05	_	
136-22	27476-27479	and	_	
136-23	27480-27481	*	_	
136-24	27481-27482	*	_	
136-25	27483-27484	=	_	
136-26	27485-27486	p	_	
136-27	27487-27488	<	_	
136-28	27489-27492	.01	_	
136-29	27492-27493	)	_	
136-30	27494-27501	between	_	
136-31	27502-27512	conditions	_	
136-32	27513-27519	within	_	
136-33	27520-27526	groups	_	
136-34	27526-27527	.	_	

#Text=The results in the graphics on the right represent the Pearson correlation values between self-reported interest in the reward value and each behavioral variable of interest for each reward magnitude.
137-1	27528-27531	The	_	
137-2	27532-27539	results	_	
137-3	27540-27542	in	_	
137-4	27543-27546	the	_	
137-5	27547-27555	graphics	_	
137-6	27556-27558	on	_	
137-7	27559-27562	the	_	
137-8	27563-27568	right	_	
137-9	27569-27578	represent	_	
137-10	27579-27582	the	_	
137-11	27583-27590	Pearson	_	
137-12	27591-27602	correlation	_	
137-13	27603-27609	values	_	
137-14	27610-27617	between	_	
137-15	27618-27631	self-reported	_	
137-16	27632-27640	interest	_	
137-17	27641-27643	in	_	
137-18	27644-27647	the	_	
137-19	27648-27654	reward	_	
137-20	27655-27660	value	_	
137-21	27661-27664	and	_	
137-22	27665-27669	each	_	
137-23	27670-27680	behavioral	_	
137-24	27681-27689	variable	_	
137-25	27690-27692	of	_	
137-26	27693-27701	interest	_	
137-27	27702-27705	for	_	
137-28	27706-27710	each	_	
137-29	27711-27717	reward	_	
137-30	27718-27727	magnitude	_	
137-31	27727-27728	.	_	

#Text=The “*” represents significant (p < .05) and “**” represents significant (p < .01) in correlation coefficients.
138-1	27729-27732	The	_	
138-2	27733-27734	“	_	
138-3	27734-27735	*	_	
138-4	27735-27736	”	_	
138-5	27737-27747	represents	_	
138-6	27748-27759	significant	_	
138-7	27760-27761	(	_	
138-8	27761-27762	p	_	
138-9	27763-27764	<	_	
138-10	27765-27768	.05	_	
138-11	27768-27769	)	_	
138-12	27770-27773	and	_	
138-13	27774-27775	“	_	
138-14	27775-27776	*	_	
138-15	27776-27777	*	_	
138-16	27777-27778	”	_	
138-17	27779-27789	represents	_	
138-18	27790-27801	significant	_	
138-19	27802-27803	(	_	
138-20	27803-27804	p	_	
138-21	27805-27806	<	_	
138-22	27807-27810	.01	_	
138-23	27810-27811	)	_	
138-24	27812-27814	in	_	
138-25	27815-27826	correlation	_	
138-26	27827-27839	coefficients	_	
138-27	27839-27840	.	_	

#Text=The numbers next to the vertical lines indicate the statistically significant between-group z-score after Bonferroni correction.
139-1	27841-27844	The	_	
139-2	27845-27852	numbers	_	
139-3	27853-27857	next	_	
139-4	27858-27860	to	_	
139-5	27861-27864	the	_	
139-6	27865-27873	vertical	_	
139-7	27874-27879	lines	_	
139-8	27880-27888	indicate	_	
139-9	27889-27892	the	_	
139-10	27893-27906	statistically	_	
139-11	27907-27918	significant	_	
139-12	27919-27932	between-group	_	
139-13	27933-27940	z-score	_	
139-14	27941-27946	after	_	
139-15	27947-27957	Bonferroni	_	
139-16	27958-27968	correction	_	
139-17	27968-27969	.	_	

#Text=RT, reaction time; SDrt, reaction time Standard Deviation; HC, Healthy Control; ACD, Abstinent Cocaine Dependent; €, euro.
140-1	27970-27972	RT	_	
140-2	27972-27973	,	_	
140-3	27974-27982	reaction	_	
140-4	27983-27987	time	_	
140-5	27987-27988	;	_	
140-6	27989-27993	SDrt	_	
140-7	27993-27994	,	_	
140-8	27995-28003	reaction	_	
140-9	28004-28008	time	_	
140-10	28009-28017	Standard	_	
140-11	28018-28027	Deviation	_	
140-12	28027-28028	;	_	
140-13	28029-28031	HC	_	
140-14	28031-28032	,	_	
140-15	28033-28040	Healthy	_	
140-16	28041-28048	Control	_	
140-17	28048-28049	;	_	
140-18	28050-28053	ACD	_	
140-19	28053-28054	,	_	
140-20	28055-28064	Abstinent	_	
140-21	28065-28072	Cocaine	_	
140-22	28073-28082	Dependent	_	
140-23	28082-28083	;	_	
140-24	28084-28085	€	_	
140-25	28085-28086	,	_	
140-26	28087-28091	euro	_	
140-27	28091-28092	.	_	

#Text=Functional results
#Text=The second goal of the current study was to test whether the magnitude of the reward contingency differently modulates the activity of prefrontal regions in ACD compared to HC, although ACD show a compensatory brain activation in other brain regions to counteract prefrontal impairment.
141-1	28093-28103	Functional	_	
141-2	28104-28111	results	_	
141-3	28112-28115	The	_	
141-4	28116-28122	second	_	
141-5	28123-28127	goal	_	
141-6	28128-28130	of	_	
141-7	28131-28134	the	_	
141-8	28135-28142	current	_	
141-9	28143-28148	study	_	
141-10	28149-28152	was	_	
141-11	28153-28155	to	_	
141-12	28156-28160	test	_	
141-13	28161-28168	whether	_	
141-14	28169-28172	the	_	
141-15	28173-28182	magnitude	_	
141-16	28183-28185	of	_	
141-17	28186-28189	the	_	
141-18	28190-28196	reward	_	
141-19	28197-28208	contingency	_	
141-20	28209-28220	differently	_	
141-21	28221-28230	modulates	_	
141-22	28231-28234	the	_	
141-23	28235-28243	activity	_	
141-24	28244-28246	of	_	
141-25	28247-28257	prefrontal	_	
141-26	28258-28265	regions	_	
141-27	28266-28268	in	_	
141-28	28269-28272	ACD	_	
141-29	28273-28281	compared	_	
141-30	28282-28284	to	_	
141-31	28285-28287	HC	_	
141-32	28287-28288	,	_	
141-33	28289-28297	although	_	
141-34	28298-28301	ACD	_	
141-35	28302-28306	show	_	
141-36	28307-28308	a	_	
141-37	28309-28321	compensatory	_	
141-38	28322-28327	brain	_	
141-39	28328-28338	activation	_	
141-40	28339-28341	in	_	
141-41	28342-28347	other	_	
141-42	28348-28353	brain	_	
141-43	28354-28361	regions	_	
141-44	28362-28364	to	_	
141-45	28365-28375	counteract	_	
141-46	28376-28386	prefrontal	_	
141-47	28387-28397	impairment	_	
141-48	28397-28398	.	_	

#Text=As Table 3 shows, we observed that HC showed greater activation than ACD in the left DLPFC, whereas ACD showed greater activation than HC in the left superior occipital cortex when we analyzed the parametric reward effect (R1<R2<R3<R4) (FWE at p<0.05).
142-1	28399-28401	As	_	
142-2	28402-28407	Table	_	
142-3	28408-28409	3	_	
142-4	28410-28415	shows	_	
142-5	28415-28416	,	_	
142-6	28417-28419	we	_	
142-7	28420-28428	observed	_	
142-8	28429-28433	that	_	
142-9	28434-28436	HC	_	
142-10	28437-28443	showed	_	
142-11	28444-28451	greater	_	
142-12	28452-28462	activation	_	
142-13	28463-28467	than	_	
142-14	28468-28471	ACD	_	
142-15	28472-28474	in	_	
142-16	28475-28478	the	_	
142-17	28479-28483	left	_	
142-18	28484-28489	DLPFC	_	
142-19	28489-28490	,	_	
142-20	28491-28498	whereas	_	
142-21	28499-28502	ACD	_	
142-22	28503-28509	showed	_	
142-23	28510-28517	greater	_	
142-24	28518-28528	activation	_	
142-25	28529-28533	than	_	
142-26	28534-28536	HC	_	
142-27	28537-28539	in	_	
142-28	28540-28543	the	_	
142-29	28544-28548	left	_	
142-30	28549-28557	superior	_	
142-31	28558-28567	occipital	_	
142-32	28568-28574	cortex	_	
142-33	28575-28579	when	_	
142-34	28580-28582	we	_	
142-35	28583-28591	analyzed	_	
142-36	28592-28595	the	_	
142-37	28596-28606	parametric	_	
142-38	28607-28613	reward	_	
142-39	28614-28620	effect	_	
142-40	28621-28622	(	_	
142-41	28622-28624	R1	_	
142-42	28624-28625	<	_	
142-43	28625-28627	R2	_	
142-44	28627-28628	<	_	
142-45	28628-28630	R3	_	
142-46	28630-28631	<	_	
142-47	28631-28633	R4	_	
142-48	28633-28634	)	_	
142-49	28635-28636	(	_	
142-50	28636-28639	FWE	_	
142-51	28640-28642	at	_	
142-52	28643-28644	p	_	
142-53	28644-28645	<	_	
142-54	28645-28649	0.05	_	
142-55	28649-28650	)	_	
142-56	28650-28651	.	_	

#Text=The rest of the ROIs did not show any significant differences between the HC and ACD groups.
143-1	28652-28655	The	_	
143-2	28656-28660	rest	_	
143-3	28661-28663	of	_	
143-4	28664-28667	the	_	
143-5	28668-28672	ROIs	_	
143-6	28673-28676	did	_	
143-7	28677-28680	not	_	
143-8	28681-28685	show	_	
143-9	28686-28689	any	_	
143-10	28690-28701	significant	_	
143-11	28702-28713	differences	_	
143-12	28714-28721	between	_	
143-13	28722-28725	the	_	
143-14	28726-28728	HC	_	
143-15	28729-28732	and	_	
143-16	28733-28736	ACD	_	
143-17	28737-28743	groups	_	
143-18	28743-28744	.	_	

#Text=For illustration purposes, we plotted the parametric effect (R1<R2<R3<R4) by extracting the eigenvalues for each separate monetary condition (R1, R2, R3, R4) and for each group, from the suprathreshold voxels in the DLPFC and superior occipital cortex (see Fig 4).
144-1	28745-28748	For	_	
144-2	28749-28761	illustration	_	
144-3	28762-28770	purposes	_	
144-4	28770-28771	,	_	
144-5	28772-28774	we	_	
144-6	28775-28782	plotted	_	
144-7	28783-28786	the	_	
144-8	28787-28797	parametric	_	
144-9	28798-28804	effect	_	
144-10	28805-28806	(	_	
144-11	28806-28808	R1	_	
144-12	28808-28809	<	_	
144-13	28809-28811	R2	_	
144-14	28811-28812	<	_	
144-15	28812-28814	R3	_	
144-16	28814-28815	<	_	
144-17	28815-28817	R4	_	
144-18	28817-28818	)	_	
144-19	28819-28821	by	_	
144-20	28822-28832	extracting	_	
144-21	28833-28836	the	_	
144-22	28837-28848	eigenvalues	_	
144-23	28849-28852	for	_	
144-24	28853-28857	each	_	
144-25	28858-28866	separate	_	
144-26	28867-28875	monetary	_	
144-27	28876-28885	condition	_	
144-28	28886-28887	(	_	
144-29	28887-28889	R1	_	
144-30	28889-28890	,	_	
144-31	28891-28893	R2	_	
144-32	28893-28894	,	_	
144-33	28895-28897	R3	_	
144-34	28897-28898	,	_	
144-35	28899-28901	R4	_	
144-36	28901-28902	)	_	
144-37	28903-28906	and	_	
144-38	28907-28910	for	_	
144-39	28911-28915	each	_	
144-40	28916-28921	group	_	
144-41	28921-28922	,	_	
144-42	28923-28927	from	_	
144-43	28928-28931	the	_	
144-44	28932-28946	suprathreshold	_	
144-45	28947-28953	voxels	_	
144-46	28954-28956	in	_	
144-47	28957-28960	the	_	
144-48	28961-28966	DLPFC	_	
144-49	28967-28970	and	_	
144-50	28971-28979	superior	_	
144-51	28980-28989	occipital	_	
144-52	28990-28996	cortex	_	
144-53	28997-28998	(	_	
144-54	28998-29001	see	_	
144-55	29002-29005	Fig	_	
144-56	29006-29007	4	_	
144-57	29007-29008	)	_	
144-58	29008-29009	.	_	

#Text=The beta-weights were analyzed using the SPSS software package, v.20 by performing the following analyses for each region: (1) a 4x2 mixed-design ANOVA including the within-subject factor Reward (R1, R2, R3, R4) for each group; (2) within groups pairwise comparisons between reward conditions; and (3) pairwise comparisons between groups for each reward condition (e.g., €0.5 for HC vs €0.5 for ACD).
145-1	29010-29013	The	_	
145-2	29014-29026	beta-weights	_	
145-3	29027-29031	were	_	
145-4	29032-29040	analyzed	_	
145-5	29041-29046	using	_	
145-6	29047-29050	the	_	
145-7	29051-29055	SPSS	_	
145-8	29056-29064	software	_	
145-9	29065-29072	package	_	
145-10	29072-29073	,	_	
145-11	29074-29075	v	_	
145-12	29075-29078	.20	_	
145-13	29079-29081	by	_	
145-14	29082-29092	performing	_	
145-15	29093-29096	the	_	
145-16	29097-29106	following	_	
145-17	29107-29115	analyses	_	
145-18	29116-29119	for	_	
145-19	29120-29124	each	_	
145-20	29125-29131	region	_	
145-21	29131-29132	:	_	
145-22	29133-29134	(	_	
145-23	29134-29135	1	_	
145-24	29135-29136	)	_	
145-25	29137-29138	a	_	
145-26	29139-29142	4x2	_	
145-27	29143-29155	mixed-design	_	
145-28	29156-29161	ANOVA	_	
145-29	29162-29171	including	_	
145-30	29172-29175	the	_	
145-31	29176-29190	within-subject	_	
145-32	29191-29197	factor	_	
145-33	29198-29204	Reward	_	
145-34	29205-29206	(	_	
145-35	29206-29208	R1	_	
145-36	29208-29209	,	_	
145-37	29210-29212	R2	_	
145-38	29212-29213	,	_	
145-39	29214-29216	R3	_	
145-40	29216-29217	,	_	
145-41	29218-29220	R4	_	
145-42	29220-29221	)	_	
145-43	29222-29225	for	_	
145-44	29226-29230	each	_	
145-45	29231-29236	group	_	
145-46	29236-29237	;	_	
145-47	29238-29239	(	_	
145-48	29239-29240	2	_	
145-49	29240-29241	)	_	
145-50	29242-29248	within	_	
145-51	29249-29255	groups	_	
145-52	29256-29264	pairwise	_	
145-53	29265-29276	comparisons	_	
145-54	29277-29284	between	_	
145-55	29285-29291	reward	_	
145-56	29292-29302	conditions	_	
145-57	29302-29303	;	_	
145-58	29304-29307	and	_	
145-59	29308-29309	(	_	
145-60	29309-29310	3	_	
145-61	29310-29311	)	_	
145-62	29312-29320	pairwise	_	
145-63	29321-29332	comparisons	_	
145-64	29333-29340	between	_	
145-65	29341-29347	groups	_	
145-66	29348-29351	for	_	
145-67	29352-29356	each	_	
145-68	29357-29363	reward	_	
145-69	29364-29373	condition	_	
145-70	29374-29375	(	_	
145-71	29375-29378	e.g	_	
145-72	29378-29379	.	_	
145-73	29379-29380	,	_	
145-74	29381-29385	€0.5	_	
145-75	29386-29389	for	_	
145-76	29390-29392	HC	_	
145-77	29393-29395	vs	_	
145-78	29396-29400	€0.5	_	
145-79	29401-29404	for	_	
145-80	29405-29408	ACD	_	
145-81	29408-29409	)	_	
145-82	29409-29410	.	_	

#Text=It should be pointed out that these post-hoc analyses were run to examine what drove the parametric effects, obtaining a more thorough picture of what is driving the effect.
146-1	29411-29413	It	_	
146-2	29414-29420	should	_	
146-3	29421-29423	be	_	
146-4	29424-29431	pointed	_	
146-5	29432-29435	out	_	
146-6	29436-29440	that	_	
146-7	29441-29446	these	_	
146-8	29447-29455	post-hoc	_	
146-9	29456-29464	analyses	_	
146-10	29465-29469	were	_	
146-11	29470-29473	run	_	
146-12	29474-29476	to	_	
146-13	29477-29484	examine	_	
146-14	29485-29489	what	_	
146-15	29490-29495	drove	_	
146-16	29496-29499	the	_	
146-17	29500-29510	parametric	_	
146-18	29511-29518	effects	_	
146-19	29518-29519	,	_	
146-20	29520-29529	obtaining	_	
146-21	29530-29531	a	_	
146-22	29532-29536	more	_	
146-23	29537-29545	thorough	_	
146-24	29546-29553	picture	_	
146-25	29554-29556	of	_	
146-26	29557-29561	what	_	
146-27	29562-29564	is	_	
146-28	29565-29572	driving	_	
146-29	29573-29576	the	_	
146-30	29577-29583	effect	_	
146-31	29583-29584	.	_	

#Text=However, they should not be considered for statistical inference, as they are biased estimates of the effects because the ROIs were non-independent but based on the parametric contrast.
147-1	29585-29592	However	_	
147-2	29592-29593	,	_	
147-3	29594-29598	they	_	
147-4	29599-29605	should	_	
147-5	29606-29609	not	_	
147-6	29610-29612	be	_	
147-7	29613-29623	considered	_	
147-8	29624-29627	for	_	
147-9	29628-29639	statistical	_	
147-10	29640-29649	inference	_	
147-11	29649-29650	,	_	
147-12	29651-29653	as	_	
147-13	29654-29658	they	_	
147-14	29659-29662	are	_	
147-15	29663-29669	biased	_	
147-16	29670-29679	estimates	_	
147-17	29680-29682	of	_	
147-18	29683-29686	the	_	
147-19	29687-29694	effects	_	
147-20	29695-29702	because	_	
147-21	29703-29706	the	_	
147-22	29707-29711	ROIs	_	
147-23	29712-29716	were	_	
147-24	29717-29732	non-independent	_	
147-25	29733-29736	but	_	
147-26	29737-29742	based	_	
147-27	29743-29745	on	_	
147-28	29746-29749	the	_	
147-29	29750-29760	parametric	_	
147-30	29761-29769	contrast	_	
147-31	29769-29770	.	_	

#Text=For the DLPFC, we observed that while HC showed a parametric effect of reward (F(3,34) = 5.058; p = 0.005), ACD did not show this effect (F(3,31) = 1.504; p = 0.233).
148-1	29771-29774	For	_	
148-2	29775-29778	the	_	
148-3	29779-29784	DLPFC	_	
148-4	29784-29785	,	_	
148-5	29786-29788	we	_	
148-6	29789-29797	observed	_	
148-7	29798-29802	that	_	
148-8	29803-29808	while	_	
148-9	29809-29811	HC	_	
148-10	29812-29818	showed	_	
148-11	29819-29820	a	_	
148-12	29821-29831	parametric	_	
148-13	29832-29838	effect	_	
148-14	29839-29841	of	_	
148-15	29842-29848	reward	_	
148-16	29849-29850	(	_	
148-17	29850-29851	F	_	
148-18	29851-29852	(	_	
148-19	29852-29856	3,34	_	
148-20	29856-29857	)	_	
148-21	29858-29859	=	_	
148-22	29860-29865	5.058	_	
148-23	29865-29866	;	_	
148-24	29867-29868	p	_	
148-25	29869-29870	=	_	
148-26	29871-29876	0.005	_	
148-27	29876-29877	)	_	
148-28	29877-29878	,	_	
148-29	29879-29882	ACD	_	
148-30	29883-29886	did	_	
148-31	29887-29890	not	_	
148-32	29891-29895	show	_	
148-33	29896-29900	this	_	
148-34	29901-29907	effect	_	
148-35	29908-29909	(	_	
148-36	29909-29910	F	_	
148-37	29910-29911	(	_	
148-38	29911-29915	3,31	_	
148-39	29915-29916	)	_	
148-40	29917-29918	=	_	
148-41	29919-29924	1.504	_	
148-42	29924-29925	;	_	
148-43	29926-29927	p	_	
148-44	29928-29929	=	_	
148-45	29930-29935	0.233	_	
148-46	29935-29936	)	_	
148-47	29936-29937	.	_	

#Text=For the superior occipital cortex, we observed again that HC showed a parametric effect of reward (F(3,34) = 6.048; p = 0.002), but ACD did not show this effect (F(3,31) = 1.003; p = 0.404).
149-1	29938-29941	For	_	
149-2	29942-29945	the	_	
149-3	29946-29954	superior	_	
149-4	29955-29964	occipital	_	
149-5	29965-29971	cortex	_	
149-6	29971-29972	,	_	
149-7	29973-29975	we	_	
149-8	29976-29984	observed	_	
149-9	29985-29990	again	_	
149-10	29991-29995	that	_	
149-11	29996-29998	HC	_	
149-12	29999-30005	showed	_	
149-13	30006-30007	a	_	
149-14	30008-30018	parametric	_	
149-15	30019-30025	effect	_	
149-16	30026-30028	of	_	
149-17	30029-30035	reward	_	
149-18	30036-30037	(	_	
149-19	30037-30038	F	_	
149-20	30038-30039	(	_	
149-21	30039-30043	3,34	_	
149-22	30043-30044	)	_	
149-23	30045-30046	=	_	
149-24	30047-30052	6.048	_	
149-25	30052-30053	;	_	
149-26	30054-30055	p	_	
149-27	30056-30057	=	_	
149-28	30058-30063	0.002	_	
149-29	30063-30064	)	_	
149-30	30064-30065	,	_	
149-31	30066-30069	but	_	
149-32	30070-30073	ACD	_	
149-33	30074-30077	did	_	
149-34	30078-30081	not	_	
149-35	30082-30086	show	_	
149-36	30087-30091	this	_	
149-37	30092-30098	effect	_	
149-38	30099-30100	(	_	
149-39	30100-30101	F	_	
149-40	30101-30102	(	_	
149-41	30102-30106	3,31	_	
149-42	30106-30107	)	_	
149-43	30108-30109	=	_	
149-44	30110-30115	1.003	_	
149-45	30115-30116	;	_	
149-46	30117-30118	p	_	
149-47	30119-30120	=	_	
149-48	30121-30126	0.404	_	
149-49	30126-30127	)	_	
149-50	30127-30128	.	_	

#Text=Within groups pairwise comparisons between reward conditions are depicted in Fig 4.
150-1	30129-30135	Within	_	
150-2	30136-30142	groups	_	
150-3	30143-30151	pairwise	_	
150-4	30152-30163	comparisons	_	
150-5	30164-30171	between	_	
150-6	30172-30178	reward	_	
150-7	30179-30189	conditions	_	
150-8	30190-30193	are	_	
150-9	30194-30202	depicted	_	
150-10	30203-30205	in	_	
150-11	30206-30209	Fig	_	
150-12	30210-30211	4	_	
150-13	30211-30212	.	_	

#Text=Brain regions showing parametric modulation by reward magnitude in HC>ACD and HC<ACD.
151-1	30213-30218	Brain	_	
151-2	30219-30226	regions	_	
151-3	30227-30234	showing	_	
151-4	30235-30245	parametric	_	
151-5	30246-30256	modulation	_	
151-6	30257-30259	by	_	
151-7	30260-30266	reward	_	
151-8	30267-30276	magnitude	_	
151-9	30277-30279	in	_	
151-10	30280-30282	HC	_	
151-11	30282-30283	>	_	
151-12	30283-30286	ACD	_	
151-13	30287-30290	and	_	
151-14	30291-30293	HC	_	
151-15	30293-30294	<	_	
151-16	30294-30297	ACD	_	
151-17	30297-30298	.	_	

#Text=The color bar represents the parameter estimates of the parametric contrast (R1<R2<R3<R4) = -2–1 1 2 for each reward magnitude.
152-1	30299-30302	The	_	
152-2	30303-30308	color	_	
152-3	30309-30312	bar	_	
152-4	30313-30323	represents	_	
152-5	30324-30327	the	_	
152-6	30328-30337	parameter	_	
152-7	30338-30347	estimates	_	
152-8	30348-30350	of	_	
152-9	30351-30354	the	_	
152-10	30355-30365	parametric	_	
152-11	30366-30374	contrast	_	
152-12	30375-30376	(	_	
152-13	30376-30378	R1	_	
152-14	30378-30379	<	_	
152-15	30379-30381	R2	_	
152-16	30381-30382	<	_	
152-17	30382-30384	R3	_	
152-18	30384-30385	<	_	
152-19	30385-30387	R4	_	
152-20	30387-30388	)	_	
152-21	30389-30390	=	_	
152-22	30391-30392	-	_	
152-23	30392-30393	2	_	
152-24	30393-30394	–	_	
152-25	30394-30395	1	_	
152-26	30396-30397	1	_	
152-27	30398-30399	2	_	
152-28	30400-30403	for	_	
152-29	30404-30408	each	_	
152-30	30409-30415	reward	_	
152-31	30416-30425	magnitude	_	
152-32	30425-30426	.	_	

#Text=Error bars show within-subject standard error.
153-1	30427-30432	Error	_	
153-2	30433-30437	bars	_	
153-3	30438-30442	show	_	
153-4	30443-30457	within-subject	_	
153-5	30458-30466	standard	_	
153-6	30467-30472	error	_	
153-7	30472-30473	.	_	

#Text=The results in the tables show the pairwise comparison t values (* = p < .05 and ** = p < .01).
154-1	30474-30477	The	_	
154-2	30478-30485	results	_	
154-3	30486-30488	in	_	
154-4	30489-30492	the	_	
154-5	30493-30499	tables	_	
154-6	30500-30504	show	_	
154-7	30505-30508	the	_	
154-8	30509-30517	pairwise	_	
154-9	30518-30528	comparison	_	
154-10	30529-30530	t	_	
154-11	30531-30537	values	_	
154-12	30538-30539	(	_	
154-13	30539-30540	*	_	
154-14	30541-30542	=	_	
154-15	30543-30544	p	_	
154-16	30545-30546	<	_	
154-17	30547-30550	.05	_	
154-18	30551-30554	and	_	
154-19	30555-30556	*	_	
154-20	30556-30557	*	_	
154-21	30558-30559	=	_	
154-22	30560-30561	p	_	
154-23	30562-30563	<	_	
154-24	30564-30567	.01	_	
154-25	30567-30568	)	_	
154-26	30568-30569	.	_	

#Text=DLPFC, dorsolateral prefrontal cortex; HC, Healthy Control; ACD, Abstinent Cocaine Dependent; €, euro.
155-1	30570-30575	DLPFC	_	
155-2	30575-30576	,	_	
155-3	30577-30589	dorsolateral	_	
155-4	30590-30600	prefrontal	_	
155-5	30601-30607	cortex	_	
155-6	30607-30608	;	_	
155-7	30609-30611	HC	_	
155-8	30611-30612	,	_	
155-9	30613-30620	Healthy	_	
155-10	30621-30628	Control	_	
155-11	30628-30629	;	_	
155-12	30630-30633	ACD	_	
155-13	30633-30634	,	_	
155-14	30635-30644	Abstinent	_	
155-15	30645-30652	Cocaine	_	
155-16	30653-30662	Dependent	_	
155-17	30662-30663	;	_	
155-18	30664-30665	€	_	
155-19	30665-30666	,	_	
155-20	30667-30671	euro	_	
155-21	30671-30672	.	_	

#Text=R1 = “€0.01 vs. €0”; R2 = “€0.5 vs. €0”; R3 = “€1 vs. €0”; R4 = “€1.5 vs. €0”
#Text=Functional results (p = .05 family-wise error (FWE) cluster corrected).
156-1	30673-30675	R1	_	
156-2	30676-30677	=	_	
156-3	30678-30679	“	_	
156-4	30679-30684	€0.01	_	
156-5	30685-30687	vs	_	
156-6	30687-30688	.	_	
156-7	30689-30691	€0	_	
156-8	30691-30692	”	_	
156-9	30692-30693	;	_	
156-10	30694-30696	R2	_	
156-11	30697-30698	=	_	
156-12	30699-30700	“	_	
156-13	30700-30704	€0.5	_	
156-14	30705-30707	vs	_	
156-15	30707-30708	.	_	
156-16	30709-30711	€0	_	
156-17	30711-30712	”	_	
156-18	30712-30713	;	_	
156-19	30714-30716	R3	_	
156-20	30717-30718	=	_	
156-21	30719-30720	“	_	
156-22	30720-30722	€1	_	
156-23	30723-30725	vs	_	
156-24	30725-30726	.	_	
156-25	30727-30729	€0	_	
156-26	30729-30730	”	_	
156-27	30730-30731	;	_	
156-28	30732-30734	R4	_	
156-29	30735-30736	=	_	
156-30	30737-30738	“	_	
156-31	30738-30742	€1.5	_	
156-32	30743-30745	vs	_	
156-33	30745-30746	.	_	
156-34	30747-30749	€0	_	
156-35	30749-30750	”	_	
156-36	30751-30761	Functional	_	
156-37	30762-30769	results	_	
156-38	30770-30771	(	_	
156-39	30771-30772	p	_	
156-40	30773-30774	=	_	
156-41	30775-30778	.05	_	
156-42	30779-30790	family-wise	_	
156-43	30791-30796	error	_	
156-44	30797-30798	(	_	
156-45	30798-30801	FWE	_	
156-46	30801-30802	)	_	
156-47	30803-30810	cluster	_	
156-48	30811-30820	corrected	_	
156-49	30820-30821	)	_	
156-50	30821-30822	.	_	

#Text=Brain region\tMNI coordinates\tVolume (mm3)\tZ score\t \tParametric effect; HC>ACD\tLeft DLPFC\t-42\t26\t16\t567\t3.47\t \tParametric effect; ACD>HC\tLeft superior occipital cortex\t-39\t-85\t22\t270\t3.43\t \tLeft DLPFC connectivity during parametric modulation; ACD>HC\tLeft putamen\t-27\t-4\t-8\t243\t4.09\t \tRegression\tNegative correlation of SCQ-G score with parametric effect\tLeft caudate\t-9\t2\t19\t351\t3.75\t \tPositive correlation of CSSA score with parametric effect\tRight pallidum\t15\t-1\t-5\t243\t3.27\t \t
#Text=DLPFC, dorsolateral prefrontal cortex; MNI, Montreal Neurologic Institute
#Text=Psychophysiological results
#Text=The third goal of the current study was to test whether ACD prefrontal impairment was related to an altered frontostriatal connectivity pattern, as previous studies have suggested.
157-1	30824-30829	Brain	_	
157-2	30830-30836	region	_	
157-3	30837-30840	MNI	_	
157-4	30841-30852	coordinates	_	
157-5	30853-30859	Volume	_	
157-6	30860-30861	(	_	
157-7	30861-30864	mm3	_	
157-8	30864-30865	)	_	
157-9	30866-30867	Z	_	
157-10	30868-30873	score	_	
157-11	30876-30886	Parametric	_	
157-12	30887-30893	effect	_	
157-13	30893-30894	;	_	
157-14	30895-30897	HC	_	
157-15	30897-30898	>	_	
157-16	30898-30901	ACD	_	
157-17	30902-30906	Left	_	
157-18	30907-30912	DLPFC	_	
157-19	30913-30914	-	_	
157-20	30914-30916	42	_	
157-21	30917-30919	26	_	
157-22	30920-30922	16	_	
157-23	30923-30926	567	_	
157-24	30927-30931	3.47	_	
157-25	30934-30944	Parametric	_	
157-26	30945-30951	effect	_	
157-27	30951-30952	;	_	
157-28	30953-30956	ACD	_	
157-29	30956-30957	>	_	
157-30	30957-30959	HC	_	
157-31	30960-30964	Left	_	
157-32	30965-30973	superior	_	
157-33	30974-30983	occipital	_	
157-34	30984-30990	cortex	_	
157-35	30991-30992	-	_	
157-36	30992-30994	39	_	
157-37	30995-30996	-	_	
157-38	30996-30998	85	_	
157-39	30999-31001	22	_	
157-40	31002-31005	270	_	
157-41	31006-31010	3.43	_	
157-42	31013-31017	Left	_	
157-43	31018-31023	DLPFC	_	
157-44	31024-31036	connectivity	_	
157-45	31037-31043	during	_	
157-46	31044-31054	parametric	_	
157-47	31055-31065	modulation	_	
157-48	31065-31066	;	_	
157-49	31067-31070	ACD	_	
157-50	31070-31071	>	_	
157-51	31071-31073	HC	_	
157-52	31074-31078	Left	_	
157-53	31079-31086	putamen	_	
157-54	31087-31088	-	_	
157-55	31088-31090	27	_	
157-56	31091-31092	-	_	
157-57	31092-31093	4	_	
157-58	31094-31095	-	_	
157-59	31095-31096	8	_	
157-60	31097-31100	243	_	
157-61	31101-31105	4.09	_	
157-62	31108-31118	Regression	_	
157-63	31119-31127	Negative	_	
157-64	31128-31139	correlation	_	
157-65	31140-31142	of	_	
157-66	31143-31148	SCQ-G	_	
157-67	31149-31154	score	_	
157-68	31155-31159	with	_	
157-69	31160-31170	parametric	_	
157-70	31171-31177	effect	_	
157-71	31178-31182	Left	_	
157-72	31183-31190	caudate	_	
157-73	31191-31192	-	_	
157-74	31192-31193	9	_	
157-75	31194-31195	2	_	
157-76	31196-31198	19	_	
157-77	31199-31202	351	_	
157-78	31203-31207	3.75	_	
157-79	31210-31218	Positive	_	
157-80	31219-31230	correlation	_	
157-81	31231-31233	of	_	
157-82	31234-31238	CSSA	_	
157-83	31239-31244	score	_	
157-84	31245-31249	with	_	
157-85	31250-31260	parametric	_	
157-86	31261-31267	effect	_	
157-87	31268-31273	Right	_	
157-88	31274-31282	pallidum	_	
157-89	31283-31285	15	_	
157-90	31286-31287	-	_	
157-91	31287-31288	1	_	
157-92	31289-31290	-	_	
157-93	31290-31291	5	_	
157-94	31292-31295	243	_	
157-95	31296-31300	3.27	_	
157-96	31304-31309	DLPFC	_	
157-97	31309-31310	,	_	
157-98	31311-31323	dorsolateral	_	
157-99	31324-31334	prefrontal	_	
157-100	31335-31341	cortex	_	
157-101	31341-31342	;	_	
157-102	31343-31346	MNI	_	
157-103	31346-31347	,	_	
157-104	31348-31356	Montreal	_	
157-105	31357-31367	Neurologic	_	
157-106	31368-31377	Institute	_	
157-107	31378-31397	Psychophysiological	_	
157-108	31398-31405	results	_	
157-109	31406-31409	The	_	
157-110	31410-31415	third	_	
157-111	31416-31420	goal	_	
157-112	31421-31423	of	_	
157-113	31424-31427	the	_	
157-114	31428-31435	current	_	
157-115	31436-31441	study	_	
157-116	31442-31445	was	_	
157-117	31446-31448	to	_	
157-118	31449-31453	test	_	
157-119	31454-31461	whether	_	
157-120	31462-31465	ACD	_	
157-121	31466-31476	prefrontal	_	
157-122	31477-31487	impairment	_	
157-123	31488-31491	was	_	
157-124	31492-31499	related	_	
157-125	31500-31502	to	_	
157-126	31503-31505	an	_	
157-127	31506-31513	altered	_	
157-128	31514-31528	frontostriatal	_	
157-129	31529-31541	connectivity	_	
157-130	31542-31549	pattern	_	
157-131	31549-31550	,	_	
157-132	31551-31553	as	_	
157-133	31554-31562	previous	_	
157-134	31563-31570	studies	_	
157-135	31571-31575	have	_	
157-136	31576-31585	suggested	_	
157-137	31585-31586	.	_	

#Text=We computed a psychophysiological analysis using the left DLPFC as a seed region because it was the only area that showed between-group differences in sensitivity to reward gradients in the PFC.
158-1	31587-31589	We	_	
158-2	31590-31598	computed	_	
158-3	31599-31600	a	_	
158-4	31601-31620	psychophysiological	_	
158-5	31621-31629	analysis	_	
158-6	31630-31635	using	_	
158-7	31636-31639	the	_	
158-8	31640-31644	left	_	
158-9	31645-31650	DLPFC	_	
158-10	31651-31653	as	_	
158-11	31654-31655	a	_	
158-12	31656-31660	seed	_	
158-13	31661-31667	region	_	
158-14	31668-31675	because	_	
158-15	31676-31678	it	_	
158-16	31679-31682	was	_	
158-17	31683-31686	the	_	
158-18	31687-31691	only	_	
158-19	31692-31696	area	_	
158-20	31697-31701	that	_	
158-21	31702-31708	showed	_	
158-22	31709-31722	between-group	_	
158-23	31723-31734	differences	_	
158-24	31735-31737	in	_	
158-25	31738-31749	sensitivity	_	
158-26	31750-31752	to	_	
158-27	31753-31759	reward	_	
158-28	31760-31769	gradients	_	
158-29	31770-31772	in	_	
158-30	31773-31776	the	_	
158-31	31777-31780	PFC	_	
158-32	31780-31781	.	_	

#Text=Then, we ran a gPPI analysis using the same ROI that we used for the previous functional analyses in this area.
159-1	31782-31786	Then	_	
159-2	31786-31787	,	_	
159-3	31788-31790	we	_	
159-4	31791-31794	ran	_	
159-5	31795-31796	a	_	
159-6	31797-31801	gPPI	_	
159-7	31802-31810	analysis	_	
159-8	31811-31816	using	_	
159-9	31817-31820	the	_	
159-10	31821-31825	same	_	
159-11	31826-31829	ROI	_	
159-12	31830-31834	that	_	
159-13	31835-31837	we	_	
159-14	31838-31842	used	_	
159-15	31843-31846	for	_	
159-16	31847-31850	the	_	
159-17	31851-31859	previous	_	
159-18	31860-31870	functional	_	
159-19	31871-31879	analyses	_	
159-20	31880-31882	in	_	
159-21	31883-31887	this	_	
159-22	31888-31892	area	_	
159-23	31892-31893	.	_	

#Text=As Table 3 shows, we observed greater connectivity between the left DLPFC and the left putamen in ACD than in HC when we analyzed the parametric effect (R1<R2<R3<R4) (FWE at p<0.05).
160-1	31894-31896	As	_	
160-2	31897-31902	Table	_	
160-3	31903-31904	3	_	
160-4	31905-31910	shows	_	
160-5	31910-31911	,	_	
160-6	31912-31914	we	_	
160-7	31915-31923	observed	_	
160-8	31924-31931	greater	_	
160-9	31932-31944	connectivity	_	
160-10	31945-31952	between	_	
160-11	31953-31956	the	_	
160-12	31957-31961	left	_	
160-13	31962-31967	DLPFC	_	
160-14	31968-31971	and	_	
160-15	31972-31975	the	_	
160-16	31976-31980	left	_	
160-17	31981-31988	putamen	_	
160-18	31989-31991	in	_	
160-19	31992-31995	ACD	_	
160-20	31996-32000	than	_	
160-21	32001-32003	in	_	
160-22	32004-32006	HC	_	
160-23	32007-32011	when	_	
160-24	32012-32014	we	_	
160-25	32015-32023	analyzed	_	
160-26	32024-32027	the	_	
160-27	32028-32038	parametric	_	
160-28	32039-32045	effect	_	
160-29	32046-32047	(	_	
160-30	32047-32049	R1	_	
160-31	32049-32050	<	_	
160-32	32050-32052	R2	_	
160-33	32052-32053	<	_	
160-34	32053-32055	R3	_	
160-35	32055-32056	<	_	
160-36	32056-32058	R4	_	
160-37	32058-32059	)	_	
160-38	32060-32061	(	_	
160-39	32061-32064	FWE	_	
160-40	32065-32067	at	_	
160-41	32068-32069	p	_	
160-42	32069-32070	<	_	
160-43	32070-32074	0.05	_	
160-44	32074-32075	)	_	
160-45	32075-32076	.	_	

#Text=For illustration purposes, we plotted the parametric effect (R1<R2<R3<R4) by extracting the eigenvalues for each separate monetary condition (R1, R2, R3, R4) and for each group, from the suprathreshold voxels in the putamen (see Fig 5).
161-1	32077-32080	For	_	
161-2	32081-32093	illustration	_	
161-3	32094-32102	purposes	_	
161-4	32102-32103	,	_	
161-5	32104-32106	we	_	
161-6	32107-32114	plotted	_	
161-7	32115-32118	the	_	
161-8	32119-32129	parametric	_	
161-9	32130-32136	effect	_	
161-10	32137-32138	(	_	
161-11	32138-32140	R1	_	
161-12	32140-32141	<	_	
161-13	32141-32143	R2	_	
161-14	32143-32144	<	_	
161-15	32144-32146	R3	_	
161-16	32146-32147	<	_	
161-17	32147-32149	R4	_	
161-18	32149-32150	)	_	
161-19	32151-32153	by	_	
161-20	32154-32164	extracting	_	
161-21	32165-32168	the	_	
161-22	32169-32180	eigenvalues	_	
161-23	32181-32184	for	_	
161-24	32185-32189	each	_	
161-25	32190-32198	separate	_	
161-26	32199-32207	monetary	_	
161-27	32208-32217	condition	_	
161-28	32218-32219	(	_	
161-29	32219-32221	R1	_	
161-30	32221-32222	,	_	
161-31	32223-32225	R2	_	
161-32	32225-32226	,	_	
161-33	32227-32229	R3	_	
161-34	32229-32230	,	_	
161-35	32231-32233	R4	_	
161-36	32233-32234	)	_	
161-37	32235-32238	and	_	
161-38	32239-32242	for	_	
161-39	32243-32247	each	_	
161-40	32248-32253	group	_	
161-41	32253-32254	,	_	
161-42	32255-32259	from	_	
161-43	32260-32263	the	_	
161-44	32264-32278	suprathreshold	_	
161-45	32279-32285	voxels	_	
161-46	32286-32288	in	_	
161-47	32289-32292	the	_	
161-48	32293-32300	putamen	_	
161-49	32301-32302	(	_	
161-50	32302-32305	see	_	
161-51	32306-32309	Fig	_	
161-52	32310-32311	5	_	
161-53	32311-32312	)	_	
161-54	32312-32313	.	_	

#Text=The beta-weights were analyzed using the SPSS software package, v.20, by performing the following analyses: (1) a 4x2 mixed-design ANOVA including the within-subject factor Reward (R1, R2, R3, R4) for each group; (2) within-group pairwise comparisons between reward conditions; and (3) pairwise comparisons between experimental groups for each reward condition.
162-1	32314-32317	The	_	
162-2	32318-32330	beta-weights	_	
162-3	32331-32335	were	_	
162-4	32336-32344	analyzed	_	
162-5	32345-32350	using	_	
162-6	32351-32354	the	_	
162-7	32355-32359	SPSS	_	
162-8	32360-32368	software	_	
162-9	32369-32376	package	_	
162-10	32376-32377	,	_	
162-11	32378-32379	v	_	
162-12	32379-32382	.20	_	
162-13	32382-32383	,	_	
162-14	32384-32386	by	_	
162-15	32387-32397	performing	_	
162-16	32398-32401	the	_	
162-17	32402-32411	following	_	
162-18	32412-32420	analyses	_	
162-19	32420-32421	:	_	
162-20	32422-32423	(	_	
162-21	32423-32424	1	_	
162-22	32424-32425	)	_	
162-23	32426-32427	a	_	
162-24	32428-32431	4x2	_	
162-25	32432-32444	mixed-design	_	
162-26	32445-32450	ANOVA	_	
162-27	32451-32460	including	_	
162-28	32461-32464	the	_	
162-29	32465-32479	within-subject	_	
162-30	32480-32486	factor	_	
162-31	32487-32493	Reward	_	
162-32	32494-32495	(	_	
162-33	32495-32497	R1	_	
162-34	32497-32498	,	_	
162-35	32499-32501	R2	_	
162-36	32501-32502	,	_	
162-37	32503-32505	R3	_	
162-38	32505-32506	,	_	
162-39	32507-32509	R4	_	
162-40	32509-32510	)	_	
162-41	32511-32514	for	_	
162-42	32515-32519	each	_	
162-43	32520-32525	group	_	
162-44	32525-32526	;	_	
162-45	32527-32528	(	_	
162-46	32528-32529	2	_	
162-47	32529-32530	)	_	
162-48	32531-32543	within-group	_	
162-49	32544-32552	pairwise	_	
162-50	32553-32564	comparisons	_	
162-51	32565-32572	between	_	
162-52	32573-32579	reward	_	
162-53	32580-32590	conditions	_	
162-54	32590-32591	;	_	
162-55	32592-32595	and	_	
162-56	32596-32597	(	_	
162-57	32597-32598	3	_	
162-58	32598-32599	)	_	
162-59	32600-32608	pairwise	_	
162-60	32609-32620	comparisons	_	
162-61	32621-32628	between	_	
162-62	32629-32641	experimental	_	
162-63	32642-32648	groups	_	
162-64	32649-32652	for	_	
162-65	32653-32657	each	_	
162-66	32658-32664	reward	_	
162-67	32665-32674	condition	_	
162-68	32674-32675	.	_	

#Text=Again, these post-hoc analyses were run to examine what drove the parametric effects, obtaining a more thorough picture of what is driving the effect, but they should not be considered for statistical inference.
163-1	32676-32681	Again	_	
163-2	32681-32682	,	_	
163-3	32683-32688	these	_	
163-4	32689-32697	post-hoc	_	
163-5	32698-32706	analyses	_	
163-6	32707-32711	were	_	
163-7	32712-32715	run	_	
163-8	32716-32718	to	_	
163-9	32719-32726	examine	_	
163-10	32727-32731	what	_	
163-11	32732-32737	drove	_	
163-12	32738-32741	the	_	
163-13	32742-32752	parametric	_	
163-14	32753-32760	effects	_	
163-15	32760-32761	,	_	
163-16	32762-32771	obtaining	_	
163-17	32772-32773	a	_	
163-18	32774-32778	more	_	
163-19	32779-32787	thorough	_	
163-20	32788-32795	picture	_	
163-21	32796-32798	of	_	
163-22	32799-32803	what	_	
163-23	32804-32806	is	_	
163-24	32807-32814	driving	_	
163-25	32815-32818	the	_	
163-26	32819-32825	effect	_	
163-27	32825-32826	,	_	
163-28	32827-32830	but	_	
163-29	32831-32835	they	_	
163-30	32836-32842	should	_	
163-31	32843-32846	not	_	
163-32	32847-32849	be	_	
163-33	32850-32860	considered	_	
163-34	32861-32864	for	_	
163-35	32865-32876	statistical	_	
163-36	32877-32886	inference	_	
163-37	32886-32887	.	_	

#Text=We observed that both HC and ACD showed a parametric effect of reward on left DLPFC and left putamen connectivity (F(3,34) = 5.092; p = .005 for HC; and F(3,31) = 7.716; p = .001 for ACD); within-group pairwise comparisons between reward conditions are displayed in Fig 5.
164-1	32888-32890	We	_	
164-2	32891-32899	observed	_	
164-3	32900-32904	that	_	
164-4	32905-32909	both	_	
164-5	32910-32912	HC	_	
164-6	32913-32916	and	_	
164-7	32917-32920	ACD	_	
164-8	32921-32927	showed	_	
164-9	32928-32929	a	_	
164-10	32930-32940	parametric	_	
164-11	32941-32947	effect	_	
164-12	32948-32950	of	_	
164-13	32951-32957	reward	_	
164-14	32958-32960	on	_	
164-15	32961-32965	left	_	
164-16	32966-32971	DLPFC	_	
164-17	32972-32975	and	_	
164-18	32976-32980	left	_	
164-19	32981-32988	putamen	_	
164-20	32989-33001	connectivity	_	
164-21	33002-33003	(	_	
164-22	33003-33004	F	_	
164-23	33004-33005	(	_	
164-24	33005-33009	3,34	_	
164-25	33009-33010	)	_	
164-26	33011-33012	=	_	
164-27	33013-33018	5.092	_	
164-28	33018-33019	;	_	
164-29	33020-33021	p	_	
164-30	33022-33023	=	_	
164-31	33024-33028	.005	_	
164-32	33029-33032	for	_	
164-33	33033-33035	HC	_	
164-34	33035-33036	;	_	
164-35	33037-33040	and	_	
164-36	33041-33042	F	_	
164-37	33042-33043	(	_	
164-38	33043-33047	3,31	_	
164-39	33047-33048	)	_	
164-40	33049-33050	=	_	
164-41	33051-33056	7.716	_	
164-42	33056-33057	;	_	
164-43	33058-33059	p	_	
164-44	33060-33061	=	_	
164-45	33062-33066	.001	_	
164-46	33067-33070	for	_	
164-47	33071-33074	ACD	_	
164-48	33074-33075	)	_	
164-49	33075-33076	;	_	
164-50	33077-33089	within-group	_	
164-51	33090-33098	pairwise	_	
164-52	33099-33110	comparisons	_	
164-53	33111-33118	between	_	
164-54	33119-33125	reward	_	
164-55	33126-33136	conditions	_	
164-56	33137-33140	are	_	
164-57	33141-33150	displayed	_	
164-58	33151-33153	in	_	
164-59	33154-33157	Fig	_	
164-60	33158-33159	5	_	
164-61	33159-33160	.	_	

#Text=Finally, we performed a post-hoc gPPI analysis of the superior occipital and the putamen, in order to test the specificity of the frontostriatal connectivity, which was not significant (p>0.1).
165-1	33161-33168	Finally	_	
165-2	33168-33169	,	_	
165-3	33170-33172	we	_	
165-4	33173-33182	performed	_	
165-5	33183-33184	a	_	
165-6	33185-33193	post-hoc	_	
165-7	33194-33198	gPPI	_	
165-8	33199-33207	analysis	_	
165-9	33208-33210	of	_	
165-10	33211-33214	the	_	
165-11	33215-33223	superior	_	
165-12	33224-33233	occipital	_	
165-13	33234-33237	and	_	
165-14	33238-33241	the	_	
165-15	33242-33249	putamen	_	
165-16	33249-33250	,	_	
165-17	33251-33253	in	_	
165-18	33254-33259	order	_	
165-19	33260-33262	to	_	
165-20	33263-33267	test	_	
165-21	33268-33271	the	_	
165-22	33272-33283	specificity	_	
165-23	33284-33286	of	_	
165-24	33287-33290	the	_	
165-25	33291-33305	frontostriatal	_	
165-26	33306-33318	connectivity	_	
165-27	33318-33319	,	_	
165-28	33320-33325	which	_	
165-29	33326-33329	was	_	
165-30	33330-33333	not	_	
165-31	33334-33345	significant	_	
165-32	33346-33347	(	_	
165-33	33347-33348	p	_	
165-34	33348-33349	>	_	
165-35	33349-33352	0.1	_	
165-36	33352-33353	)	_	
165-37	33353-33354	.	_	

#Text=Brain regions showing changes in connectivity during parametric modulation by reward magnitude (R1<R2<R3<R4) in ACD>HC; and parameter estimates for each magnitude.
166-1	33355-33360	Brain	_	
166-2	33361-33368	regions	_	
166-3	33369-33376	showing	_	
166-4	33377-33384	changes	_	
166-5	33385-33387	in	_	
166-6	33388-33400	connectivity	_	
166-7	33401-33407	during	_	
166-8	33408-33418	parametric	_	
166-9	33419-33429	modulation	_	
166-10	33430-33432	by	_	
166-11	33433-33439	reward	_	
166-12	33440-33449	magnitude	_	
166-13	33450-33451	(	_	
166-14	33451-33453	R1	_	
166-15	33453-33454	<	_	
166-16	33454-33456	R2	_	
166-17	33456-33457	<	_	
166-18	33457-33459	R3	_	
166-19	33459-33460	<	_	
166-20	33460-33462	R4	_	
166-21	33462-33463	)	_	
166-22	33464-33466	in	_	
166-23	33467-33470	ACD	_	
166-24	33470-33471	>	_	
166-25	33471-33473	HC	_	
166-26	33473-33474	;	_	
166-27	33475-33478	and	_	
166-28	33479-33488	parameter	_	
166-29	33489-33498	estimates	_	
166-30	33499-33502	for	_	
166-31	33503-33507	each	_	
166-32	33508-33517	magnitude	_	
166-33	33517-33518	.	_	

#Text=DLPFC pale blue color inside the brain represents the seed region used for PPI analysis, whereas the putamen yellow color represents the color scale identified in the bar plot representing the z-values.
167-1	33519-33524	DLPFC	_	
167-2	33525-33529	pale	_	
167-3	33530-33534	blue	_	
167-4	33535-33540	color	_	
167-5	33541-33547	inside	_	
167-6	33548-33551	the	_	
167-7	33552-33557	brain	_	
167-8	33558-33568	represents	_	
167-9	33569-33572	the	_	
167-10	33573-33577	seed	_	
167-11	33578-33584	region	_	
167-12	33585-33589	used	_	
167-13	33590-33593	for	_	
167-14	33594-33597	PPI	_	
167-15	33598-33606	analysis	_	
167-16	33606-33607	,	_	
167-17	33608-33615	whereas	_	
167-18	33616-33619	the	_	
167-19	33620-33627	putamen	_	
167-20	33628-33634	yellow	_	
167-21	33635-33640	color	_	
167-22	33641-33651	represents	_	
167-23	33652-33655	the	_	
167-24	33656-33661	color	_	
167-25	33662-33667	scale	_	
167-26	33668-33678	identified	_	
167-27	33679-33681	in	_	
167-28	33682-33685	the	_	
167-29	33686-33689	bar	_	
167-30	33690-33694	plot	_	
167-31	33695-33707	representing	_	
167-32	33708-33711	the	_	
167-33	33712-33720	z-values	_	
167-34	33720-33721	.	_	

#Text=In the graphical representation below the images, the color bar represents the parameter estimates of the parametric contrast (R1<R2<R3<R4) = -2–1 1 2 for each reward magnitude.
168-1	33722-33724	In	_	
168-2	33725-33728	the	_	
168-3	33729-33738	graphical	_	
168-4	33739-33753	representation	_	
168-5	33754-33759	below	_	
168-6	33760-33763	the	_	
168-7	33764-33770	images	_	
168-8	33770-33771	,	_	
168-9	33772-33775	the	_	
168-10	33776-33781	color	_	
168-11	33782-33785	bar	_	
168-12	33786-33796	represents	_	
168-13	33797-33800	the	_	
168-14	33801-33810	parameter	_	
168-15	33811-33820	estimates	_	
168-16	33821-33823	of	_	
168-17	33824-33827	the	_	
168-18	33828-33838	parametric	_	
168-19	33839-33847	contrast	_	
168-20	33848-33849	(	_	
168-21	33849-33851	R1	_	
168-22	33851-33852	<	_	
168-23	33852-33854	R2	_	
168-24	33854-33855	<	_	
168-25	33855-33857	R3	_	
168-26	33857-33858	<	_	
168-27	33858-33860	R4	_	
168-28	33860-33861	)	_	
168-29	33862-33863	=	_	
168-30	33864-33865	-	_	
168-31	33865-33866	2	_	
168-32	33866-33867	–	_	
168-33	33867-33868	1	_	
168-34	33869-33870	1	_	
168-35	33871-33872	2	_	
168-36	33873-33876	for	_	
168-37	33877-33881	each	_	
168-38	33882-33888	reward	_	
168-39	33889-33898	magnitude	_	
168-40	33898-33899	.	_	

#Text=Error bars show within-subject standard error.
169-1	33900-33905	Error	_	
169-2	33906-33910	bars	_	
169-3	33911-33915	show	_	
169-4	33916-33930	within-subject	_	
169-5	33931-33939	standard	_	
169-6	33940-33945	error	_	
169-7	33945-33946	.	_	

#Text=The results inside the table show the pairwise comparisons t values (* = p < .05 and ** = p < .01).
170-1	33947-33950	The	_	
170-2	33951-33958	results	_	
170-3	33959-33965	inside	_	
170-4	33966-33969	the	_	
170-5	33970-33975	table	_	
170-6	33976-33980	show	_	
170-7	33981-33984	the	_	
170-8	33985-33993	pairwise	_	
170-9	33994-34005	comparisons	_	
170-10	34006-34007	t	_	
170-11	34008-34014	values	_	
170-12	34015-34016	(	_	
170-13	34016-34017	*	_	
170-14	34018-34019	=	_	
170-15	34020-34021	p	_	
170-16	34022-34023	<	_	
170-17	34024-34027	.05	_	
170-18	34028-34031	and	_	
170-19	34032-34033	*	_	
170-20	34033-34034	*	_	
170-21	34035-34036	=	_	
170-22	34037-34038	p	_	
170-23	34039-34040	<	_	
170-24	34041-34044	.01	_	
170-25	34044-34045	)	_	
170-26	34045-34046	.	_	

#Text=DLPFC, dorsolateral prefrontal cortex; HC, Healthy Control; ACD, Abstinent Cocaine Dependent; €, euro.
171-1	34047-34052	DLPFC	_	
171-2	34052-34053	,	_	
171-3	34054-34066	dorsolateral	_	
171-4	34067-34077	prefrontal	_	
171-5	34078-34084	cortex	_	
171-6	34084-34085	;	_	
171-7	34086-34088	HC	_	
171-8	34088-34089	,	_	
171-9	34090-34097	Healthy	_	
171-10	34098-34105	Control	_	
171-11	34105-34106	;	_	
171-12	34107-34110	ACD	_	
171-13	34110-34111	,	_	
171-14	34112-34121	Abstinent	_	
171-15	34122-34129	Cocaine	_	
171-16	34130-34139	Dependent	_	
171-17	34139-34140	;	_	
171-18	34141-34142	€	_	
171-19	34142-34143	,	_	
171-20	34144-34148	euro	_	
171-21	34148-34149	.	_	

#Text=R1 = “€0.01 vs. €0”; R2 = “€0.5 vs. €0”; R3 = “€1 vs. €0”; R4 = “€1.5 vs. €0”
#Text=Regression results
#Text=Our last goal was to test whether higher scores on clinical variable scales were related to activation of frontal and striatal parametric modulation of reward magnitude.
172-1	34150-34152	R1	_	
172-2	34153-34154	=	_	
172-3	34155-34156	“	_	
172-4	34156-34161	€0.01	_	
172-5	34162-34164	vs	_	
172-6	34164-34165	.	_	
172-7	34166-34168	€0	_	
172-8	34168-34169	”	_	
172-9	34169-34170	;	_	
172-10	34171-34173	R2	_	
172-11	34174-34175	=	_	
172-12	34176-34177	“	_	
172-13	34177-34181	€0.5	_	
172-14	34182-34184	vs	_	
172-15	34184-34185	.	_	
172-16	34186-34188	€0	_	
172-17	34188-34189	”	_	
172-18	34189-34190	;	_	
172-19	34191-34193	R3	_	
172-20	34194-34195	=	_	
172-21	34196-34197	“	_	
172-22	34197-34199	€1	_	
172-23	34200-34202	vs	_	
172-24	34202-34203	.	_	
172-25	34204-34206	€0	_	
172-26	34206-34207	”	_	
172-27	34207-34208	;	_	
172-28	34209-34211	R4	_	
172-29	34212-34213	=	_	
172-30	34214-34215	“	_	
172-31	34215-34219	€1.5	_	
172-32	34220-34222	vs	_	
172-33	34222-34223	.	_	
172-34	34224-34226	€0	_	
172-35	34226-34227	”	_	
172-36	34228-34238	Regression	_	
172-37	34239-34246	results	_	
172-38	34247-34250	Our	_	
172-39	34251-34255	last	_	
172-40	34256-34260	goal	_	
172-41	34261-34264	was	_	
172-42	34265-34267	to	_	
172-43	34268-34272	test	_	
172-44	34273-34280	whether	_	
172-45	34281-34287	higher	_	
172-46	34288-34294	scores	_	
172-47	34295-34297	on	_	
172-48	34298-34306	clinical	_	
172-49	34307-34315	variable	_	
172-50	34316-34322	scales	_	
172-51	34323-34327	were	_	
172-52	34328-34335	related	_	
172-53	34336-34338	to	_	
172-54	34339-34349	activation	_	
172-55	34350-34352	of	_	
172-56	34353-34360	frontal	_	
172-57	34361-34364	and	_	
172-58	34365-34373	striatal	_	
172-59	34374-34384	parametric	_	
172-60	34385-34395	modulation	_	
172-61	34396-34398	of	_	
172-62	34399-34405	reward	_	
172-63	34406-34415	magnitude	_	
172-64	34415-34416	.	_	

#Text=We obtained a negative relationship between left caudate activity and SCCQ-G-12 scores (FWE at p<0.05; r(34) = -0.639, p< .001).
173-1	34417-34419	We	_	
173-2	34420-34428	obtained	_	
173-3	34429-34430	a	_	
173-4	34431-34439	negative	_	
173-5	34440-34452	relationship	_	
173-6	34453-34460	between	_	
173-7	34461-34465	left	_	
173-8	34466-34473	caudate	_	
173-9	34474-34482	activity	_	
173-10	34483-34486	and	_	
173-11	34487-34493	SCCQ-G	_	
173-12	34493-34494	-	_	
173-13	34494-34496	12	_	
173-14	34497-34503	scores	_	
173-15	34504-34505	(	_	
173-16	34505-34508	FWE	_	
173-17	34509-34511	at	_	
173-18	34512-34513	p	_	
173-19	34513-34514	<	_	
173-20	34514-34518	0.05	_	
173-21	34518-34519	;	_	
173-22	34520-34521	r	_	
173-23	34521-34522	(	_	
173-24	34522-34524	34	_	
173-25	34524-34525	)	_	
173-26	34526-34527	=	_	
173-27	34528-34529	-	_	
173-28	34529-34534	0.639	_	
173-29	34534-34535	,	_	
173-30	34536-34537	p	_	
173-31	34537-34538	<	_	
173-32	34539-34543	.001	_	
173-33	34543-34544	)	_	
173-34	34544-34545	.	_	

#Text=The correlation between CSSA scores and the right pallidum was positive (FWE at p<0.05; r(34) = 0.529, p = .001).
174-1	34546-34549	The	_	
174-2	34550-34561	correlation	_	
174-3	34562-34569	between	_	
174-4	34570-34574	CSSA	_	
174-5	34575-34581	scores	_	
174-6	34582-34585	and	_	
174-7	34586-34589	the	_	
174-8	34590-34595	right	_	
174-9	34596-34604	pallidum	_	
174-10	34605-34608	was	_	
174-11	34609-34617	positive	_	
174-12	34618-34619	(	_	
174-13	34619-34622	FWE	_	
174-14	34623-34625	at	_	
174-15	34626-34627	p	_	
174-16	34627-34628	<	_	
174-17	34628-34632	0.05	_	
174-18	34632-34633	;	_	
174-19	34634-34635	r	_	
174-20	34635-34636	(	_	
174-21	34636-34638	34	_	
174-22	34638-34639	)	_	
174-23	34640-34641	=	_	
174-24	34642-34647	0.529	_	
174-25	34647-34648	,	_	
174-26	34649-34650	p	_	
174-27	34651-34652	=	_	
174-28	34653-34657	.001	_	
174-29	34657-34658	)	_	
174-30	34658-34659	.	_	

#Text=For illustration purposes, we plotted the parametric effect (R1<R2<R3<R4) by extracting the eigenvalues for each separate monetary condition (R1, R2, R3, R4), from the suprathreshold voxels in the caudate and pallidum (see Fig 6).
175-1	34660-34663	For	_	
175-2	34664-34676	illustration	_	
175-3	34677-34685	purposes	_	
175-4	34685-34686	,	_	
175-5	34687-34689	we	_	
175-6	34690-34697	plotted	_	
175-7	34698-34701	the	_	
175-8	34702-34712	parametric	_	
175-9	34713-34719	effect	_	
175-10	34720-34721	(	_	
175-11	34721-34723	R1	_	
175-12	34723-34724	<	_	
175-13	34724-34726	R2	_	
175-14	34726-34727	<	_	
175-15	34727-34729	R3	_	
175-16	34729-34730	<	_	
175-17	34730-34732	R4	_	
175-18	34732-34733	)	_	
175-19	34734-34736	by	_	
175-20	34737-34747	extracting	_	
175-21	34748-34751	the	_	
175-22	34752-34763	eigenvalues	_	
175-23	34764-34767	for	_	
175-24	34768-34772	each	_	
175-25	34773-34781	separate	_	
175-26	34782-34790	monetary	_	
175-27	34791-34800	condition	_	
175-28	34801-34802	(	_	
175-29	34802-34804	R1	_	
175-30	34804-34805	,	_	
175-31	34806-34808	R2	_	
175-32	34808-34809	,	_	
175-33	34810-34812	R3	_	
175-34	34812-34813	,	_	
175-35	34814-34816	R4	_	
175-36	34816-34817	)	_	
175-37	34817-34818	,	_	
175-38	34819-34823	from	_	
175-39	34824-34827	the	_	
175-40	34828-34842	suprathreshold	_	
175-41	34843-34849	voxels	_	
175-42	34850-34852	in	_	
175-43	34853-34856	the	_	
175-44	34857-34864	caudate	_	
175-45	34865-34868	and	_	
175-46	34869-34877	pallidum	_	
175-47	34878-34879	(	_	
175-48	34879-34882	see	_	
175-49	34883-34886	Fig	_	
175-50	34887-34888	6	_	
175-51	34888-34889	)	_	
175-52	34889-34890	.	_	

#Text=Again, these post-hoc analyses were run to examine what drove the parametric effects, obtaining a more thorough picture of what is driving the effect, but they should not be considered for statistical inference.
176-1	34891-34896	Again	_	
176-2	34896-34897	,	_	
176-3	34898-34903	these	_	
176-4	34904-34912	post-hoc	_	
176-5	34913-34921	analyses	_	
176-6	34922-34926	were	_	
176-7	34927-34930	run	_	
176-8	34931-34933	to	_	
176-9	34934-34941	examine	_	
176-10	34942-34946	what	_	
176-11	34947-34952	drove	_	
176-12	34953-34956	the	_	
176-13	34957-34967	parametric	_	
176-14	34968-34975	effects	_	
176-15	34975-34976	,	_	
176-16	34977-34986	obtaining	_	
176-17	34987-34988	a	_	
176-18	34989-34993	more	_	
176-19	34994-35002	thorough	_	
176-20	35003-35010	picture	_	
176-21	35011-35013	of	_	
176-22	35014-35018	what	_	
176-23	35019-35021	is	_	
176-24	35022-35029	driving	_	
176-25	35030-35033	the	_	
176-26	35034-35040	effect	_	
176-27	35040-35041	,	_	
176-28	35042-35045	but	_	
176-29	35046-35050	they	_	
176-30	35051-35057	should	_	
176-31	35058-35061	not	_	
176-32	35062-35064	be	_	
176-33	35065-35075	considered	_	
176-34	35076-35079	for	_	
176-35	35080-35091	statistical	_	
176-36	35092-35101	inference	_	
176-37	35101-35102	.	_	

#Text=Graphical representation of the relation between CSSA (left) and SCCQ-G-12 (right) and striatal and pallidum activity for each separate reward condition.
177-1	35103-35112	Graphical	_	
177-2	35113-35127	representation	_	
177-3	35128-35130	of	_	
177-4	35131-35134	the	_	
177-5	35135-35143	relation	_	
177-6	35144-35151	between	_	
177-7	35152-35156	CSSA	_	
177-8	35157-35158	(	_	
177-9	35158-35162	left	_	
177-10	35162-35163	)	_	
177-11	35164-35167	and	_	
177-12	35168-35174	SCCQ-G	_	
177-13	35174-35175	-	_	
177-14	35175-35177	12	_	
177-15	35178-35179	(	_	
177-16	35179-35184	right	_	
177-17	35184-35185	)	_	
177-18	35186-35189	and	_	
177-19	35190-35198	striatal	_	
177-20	35199-35202	and	_	
177-21	35203-35211	pallidum	_	
177-22	35212-35220	activity	_	
177-23	35221-35224	for	_	
177-24	35225-35229	each	_	
177-25	35230-35238	separate	_	
177-26	35239-35245	reward	_	
177-27	35246-35255	condition	_	
177-28	35255-35256	.	_	

#Text=The results in the graphics represent the Pearson correlation values (* = p < .05 and ** = p < .01)
#Text=Discussion
#Text=In our study, we examined whether increasing the monetary reward magnitude modulated the goal-directed behavior and neural activation in HC and ACD during a counting Stroop condition.
178-1	35257-35260	The	_	
178-2	35261-35268	results	_	
178-3	35269-35271	in	_	
178-4	35272-35275	the	_	
178-5	35276-35284	graphics	_	
178-6	35285-35294	represent	_	
178-7	35295-35298	the	_	
178-8	35299-35306	Pearson	_	
178-9	35307-35318	correlation	_	
178-10	35319-35325	values	_	
178-11	35326-35327	(	_	
178-12	35327-35328	*	_	
178-13	35329-35330	=	_	
178-14	35331-35332	p	_	
178-15	35333-35334	<	_	
178-16	35335-35338	.05	_	
178-17	35339-35342	and	_	
178-18	35343-35344	*	_	
178-19	35344-35345	*	_	
178-20	35346-35347	=	_	
178-21	35348-35349	p	_	
178-22	35350-35351	<	_	
178-23	35352-35355	.01	_	
178-24	35355-35356	)	_	
178-25	35357-35367	Discussion	_	
178-26	35368-35370	In	_	
178-27	35371-35374	our	_	
178-28	35375-35380	study	_	
178-29	35380-35381	,	_	
178-30	35382-35384	we	_	
178-31	35385-35393	examined	_	
178-32	35394-35401	whether	_	
178-33	35402-35412	increasing	_	
178-34	35413-35416	the	_	
178-35	35417-35425	monetary	_	
178-36	35426-35432	reward	_	
178-37	35433-35442	magnitude	_	
178-38	35443-35452	modulated	_	
178-39	35453-35456	the	_	
178-40	35457-35470	goal-directed	_	
178-41	35471-35479	behavior	_	
178-42	35480-35483	and	_	
178-43	35484-35490	neural	_	
178-44	35491-35501	activation	_	
178-45	35502-35504	in	_	
178-46	35505-35507	HC	_	
178-47	35508-35511	and	_	
178-48	35512-35515	ACD	_	
178-49	35516-35522	during	_	
178-50	35523-35524	a	_	
178-51	35525-35533	counting	_	
178-52	35534-35540	Stroop	_	
178-53	35541-35550	condition	_	
178-54	35550-35551	.	_	

#Text=At the behavioral level, our study showed that the monetary reward reduces the RT and error rates similarly in both groups.
179-1	35552-35554	At	_	
179-2	35555-35558	the	_	
179-3	35559-35569	behavioral	_	
179-4	35570-35575	level	_	
179-5	35575-35576	,	_	
179-6	35577-35580	our	_	
179-7	35581-35586	study	_	
179-8	35587-35593	showed	_	
179-9	35594-35598	that	_	
179-10	35599-35602	the	_	
179-11	35603-35611	monetary	_	
179-12	35612-35618	reward	_	
179-13	35619-35626	reduces	_	
179-14	35627-35630	the	_	
179-15	35631-35633	RT	_	
179-16	35634-35637	and	_	
179-17	35638-35643	error	_	
179-18	35644-35649	rates	_	
179-19	35650-35659	similarly	_	
179-20	35660-35662	in	_	
179-21	35663-35667	both	_	
179-22	35668-35674	groups	_	
179-23	35674-35675	.	_	

#Text=In the absence of between group differences, we observed that self-reported interest in the reward value was related to RT and SDrt in both groups, but these correlations were negative for HC and positive for ACD.
180-1	35676-35678	In	_	
180-2	35679-35682	the	_	
180-3	35683-35690	absence	_	
180-4	35691-35693	of	_	
180-5	35694-35701	between	_	
180-6	35702-35707	group	_	
180-7	35708-35719	differences	_	
180-8	35719-35720	,	_	
180-9	35721-35723	we	_	
180-10	35724-35732	observed	_	
180-11	35733-35737	that	_	
180-12	35738-35751	self-reported	_	
180-13	35752-35760	interest	_	
180-14	35761-35763	in	_	
180-15	35764-35767	the	_	
180-16	35768-35774	reward	_	
180-17	35775-35780	value	_	
180-18	35781-35784	was	_	
180-19	35785-35792	related	_	
180-20	35793-35795	to	_	
180-21	35796-35798	RT	_	
180-22	35799-35802	and	_	
180-23	35803-35807	SDrt	_	
180-24	35808-35810	in	_	
180-25	35811-35815	both	_	
180-26	35816-35822	groups	_	
180-27	35822-35823	,	_	
180-28	35824-35827	but	_	
180-29	35828-35833	these	_	
180-30	35834-35846	correlations	_	
180-31	35847-35851	were	_	
180-32	35852-35860	negative	_	
180-33	35861-35864	for	_	
180-34	35865-35867	HC	_	
180-35	35868-35871	and	_	
180-36	35872-35880	positive	_	
180-37	35881-35884	for	_	
180-38	35885-35888	ACD	_	
180-39	35888-35889	.	_	

#Text=At the brain level, increasing the reward magnitude increased left DLPFC activation in HC compared to ACD, whereas it increased left superior occipital cortex activation in ACD compared to HC.
181-1	35890-35892	At	_	
181-2	35893-35896	the	_	
181-3	35897-35902	brain	_	
181-4	35903-35908	level	_	
181-5	35908-35909	,	_	
181-6	35910-35920	increasing	_	
181-7	35921-35924	the	_	
181-8	35925-35931	reward	_	
181-9	35932-35941	magnitude	_	
181-10	35942-35951	increased	_	
181-11	35952-35956	left	_	
181-12	35957-35962	DLPFC	_	
181-13	35963-35973	activation	_	
181-14	35974-35976	in	_	
181-15	35977-35979	HC	_	
181-16	35980-35988	compared	_	
181-17	35989-35991	to	_	
181-18	35992-35995	ACD	_	
181-19	35995-35996	,	_	
181-20	35997-36004	whereas	_	
181-21	36005-36007	it	_	
181-22	36008-36017	increased	_	
181-23	36018-36022	left	_	
181-24	36023-36031	superior	_	
181-25	36032-36041	occipital	_	
181-26	36042-36048	cortex	_	
181-27	36049-36059	activation	_	
181-28	36060-36062	in	_	
181-29	36063-36066	ACD	_	
181-30	36067-36075	compared	_	
181-31	36076-36078	to	_	
181-32	36079-36081	HC	_	
181-33	36081-36082	.	_	

#Text=In addition, increasing the reward magnitude strengthened the connectivity between the left DLPFC and the left putamen more in ACD than in HC.
182-1	36083-36085	In	_	
182-2	36086-36094	addition	_	
182-3	36094-36095	,	_	
182-4	36096-36106	increasing	_	
182-5	36107-36110	the	_	
182-6	36111-36117	reward	_	
182-7	36118-36127	magnitude	_	
182-8	36128-36140	strengthened	_	
182-9	36141-36144	the	_	
182-10	36145-36157	connectivity	_	
182-11	36158-36165	between	_	
182-12	36166-36169	the	_	
182-13	36170-36174	left	_	
182-14	36175-36180	DLPFC	_	
182-15	36181-36184	and	_	
182-16	36185-36188	the	_	
182-17	36189-36193	left	_	
182-18	36194-36201	putamen	_	
182-19	36202-36206	more	_	
182-20	36207-36209	in	_	
182-21	36210-36213	ACD	_	
182-22	36214-36218	than	_	
182-23	36219-36221	in	_	
182-24	36222-36224	HC	_	
182-25	36224-36225	.	_	

#Text=Finally, high individual craving scores were negatively associated with the left caudate, and dependence severity scores were positively related to the right pallidum during parametric reward increases.
183-1	36226-36233	Finally	_	
183-2	36233-36234	,	_	
183-3	36235-36239	high	_	
183-4	36240-36250	individual	_	
183-5	36251-36258	craving	_	
183-6	36259-36265	scores	_	
183-7	36266-36270	were	_	
183-8	36271-36281	negatively	_	
183-9	36282-36292	associated	_	
183-10	36293-36297	with	_	
183-11	36298-36301	the	_	
183-12	36302-36306	left	_	
183-13	36307-36314	caudate	_	
183-14	36314-36315	,	_	
183-15	36316-36319	and	_	
183-16	36320-36330	dependence	_	
183-17	36331-36339	severity	_	
183-18	36340-36346	scores	_	
183-19	36347-36351	were	_	
183-20	36352-36362	positively	_	
183-21	36363-36370	related	_	
183-22	36371-36373	to	_	
183-23	36374-36377	the	_	
183-24	36378-36383	right	_	
183-25	36384-36392	pallidum	_	
183-26	36393-36399	during	_	
183-27	36400-36410	parametric	_	
183-28	36411-36417	reward	_	
183-29	36418-36427	increases	_	
183-30	36427-36428	.	_	

#Text=Therefore, the present study shows differences between HC and ACD in the regional brain activation and connectivity involving the frontostriatal circuitry and other areas, as a function of increasing the monetary reward magnitudes and clinical variables, with no behavioral differences between the groups’ performance, but within-group enhanced behavioral performance under reward conditions.
184-1	36429-36438	Therefore	_	
184-2	36438-36439	,	_	
184-3	36440-36443	the	_	
184-4	36444-36451	present	_	
184-5	36452-36457	study	_	
184-6	36458-36463	shows	_	
184-7	36464-36475	differences	_	
184-8	36476-36483	between	_	
184-9	36484-36486	HC	_	
184-10	36487-36490	and	_	
184-11	36491-36494	ACD	_	
184-12	36495-36497	in	_	
184-13	36498-36501	the	_	
184-14	36502-36510	regional	_	
184-15	36511-36516	brain	_	
184-16	36517-36527	activation	_	
184-17	36528-36531	and	_	
184-18	36532-36544	connectivity	_	
184-19	36545-36554	involving	_	
184-20	36555-36558	the	_	
184-21	36559-36573	frontostriatal	_	
184-22	36574-36583	circuitry	_	
184-23	36584-36587	and	_	
184-24	36588-36593	other	_	
184-25	36594-36599	areas	_	
184-26	36599-36600	,	_	
184-27	36601-36603	as	_	
184-28	36604-36605	a	_	
184-29	36606-36614	function	_	
184-30	36615-36617	of	_	
184-31	36618-36628	increasing	_	
184-32	36629-36632	the	_	
184-33	36633-36641	monetary	_	
184-34	36642-36648	reward	_	
184-35	36649-36659	magnitudes	_	
184-36	36660-36663	and	_	
184-37	36664-36672	clinical	_	
184-38	36673-36682	variables	_	
184-39	36682-36683	,	_	
184-40	36684-36688	with	_	
184-41	36689-36691	no	_	
184-42	36692-36702	behavioral	_	
184-43	36703-36714	differences	_	
184-44	36715-36722	between	_	
184-45	36723-36726	the	_	
184-46	36727-36733	groups	_	
184-47	36733-36734	’	_	
184-48	36735-36746	performance	_	
184-49	36746-36747	,	_	
184-50	36748-36751	but	_	
184-51	36752-36764	within-group	_	
184-52	36765-36773	enhanced	_	
184-53	36774-36784	behavioral	_	
184-54	36785-36796	performance	_	
184-55	36797-36802	under	_	
184-56	36803-36809	reward	_	
184-57	36810-36820	conditions	_	
184-58	36820-36821	.	_	

#Text=Impact of reward on performance and its relation with self-reported interest on reward value
#Text=The behavioral results confirm the enhanced task performance in both groups under monetary reward contingencies in the absence of significant differences between HC and ACD in performance improvement; that is, both groups decreased their RTs and error rate as the monetary reward increased.
185-1	36822-36828	Impact	_	
185-2	36829-36831	of	_	
185-3	36832-36838	reward	_	
185-4	36839-36841	on	_	
185-5	36842-36853	performance	_	
185-6	36854-36857	and	_	
185-7	36858-36861	its	_	
185-8	36862-36870	relation	_	
185-9	36871-36875	with	_	
185-10	36876-36889	self-reported	_	
185-11	36890-36898	interest	_	
185-12	36899-36901	on	_	
185-13	36902-36908	reward	_	
185-14	36909-36914	value	_	
185-15	36915-36918	The	_	
185-16	36919-36929	behavioral	_	
185-17	36930-36937	results	_	
185-18	36938-36945	confirm	_	
185-19	36946-36949	the	_	
185-20	36950-36958	enhanced	_	
185-21	36959-36963	task	_	
185-22	36964-36975	performance	_	
185-23	36976-36978	in	_	
185-24	36979-36983	both	_	
185-25	36984-36990	groups	_	
185-26	36991-36996	under	_	
185-27	36997-37005	monetary	_	
185-28	37006-37012	reward	_	
185-29	37013-37026	contingencies	_	
185-30	37027-37029	in	_	
185-31	37030-37033	the	_	
185-32	37034-37041	absence	_	
185-33	37042-37044	of	_	
185-34	37045-37056	significant	_	
185-35	37057-37068	differences	_	
185-36	37069-37076	between	_	
185-37	37077-37079	HC	_	
185-38	37080-37083	and	_	
185-39	37084-37087	ACD	_	
185-40	37088-37090	in	_	
185-41	37091-37102	performance	_	
185-42	37103-37114	improvement	_	
185-43	37114-37115	;	_	
185-44	37116-37120	that	_	
185-45	37121-37123	is	_	
185-46	37123-37124	,	_	
185-47	37125-37129	both	_	
185-48	37130-37136	groups	_	
185-49	37137-37146	decreased	_	
185-50	37147-37152	their	_	
185-51	37153-37156	RTs	_	
185-52	37157-37160	and	_	
185-53	37161-37166	error	_	
185-54	37167-37171	rate	_	
185-55	37172-37174	as	_	
185-56	37175-37178	the	_	
185-57	37179-37187	monetary	_	
185-58	37188-37194	reward	_	
185-59	37195-37204	increased	_	
185-60	37204-37205	.	_	

#Text=Reward-associated enhanced performance in our study agrees with previous reports that evaluated the effects of a monetary reward in cocaine addicts and healthy controls during cognitive control tasks such as drug Stroop, spatial learning, and decision making.
186-1	37206-37223	Reward-associated	_	
186-2	37224-37232	enhanced	_	
186-3	37233-37244	performance	_	
186-4	37245-37247	in	_	
186-5	37248-37251	our	_	
186-6	37252-37257	study	_	
186-7	37258-37264	agrees	_	
186-8	37265-37269	with	_	
186-9	37270-37278	previous	_	
186-10	37279-37286	reports	_	
186-11	37287-37291	that	_	
186-12	37292-37301	evaluated	_	
186-13	37302-37305	the	_	
186-14	37306-37313	effects	_	
186-15	37314-37316	of	_	
186-16	37317-37318	a	_	
186-17	37319-37327	monetary	_	
186-18	37328-37334	reward	_	
186-19	37335-37337	in	_	
186-20	37338-37345	cocaine	_	
186-21	37346-37353	addicts	_	
186-22	37354-37357	and	_	
186-23	37358-37365	healthy	_	
186-24	37366-37374	controls	_	
186-25	37375-37381	during	_	
186-26	37382-37391	cognitive	_	
186-27	37392-37399	control	_	
186-28	37400-37405	tasks	_	
186-29	37406-37410	such	_	
186-30	37411-37413	as	_	
186-31	37414-37418	drug	_	
186-32	37419-37425	Stroop	_	
186-33	37425-37426	,	_	
186-34	37427-37434	spatial	_	
186-35	37435-37443	learning	_	
186-36	37443-37444	,	_	
186-37	37445-37448	and	_	
186-38	37449-37457	decision	_	
186-39	37458-37464	making	_	
186-40	37464-37465	.	_	

#Text=Therefore, although drug addiction is characterized by an enhanced motivational value of the drug at the expense of other reinforcers and impaired cognitive control, our results and previous ones suggest that cocaine addicts’ goal-directed behavior benefits from an immediate monetary reward contingency.
187-1	37466-37475	Therefore	_	
187-2	37475-37476	,	_	
187-3	37477-37485	although	_	
187-4	37486-37490	drug	_	
187-5	37491-37500	addiction	_	
187-6	37501-37503	is	_	
187-7	37504-37517	characterized	_	
187-8	37518-37520	by	_	
187-9	37521-37523	an	_	
187-10	37524-37532	enhanced	_	
187-11	37533-37545	motivational	_	
187-12	37546-37551	value	_	
187-13	37552-37554	of	_	
187-14	37555-37558	the	_	
187-15	37559-37563	drug	_	
187-16	37564-37566	at	_	
187-17	37567-37570	the	_	
187-18	37571-37578	expense	_	
187-19	37579-37581	of	_	
187-20	37582-37587	other	_	
187-21	37588-37599	reinforcers	_	
187-22	37600-37603	and	_	
187-23	37604-37612	impaired	_	
187-24	37613-37622	cognitive	_	
187-25	37623-37630	control	_	
187-26	37630-37631	,	_	
187-27	37632-37635	our	_	
187-28	37636-37643	results	_	
187-29	37644-37647	and	_	
187-30	37648-37656	previous	_	
187-31	37657-37661	ones	_	
187-32	37662-37669	suggest	_	
187-33	37670-37674	that	_	
187-34	37675-37682	cocaine	_	
187-35	37683-37690	addicts	_	
187-36	37690-37691	’	_	
187-37	37692-37705	goal-directed	_	
187-38	37706-37714	behavior	_	
187-39	37715-37723	benefits	_	
187-40	37724-37728	from	_	
187-41	37729-37731	an	_	
187-42	37732-37741	immediate	_	
187-43	37742-37750	monetary	_	
187-44	37751-37757	reward	_	
187-45	37758-37769	contingency	_	
187-46	37769-37770	.	_	

#Text=Regarding the relationship between self-reported interest and behavioral improvement, similarly to Goldstein et al., we did not observe a group effect or an interaction effect on self-reported interest.
188-1	37771-37780	Regarding	_	
188-2	37781-37784	the	_	
188-3	37785-37797	relationship	_	
188-4	37798-37805	between	_	
188-5	37806-37819	self-reported	_	
188-6	37820-37828	interest	_	
188-7	37829-37832	and	_	
188-8	37833-37843	behavioral	_	
188-9	37844-37855	improvement	_	
188-10	37855-37856	,	_	
188-11	37857-37866	similarly	_	
188-12	37867-37869	to	_	
188-13	37870-37879	Goldstein	_	
188-14	37880-37882	et	_	
188-15	37883-37885	al	_	
188-16	37885-37886	.	_	
188-17	37886-37887	,	_	
188-18	37888-37890	we	_	
188-19	37891-37894	did	_	
188-20	37895-37898	not	_	
188-21	37899-37906	observe	_	
188-22	37907-37908	a	_	
188-23	37909-37914	group	_	
188-24	37915-37921	effect	_	
188-25	37922-37924	or	_	
188-26	37925-37927	an	_	
188-27	37928-37939	interaction	_	
188-28	37940-37946	effect	_	
188-29	37947-37949	on	_	
188-30	37950-37963	self-reported	_	
188-31	37964-37972	interest	_	
188-32	37972-37973	.	_	

#Text=However, we obtained between-group differences when comparing the correlation coefficients, with a trend toward showing the opposite pattern of correlations for HC and ACD between self-reported interest and RT and SDrt.
189-1	37974-37981	However	_	
189-2	37981-37982	,	_	
189-3	37983-37985	we	_	
189-4	37986-37994	obtained	_	
189-5	37995-38008	between-group	_	
189-6	38009-38020	differences	_	
189-7	38021-38025	when	_	
189-8	38026-38035	comparing	_	
189-9	38036-38039	the	_	
189-10	38040-38051	correlation	_	
189-11	38052-38064	coefficients	_	
189-12	38064-38065	,	_	
189-13	38066-38070	with	_	
189-14	38071-38072	a	_	
189-15	38073-38078	trend	_	
189-16	38079-38085	toward	_	
189-17	38086-38093	showing	_	
189-18	38094-38097	the	_	
189-19	38098-38106	opposite	_	
189-20	38107-38114	pattern	_	
189-21	38115-38117	of	_	
189-22	38118-38130	correlations	_	
189-23	38131-38134	for	_	
189-24	38135-38137	HC	_	
189-25	38138-38141	and	_	
189-26	38142-38145	ACD	_	
189-27	38146-38153	between	_	
189-28	38154-38167	self-reported	_	
189-29	38168-38176	interest	_	
189-30	38177-38180	and	_	
189-31	38181-38183	RT	_	
189-32	38184-38187	and	_	
189-33	38188-38192	SDrt	_	
189-34	38192-38193	.	_	

#Text=These results might be interpreted as additional evidence for reward threshold elevations or reward sensitivity decreases in cocaine addicts.
190-1	38194-38199	These	_	
190-2	38200-38207	results	_	
190-3	38208-38213	might	_	
190-4	38214-38216	be	_	
190-5	38217-38228	interpreted	_	
190-6	38229-38231	as	_	
190-7	38232-38242	additional	_	
190-8	38243-38251	evidence	_	
190-9	38252-38255	for	_	
190-10	38256-38262	reward	_	
190-11	38263-38272	threshold	_	
190-12	38273-38283	elevations	_	
190-13	38284-38286	or	_	
190-14	38287-38293	reward	_	
190-15	38294-38305	sensitivity	_	
190-16	38306-38315	decreases	_	
190-17	38316-38318	in	_	
190-18	38319-38326	cocaine	_	
190-19	38327-38334	addicts	_	
190-20	38334-38335	.	_	

#Text=Otherwise, these results can be explained in the context of secondary reinforcing effects of money in rewarding drug procurement, associated with money availability.
191-1	38336-38345	Otherwise	_	
191-2	38345-38346	,	_	
191-3	38347-38352	these	_	
191-4	38353-38360	results	_	
191-5	38361-38364	can	_	
191-6	38365-38367	be	_	
191-7	38368-38377	explained	_	
191-8	38378-38380	in	_	
191-9	38381-38384	the	_	
191-10	38385-38392	context	_	
191-11	38393-38395	of	_	
191-12	38396-38405	secondary	_	
191-13	38406-38417	reinforcing	_	
191-14	38418-38425	effects	_	
191-15	38426-38428	of	_	
191-16	38429-38434	money	_	
191-17	38435-38437	in	_	
191-18	38438-38447	rewarding	_	
191-19	38448-38452	drug	_	
191-20	38453-38464	procurement	_	
191-21	38464-38465	,	_	
191-22	38466-38476	associated	_	
191-23	38477-38481	with	_	
191-24	38482-38487	money	_	
191-25	38488-38500	availability	_	
191-26	38500-38501	.	_	

#Text=We speculate about whether the fact that increases in the monetary reward magnitude improved goal-directed behavior in ACD would suggest the need to change strategies in abstinence therapies by weighting up reward rather than using other reinforcing contingencies (e.g., motivate drug users to attend treatment sessions regularly).
192-1	38502-38504	We	_	
192-2	38505-38514	speculate	_	
192-3	38515-38520	about	_	
192-4	38521-38528	whether	_	
192-5	38529-38532	the	_	
192-6	38533-38537	fact	_	
192-7	38538-38542	that	_	
192-8	38543-38552	increases	_	
192-9	38553-38555	in	_	
192-10	38556-38559	the	_	
192-11	38560-38568	monetary	_	
192-12	38569-38575	reward	_	
192-13	38576-38585	magnitude	_	
192-14	38586-38594	improved	_	
192-15	38595-38608	goal-directed	_	
192-16	38609-38617	behavior	_	
192-17	38618-38620	in	_	
192-18	38621-38624	ACD	_	
192-19	38625-38630	would	_	
192-20	38631-38638	suggest	_	
192-21	38639-38642	the	_	
192-22	38643-38647	need	_	
192-23	38648-38650	to	_	
192-24	38651-38657	change	_	
192-25	38658-38668	strategies	_	
192-26	38669-38671	in	_	
192-27	38672-38682	abstinence	_	
192-28	38683-38692	therapies	_	
192-29	38693-38695	by	_	
192-30	38696-38705	weighting	_	
192-31	38706-38708	up	_	
192-32	38709-38715	reward	_	
192-33	38716-38722	rather	_	
192-34	38723-38727	than	_	
192-35	38728-38733	using	_	
192-36	38734-38739	other	_	
192-37	38740-38751	reinforcing	_	
192-38	38752-38765	contingencies	_	
192-39	38766-38767	(	_	
192-40	38767-38770	e.g	_	
192-41	38770-38771	.	_	
192-42	38771-38772	,	_	
192-43	38773-38781	motivate	_	
192-44	38782-38786	drug	_	
192-45	38787-38792	users	_	
192-46	38793-38795	to	_	
192-47	38796-38802	attend	_	
192-48	38803-38812	treatment	_	
192-49	38813-38821	sessions	_	
192-50	38822-38831	regularly	_	
192-51	38831-38832	)	_	
192-52	38832-38833	.	_	

#Text=In this regard, the fact that money availability can condition drug procurement might mean that clinical interventions should focus on promoting the more immediate and reinforcing goal of social, family, and health rewards because monetary reward cues could increase craving or drug urges, contributing to maintained drug use.
193-1	38834-38836	In	_	
193-2	38837-38841	this	_	
193-3	38842-38848	regard	_	
193-4	38848-38849	,	_	
193-5	38850-38853	the	_	
193-6	38854-38858	fact	_	
193-7	38859-38863	that	_	
193-8	38864-38869	money	_	
193-9	38870-38882	availability	_	
193-10	38883-38886	can	_	
193-11	38887-38896	condition	_	
193-12	38897-38901	drug	_	
193-13	38902-38913	procurement	_	
193-14	38914-38919	might	_	
193-15	38920-38924	mean	_	
193-16	38925-38929	that	_	
193-17	38930-38938	clinical	_	
193-18	38939-38952	interventions	_	
193-19	38953-38959	should	_	
193-20	38960-38965	focus	_	
193-21	38966-38968	on	_	
193-22	38969-38978	promoting	_	
193-23	38979-38982	the	_	
193-24	38983-38987	more	_	
193-25	38988-38997	immediate	_	
193-26	38998-39001	and	_	
193-27	39002-39013	reinforcing	_	
193-28	39014-39018	goal	_	
193-29	39019-39021	of	_	
193-30	39022-39028	social	_	
193-31	39028-39029	,	_	
193-32	39030-39036	family	_	
193-33	39036-39037	,	_	
193-34	39038-39041	and	_	
193-35	39042-39048	health	_	
193-36	39049-39056	rewards	_	
193-37	39057-39064	because	_	
193-38	39065-39073	monetary	_	
193-39	39074-39080	reward	_	
193-40	39081-39085	cues	_	
193-41	39086-39091	could	_	
193-42	39092-39100	increase	_	
193-43	39101-39108	craving	_	
193-44	39109-39111	or	_	
193-45	39112-39116	drug	_	
193-46	39117-39122	urges	_	
193-47	39122-39123	,	_	
193-48	39124-39136	contributing	_	
193-49	39137-39139	to	_	
193-50	39140-39150	maintained	_	
193-51	39151-39155	drug	_	
193-52	39156-39159	use	_	
193-53	39159-39160	.	_	

#Text=Impact of monetary reward gradients on brain activity
#Text=Functional results confirm our second hypothesis because the activity of the prefrontal regions was negatively modulated by the increasing monetary reward magnitude in ACD compared to HC, but ACD increase the activation of other brain regions, such as the superior occipital cortex, which might counteract prefrontal differences with HC.
194-1	39161-39167	Impact	_	
194-2	39168-39170	of	_	
194-3	39171-39179	monetary	_	
194-4	39180-39186	reward	_	
194-5	39187-39196	gradients	_	
194-6	39197-39199	on	_	
194-7	39200-39205	brain	_	
194-8	39206-39214	activity	_	
194-9	39215-39225	Functional	_	
194-10	39226-39233	results	_	
194-11	39234-39241	confirm	_	
194-12	39242-39245	our	_	
194-13	39246-39252	second	_	
194-14	39253-39263	hypothesis	_	
194-15	39264-39271	because	_	
194-16	39272-39275	the	_	
194-17	39276-39284	activity	_	
194-18	39285-39287	of	_	
194-19	39288-39291	the	_	
194-20	39292-39302	prefrontal	_	
194-21	39303-39310	regions	_	
194-22	39311-39314	was	_	
194-23	39315-39325	negatively	_	
194-24	39326-39335	modulated	_	
194-25	39336-39338	by	_	
194-26	39339-39342	the	_	
194-27	39343-39353	increasing	_	
194-28	39354-39362	monetary	_	
194-29	39363-39369	reward	_	
194-30	39370-39379	magnitude	_	
194-31	39380-39382	in	_	
194-32	39383-39386	ACD	_	
194-33	39387-39395	compared	_	
194-34	39396-39398	to	_	
194-35	39399-39401	HC	_	
194-36	39401-39402	,	_	
194-37	39403-39406	but	_	
194-38	39407-39410	ACD	_	
194-39	39411-39419	increase	_	
194-40	39420-39423	the	_	
194-41	39424-39434	activation	_	
194-42	39435-39437	of	_	
194-43	39438-39443	other	_	
194-44	39444-39449	brain	_	
194-45	39450-39457	regions	_	
194-46	39457-39458	,	_	
194-47	39459-39463	such	_	
194-48	39464-39466	as	_	
194-49	39467-39470	the	_	
194-50	39471-39479	superior	_	
194-51	39480-39489	occipital	_	
194-52	39490-39496	cortex	_	
194-53	39496-39497	,	_	
194-54	39498-39503	which	_	
194-55	39504-39509	might	_	
194-56	39510-39520	counteract	_	
194-57	39521-39531	prefrontal	_	
194-58	39532-39543	differences	_	
194-59	39544-39548	with	_	
194-60	39549-39551	HC	_	
194-61	39551-39552	.	_	

#Text=The brain activation in the absence of performance differences between these same groups may be interpreted in several ways (see for a discussion on similar effects), but the most frequent interpretation in drug addiction research would be to consider differences in patients’ brain activation as a vulnerability index for the cognitive dysfunction underlying the neuronal changes associated with lengthy drug use.
195-1	39553-39556	The	_	
195-2	39557-39562	brain	_	
195-3	39563-39573	activation	_	
195-4	39574-39576	in	_	
195-5	39577-39580	the	_	
195-6	39581-39588	absence	_	
195-7	39589-39591	of	_	
195-8	39592-39603	performance	_	
195-9	39604-39615	differences	_	
195-10	39616-39623	between	_	
195-11	39624-39629	these	_	
195-12	39630-39634	same	_	
195-13	39635-39641	groups	_	
195-14	39642-39645	may	_	
195-15	39646-39648	be	_	
195-16	39649-39660	interpreted	_	
195-17	39661-39663	in	_	
195-18	39664-39671	several	_	
195-19	39672-39676	ways	_	
195-20	39677-39678	(	_	
195-21	39678-39681	see	_	
195-22	39682-39685	for	_	
195-23	39686-39687	a	_	
195-24	39688-39698	discussion	_	
195-25	39699-39701	on	_	
195-26	39702-39709	similar	_	
195-27	39710-39717	effects	_	
195-28	39717-39718	)	_	
195-29	39718-39719	,	_	
195-30	39720-39723	but	_	
195-31	39724-39727	the	_	
195-32	39728-39732	most	_	
195-33	39733-39741	frequent	_	
195-34	39742-39756	interpretation	_	
195-35	39757-39759	in	_	
195-36	39760-39764	drug	_	
195-37	39765-39774	addiction	_	
195-38	39775-39783	research	_	
195-39	39784-39789	would	_	
195-40	39790-39792	be	_	
195-41	39793-39795	to	_	
195-42	39796-39804	consider	_	
195-43	39805-39816	differences	_	
195-44	39817-39819	in	_	
195-45	39820-39828	patients	_	
195-46	39828-39829	’	_	
195-47	39830-39835	brain	_	
195-48	39836-39846	activation	_	
195-49	39847-39849	as	_	
195-50	39850-39851	a	_	
195-51	39852-39865	vulnerability	_	
195-52	39866-39871	index	_	
195-53	39872-39875	for	_	
195-54	39876-39879	the	_	
195-55	39880-39889	cognitive	_	
195-56	39890-39901	dysfunction	_	
195-57	39902-39912	underlying	_	
195-58	39913-39916	the	_	
195-59	39917-39925	neuronal	_	
195-60	39926-39933	changes	_	
195-61	39934-39944	associated	_	
195-62	39945-39949	with	_	
195-63	39950-39957	lengthy	_	
195-64	39958-39962	drug	_	
195-65	39963-39966	use	_	
195-66	39966-39967	.	_	

#Text=The DLPFC plays an important role in integrating cognitive and motivational information processing, and previous studies using cognitive tasks have shown its involvement in reward modulation.
196-1	39968-39971	The	_	
196-2	39972-39977	DLPFC	_	
196-3	39978-39983	plays	_	
196-4	39984-39986	an	_	
196-5	39987-39996	important	_	
196-6	39997-40001	role	_	
196-7	40002-40004	in	_	
196-8	40005-40016	integrating	_	
196-9	40017-40026	cognitive	_	
196-10	40027-40030	and	_	
196-11	40031-40043	motivational	_	
196-12	40044-40055	information	_	
196-13	40056-40066	processing	_	
196-14	40066-40067	,	_	
196-15	40068-40071	and	_	
196-16	40072-40080	previous	_	
196-17	40081-40088	studies	_	
196-18	40089-40094	using	_	
196-19	40095-40104	cognitive	_	
196-20	40105-40110	tasks	_	
196-21	40111-40115	have	_	
196-22	40116-40121	shown	_	
196-23	40122-40125	its	_	
196-24	40126-40137	involvement	_	
196-25	40138-40140	in	_	
196-26	40141-40147	reward	_	
196-27	40148-40158	modulation	_	
196-28	40158-40159	.	_	

#Text=The interaction effect obtained in the DLPFC shows a difference between the groups’ BOLD signal in relation to their sensitivity to reward gradients.
197-1	40160-40163	The	_	
197-2	40164-40175	interaction	_	
197-3	40176-40182	effect	_	
197-4	40183-40191	obtained	_	
197-5	40192-40194	in	_	
197-6	40195-40198	the	_	
197-7	40199-40204	DLPFC	_	
197-8	40205-40210	shows	_	
197-9	40211-40212	a	_	
197-10	40213-40223	difference	_	
197-11	40224-40231	between	_	
197-12	40232-40235	the	_	
197-13	40236-40242	groups	_	
197-14	40242-40243	’	_	
197-15	40244-40248	BOLD	_	
197-16	40249-40255	signal	_	
197-17	40256-40258	in	_	
197-18	40259-40267	relation	_	
197-19	40268-40270	to	_	
197-20	40271-40276	their	_	
197-21	40277-40288	sensitivity	_	
197-22	40289-40291	to	_	
197-23	40292-40298	reward	_	
197-24	40299-40308	gradients	_	
197-25	40308-40309	.	_	

#Text=Thus, the reduced activation in the DLPFC during goal-directed behavior associated with achieving higher monetary rewards in ACD agrees with addiction features that compromise cognitive control and reduce reward sensitivity associated with drug-related changes and frontal lobe functioning and top-down processes; although we observed increased activation in occipital regions in the ACD group.
198-1	40310-40314	Thus	_	
198-2	40314-40315	,	_	
198-3	40316-40319	the	_	
198-4	40320-40327	reduced	_	
198-5	40328-40338	activation	_	
198-6	40339-40341	in	_	
198-7	40342-40345	the	_	
198-8	40346-40351	DLPFC	_	
198-9	40352-40358	during	_	
198-10	40359-40372	goal-directed	_	
198-11	40373-40381	behavior	_	
198-12	40382-40392	associated	_	
198-13	40393-40397	with	_	
198-14	40398-40407	achieving	_	
198-15	40408-40414	higher	_	
198-16	40415-40423	monetary	_	
198-17	40424-40431	rewards	_	
198-18	40432-40434	in	_	
198-19	40435-40438	ACD	_	
198-20	40439-40445	agrees	_	
198-21	40446-40450	with	_	
198-22	40451-40460	addiction	_	
198-23	40461-40469	features	_	
198-24	40470-40474	that	_	
198-25	40475-40485	compromise	_	
198-26	40486-40495	cognitive	_	
198-27	40496-40503	control	_	
198-28	40504-40507	and	_	
198-29	40508-40514	reduce	_	
198-30	40515-40521	reward	_	
198-31	40522-40533	sensitivity	_	
198-32	40534-40544	associated	_	
198-33	40545-40549	with	_	
198-34	40550-40562	drug-related	_	
198-35	40563-40570	changes	_	
198-36	40571-40574	and	_	
198-37	40575-40582	frontal	_	
198-38	40583-40587	lobe	_	
198-39	40588-40599	functioning	_	
198-40	40600-40603	and	_	
198-41	40604-40612	top-down	_	
198-42	40613-40622	processes	_	
198-43	40622-40623	;	_	
198-44	40624-40632	although	_	
198-45	40633-40635	we	_	
198-46	40636-40644	observed	_	
198-47	40645-40654	increased	_	
198-48	40655-40665	activation	_	
198-49	40666-40668	in	_	
198-50	40669-40678	occipital	_	
198-51	40679-40686	regions	_	
198-52	40687-40689	in	_	
198-53	40690-40693	the	_	
198-54	40694-40697	ACD	_	
198-55	40698-40703	group	_	
198-56	40703-40704	.	_	

#Text=We suggest that reward may modulate different neural pathways from those shown to be modulated by monetary gradients in ACD compared to HC.
199-1	40705-40707	We	_	
199-2	40708-40715	suggest	_	
199-3	40716-40720	that	_	
199-4	40721-40727	reward	_	
199-5	40728-40731	may	_	
199-6	40732-40740	modulate	_	
199-7	40741-40750	different	_	
199-8	40751-40757	neural	_	
199-9	40758-40766	pathways	_	
199-10	40767-40771	from	_	
199-11	40772-40777	those	_	
199-12	40778-40783	shown	_	
199-13	40784-40786	to	_	
199-14	40787-40789	be	_	
199-15	40790-40799	modulated	_	
199-16	40800-40802	by	_	
199-17	40803-40811	monetary	_	
199-18	40812-40821	gradients	_	
199-19	40822-40824	in	_	
199-20	40825-40828	ACD	_	
199-21	40829-40837	compared	_	
199-22	40838-40840	to	_	
199-23	40841-40843	HC	_	
199-24	40843-40844	.	_	

#Text=We observed an interaction effect in the superior occipital cortex which could be interpreted as an attentional reactivity to reward that allowed functional compensation.
200-1	40845-40847	We	_	
200-2	40848-40856	observed	_	
200-3	40857-40859	an	_	
200-4	40860-40871	interaction	_	
200-5	40872-40878	effect	_	
200-6	40879-40881	in	_	
200-7	40882-40885	the	_	
200-8	40886-40894	superior	_	
200-9	40895-40904	occipital	_	
200-10	40905-40911	cortex	_	
200-11	40912-40917	which	_	
200-12	40918-40923	could	_	
200-13	40924-40926	be	_	
200-14	40927-40938	interpreted	_	
200-15	40939-40941	as	_	
200-16	40942-40944	an	_	
200-17	40945-40956	attentional	_	
200-18	40957-40967	reactivity	_	
200-19	40968-40970	to	_	
200-20	40971-40977	reward	_	
200-21	40978-40982	that	_	
200-22	40983-40990	allowed	_	
200-23	40991-41001	functional	_	
200-24	41002-41014	compensation	_	
200-25	41014-41015	.	_	

#Text=In fact, previous studies evaluating the involvement of cocaine addiction in cognitive control functions such as attention and working memory found that, compared to HC, ACD showed hyperactivity in brain areas such as the parietal and occipital cortex.
201-1	41016-41018	In	_	
201-2	41019-41023	fact	_	
201-3	41023-41024	,	_	
201-4	41025-41033	previous	_	
201-5	41034-41041	studies	_	
201-6	41042-41052	evaluating	_	
201-7	41053-41056	the	_	
201-8	41057-41068	involvement	_	
201-9	41069-41071	of	_	
201-10	41072-41079	cocaine	_	
201-11	41080-41089	addiction	_	
201-12	41090-41092	in	_	
201-13	41093-41102	cognitive	_	
201-14	41103-41110	control	_	
201-15	41111-41120	functions	_	
201-16	41121-41125	such	_	
201-17	41126-41128	as	_	
201-18	41129-41138	attention	_	
201-19	41139-41142	and	_	
201-20	41143-41150	working	_	
201-21	41151-41157	memory	_	
201-22	41158-41163	found	_	
201-23	41164-41168	that	_	
201-24	41168-41169	,	_	
201-25	41170-41178	compared	_	
201-26	41179-41181	to	_	
201-27	41182-41184	HC	_	
201-28	41184-41185	,	_	
201-29	41186-41189	ACD	_	
201-30	41190-41196	showed	_	
201-31	41197-41210	hyperactivity	_	
201-32	41211-41213	in	_	
201-33	41214-41219	brain	_	
201-34	41220-41225	areas	_	
201-35	41226-41230	such	_	
201-36	41231-41233	as	_	
201-37	41234-41237	the	_	
201-38	41238-41246	parietal	_	
201-39	41247-41250	and	_	
201-40	41251-41260	occipital	_	
201-41	41261-41267	cortex	_	
201-42	41267-41268	.	_	

#Text=This result was interpreted as a greater recruitment of the visual attention network to support sustained visual processing, in order to compensate for the deficit in executive functions.
202-1	41269-41273	This	_	
202-2	41274-41280	result	_	
202-3	41281-41284	was	_	
202-4	41285-41296	interpreted	_	
202-5	41297-41299	as	_	
202-6	41300-41301	a	_	
202-7	41302-41309	greater	_	
202-8	41310-41321	recruitment	_	
202-9	41322-41324	of	_	
202-10	41325-41328	the	_	
202-11	41329-41335	visual	_	
202-12	41336-41345	attention	_	
202-13	41346-41353	network	_	
202-14	41354-41356	to	_	
202-15	41357-41364	support	_	
202-16	41365-41374	sustained	_	
202-17	41375-41381	visual	_	
202-18	41382-41392	processing	_	
202-19	41392-41393	,	_	
202-20	41394-41396	in	_	
202-21	41397-41402	order	_	
202-22	41403-41405	to	_	
202-23	41406-41416	compensate	_	
202-24	41417-41420	for	_	
202-25	41421-41424	the	_	
202-26	41425-41432	deficit	_	
202-27	41433-41435	in	_	
202-28	41436-41445	executive	_	
202-29	41446-41455	functions	_	
202-30	41455-41456	.	_	

#Text=In addition, previous studies using control attention tasks with monetary contingencies have related the enhancement of the bilateral occipital cortex to visual spatial attention, suggesting that the superior occipital cortex is an important area involved in attentional orientation, depending on the motivational meaning of the stimulus.
203-1	41457-41459	In	_	
203-2	41460-41468	addition	_	
203-3	41468-41469	,	_	
203-4	41470-41478	previous	_	
203-5	41479-41486	studies	_	
203-6	41487-41492	using	_	
203-7	41493-41500	control	_	
203-8	41501-41510	attention	_	
203-9	41511-41516	tasks	_	
203-10	41517-41521	with	_	
203-11	41522-41530	monetary	_	
203-12	41531-41544	contingencies	_	
203-13	41545-41549	have	_	
203-14	41550-41557	related	_	
203-15	41558-41561	the	_	
203-16	41562-41573	enhancement	_	
203-17	41574-41576	of	_	
203-18	41577-41580	the	_	
203-19	41581-41590	bilateral	_	
203-20	41591-41600	occipital	_	
203-21	41601-41607	cortex	_	
203-22	41608-41610	to	_	
203-23	41611-41617	visual	_	
203-24	41618-41625	spatial	_	
203-25	41626-41635	attention	_	
203-26	41635-41636	,	_	
203-27	41637-41647	suggesting	_	
203-28	41648-41652	that	_	
203-29	41653-41656	the	_	
203-30	41657-41665	superior	_	
203-31	41666-41675	occipital	_	
203-32	41676-41682	cortex	_	
203-33	41683-41685	is	_	
203-34	41686-41688	an	_	
203-35	41689-41698	important	_	
203-36	41699-41703	area	_	
203-37	41704-41712	involved	_	
203-38	41713-41715	in	_	
203-39	41716-41727	attentional	_	
203-40	41728-41739	orientation	_	
203-41	41739-41740	,	_	
203-42	41741-41750	depending	_	
203-43	41751-41753	on	_	
203-44	41754-41757	the	_	
203-45	41758-41770	motivational	_	
203-46	41771-41778	meaning	_	
203-47	41779-41781	of	_	
203-48	41782-41785	the	_	
203-49	41786-41794	stimulus	_	
203-50	41794-41795	.	_	

#Text=Brain connectivity between left DLPFC and left putamen
#Text=We confirmed our third hypothesis.
204-1	41796-41801	Brain	_	
204-2	41802-41814	connectivity	_	
204-3	41815-41822	between	_	
204-4	41823-41827	left	_	
204-5	41828-41833	DLPFC	_	
204-6	41834-41837	and	_	
204-7	41838-41842	left	_	
204-8	41843-41850	putamen	_	
204-9	41851-41853	We	_	
204-10	41854-41863	confirmed	_	
204-11	41864-41867	our	_	
204-12	41868-41873	third	_	
204-13	41874-41884	hypothesis	_	
204-14	41884-41885	.	_	

#Text=The DLPFC region that showed a reduced activation in response to the parametric increase in the monetary reward in ACD showed a greater connectivity with the left putamen in ACD than in HC.
205-1	41886-41889	The	_	
205-2	41890-41895	DLPFC	_	
205-3	41896-41902	region	_	
205-4	41903-41907	that	_	
205-5	41908-41914	showed	_	
205-6	41915-41916	a	_	
205-7	41917-41924	reduced	_	
205-8	41925-41935	activation	_	
205-9	41936-41938	in	_	
205-10	41939-41947	response	_	
205-11	41948-41950	to	_	
205-12	41951-41954	the	_	
205-13	41955-41965	parametric	_	
205-14	41966-41974	increase	_	
205-15	41975-41977	in	_	
205-16	41978-41981	the	_	
205-17	41982-41990	monetary	_	
205-18	41991-41997	reward	_	
205-19	41998-42000	in	_	
205-20	42001-42004	ACD	_	
205-21	42005-42011	showed	_	
205-22	42012-42013	a	_	
205-23	42014-42021	greater	_	
205-24	42022-42034	connectivity	_	
205-25	42035-42039	with	_	
205-26	42040-42043	the	_	
205-27	42044-42048	left	_	
205-28	42049-42056	putamen	_	
205-29	42057-42059	in	_	
205-30	42060-42063	ACD	_	
205-31	42064-42068	than	_	
205-32	42069-42071	in	_	
205-33	42072-42074	HC	_	
205-34	42074-42075	.	_	

#Text=DLPFC-striatum connectivity has been described in classic accounts of motivation system anatomy as an associative network involved in goal-directed instrumental behavior sensitive to changes in the outcome of the action; that is, DLPFC motivational and cognitive information integration appears to rely on interactions with the striatum.
206-1	42076-42090	DLPFC-striatum	_	
206-2	42091-42103	connectivity	_	
206-3	42104-42107	has	_	
206-4	42108-42112	been	_	
206-5	42113-42122	described	_	
206-6	42123-42125	in	_	
206-7	42126-42133	classic	_	
206-8	42134-42142	accounts	_	
206-9	42143-42145	of	_	
206-10	42146-42156	motivation	_	
206-11	42157-42163	system	_	
206-12	42164-42171	anatomy	_	
206-13	42172-42174	as	_	
206-14	42175-42177	an	_	
206-15	42178-42189	associative	_	
206-16	42190-42197	network	_	
206-17	42198-42206	involved	_	
206-18	42207-42209	in	_	
206-19	42210-42223	goal-directed	_	
206-20	42224-42236	instrumental	_	
206-21	42237-42245	behavior	_	
206-22	42246-42255	sensitive	_	
206-23	42256-42258	to	_	
206-24	42259-42266	changes	_	
206-25	42267-42269	in	_	
206-26	42270-42273	the	_	
206-27	42274-42281	outcome	_	
206-28	42282-42284	of	_	
206-29	42285-42288	the	_	
206-30	42289-42295	action	_	
206-31	42295-42296	;	_	
206-32	42297-42301	that	_	
206-33	42302-42304	is	_	
206-34	42304-42305	,	_	
206-35	42306-42311	DLPFC	_	
206-36	42312-42324	motivational	_	
206-37	42325-42328	and	_	
206-38	42329-42338	cognitive	_	
206-39	42339-42350	information	_	
206-40	42351-42362	integration	_	
206-41	42363-42370	appears	_	
206-42	42371-42373	to	_	
206-43	42374-42378	rely	_	
206-44	42379-42381	on	_	
206-45	42382-42394	interactions	_	
206-46	42395-42399	with	_	
206-47	42400-42403	the	_	
206-48	42404-42412	striatum	_	
206-49	42412-42413	.	_	

#Text=Although no previous studies have investigated the connectivity in the frontrostriatal network related to reward contingencies in cocaine addicts, Konova et al. and Tau et al. related the response to money in the striatum to impaired involvement of brain regions during task performance.
207-1	42414-42422	Although	_	
207-2	42423-42425	no	_	
207-3	42426-42434	previous	_	
207-4	42435-42442	studies	_	
207-5	42443-42447	have	_	
207-6	42448-42460	investigated	_	
207-7	42461-42464	the	_	
207-8	42465-42477	connectivity	_	
207-9	42478-42480	in	_	
207-10	42481-42484	the	_	
207-11	42485-42500	frontrostriatal	_	
207-12	42501-42508	network	_	
207-13	42509-42516	related	_	
207-14	42517-42519	to	_	
207-15	42520-42526	reward	_	
207-16	42527-42540	contingencies	_	
207-17	42541-42543	in	_	
207-18	42544-42551	cocaine	_	
207-19	42552-42559	addicts	_	
207-20	42559-42560	,	_	
207-21	42561-42567	Konova	_	
207-22	42568-42570	et	_	
207-23	42571-42573	al	_	
207-24	42573-42574	.	_	
207-25	42575-42578	and	_	
207-26	42579-42582	Tau	_	
207-27	42583-42585	et	_	
207-28	42586-42588	al	_	
207-29	42588-42589	.	_	
207-30	42590-42597	related	_	
207-31	42598-42601	the	_	
207-32	42602-42610	response	_	
207-33	42611-42613	to	_	
207-34	42614-42619	money	_	
207-35	42620-42622	in	_	
207-36	42623-42626	the	_	
207-37	42627-42635	striatum	_	
207-38	42636-42638	to	_	
207-39	42639-42647	impaired	_	
207-40	42648-42659	involvement	_	
207-41	42660-42662	of	_	
207-42	42663-42668	brain	_	
207-43	42669-42676	regions	_	
207-44	42677-42683	during	_	
207-45	42684-42688	task	_	
207-46	42689-42700	performance	_	
207-47	42700-42701	.	_	

#Text=Specifically, Konova et al. associated putamen hyperactivity during a parametric increase in the monetary reward on a drug Stroop task with a general ventromedial prefrontal deactivation across reward conditions, which was interpreted as a compensatory mechanism necessary to maintain similar levels of performance.
208-1	42702-42714	Specifically	_	
208-2	42714-42715	,	_	
208-3	42716-42722	Konova	_	
208-4	42723-42725	et	_	
208-5	42726-42728	al	_	
208-6	42728-42729	.	_	
208-7	42730-42740	associated	_	
208-8	42741-42748	putamen	_	
208-9	42749-42762	hyperactivity	_	
208-10	42763-42769	during	_	
208-11	42770-42771	a	_	
208-12	42772-42782	parametric	_	
208-13	42783-42791	increase	_	
208-14	42792-42794	in	_	
208-15	42795-42798	the	_	
208-16	42799-42807	monetary	_	
208-17	42808-42814	reward	_	
208-18	42815-42817	on	_	
208-19	42818-42819	a	_	
208-20	42820-42824	drug	_	
208-21	42825-42831	Stroop	_	
208-22	42832-42836	task	_	
208-23	42837-42841	with	_	
208-24	42842-42843	a	_	
208-25	42844-42851	general	_	
208-26	42852-42864	ventromedial	_	
208-27	42865-42875	prefrontal	_	
208-28	42876-42888	deactivation	_	
208-29	42889-42895	across	_	
208-30	42896-42902	reward	_	
208-31	42903-42913	conditions	_	
208-32	42913-42914	,	_	
208-33	42915-42920	which	_	
208-34	42921-42924	was	_	
208-35	42925-42936	interpreted	_	
208-36	42937-42939	as	_	
208-37	42940-42941	a	_	
208-38	42942-42954	compensatory	_	
208-39	42955-42964	mechanism	_	
208-40	42965-42974	necessary	_	
208-41	42975-42977	to	_	
208-42	42978-42986	maintain	_	
208-43	42987-42994	similar	_	
208-44	42995-43001	levels	_	
208-45	43002-43004	of	_	
208-46	43005-43016	performance	_	
208-47	43016-43017	.	_	

#Text=In our case, ACD showed an increased connectivity between the DLPFC and the putamen for higher reward gradients, which could represent the manifestation of the engagement of the frontostriatal circuits to support goal-directed behaviors in more effortful conditions, as previously suggested.
209-1	43018-43020	In	_	
209-2	43021-43024	our	_	
209-3	43025-43029	case	_	
209-4	43029-43030	,	_	
209-5	43031-43034	ACD	_	
209-6	43035-43041	showed	_	
209-7	43042-43044	an	_	
209-8	43045-43054	increased	_	
209-9	43055-43067	connectivity	_	
209-10	43068-43075	between	_	
209-11	43076-43079	the	_	
209-12	43080-43085	DLPFC	_	
209-13	43086-43089	and	_	
209-14	43090-43093	the	_	
209-15	43094-43101	putamen	_	
209-16	43102-43105	for	_	
209-17	43106-43112	higher	_	
209-18	43113-43119	reward	_	
209-19	43120-43129	gradients	_	
209-20	43129-43130	,	_	
209-21	43131-43136	which	_	
209-22	43137-43142	could	_	
209-23	43143-43152	represent	_	
209-24	43153-43156	the	_	
209-25	43157-43170	manifestation	_	
209-26	43171-43173	of	_	
209-27	43174-43177	the	_	
209-28	43178-43188	engagement	_	
209-29	43189-43191	of	_	
209-30	43192-43195	the	_	
209-31	43196-43210	frontostriatal	_	
209-32	43211-43219	circuits	_	
209-33	43220-43222	to	_	
209-34	43223-43230	support	_	
209-35	43231-43244	goal-directed	_	
209-36	43245-43254	behaviors	_	
209-37	43255-43257	in	_	
209-38	43258-43262	more	_	
209-39	43263-43272	effortful	_	
209-40	43273-43283	conditions	_	
209-41	43283-43284	,	_	
209-42	43285-43287	as	_	
209-43	43288-43298	previously	_	
209-44	43299-43308	suggested	_	
209-45	43308-43309	.	_	

#Text=Impact of craving and dependence severity on dorsal striatum modulation by reward
#Text=We partly confirmed our fourth hypothesis because regression results showed that high scores on self-reported craving were related to reduced activation of the left caudate during parametric increases in the monetary reward; however, high scores on self-reported dependence severity were related to enhanced activation of the right pallidum.
210-1	43310-43316	Impact	_	
210-2	43317-43319	of	_	
210-3	43320-43327	craving	_	
210-4	43328-43331	and	_	
210-5	43332-43342	dependence	_	
210-6	43343-43351	severity	_	
210-7	43352-43354	on	_	
210-8	43355-43361	dorsal	_	
210-9	43362-43370	striatum	_	
210-10	43371-43381	modulation	_	
210-11	43382-43384	by	_	
210-12	43385-43391	reward	_	
210-13	43392-43394	We	_	
210-14	43395-43401	partly	_	
210-15	43402-43411	confirmed	_	
210-16	43412-43415	our	_	
210-17	43416-43422	fourth	_	
210-18	43423-43433	hypothesis	_	
210-19	43434-43441	because	_	
210-20	43442-43452	regression	_	
210-21	43453-43460	results	_	
210-22	43461-43467	showed	_	
210-23	43468-43472	that	_	
210-24	43473-43477	high	_	
210-25	43478-43484	scores	_	
210-26	43485-43487	on	_	
210-27	43488-43501	self-reported	_	
210-28	43502-43509	craving	_	
210-29	43510-43514	were	_	
210-30	43515-43522	related	_	
210-31	43523-43525	to	_	
210-32	43526-43533	reduced	_	
210-33	43534-43544	activation	_	
210-34	43545-43547	of	_	
210-35	43548-43551	the	_	
210-36	43552-43556	left	_	
210-37	43557-43564	caudate	_	
210-38	43565-43571	during	_	
210-39	43572-43582	parametric	_	
210-40	43583-43592	increases	_	
210-41	43593-43595	in	_	
210-42	43596-43599	the	_	
210-43	43600-43608	monetary	_	
210-44	43609-43615	reward	_	
210-45	43615-43616	;	_	
210-46	43617-43624	however	_	
210-47	43624-43625	,	_	
210-48	43626-43630	high	_	
210-49	43631-43637	scores	_	
210-50	43638-43640	on	_	
210-51	43641-43654	self-reported	_	
210-52	43655-43665	dependence	_	
210-53	43666-43674	severity	_	
210-54	43675-43679	were	_	
210-55	43680-43687	related	_	
210-56	43688-43690	to	_	
210-57	43691-43699	enhanced	_	
210-58	43700-43710	activation	_	
210-59	43711-43713	of	_	
210-60	43714-43717	the	_	
210-61	43718-43723	right	_	
210-62	43724-43732	pallidum	_	
210-63	43732-43733	.	_	

#Text=Regarding the former, previous studies exploring cocaine craving observed that caudate activation increased during higher self-reported craving.
211-1	43734-43743	Regarding	_	
211-2	43744-43747	the	_	
211-3	43748-43754	former	_	
211-4	43754-43755	,	_	
211-5	43756-43764	previous	_	
211-6	43765-43772	studies	_	
211-7	43773-43782	exploring	_	
211-8	43783-43790	cocaine	_	
211-9	43791-43798	craving	_	
211-10	43799-43807	observed	_	
211-11	43808-43812	that	_	
211-12	43813-43820	caudate	_	
211-13	43821-43831	activation	_	
211-14	43832-43841	increased	_	
211-15	43842-43848	during	_	
211-16	43849-43855	higher	_	
211-17	43856-43869	self-reported	_	
211-18	43870-43877	craving	_	
211-19	43877-43878	.	_	

#Text=However, we should take into account that the methodology employed in these studies was quite different from ours because these paradigms induced craving by showing a cocaine video, and then they evaluated the relationship between self-reported craving at that moment and brain activity.
212-1	43879-43886	However	_	
212-2	43886-43887	,	_	
212-3	43888-43890	we	_	
212-4	43891-43897	should	_	
212-5	43898-43902	take	_	
212-6	43903-43907	into	_	
212-7	43908-43915	account	_	
212-8	43916-43920	that	_	
212-9	43921-43924	the	_	
212-10	43925-43936	methodology	_	
212-11	43937-43945	employed	_	
212-12	43946-43948	in	_	
212-13	43949-43954	these	_	
212-14	43955-43962	studies	_	
212-15	43963-43966	was	_	
212-16	43967-43972	quite	_	
212-17	43973-43982	different	_	
212-18	43983-43987	from	_	
212-19	43988-43992	ours	_	
212-20	43993-44000	because	_	
212-21	44001-44006	these	_	
212-22	44007-44016	paradigms	_	
212-23	44017-44024	induced	_	
212-24	44025-44032	craving	_	
212-25	44033-44035	by	_	
212-26	44036-44043	showing	_	
212-27	44044-44045	a	_	
212-28	44046-44053	cocaine	_	
212-29	44054-44059	video	_	
212-30	44059-44060	,	_	
212-31	44061-44064	and	_	
212-32	44065-44069	then	_	
212-33	44070-44074	they	_	
212-34	44075-44084	evaluated	_	
212-35	44085-44088	the	_	
212-36	44089-44101	relationship	_	
212-37	44102-44109	between	_	
212-38	44110-44123	self-reported	_	
212-39	44124-44131	craving	_	
212-40	44132-44134	at	_	
212-41	44135-44139	that	_	
212-42	44140-44146	moment	_	
212-43	44147-44150	and	_	
212-44	44151-44156	brain	_	
212-45	44157-44165	activity	_	
212-46	44165-44166	.	_	

#Text=By contrast, we used an interference Stroop condition in which participants were requested to involve cognitive-control processes to obtain money, whereas craving reported by the cocaine addicts refers to what they felt during the past two weeks.
213-1	44167-44169	By	_	
213-2	44170-44178	contrast	_	
213-3	44178-44179	,	_	
213-4	44180-44182	we	_	
213-5	44183-44187	used	_	
213-6	44188-44190	an	_	
213-7	44191-44203	interference	_	
213-8	44204-44210	Stroop	_	
213-9	44211-44220	condition	_	
213-10	44221-44223	in	_	
213-11	44224-44229	which	_	
213-12	44230-44242	participants	_	
213-13	44243-44247	were	_	
213-14	44248-44257	requested	_	
213-15	44258-44260	to	_	
213-16	44261-44268	involve	_	
213-17	44269-44286	cognitive-control	_	
213-18	44287-44296	processes	_	
213-19	44297-44299	to	_	
213-20	44300-44306	obtain	_	
213-21	44307-44312	money	_	
213-22	44312-44313	,	_	
213-23	44314-44321	whereas	_	
213-24	44322-44329	craving	_	
213-25	44330-44338	reported	_	
213-26	44339-44341	by	_	
213-27	44342-44345	the	_	
213-28	44346-44353	cocaine	_	
213-29	44354-44361	addicts	_	
213-30	44362-44368	refers	_	
213-31	44369-44371	to	_	
213-32	44372-44376	what	_	
213-33	44377-44381	they	_	
213-34	44382-44386	felt	_	
213-35	44387-44393	during	_	
213-36	44394-44397	the	_	
213-37	44398-44402	past	_	
213-38	44403-44406	two	_	
213-39	44407-44412	weeks	_	
213-40	44412-44413	.	_	

#Text=We suggest that left caudate hypoactivation could be related to poor cognitive control associated with craving according to previous studies.
214-1	44414-44416	We	_	
214-2	44417-44424	suggest	_	
214-3	44425-44429	that	_	
214-4	44430-44434	left	_	
214-5	44435-44442	caudate	_	
214-6	44443-44457	hypoactivation	_	
214-7	44458-44463	could	_	
214-8	44464-44466	be	_	
214-9	44467-44474	related	_	
214-10	44475-44477	to	_	
214-11	44478-44482	poor	_	
214-12	44483-44492	cognitive	_	
214-13	44493-44500	control	_	
214-14	44501-44511	associated	_	
214-15	44512-44516	with	_	
214-16	44517-44524	craving	_	
214-17	44525-44534	according	_	
214-18	44535-44537	to	_	
214-19	44538-44546	previous	_	
214-20	44547-44554	studies	_	
214-21	44554-44555	.	_	

#Text=Regarding addiction severity, taking into account the pallidum implication in the habitual behavior and the drug-seeking habit, its involvement in increasing reward processing may be identifying individual differences in disease severity.
215-1	44556-44565	Regarding	_	
215-2	44566-44575	addiction	_	
215-3	44576-44584	severity	_	
215-4	44584-44585	,	_	
215-5	44586-44592	taking	_	
215-6	44593-44597	into	_	
215-7	44598-44605	account	_	
215-8	44606-44609	the	_	
215-9	44610-44618	pallidum	_	
215-10	44619-44630	implication	_	
215-11	44631-44633	in	_	
215-12	44634-44637	the	_	
215-13	44638-44646	habitual	_	
215-14	44647-44655	behavior	_	
215-15	44656-44659	and	_	
215-16	44660-44663	the	_	
215-17	44664-44676	drug-seeking	_	
215-18	44677-44682	habit	_	
215-19	44682-44683	,	_	
215-20	44684-44687	its	_	
215-21	44688-44699	involvement	_	
215-22	44700-44702	in	_	
215-23	44703-44713	increasing	_	
215-24	44714-44720	reward	_	
215-25	44721-44731	processing	_	
215-26	44732-44735	may	_	
215-27	44736-44738	be	_	
215-28	44739-44750	identifying	_	
215-29	44751-44761	individual	_	
215-30	44762-44773	differences	_	
215-31	44774-44776	in	_	
215-32	44777-44784	disease	_	
215-33	44785-44793	severity	_	
215-34	44793-44794	.	_	

#Text=Limitations
#Text=Our methodological approach has some limitations.
216-1	44795-44806	Limitations	_	
216-2	44807-44810	Our	_	
216-3	44811-44825	methodological	_	
216-4	44826-44834	approach	_	
216-5	44835-44838	has	_	
216-6	44839-44843	some	_	
216-7	44844-44855	limitations	_	
216-8	44855-44856	.	_	

#Text=We applied an fMRI block design, which entails problems such as habituation and anticipation and facilitates the application of strategic factors related to stimulus processing.
217-1	44857-44859	We	_	
217-2	44860-44867	applied	_	
217-3	44868-44870	an	_	
217-4	44871-44875	fMRI	_	
217-5	44876-44881	block	_	
217-6	44882-44888	design	_	
217-7	44888-44889	,	_	
217-8	44890-44895	which	_	
217-9	44896-44903	entails	_	
217-10	44904-44912	problems	_	
217-11	44913-44917	such	_	
217-12	44918-44920	as	_	
217-13	44921-44932	habituation	_	
217-14	44933-44936	and	_	
217-15	44937-44949	anticipation	_	
217-16	44950-44953	and	_	
217-17	44954-44965	facilitates	_	
217-18	44966-44969	the	_	
217-19	44970-44981	application	_	
217-20	44982-44984	of	_	
217-21	44985-44994	strategic	_	
217-22	44995-45002	factors	_	
217-23	45003-45010	related	_	
217-24	45011-45013	to	_	
217-25	45014-45022	stimulus	_	
217-26	45023-45033	processing	_	
217-27	45033-45034	.	_	

#Text=To avoid these effects, we included no-conflict trials among the conflict ones (an approximate ratio of 1:4 for no-conflict: conflict trials).
218-1	45035-45037	To	_	
218-2	45038-45043	avoid	_	
218-3	45044-45049	these	_	
218-4	45050-45057	effects	_	
218-5	45057-45058	,	_	
218-6	45059-45061	we	_	
218-7	45062-45070	included	_	
218-8	45071-45082	no-conflict	_	
218-9	45083-45089	trials	_	
218-10	45090-45095	among	_	
218-11	45096-45099	the	_	
218-12	45100-45108	conflict	_	
218-13	45109-45113	ones	_	
218-14	45114-45115	(	_	
218-15	45115-45117	an	_	
218-16	45118-45129	approximate	_	
218-17	45130-45135	ratio	_	
218-18	45136-45138	of	_	
218-19	45139-45140	1	_	
218-20	45140-45141	:	_	
218-21	45141-45142	4	_	
218-22	45143-45146	for	_	
218-23	45147-45158	no-conflict	_	
218-24	45158-45159	:	_	
218-25	45160-45168	conflict	_	
218-26	45169-45175	trials	_	
218-27	45175-45176	)	_	
218-28	45176-45177	.	_	

#Text=Although ROI is one of the most commonly used approaches because it is reliable and appropriate when studies have specific a priori hypotheses, it is limited by the constricted areas explored and the susceptibility of seed positioning variations.
219-1	45178-45186	Although	_	
219-2	45187-45190	ROI	_	
219-3	45191-45193	is	_	
219-4	45194-45197	one	_	
219-5	45198-45200	of	_	
219-6	45201-45204	the	_	
219-7	45205-45209	most	_	
219-8	45210-45218	commonly	_	
219-9	45219-45223	used	_	
219-10	45224-45234	approaches	_	
219-11	45235-45242	because	_	
219-12	45243-45245	it	_	
219-13	45246-45248	is	_	
219-14	45249-45257	reliable	_	
219-15	45258-45261	and	_	
219-16	45262-45273	appropriate	_	
219-17	45274-45278	when	_	
219-18	45279-45286	studies	_	
219-19	45287-45291	have	_	
219-20	45292-45300	specific	_	
219-21	45301-45302	a	_	
219-22	45303-45309	priori	_	
219-23	45310-45320	hypotheses	_	
219-24	45320-45321	,	_	
219-25	45322-45324	it	_	
219-26	45325-45327	is	_	
219-27	45328-45335	limited	_	
219-28	45336-45338	by	_	
219-29	45339-45342	the	_	
219-30	45343-45354	constricted	_	
219-31	45355-45360	areas	_	
219-32	45361-45369	explored	_	
219-33	45370-45373	and	_	
219-34	45374-45377	the	_	
219-35	45378-45392	susceptibility	_	
219-36	45393-45395	of	_	
219-37	45396-45400	seed	_	
219-38	45401-45412	positioning	_	
219-39	45413-45423	variations	_	
219-40	45423-45424	.	_	

#Text=Our data cannot address the causal relationship between neural imaging measurements and behavioral improvement because we did not find a correlation between them.
220-1	45425-45428	Our	_	
220-2	45429-45433	data	_	
220-3	45434-45440	cannot	_	
220-4	45441-45448	address	_	
220-5	45449-45452	the	_	
220-6	45453-45459	causal	_	
220-7	45460-45472	relationship	_	
220-8	45473-45480	between	_	
220-9	45481-45487	neural	_	
220-10	45488-45495	imaging	_	
220-11	45496-45508	measurements	_	
220-12	45509-45512	and	_	
220-13	45513-45523	behavioral	_	
220-14	45524-45535	improvement	_	
220-15	45536-45543	because	_	
220-16	45544-45546	we	_	
220-17	45547-45550	did	_	
220-18	45551-45554	not	_	
220-19	45555-45559	find	_	
220-20	45560-45561	a	_	
220-21	45562-45573	correlation	_	
220-22	45574-45581	between	_	
220-23	45582-45586	them	_	
220-24	45586-45587	.	_	

#Text=The present study does not include other psychometric psychological assessments, such as impulsivity or compulsivity, which are related to a neurobehavioral pattern of addiction.
221-1	45588-45591	The	_	
221-2	45592-45599	present	_	
221-3	45600-45605	study	_	
221-4	45606-45610	does	_	
221-5	45611-45614	not	_	
221-6	45615-45622	include	_	
221-7	45623-45628	other	_	
221-8	45629-45641	psychometric	_	
221-9	45642-45655	psychological	_	
221-10	45656-45667	assessments	_	
221-11	45667-45668	,	_	
221-12	45669-45673	such	_	
221-13	45674-45676	as	_	
221-14	45677-45688	impulsivity	_	
221-15	45689-45691	or	_	
221-16	45692-45704	compulsivity	_	
221-17	45704-45705	,	_	
221-18	45706-45711	which	_	
221-19	45712-45715	are	_	
221-20	45716-45723	related	_	
221-21	45724-45726	to	_	
221-22	45727-45728	a	_	
221-23	45729-45744	neurobehavioral	_	
221-24	45745-45752	pattern	_	
221-25	45753-45755	of	_	
221-26	45756-45765	addiction	_	
221-27	45765-45766	.	_	

#Text=Finally, as in most studies with human clinical groups, it is not possible to address the etiology of these activity pattern differences; that is, we cannot say whether the differential brain recruitment patterns reported above pre-date and facilitate cocaine consumption, or whether they arose as a consequence of prolonged cocaine use.
222-1	45767-45774	Finally	_	
222-2	45774-45775	,	_	
222-3	45776-45778	as	_	
222-4	45779-45781	in	_	
222-5	45782-45786	most	_	
222-6	45787-45794	studies	_	
222-7	45795-45799	with	_	
222-8	45800-45805	human	_	
222-9	45806-45814	clinical	_	
222-10	45815-45821	groups	_	
222-11	45821-45822	,	_	
222-12	45823-45825	it	_	
222-13	45826-45828	is	_	
222-14	45829-45832	not	_	
222-15	45833-45841	possible	_	
222-16	45842-45844	to	_	
222-17	45845-45852	address	_	
222-18	45853-45856	the	_	
222-19	45857-45865	etiology	_	
222-20	45866-45868	of	_	
222-21	45869-45874	these	_	
222-22	45875-45883	activity	_	
222-23	45884-45891	pattern	_	
222-24	45892-45903	differences	_	
222-25	45903-45904	;	_	
222-26	45905-45909	that	_	
222-27	45910-45912	is	_	
222-28	45912-45913	,	_	
222-29	45914-45916	we	_	
222-30	45917-45923	cannot	_	
222-31	45924-45927	say	_	
222-32	45928-45935	whether	_	
222-33	45936-45939	the	_	
222-34	45940-45952	differential	_	
222-35	45953-45958	brain	_	
222-36	45959-45970	recruitment	_	
222-37	45971-45979	patterns	_	
222-38	45980-45988	reported	_	
222-39	45989-45994	above	_	
222-40	45995-46003	pre-date	_	
222-41	46004-46007	and	_	
222-42	46008-46018	facilitate	_	
222-43	46019-46026	cocaine	_	
222-44	46027-46038	consumption	_	
222-45	46038-46039	,	_	
222-46	46040-46042	or	_	
222-47	46043-46050	whether	_	
222-48	46051-46055	they	_	
222-49	46056-46061	arose	_	
222-50	46062-46064	as	_	
222-51	46065-46066	a	_	
222-52	46067-46078	consequence	_	
222-53	46079-46081	of	_	
222-54	46082-46091	prolonged	_	
222-55	46092-46099	cocaine	_	
222-56	46100-46103	use	_	
222-57	46103-46104	.	_	

#Text=Supporting Information
#Text=References
#Text=Addiction circuitry in the human brain
#Text=The neural basis of addiction: A pathology of motivation and choice
#Text=Bustamante J.
223-1	46105-46115	Supporting	_	
223-2	46116-46127	Information	_	
223-3	46128-46138	References	_	
223-4	46139-46148	Addiction	_	
223-5	46149-46158	circuitry	_	
223-6	46159-46161	in	_	
223-7	46162-46165	the	_	
223-8	46166-46171	human	_	
223-9	46172-46177	brain	_	
223-10	46178-46181	The	_	
223-11	46182-46188	neural	_	
223-12	46189-46194	basis	_	
223-13	46195-46197	of	_	
223-14	46198-46207	addiction	_	
223-15	46207-46208	:	_	
223-16	46209-46210	A	_	
223-17	46211-46220	pathology	_	
223-18	46221-46223	of	_	
223-19	46224-46234	motivation	_	
223-20	46235-46238	and	_	
223-21	46239-46245	choice	_	
223-22	46246-46256	Bustamante	_	
223-23	46257-46258	J	_	
223-24	46258-46259	.	_	

#Text=C, Costumero V, Fuentes-Claramonte P, Rosell-Negre P, Ávila C.
224-1	46260-46261	C	_	
224-2	46261-46262	,	_	
224-3	46263-46272	Costumero	_	
224-4	46273-46274	V	_	
224-5	46274-46275	,	_	
224-6	46276-46294	Fuentes-Claramonte	_	
224-7	46295-46296	P	_	
224-8	46296-46297	,	_	
224-9	46298-46310	Rosell-Negre	_	
224-10	46311-46312	P	_	
224-11	46312-46313	,	_	
224-12	46314-46319	Ávila	_	
224-13	46320-46321	C	_	
224-14	46321-46322	.	_	

#Text=C OMPULSIVE D RUG S ELF -A DMINISTRATION: I NCENTIVE S ENSITIZATION AND L OSS OF T OP -D OWN C ONTROL IN C OCAINE A DDICTION.
225-1	46323-46324	C	_	
225-2	46325-46334	OMPULSIVE	_	
225-3	46335-46336	D	_	
225-4	46337-46340	RUG	_	
225-5	46341-46342	S	_	
225-6	46343-46346	ELF	_	
225-7	46347-46348	-	_	
225-8	46348-46349	A	_	
225-9	46350-46363	DMINISTRATION	_	
225-10	46363-46364	:	_	
225-11	46365-46366	I	_	
225-12	46367-46375	NCENTIVE	_	
225-13	46376-46377	S	_	
225-14	46378-46390	ENSITIZATION	_	
225-15	46391-46394	AND	_	
225-16	46395-46396	L	_	
225-17	46397-46400	OSS	_	
225-18	46401-46403	OF	_	
225-19	46404-46405	T	_	
225-20	46406-46408	OP	_	
225-21	46409-46410	-	_	
225-22	46410-46411	D	_	
225-23	46412-46415	OWN	_	
225-24	46416-46417	C	_	
225-25	46418-46424	ONTROL	_	
225-26	46425-46427	IN	_	
225-27	46428-46429	C	_	
225-28	46430-46436	OCAINE	_	
225-29	46437-46438	A	_	
225-30	46439-46447	DDICTION	_	
225-31	46447-46448	.	_	

#Text=Cocaine Abus Pharmacol Treat Relapse Prev. 2012;In: Xi Chu(Substance Abuse Assessment, Interventions and Treatment; Public Health in the 21st Century):7x10 (NBC–R); ISBN: 978–1–61942–202–5.
226-1	46449-46456	Cocaine	_	
226-2	46457-46461	Abus	_	
226-3	46462-46471	Pharmacol	_	
226-4	46472-46477	Treat	_	
226-5	46478-46485	Relapse	_	
226-6	46486-46490	Prev	_	
226-7	46490-46491	.	_	
226-8	46492-46496	2012	_	
226-9	46496-46497	;	_	
226-10	46497-46499	In	_	
226-11	46499-46500	:	_	
226-12	46501-46503	Xi	_	
226-13	46504-46507	Chu	_	
226-14	46507-46508	(	_	
226-15	46508-46517	Substance	_	
226-16	46518-46523	Abuse	_	
226-17	46524-46534	Assessment	_	
226-18	46534-46535	,	_	
226-19	46536-46549	Interventions	_	
226-20	46550-46553	and	_	
226-21	46554-46563	Treatment	_	
226-22	46563-46564	;	_	
226-23	46565-46571	Public	_	
226-24	46572-46578	Health	_	
226-25	46579-46581	in	_	
226-26	46582-46585	the	_	
226-27	46586-46590	21st	_	
226-28	46591-46598	Century	_	
226-29	46598-46599	)	_	
226-30	46599-46600	:	_	
226-31	46600-46604	7x10	_	
226-32	46605-46606	(	_	
226-33	46606-46611	NBC–R	_	
226-34	46611-46612	)	_	
226-35	46612-46613	;	_	
226-36	46614-46618	ISBN	_	
226-37	46618-46619	:	_	
226-38	46620-46623	978	_	
226-39	46623-46624	–	_	
226-40	46624-46625	1	_	
226-41	46625-46626	–	_	
226-42	46626-46631	61942	_	
226-43	46631-46632	–	_	
226-44	46632-46635	202	_	
226-45	46635-46636	–	_	
226-46	46636-46637	5	_	
226-47	46637-46638	.	_	

#Text=Review.
227-1	46639-46645	Review	_	
227-2	46645-46646	.	_	

#Text=The incentive sensitization theory of addiction: some current issues
#Text=Addiction
#Text=Striatal Dopamine and the Interface between Motivation and Cognition
#Text=Mechanisms of motivation-cognition interaction: challenges and opportunities
#Text=Prefrontal cortex mediation of cognitive enhancement in rewarding motivational contexts
#Text=Dopaminergic reward system: a short integrative review
#Text=Dopamine, learning and motivation
#Text=Striatal dopamine mediates the interface between motivational and cognitive control in humans: evidence from genetic imaging
#Text=Abstinence duration modulates striatal functioning during monetary reward processing in cocaine patients
#Text=The dopamine theory of addiction: 40 years of highs and lows
#Text=From the ventral to the dorsal striatum: Devolving views of their roles in drug addiction
#Text=Imaging the addicted human brain
#Text=The role of cognitive control in cocaine dependence
#Text=The neurobiology of reward and cognitive control systems and their role in incentivizing health behavior
#Text=The neurocircuitry of impaired insight in drug addiction
#Text=Dopaminergic involvement during mental fatigue in health and cocaine addiction
#Text=The ins and outs of the striatum: Role in drug addiction
#Text=Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications
#Text=Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli
#Text=Motivated attention to cocaine and emotional cues in abstinent and current cocaine users—an ERP study
#Text=Enhanced cue reactivity and fronto-striatal functional connectivity in cocaine use disorders
#Text=Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies
#Text=Effects of naltrexone on cue-elicited craving for alcohol and cocaine
#Text=Impaired inhibitory control in recreational cocaine users
#Text=Impaired inhibitory control of behavior in chronic cocaine users
#Text=Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity
#Text=Chronic and recreational use of cocaine is associated with a vulnerability to semantic interference
#Text=Widespread disruption in brain activation patterns to a working memory task during cocaine abstinence
#Text=Structural and behavioral correlates of abnormal encoding of money value in the sensorimotor striatum in cocaine addiction
#Text=Neural correlates of reward-based spatial learning in persons with cocaine dependence
#Text=Decision-making in long-term cocaine users: Effects of a cash monetary contingency on Gambling task performance
#Text=Combined effects of attention and motivation on visual task performance: transient and sustained motivational effects
#Text=Go and no-go learning in reward and punishment: interactions between affect and effect
#Text=Is Decreased Prefrontal Cortical Sensitivity to Monetary and Self-Control in Cocaine Addiction?
228-1	46647-46650	The	_	
228-2	46651-46660	incentive	_	
228-3	46661-46674	sensitization	_	
228-4	46675-46681	theory	_	
228-5	46682-46684	of	_	
228-6	46685-46694	addiction	_	
228-7	46694-46695	:	_	
228-8	46696-46700	some	_	
228-9	46701-46708	current	_	
228-10	46709-46715	issues	_	
228-11	46716-46725	Addiction	_	
228-12	46726-46734	Striatal	_	
228-13	46735-46743	Dopamine	_	
228-14	46744-46747	and	_	
228-15	46748-46751	the	_	
228-16	46752-46761	Interface	_	
228-17	46762-46769	between	_	
228-18	46770-46780	Motivation	_	
228-19	46781-46784	and	_	
228-20	46785-46794	Cognition	_	
228-21	46795-46805	Mechanisms	_	
228-22	46806-46808	of	_	
228-23	46809-46829	motivation-cognition	_	
228-24	46830-46841	interaction	_	
228-25	46841-46842	:	_	
228-26	46843-46853	challenges	_	
228-27	46854-46857	and	_	
228-28	46858-46871	opportunities	_	
228-29	46872-46882	Prefrontal	_	
228-30	46883-46889	cortex	_	
228-31	46890-46899	mediation	_	
228-32	46900-46902	of	_	
228-33	46903-46912	cognitive	_	
228-34	46913-46924	enhancement	_	
228-35	46925-46927	in	_	
228-36	46928-46937	rewarding	_	
228-37	46938-46950	motivational	_	
228-38	46951-46959	contexts	_	
228-39	46960-46972	Dopaminergic	_	
228-40	46973-46979	reward	_	
228-41	46980-46986	system	_	
228-42	46986-46987	:	_	
228-43	46988-46989	a	_	
228-44	46990-46995	short	_	
228-45	46996-47007	integrative	_	
228-46	47008-47014	review	_	
228-47	47015-47023	Dopamine	_	
228-48	47023-47024	,	_	
228-49	47025-47033	learning	_	
228-50	47034-47037	and	_	
228-51	47038-47048	motivation	_	
228-52	47049-47057	Striatal	_	
228-53	47058-47066	dopamine	_	
228-54	47067-47075	mediates	_	
228-55	47076-47079	the	_	
228-56	47080-47089	interface	_	
228-57	47090-47097	between	_	
228-58	47098-47110	motivational	_	
228-59	47111-47114	and	_	
228-60	47115-47124	cognitive	_	
228-61	47125-47132	control	_	
228-62	47133-47135	in	_	
228-63	47136-47142	humans	_	
228-64	47142-47143	:	_	
228-65	47144-47152	evidence	_	
228-66	47153-47157	from	_	
228-67	47158-47165	genetic	_	
228-68	47166-47173	imaging	_	
228-69	47174-47184	Abstinence	_	
228-70	47185-47193	duration	_	
228-71	47194-47203	modulates	_	
228-72	47204-47212	striatal	_	
228-73	47213-47224	functioning	_	
228-74	47225-47231	during	_	
228-75	47232-47240	monetary	_	
228-76	47241-47247	reward	_	
228-77	47248-47258	processing	_	
228-78	47259-47261	in	_	
228-79	47262-47269	cocaine	_	
228-80	47270-47278	patients	_	
228-81	47279-47282	The	_	
228-82	47283-47291	dopamine	_	
228-83	47292-47298	theory	_	
228-84	47299-47301	of	_	
228-85	47302-47311	addiction	_	
228-86	47311-47312	:	_	
228-87	47313-47315	40	_	
228-88	47316-47321	years	_	
228-89	47322-47324	of	_	
228-90	47325-47330	highs	_	
228-91	47331-47334	and	_	
228-92	47335-47339	lows	_	
228-93	47340-47344	From	_	
228-94	47345-47348	the	_	
228-95	47349-47356	ventral	_	
228-96	47357-47359	to	_	
228-97	47360-47363	the	_	
228-98	47364-47370	dorsal	_	
228-99	47371-47379	striatum	_	
228-100	47379-47380	:	_	
228-101	47381-47390	Devolving	_	
228-102	47391-47396	views	_	
228-103	47397-47399	of	_	
228-104	47400-47405	their	_	
228-105	47406-47411	roles	_	
228-106	47412-47414	in	_	
228-107	47415-47419	drug	_	
228-108	47420-47429	addiction	_	
228-109	47430-47437	Imaging	_	
228-110	47438-47441	the	_	
228-111	47442-47450	addicted	_	
228-112	47451-47456	human	_	
228-113	47457-47462	brain	_	
228-114	47463-47466	The	_	
228-115	47467-47471	role	_	
228-116	47472-47474	of	_	
228-117	47475-47484	cognitive	_	
228-118	47485-47492	control	_	
228-119	47493-47495	in	_	
228-120	47496-47503	cocaine	_	
228-121	47504-47514	dependence	_	
228-122	47515-47518	The	_	
228-123	47519-47531	neurobiology	_	
228-124	47532-47534	of	_	
228-125	47535-47541	reward	_	
228-126	47542-47545	and	_	
228-127	47546-47555	cognitive	_	
228-128	47556-47563	control	_	
228-129	47564-47571	systems	_	
228-130	47572-47575	and	_	
228-131	47576-47581	their	_	
228-132	47582-47586	role	_	
228-133	47587-47589	in	_	
228-134	47590-47603	incentivizing	_	
228-135	47604-47610	health	_	
228-136	47611-47619	behavior	_	
228-137	47620-47623	The	_	
228-138	47624-47638	neurocircuitry	_	
228-139	47639-47641	of	_	
228-140	47642-47650	impaired	_	
228-141	47651-47658	insight	_	
228-142	47659-47661	in	_	
228-143	47662-47666	drug	_	
228-144	47667-47676	addiction	_	
228-145	47677-47689	Dopaminergic	_	
228-146	47690-47701	involvement	_	
228-147	47702-47708	during	_	
228-148	47709-47715	mental	_	
228-149	47716-47723	fatigue	_	
228-150	47724-47726	in	_	
228-151	47727-47733	health	_	
228-152	47734-47737	and	_	
228-153	47738-47745	cocaine	_	
228-154	47746-47755	addiction	_	
228-155	47756-47759	The	_	
228-156	47760-47763	ins	_	
228-157	47764-47767	and	_	
228-158	47768-47772	outs	_	
228-159	47773-47775	of	_	
228-160	47776-47779	the	_	
228-161	47780-47788	striatum	_	
228-162	47788-47789	:	_	
228-163	47790-47794	Role	_	
228-164	47795-47797	in	_	
228-165	47798-47802	drug	_	
228-166	47803-47812	addiction	_	
228-167	47813-47824	Dysfunction	_	
228-168	47825-47827	of	_	
228-169	47828-47831	the	_	
228-170	47832-47842	prefrontal	_	
228-171	47843-47849	cortex	_	
228-172	47850-47852	in	_	
228-173	47853-47862	addiction	_	
228-174	47862-47863	:	_	
228-175	47864-47876	neuroimaging	_	
228-176	47877-47885	findings	_	
228-177	47886-47889	and	_	
228-178	47890-47898	clinical	_	
228-179	47899-47911	implications	_	
228-180	47912-47923	Cue-induced	_	
228-181	47924-47931	cocaine	_	
228-182	47932-47939	craving	_	
228-183	47939-47940	:	_	
228-184	47941-47956	neuroanatomical	_	
228-185	47957-47968	specificity	_	
228-186	47969-47972	for	_	
228-187	47973-47977	drug	_	
228-188	47978-47983	users	_	
228-189	47984-47987	and	_	
228-190	47988-47992	drug	_	
228-191	47993-48000	stimuli	_	
228-192	48001-48010	Motivated	_	
228-193	48011-48020	attention	_	
228-194	48021-48023	to	_	
228-195	48024-48031	cocaine	_	
228-196	48032-48035	and	_	
228-197	48036-48045	emotional	_	
228-198	48046-48050	cues	_	
228-199	48051-48053	in	_	
228-200	48054-48063	abstinent	_	
228-201	48064-48067	and	_	
228-202	48068-48075	current	_	
228-203	48076-48083	cocaine	_	
228-204	48084-48092	users—an	_	
228-205	48093-48096	ERP	_	
228-206	48097-48102	study	_	
228-207	48103-48111	Enhanced	_	
228-208	48112-48115	cue	_	
228-209	48116-48126	reactivity	_	
228-210	48127-48130	and	_	
228-211	48131-48146	fronto-striatal	_	
228-212	48147-48157	functional	_	
228-213	48158-48170	connectivity	_	
228-214	48171-48173	in	_	
228-215	48174-48181	cocaine	_	
228-216	48182-48185	use	_	
228-217	48186-48195	disorders	_	
228-218	48196-48203	Factors	_	
228-219	48204-48214	modulating	_	
228-220	48215-48221	neural	_	
228-221	48222-48232	reactivity	_	
228-222	48233-48235	to	_	
228-223	48236-48240	drug	_	
228-224	48241-48245	cues	_	
228-225	48246-48248	in	_	
228-226	48249-48258	addiction	_	
228-227	48258-48259	:	_	
228-228	48260-48261	a	_	
228-229	48262-48268	survey	_	
228-230	48269-48271	of	_	
228-231	48272-48277	human	_	
228-232	48278-48290	neuroimaging	_	
228-233	48291-48298	studies	_	
228-234	48299-48306	Effects	_	
228-235	48307-48309	of	_	
228-236	48310-48320	naltrexone	_	
228-237	48321-48323	on	_	
228-238	48324-48336	cue-elicited	_	
228-239	48337-48344	craving	_	
228-240	48345-48348	for	_	
228-241	48349-48356	alcohol	_	
228-242	48357-48360	and	_	
228-243	48361-48368	cocaine	_	
228-244	48369-48377	Impaired	_	
228-245	48378-48388	inhibitory	_	
228-246	48389-48396	control	_	
228-247	48397-48399	in	_	
228-248	48400-48412	recreational	_	
228-249	48413-48420	cocaine	_	
228-250	48421-48426	users	_	
228-251	48427-48435	Impaired	_	
228-252	48436-48446	inhibitory	_	
228-253	48447-48454	control	_	
228-254	48455-48457	of	_	
228-255	48458-48466	behavior	_	
228-256	48467-48469	in	_	
228-257	48470-48477	chronic	_	
228-258	48478-48485	cocaine	_	
228-259	48486-48491	users	_	
228-260	48492-48501	Executive	_	
228-261	48502-48513	dysfunction	_	
228-262	48514-48516	in	_	
228-263	48517-48524	cocaine	_	
228-264	48525-48534	addiction	_	
228-265	48534-48535	:	_	
228-266	48536-48544	evidence	_	
228-267	48545-48548	for	_	
228-268	48549-48559	discordant	_	
228-269	48560-48567	frontal	_	
228-270	48567-48568	,	_	
228-271	48569-48578	cingulate	_	
228-272	48578-48579	,	_	
228-273	48580-48583	and	_	
228-274	48584-48594	cerebellar	_	
228-275	48595-48603	activity	_	
228-276	48604-48611	Chronic	_	
228-277	48612-48615	and	_	
228-278	48616-48628	recreational	_	
228-279	48629-48632	use	_	
228-280	48633-48635	of	_	
228-281	48636-48643	cocaine	_	
228-282	48644-48646	is	_	
228-283	48647-48657	associated	_	
228-284	48658-48662	with	_	
228-285	48663-48664	a	_	
228-286	48665-48678	vulnerability	_	
228-287	48679-48681	to	_	
228-288	48682-48690	semantic	_	
228-289	48691-48703	interference	_	
228-290	48704-48714	Widespread	_	
228-291	48715-48725	disruption	_	
228-292	48726-48728	in	_	
228-293	48729-48734	brain	_	
228-294	48735-48745	activation	_	
228-295	48746-48754	patterns	_	
228-296	48755-48757	to	_	
228-297	48758-48759	a	_	
228-298	48760-48767	working	_	
228-299	48768-48774	memory	_	
228-300	48775-48779	task	_	
228-301	48780-48786	during	_	
228-302	48787-48794	cocaine	_	
228-303	48795-48805	abstinence	_	
228-304	48806-48816	Structural	_	
228-305	48817-48820	and	_	
228-306	48821-48831	behavioral	_	
228-307	48832-48842	correlates	_	
228-308	48843-48845	of	_	
228-309	48846-48854	abnormal	_	
228-310	48855-48863	encoding	_	
228-311	48864-48866	of	_	
228-312	48867-48872	money	_	
228-313	48873-48878	value	_	
228-314	48879-48881	in	_	
228-315	48882-48885	the	_	
228-316	48886-48898	sensorimotor	_	
228-317	48899-48907	striatum	_	
228-318	48908-48910	in	_	
228-319	48911-48918	cocaine	_	
228-320	48919-48928	addiction	_	
228-321	48929-48935	Neural	_	
228-322	48936-48946	correlates	_	
228-323	48947-48949	of	_	
228-324	48950-48962	reward-based	_	
228-325	48963-48970	spatial	_	
228-326	48971-48979	learning	_	
228-327	48980-48982	in	_	
228-328	48983-48990	persons	_	
228-329	48991-48995	with	_	
228-330	48996-49003	cocaine	_	
228-331	49004-49014	dependence	_	
228-332	49015-49030	Decision-making	_	
228-333	49031-49033	in	_	
228-334	49034-49043	long-term	_	
228-335	49044-49051	cocaine	_	
228-336	49052-49057	users	_	
228-337	49057-49058	:	_	
228-338	49059-49066	Effects	_	
228-339	49067-49069	of	_	
228-340	49070-49071	a	_	
228-341	49072-49076	cash	_	
228-342	49077-49085	monetary	_	
228-343	49086-49097	contingency	_	
228-344	49098-49100	on	_	
228-345	49101-49109	Gambling	_	
228-346	49110-49114	task	_	
228-347	49115-49126	performance	_	
228-348	49127-49135	Combined	_	
228-349	49136-49143	effects	_	
228-350	49144-49146	of	_	
228-351	49147-49156	attention	_	
228-352	49157-49160	and	_	
228-353	49161-49171	motivation	_	
228-354	49172-49174	on	_	
228-355	49175-49181	visual	_	
228-356	49182-49186	task	_	
228-357	49187-49198	performance	_	
228-358	49198-49199	:	_	
228-359	49200-49209	transient	_	
228-360	49210-49213	and	_	
228-361	49214-49223	sustained	_	
228-362	49224-49236	motivational	_	
228-363	49237-49244	effects	_	
228-364	49245-49247	Go	_	
228-365	49248-49251	and	_	
228-366	49252-49257	no-go	_	
228-367	49258-49266	learning	_	
228-368	49267-49269	in	_	
228-369	49270-49276	reward	_	
228-370	49277-49280	and	_	
228-371	49281-49291	punishment	_	
228-372	49291-49292	:	_	
228-373	49293-49305	interactions	_	
228-374	49306-49313	between	_	
228-375	49314-49320	affect	_	
228-376	49321-49324	and	_	
228-377	49325-49331	effect	_	
228-378	49332-49334	Is	_	
228-379	49335-49344	Decreased	_	
228-380	49345-49355	Prefrontal	_	
228-381	49356-49364	Cortical	_	
228-382	49365-49376	Sensitivity	_	
228-383	49377-49379	to	_	
228-384	49380-49388	Monetary	_	
228-385	49389-49392	and	_	
228-386	49393-49405	Self-Control	_	
228-387	49406-49408	in	_	
228-388	49409-49416	Cocaine	_	
228-389	49417-49426	Addiction	_	
228-390	49426-49427	?	_	

#Text=Reliability and validity of the cocaine selective severity assessment
#Text=Severity of Dependence Scale as a Diagnostic Tool for Heroin and Cocaine Dependence
#Text=Development of the brief Spanish cocaine craving questionnaire-general
#Text=Lower activation in the right frontoparietal network during a counting Stroop task in a cocaine-dependent group
#Text=Half a century of research on the Stroop effect: an integrative review
#Text=Does response variability predict distractibility among adults with attention-deficit/hyperactivity disorder?
229-1	49428-49439	Reliability	_	
229-2	49440-49443	and	_	
229-3	49444-49452	validity	_	
229-4	49453-49455	of	_	
229-5	49456-49459	the	_	
229-6	49460-49467	cocaine	_	
229-7	49468-49477	selective	_	
229-8	49478-49486	severity	_	
229-9	49487-49497	assessment	_	
229-10	49498-49506	Severity	_	
229-11	49507-49509	of	_	
229-12	49510-49520	Dependence	_	
229-13	49521-49526	Scale	_	
229-14	49527-49529	as	_	
229-15	49530-49531	a	_	
229-16	49532-49542	Diagnostic	_	
229-17	49543-49547	Tool	_	
229-18	49548-49551	for	_	
229-19	49552-49558	Heroin	_	
229-20	49559-49562	and	_	
229-21	49563-49570	Cocaine	_	
229-22	49571-49581	Dependence	_	
229-23	49582-49593	Development	_	
229-24	49594-49596	of	_	
229-25	49597-49600	the	_	
229-26	49601-49606	brief	_	
229-27	49607-49614	Spanish	_	
229-28	49615-49622	cocaine	_	
229-29	49623-49630	craving	_	
229-30	49631-49652	questionnaire-general	_	
229-31	49653-49658	Lower	_	
229-32	49659-49669	activation	_	
229-33	49670-49672	in	_	
229-34	49673-49676	the	_	
229-35	49677-49682	right	_	
229-36	49683-49697	frontoparietal	_	
229-37	49698-49705	network	_	
229-38	49706-49712	during	_	
229-39	49713-49714	a	_	
229-40	49715-49723	counting	_	
229-41	49724-49730	Stroop	_	
229-42	49731-49735	task	_	
229-43	49736-49738	in	_	
229-44	49739-49740	a	_	
229-45	49741-49758	cocaine-dependent	_	
229-46	49759-49764	group	_	
229-47	49765-49769	Half	_	
229-48	49770-49771	a	_	
229-49	49772-49779	century	_	
229-50	49780-49782	of	_	
229-51	49783-49791	research	_	
229-52	49792-49794	on	_	
229-53	49795-49798	the	_	
229-54	49799-49805	Stroop	_	
229-55	49806-49812	effect	_	
229-56	49812-49813	:	_	
229-57	49814-49816	an	_	
229-58	49817-49828	integrative	_	
229-59	49829-49835	review	_	
229-60	49836-49840	Does	_	
229-61	49841-49849	response	_	
229-62	49850-49861	variability	_	
229-63	49862-49869	predict	_	
229-64	49870-49885	distractibility	_	
229-65	49886-49891	among	_	
229-66	49892-49898	adults	_	
229-67	49899-49903	with	_	
229-68	49904-49921	attention-deficit	_	
229-69	49921-49922	/	_	
229-70	49922-49935	hyperactivity	_	
229-71	49936-49944	disorder	_	
229-72	49944-49945	?	_	

#Text=Response inhibition and reward anticipation in medication-na??
230-1	49946-49954	Response	_	
230-2	49955-49965	inhibition	_	
230-3	49966-49969	and	_	
230-4	49970-49976	reward	_	
230-5	49977-49989	anticipation	_	
230-6	49990-49992	in	_	
230-7	49993-50006	medication-na	_	
230-8	50006-50007	?	_	
230-9	50007-50008	?	_	

#Text=ve adults with attention-deficit/hyperactivity disorder: A within-subject case-control neuroimaging study
#Text=When it helps to be misled: Facilitative effects of increasing the frequency of conflicting stimuli in a Stroop-like task
#Text=On the ability to inhibit thought and action: A theory of an act of control
#Text=Unconscious context-specific proportion congruency effect in a stroop-like task
#Text=Analysis of fMRI time-series revisited
#Text=Accumbens functional connectivity during reward mediates sensation-seeking and alcohol use in high-risk youth
#Text=Prefrontal contributions to metacognition in perceptual decision making
#Text=A generalized form of context-dependent psychophysiological interactions (gPPI): A comparison to standard approaches
#Text=Modeling regional and psychophysiologic interactions in fMRI: The importance of hemodynamic deconvolution
#Text=Methylphenidate enhances executive function and optimizes prefrontal function in both health and cocaine addiction
#Text=An event-related functional MRI study of the stroop color word interference task
#Text=Pretreatment Brain Activation During Stroop Task Is Associated with Outcomes in Cocaine-Dependent Patients
#Text=Common and distinct neural correlates of inhibitory dysregulation: Stroop fMRI study of cocaine addiction and intermittent explosive disorder
#Text=Functional Brain Networks Associated With Cognitive Control, Cocaine Dependence, and Treatment Outcome
#Text=A preliminary investigation of Stroop-related intrinsic connectivity in cocaine dependence: Associations with treatment outcomes
#Text=Impaired insight in cocaine addiction: laboratory evidence and effects on cocaine-seeking behaviour
#Text=Prefrontal Cortical Dysfunction in Abstinent Cocaine Abusers
#Text=Common and distinct neural substrates of attentional control in an integrated Simon and spatial Stroop task as assessed by event-related fMRI
#Text=Control of visual cortical signals by prefrontal dopamine
#Text=Prefrontal contributions to visual selective attention
#Text=An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets
#Text=Neurocircuitry of drug reward
#Text=Affective neuroscience of pleasure: reward in humans and animals
#Text=From reactive to proactive and selective control: developing a richer model for stopping inappropriate responses
#Text=The cognitive functions of the caudate nucleus
#Text=The role of the dorsal striatum in reward and decision-making
#Text=The cost of dopamine for dynamic cognitive control
#Text=The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies
#Text=A neurocognitive approach to understanding the neurobiology of addiction
#Text=Substrates of neuropsychological functioning in stimulant dependence: a review of functional neuroimaging research
#Text=Region of interest analysis for fMRI
#Text=Kriegeskorte N, Simmons WK, Bellgowan PSF, Baker CI.
231-1	50008-50010	ve	_	
231-2	50011-50017	adults	_	
231-3	50018-50022	with	_	
231-4	50023-50040	attention-deficit	_	
231-5	50040-50041	/	_	
231-6	50041-50054	hyperactivity	_	
231-7	50055-50063	disorder	_	
231-8	50063-50064	:	_	
231-9	50065-50066	A	_	
231-10	50067-50081	within-subject	_	
231-11	50082-50094	case-control	_	
231-12	50095-50107	neuroimaging	_	
231-13	50108-50113	study	_	
231-14	50114-50118	When	_	
231-15	50119-50121	it	_	
231-16	50122-50127	helps	_	
231-17	50128-50130	to	_	
231-18	50131-50133	be	_	
231-19	50134-50140	misled	_	
231-20	50140-50141	:	_	
231-21	50142-50154	Facilitative	_	
231-22	50155-50162	effects	_	
231-23	50163-50165	of	_	
231-24	50166-50176	increasing	_	
231-25	50177-50180	the	_	
231-26	50181-50190	frequency	_	
231-27	50191-50193	of	_	
231-28	50194-50205	conflicting	_	
231-29	50206-50213	stimuli	_	
231-30	50214-50216	in	_	
231-31	50217-50218	a	_	
231-32	50219-50230	Stroop-like	_	
231-33	50231-50235	task	_	
231-34	50236-50238	On	_	
231-35	50239-50242	the	_	
231-36	50243-50250	ability	_	
231-37	50251-50253	to	_	
231-38	50254-50261	inhibit	_	
231-39	50262-50269	thought	_	
231-40	50270-50273	and	_	
231-41	50274-50280	action	_	
231-42	50280-50281	:	_	
231-43	50282-50283	A	_	
231-44	50284-50290	theory	_	
231-45	50291-50293	of	_	
231-46	50294-50296	an	_	
231-47	50297-50300	act	_	
231-48	50301-50303	of	_	
231-49	50304-50311	control	_	
231-50	50312-50323	Unconscious	_	
231-51	50324-50340	context-specific	_	
231-52	50341-50351	proportion	_	
231-53	50352-50362	congruency	_	
231-54	50363-50369	effect	_	
231-55	50370-50372	in	_	
231-56	50373-50374	a	_	
231-57	50375-50386	stroop-like	_	
231-58	50387-50391	task	_	
231-59	50392-50400	Analysis	_	
231-60	50401-50403	of	_	
231-61	50404-50408	fMRI	_	
231-62	50409-50420	time-series	_	
231-63	50421-50430	revisited	_	
231-64	50431-50440	Accumbens	_	
231-65	50441-50451	functional	_	
231-66	50452-50464	connectivity	_	
231-67	50465-50471	during	_	
231-68	50472-50478	reward	_	
231-69	50479-50487	mediates	_	
231-70	50488-50505	sensation-seeking	_	
231-71	50506-50509	and	_	
231-72	50510-50517	alcohol	_	
231-73	50518-50521	use	_	
231-74	50522-50524	in	_	
231-75	50525-50534	high-risk	_	
231-76	50535-50540	youth	_	
231-77	50541-50551	Prefrontal	_	
231-78	50552-50565	contributions	_	
231-79	50566-50568	to	_	
231-80	50569-50582	metacognition	_	
231-81	50583-50585	in	_	
231-82	50586-50596	perceptual	_	
231-83	50597-50605	decision	_	
231-84	50606-50612	making	_	
231-85	50613-50614	A	_	
231-86	50615-50626	generalized	_	
231-87	50627-50631	form	_	
231-88	50632-50634	of	_	
231-89	50635-50652	context-dependent	_	
231-90	50653-50672	psychophysiological	_	
231-91	50673-50685	interactions	_	
231-92	50686-50687	(	_	
231-93	50687-50691	gPPI	_	
231-94	50691-50692	)	_	
231-95	50692-50693	:	_	
231-96	50694-50695	A	_	
231-97	50696-50706	comparison	_	
231-98	50707-50709	to	_	
231-99	50710-50718	standard	_	
231-100	50719-50729	approaches	_	
231-101	50730-50738	Modeling	_	
231-102	50739-50747	regional	_	
231-103	50748-50751	and	_	
231-104	50752-50769	psychophysiologic	_	
231-105	50770-50782	interactions	_	
231-106	50783-50785	in	_	
231-107	50786-50790	fMRI	_	
231-108	50790-50791	:	_	
231-109	50792-50795	The	_	
231-110	50796-50806	importance	_	
231-111	50807-50809	of	_	
231-112	50810-50821	hemodynamic	_	
231-113	50822-50835	deconvolution	_	
231-114	50836-50851	Methylphenidate	_	
231-115	50852-50860	enhances	_	
231-116	50861-50870	executive	_	
231-117	50871-50879	function	_	
231-118	50880-50883	and	_	
231-119	50884-50893	optimizes	_	
231-120	50894-50904	prefrontal	_	
231-121	50905-50913	function	_	
231-122	50914-50916	in	_	
231-123	50917-50921	both	_	
231-124	50922-50928	health	_	
231-125	50929-50932	and	_	
231-126	50933-50940	cocaine	_	
231-127	50941-50950	addiction	_	
231-128	50951-50953	An	_	
231-129	50954-50967	event-related	_	
231-130	50968-50978	functional	_	
231-131	50979-50982	MRI	_	
231-132	50983-50988	study	_	
231-133	50989-50991	of	_	
231-134	50992-50995	the	_	
231-135	50996-51002	stroop	_	
231-136	51003-51008	color	_	
231-137	51009-51013	word	_	
231-138	51014-51026	interference	_	
231-139	51027-51031	task	_	
231-140	51032-51044	Pretreatment	_	
231-141	51045-51050	Brain	_	
231-142	51051-51061	Activation	_	
231-143	51062-51068	During	_	
231-144	51069-51075	Stroop	_	
231-145	51076-51080	Task	_	
231-146	51081-51083	Is	_	
231-147	51084-51094	Associated	_	
231-148	51095-51099	with	_	
231-149	51100-51108	Outcomes	_	
231-150	51109-51111	in	_	
231-151	51112-51129	Cocaine-Dependent	_	
231-152	51130-51138	Patients	_	
231-153	51139-51145	Common	_	
231-154	51146-51149	and	_	
231-155	51150-51158	distinct	_	
231-156	51159-51165	neural	_	
231-157	51166-51176	correlates	_	
231-158	51177-51179	of	_	
231-159	51180-51190	inhibitory	_	
231-160	51191-51204	dysregulation	_	
231-161	51204-51205	:	_	
231-162	51206-51212	Stroop	_	
231-163	51213-51217	fMRI	_	
231-164	51218-51223	study	_	
231-165	51224-51226	of	_	
231-166	51227-51234	cocaine	_	
231-167	51235-51244	addiction	_	
231-168	51245-51248	and	_	
231-169	51249-51261	intermittent	_	
231-170	51262-51271	explosive	_	
231-171	51272-51280	disorder	_	
231-172	51281-51291	Functional	_	
231-173	51292-51297	Brain	_	
231-174	51298-51306	Networks	_	
231-175	51307-51317	Associated	_	
231-176	51318-51322	With	_	
231-177	51323-51332	Cognitive	_	
231-178	51333-51340	Control	_	
231-179	51340-51341	,	_	
231-180	51342-51349	Cocaine	_	
231-181	51350-51360	Dependence	_	
231-182	51360-51361	,	_	
231-183	51362-51365	and	_	
231-184	51366-51375	Treatment	_	
231-185	51376-51383	Outcome	_	
231-186	51384-51385	A	_	
231-187	51386-51397	preliminary	_	
231-188	51398-51411	investigation	_	
231-189	51412-51414	of	_	
231-190	51415-51429	Stroop-related	_	
231-191	51430-51439	intrinsic	_	
231-192	51440-51452	connectivity	_	
231-193	51453-51455	in	_	
231-194	51456-51463	cocaine	_	
231-195	51464-51474	dependence	_	
231-196	51474-51475	:	_	
231-197	51476-51488	Associations	_	
231-198	51489-51493	with	_	
231-199	51494-51503	treatment	_	
231-200	51504-51512	outcomes	_	
231-201	51513-51521	Impaired	_	
231-202	51522-51529	insight	_	
231-203	51530-51532	in	_	
231-204	51533-51540	cocaine	_	
231-205	51541-51550	addiction	_	
231-206	51550-51551	:	_	
231-207	51552-51562	laboratory	_	
231-208	51563-51571	evidence	_	
231-209	51572-51575	and	_	
231-210	51576-51583	effects	_	
231-211	51584-51586	on	_	
231-212	51587-51602	cocaine-seeking	_	
231-213	51603-51612	behaviour	_	
231-214	51613-51623	Prefrontal	_	
231-215	51624-51632	Cortical	_	
231-216	51633-51644	Dysfunction	_	
231-217	51645-51647	in	_	
231-218	51648-51657	Abstinent	_	
231-219	51658-51665	Cocaine	_	
231-220	51666-51673	Abusers	_	
231-221	51674-51680	Common	_	
231-222	51681-51684	and	_	
231-223	51685-51693	distinct	_	
231-224	51694-51700	neural	_	
231-225	51701-51711	substrates	_	
231-226	51712-51714	of	_	
231-227	51715-51726	attentional	_	
231-228	51727-51734	control	_	
231-229	51735-51737	in	_	
231-230	51738-51740	an	_	
231-231	51741-51751	integrated	_	
231-232	51752-51757	Simon	_	
231-233	51758-51761	and	_	
231-234	51762-51769	spatial	_	
231-235	51770-51776	Stroop	_	
231-236	51777-51781	task	_	
231-237	51782-51784	as	_	
231-238	51785-51793	assessed	_	
231-239	51794-51796	by	_	
231-240	51797-51810	event-related	_	
231-241	51811-51815	fMRI	_	
231-242	51816-51823	Control	_	
231-243	51824-51826	of	_	
231-244	51827-51833	visual	_	
231-245	51834-51842	cortical	_	
231-246	51843-51850	signals	_	
231-247	51851-51853	by	_	
231-248	51854-51864	prefrontal	_	
231-249	51865-51873	dopamine	_	
231-250	51874-51884	Prefrontal	_	
231-251	51885-51898	contributions	_	
231-252	51899-51901	to	_	
231-253	51902-51908	visual	_	
231-254	51909-51918	selective	_	
231-255	51919-51928	attention	_	
231-256	51929-51931	An	_	
231-257	51932-51941	automated	_	
231-258	51942-51948	method	_	
231-259	51949-51952	for	_	
231-260	51953-51966	neuroanatomic	_	
231-261	51967-51970	and	_	
231-262	51971-51988	cytoarchitectonic	_	
231-263	51989-52000	atlas-based	_	
231-264	52001-52014	interrogation	_	
231-265	52015-52017	of	_	
231-266	52018-52022	fMRI	_	
231-267	52023-52027	data	_	
231-268	52028-52032	sets	_	
231-269	52033-52047	Neurocircuitry	_	
231-270	52048-52050	of	_	
231-271	52051-52055	drug	_	
231-272	52056-52062	reward	_	
231-273	52063-52072	Affective	_	
231-274	52073-52085	neuroscience	_	
231-275	52086-52088	of	_	
231-276	52089-52097	pleasure	_	
231-277	52097-52098	:	_	
231-278	52099-52105	reward	_	
231-279	52106-52108	in	_	
231-280	52109-52115	humans	_	
231-281	52116-52119	and	_	
231-282	52120-52127	animals	_	
231-283	52128-52132	From	_	
231-284	52133-52141	reactive	_	
231-285	52142-52144	to	_	
231-286	52145-52154	proactive	_	
231-287	52155-52158	and	_	
231-288	52159-52168	selective	_	
231-289	52169-52176	control	_	
231-290	52176-52177	:	_	
231-291	52178-52188	developing	_	
231-292	52189-52190	a	_	
231-293	52191-52197	richer	_	
231-294	52198-52203	model	_	
231-295	52204-52207	for	_	
231-296	52208-52216	stopping	_	
231-297	52217-52230	inappropriate	_	
231-298	52231-52240	responses	_	
231-299	52241-52244	The	_	
231-300	52245-52254	cognitive	_	
231-301	52255-52264	functions	_	
231-302	52265-52267	of	_	
231-303	52268-52271	the	_	
231-304	52272-52279	caudate	_	
231-305	52280-52287	nucleus	_	
231-306	52288-52291	The	_	
231-307	52292-52296	role	_	
231-308	52297-52299	of	_	
231-309	52300-52303	the	_	
231-310	52304-52310	dorsal	_	
231-311	52311-52319	striatum	_	
231-312	52320-52322	in	_	
231-313	52323-52329	reward	_	
231-314	52330-52333	and	_	
231-315	52334-52349	decision-making	_	
231-316	52350-52353	The	_	
231-317	52354-52358	cost	_	
231-318	52359-52361	of	_	
231-319	52362-52370	dopamine	_	
231-320	52371-52374	for	_	
231-321	52375-52382	dynamic	_	
231-322	52383-52392	cognitive	_	
231-323	52393-52400	control	_	
231-324	52401-52404	The	_	
231-325	52405-52413	addicted	_	
231-326	52414-52419	human	_	
231-327	52420-52425	brain	_	
231-328	52426-52432	viewed	_	
231-329	52433-52435	in	_	
231-330	52436-52439	the	_	
231-331	52440-52445	light	_	
231-332	52446-52448	of	_	
231-333	52449-52456	imaging	_	
231-334	52457-52464	studies	_	
231-335	52464-52465	:	_	
231-336	52466-52471	brain	_	
231-337	52472-52480	circuits	_	
231-338	52481-52484	and	_	
231-339	52485-52494	treatment	_	
231-340	52495-52505	strategies	_	
231-341	52506-52507	A	_	
231-342	52508-52522	neurocognitive	_	
231-343	52523-52531	approach	_	
231-344	52532-52534	to	_	
231-345	52535-52548	understanding	_	
231-346	52549-52552	the	_	
231-347	52553-52565	neurobiology	_	
231-348	52566-52568	of	_	
231-349	52569-52578	addiction	_	
231-350	52579-52589	Substrates	_	
231-351	52590-52592	of	_	
231-352	52593-52611	neuropsychological	_	
231-353	52612-52623	functioning	_	
231-354	52624-52626	in	_	
231-355	52627-52636	stimulant	_	
231-356	52637-52647	dependence	_	
231-357	52647-52648	:	_	
231-358	52649-52650	a	_	
231-359	52651-52657	review	_	
231-360	52658-52660	of	_	
231-361	52661-52671	functional	_	
231-362	52672-52684	neuroimaging	_	
231-363	52685-52693	research	_	
231-364	52694-52700	Region	_	
231-365	52701-52703	of	_	
231-366	52704-52712	interest	_	
231-367	52713-52721	analysis	_	
231-368	52722-52725	for	_	
231-369	52726-52730	fMRI	_	
231-370	52731-52743	Kriegeskorte	_	
231-371	52744-52745	N	_	
231-372	52745-52746	,	_	
231-373	52747-52754	Simmons	_	
231-374	52755-52757	WK	_	
231-375	52757-52758	,	_	
231-376	52759-52768	Bellgowan	_	
231-377	52769-52772	PSF	_	
231-378	52772-52773	,	_	
231-379	52774-52779	Baker	_	
231-380	52780-52782	CI	_	
231-381	52782-52783	.	_	

#Text=Circular analysis in systems neuroscience–the dangers of double dipping Supplementary Discussion A policy for noncircular analysis. 2009;1–30.
232-1	52784-52792	Circular	_	
232-2	52793-52801	analysis	_	
232-3	52802-52804	in	_	
232-4	52805-52812	systems	_	
232-5	52813-52829	neuroscience–the	_	
232-6	52830-52837	dangers	_	
232-7	52838-52840	of	_	
232-8	52841-52847	double	_	
232-9	52848-52855	dipping	_	
232-10	52856-52869	Supplementary	_	
232-11	52870-52880	Discussion	_	
232-12	52881-52882	A	_	
232-13	52883-52889	policy	_	
232-14	52890-52893	for	_	
232-15	52894-52905	noncircular	_	
232-16	52906-52914	analysis	_	
232-17	52914-52915	.	_	
232-18	52916-52920	2009	_	
232-19	52920-52921	;	_	
232-20	52921-52922	1	_	
232-21	52922-52923	–	_	
232-22	52923-52925	30	_	
232-23	52925-52926	.	_	

#Text=Ashburner J, Chen C, Moran R, Henson R, Glauche V, Phillips C.
233-1	52927-52936	Ashburner	_	
233-2	52937-52938	J	_	
233-3	52938-52939	,	_	
233-4	52940-52944	Chen	_	
233-5	52945-52946	C	_	
233-6	52946-52947	,	_	
233-7	52948-52953	Moran	_	
233-8	52954-52955	R	_	
233-9	52955-52956	,	_	
233-10	52957-52963	Henson	_	
233-11	52964-52965	R	_	
233-12	52965-52966	,	_	
233-13	52967-52974	Glauche	_	
233-14	52975-52976	V	_	
233-15	52976-52977	,	_	
233-16	52978-52986	Phillips	_	
233-17	52987-52988	C	_	
233-18	52988-52989	.	_	

#Text=SPM8 Manual The FIL Methods Group (and honorary members).
234-1	52990-52994	SPM8	_	
234-2	52995-53001	Manual	_	
234-3	53002-53005	The	_	
234-4	53006-53009	FIL	_	
234-5	53010-53017	Methods	_	
234-6	53018-53023	Group	_	
234-7	53024-53025	(	_	
234-8	53025-53028	and	_	
234-9	53029-53037	honorary	_	
234-10	53038-53045	members	_	
234-11	53045-53046	)	_	
234-12	53046-53047	.	_	

#Text=Preacher, K.
235-1	53048-53056	Preacher	_	
235-2	53056-53057	,	_	
235-3	53058-53059	K	_	
235-4	53059-53060	.	_	

#Text=J. (2002, May).
236-1	53061-53062	J	_	
236-2	53062-53063	.	_	
236-3	53064-53065	(	_	
236-4	53065-53069	2002	_	
236-5	53069-53070	,	_	
236-6	53071-53074	May	_	
236-7	53074-53075	)	_	
236-8	53075-53076	.	_	

#Text=Calculation for the test of the difference between two independent correlation coefficients [Computer software].
237-1	53077-53088	Calculation	_	
237-2	53089-53092	for	_	
237-3	53093-53096	the	_	
237-4	53097-53101	test	_	
237-5	53102-53104	of	_	
237-6	53105-53108	the	_	
237-7	53109-53119	difference	_	
237-8	53120-53127	between	_	
237-9	53128-53131	two	_	
237-10	53132-53143	independent	_	
237-11	53144-53155	correlation	_	
237-12	53156-53168	coefficients	_	
237-13	53169-53170	[	_	
237-14	53170-53178	Computer	_	
237-15	53179-53187	software	_	
237-16	53187-53188	]	_	
237-17	53188-53189	.	_	

#Text=Available from http://quantpsy.org.
238-1	53190-53199	Available	_	
238-2	53200-53204	from	_	
238-3	53205-53209	http	_	
238-4	53209-53210	:	_	
238-5	53210-53211	/	_	
238-6	53211-53212	/	_	
238-7	53212-53224	quantpsy.org	_	
238-8	53224-53225	.	_	

#Text=Compromised sensitivity to monetary reward in current cocaine users: an ERP study
#Text=Neurobiological evidence for hedonic allostasis associated with escalating cocaine use
#Text=Altered neural response of the appetitive emotional system in cocaine addiction: an fMRI Study
#Text=Reward-Related Dorsal Striatal Activity Differences between Former and Current Cocaine Dependent Individuals during an Interactive Competitive Game
#Text=An initial study of neural responses to monetary
#Text=Drug users’ adherence to a 6-month vaccination protocol: Effects of motivational incentives
#Text=Rogers RE, Higgins ST, Silverman K, Thomas CS, Badger J, Bigelow G, et al. drug Related Activities among Illicit Drug Abusers. 2010;22(4):544–50.
239-1	53226-53237	Compromised	_	
239-2	53238-53249	sensitivity	_	
239-3	53250-53252	to	_	
239-4	53253-53261	monetary	_	
239-5	53262-53268	reward	_	
239-6	53269-53271	in	_	
239-7	53272-53279	current	_	
239-8	53280-53287	cocaine	_	
239-9	53288-53293	users	_	
239-10	53293-53294	:	_	
239-11	53295-53297	an	_	
239-12	53298-53301	ERP	_	
239-13	53302-53307	study	_	
239-14	53308-53323	Neurobiological	_	
239-15	53324-53332	evidence	_	
239-16	53333-53336	for	_	
239-17	53337-53344	hedonic	_	
239-18	53345-53355	allostasis	_	
239-19	53356-53366	associated	_	
239-20	53367-53371	with	_	
239-21	53372-53382	escalating	_	
239-22	53383-53390	cocaine	_	
239-23	53391-53394	use	_	
239-24	53395-53402	Altered	_	
239-25	53403-53409	neural	_	
239-26	53410-53418	response	_	
239-27	53419-53421	of	_	
239-28	53422-53425	the	_	
239-29	53426-53436	appetitive	_	
239-30	53437-53446	emotional	_	
239-31	53447-53453	system	_	
239-32	53454-53456	in	_	
239-33	53457-53464	cocaine	_	
239-34	53465-53474	addiction	_	
239-35	53474-53475	:	_	
239-36	53476-53478	an	_	
239-37	53479-53483	fMRI	_	
239-38	53484-53489	Study	_	
239-39	53490-53504	Reward-Related	_	
239-40	53505-53511	Dorsal	_	
239-41	53512-53520	Striatal	_	
239-42	53521-53529	Activity	_	
239-43	53530-53541	Differences	_	
239-44	53542-53549	between	_	
239-45	53550-53556	Former	_	
239-46	53557-53560	and	_	
239-47	53561-53568	Current	_	
239-48	53569-53576	Cocaine	_	
239-49	53577-53586	Dependent	_	
239-50	53587-53598	Individuals	_	
239-51	53599-53605	during	_	
239-52	53606-53608	an	_	
239-53	53609-53620	Interactive	_	
239-54	53621-53632	Competitive	_	
239-55	53633-53637	Game	_	
239-56	53638-53640	An	_	
239-57	53641-53648	initial	_	
239-58	53649-53654	study	_	
239-59	53655-53657	of	_	
239-60	53658-53664	neural	_	
239-61	53665-53674	responses	_	
239-62	53675-53677	to	_	
239-63	53678-53686	monetary	_	
239-64	53687-53691	Drug	_	
239-65	53692-53697	users	_	
239-66	53697-53698	’	_	
239-67	53699-53708	adherence	_	
239-68	53709-53711	to	_	
239-69	53712-53713	a	_	
239-70	53714-53715	6	_	
239-71	53715-53716	-	_	
239-72	53716-53721	month	_	
239-73	53722-53733	vaccination	_	
239-74	53734-53742	protocol	_	
239-75	53742-53743	:	_	
239-76	53744-53751	Effects	_	
239-77	53752-53754	of	_	
239-78	53755-53767	motivational	_	
239-79	53768-53778	incentives	_	
239-80	53779-53785	Rogers	_	
239-81	53786-53788	RE	_	
239-82	53788-53789	,	_	
239-83	53790-53797	Higgins	_	
239-84	53798-53800	ST	_	
239-85	53800-53801	,	_	
239-86	53802-53811	Silverman	_	
239-87	53812-53813	K	_	
239-88	53813-53814	,	_	
239-89	53815-53821	Thomas	_	
239-90	53822-53824	CS	_	
239-91	53824-53825	,	_	
239-92	53826-53832	Badger	_	
239-93	53833-53834	J	_	
239-94	53834-53835	,	_	
239-95	53836-53843	Bigelow	_	
239-96	53844-53845	G	_	
239-97	53845-53846	,	_	
239-98	53847-53849	et	_	
239-99	53850-53852	al	_	
239-100	53852-53853	.	_	
239-101	53854-53858	drug	_	
239-102	53859-53866	Related	_	
239-103	53867-53877	Activities	_	
239-104	53878-53883	among	_	
239-105	53884-53891	Illicit	_	
239-106	53892-53896	Drug	_	
239-107	53897-53904	Abusers	_	
239-108	53904-53905	.	_	
239-109	53906-53910	2010	_	
239-110	53910-53911	;	_	
239-111	53911-53913	22	_	
239-112	53913-53914	(	_	
239-113	53914-53915	4	_	
239-114	53915-53916	)	_	
239-115	53916-53917	:	_	
239-116	53917-53920	544	_	
239-117	53920-53921	–	_	
239-118	53921-53923	50	_	
239-119	53923-53924	.	_	

#Text=The influence of monetary punishment on cognitive control in abstinent cocaine-users
#Text=Low-cost contingency management for treating cocaine- and opioid-abusing methadone patients
#Text=Subjective sensitivity to monetary gradients is associated with frontolimbic activation to reward in cocaine abusers
#Text=Cocaine Cues and Dopamine in Dorsal Striatum: Mechanism of Craving in Cocaine Addiction
#Text=Addiction changes orbitofrontal gyrus function: involvement in response inhibition
#Text=Prefrontal cortical dysfunction in abstinent cocaine abusers
#Text=Neural correlates of impulse control during Stop signal inhibition in cocaine-dependent men
#Text=Impaired error awareness and anterior cingulate cortex hypoactivity in chronic cannabis users
#Text=Activity of primate orbitofrontal and dorsolateral prefrontal neurons: effect of reward schedule on task-related activity
#Text=Integration of cognitive and motivational context information in the primate prefrontal cortex
#Text=The neural underpinnings of how reward associations can both guide and misguide attention
#Text=Integrating rewards and cognition in the frontal cortex
#Text=The neural system that bridges reward and cognition in humans: an fMRI study
#Text=Dorsolateral prefrontal cortex modulates striatal reward encoding during reappraisal of reward anticipation
#Text=Neural processing of reward magnitude under varying attentional demands
#Text=Thalamo-cortical dysfunction in cocaine abusers: Implications in attention and perception
#Text=Monetary incentives enhance processing in brain regions mediating top-down control of attention
#Text=Effects of motivation on reward and attentional networks: An fMRI study
#Text=Impulsive Personality Predicts Dopamine-Dependent Changes in Frontostriatal Activity during Component Processes of Working Memory
#Text=Neural activity associated with stress-induced cocaine craving: A functional magnetic resonance imaging study
#Text=A specific role for posterior dorsolateral striatum in human habit learning
#Text=Optogenetic evidence that pallidal projections, not nigral projections, from the nucleus accumbens core are necessary for reinstating cocaine seeking
#Text=Food and drug cues activate similar brain regions: a meta-analysis of functional MRI studies
#Text=Rapid phasic activity of ventral pallidum neurons during cocaine self-adminstration
#Text=The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior
240-1	53925-53928	The	_	
240-2	53929-53938	influence	_	
240-3	53939-53941	of	_	
240-4	53942-53950	monetary	_	
240-5	53951-53961	punishment	_	
240-6	53962-53964	on	_	
240-7	53965-53974	cognitive	_	
240-8	53975-53982	control	_	
240-9	53983-53985	in	_	
240-10	53986-53995	abstinent	_	
240-11	53996-54009	cocaine-users	_	
240-12	54010-54018	Low-cost	_	
240-13	54019-54030	contingency	_	
240-14	54031-54041	management	_	
240-15	54042-54045	for	_	
240-16	54046-54054	treating	_	
240-17	54055-54062	cocaine	_	
240-18	54062-54063	-	_	
240-19	54064-54067	and	_	
240-20	54068-54082	opioid-abusing	_	
240-21	54083-54092	methadone	_	
240-22	54093-54101	patients	_	
240-23	54102-54112	Subjective	_	
240-24	54113-54124	sensitivity	_	
240-25	54125-54127	to	_	
240-26	54128-54136	monetary	_	
240-27	54137-54146	gradients	_	
240-28	54147-54149	is	_	
240-29	54150-54160	associated	_	
240-30	54161-54165	with	_	
240-31	54166-54178	frontolimbic	_	
240-32	54179-54189	activation	_	
240-33	54190-54192	to	_	
240-34	54193-54199	reward	_	
240-35	54200-54202	in	_	
240-36	54203-54210	cocaine	_	
240-37	54211-54218	abusers	_	
240-38	54219-54226	Cocaine	_	
240-39	54227-54231	Cues	_	
240-40	54232-54235	and	_	
240-41	54236-54244	Dopamine	_	
240-42	54245-54247	in	_	
240-43	54248-54254	Dorsal	_	
240-44	54255-54263	Striatum	_	
240-45	54263-54264	:	_	
240-46	54265-54274	Mechanism	_	
240-47	54275-54277	of	_	
240-48	54278-54285	Craving	_	
240-49	54286-54288	in	_	
240-50	54289-54296	Cocaine	_	
240-51	54297-54306	Addiction	_	
240-52	54307-54316	Addiction	_	
240-53	54317-54324	changes	_	
240-54	54325-54338	orbitofrontal	_	
240-55	54339-54344	gyrus	_	
240-56	54345-54353	function	_	
240-57	54353-54354	:	_	
240-58	54355-54366	involvement	_	
240-59	54367-54369	in	_	
240-60	54370-54378	response	_	
240-61	54379-54389	inhibition	_	
240-62	54390-54400	Prefrontal	_	
240-63	54401-54409	cortical	_	
240-64	54410-54421	dysfunction	_	
240-65	54422-54424	in	_	
240-66	54425-54434	abstinent	_	
240-67	54435-54442	cocaine	_	
240-68	54443-54450	abusers	_	
240-69	54451-54457	Neural	_	
240-70	54458-54468	correlates	_	
240-71	54469-54471	of	_	
240-72	54472-54479	impulse	_	
240-73	54480-54487	control	_	
240-74	54488-54494	during	_	
240-75	54495-54499	Stop	_	
240-76	54500-54506	signal	_	
240-77	54507-54517	inhibition	_	
240-78	54518-54520	in	_	
240-79	54521-54538	cocaine-dependent	_	
240-80	54539-54542	men	_	
240-81	54543-54551	Impaired	_	
240-82	54552-54557	error	_	
240-83	54558-54567	awareness	_	
240-84	54568-54571	and	_	
240-85	54572-54580	anterior	_	
240-86	54581-54590	cingulate	_	
240-87	54591-54597	cortex	_	
240-88	54598-54610	hypoactivity	_	
240-89	54611-54613	in	_	
240-90	54614-54621	chronic	_	
240-91	54622-54630	cannabis	_	
240-92	54631-54636	users	_	
240-93	54637-54645	Activity	_	
240-94	54646-54648	of	_	
240-95	54649-54656	primate	_	
240-96	54657-54670	orbitofrontal	_	
240-97	54671-54674	and	_	
240-98	54675-54687	dorsolateral	_	
240-99	54688-54698	prefrontal	_	
240-100	54699-54706	neurons	_	
240-101	54706-54707	:	_	
240-102	54708-54714	effect	_	
240-103	54715-54717	of	_	
240-104	54718-54724	reward	_	
240-105	54725-54733	schedule	_	
240-106	54734-54736	on	_	
240-107	54737-54749	task-related	_	
240-108	54750-54758	activity	_	
240-109	54759-54770	Integration	_	
240-110	54771-54773	of	_	
240-111	54774-54783	cognitive	_	
240-112	54784-54787	and	_	
240-113	54788-54800	motivational	_	
240-114	54801-54808	context	_	
240-115	54809-54820	information	_	
240-116	54821-54823	in	_	
240-117	54824-54827	the	_	
240-118	54828-54835	primate	_	
240-119	54836-54846	prefrontal	_	
240-120	54847-54853	cortex	_	
240-121	54854-54857	The	_	
240-122	54858-54864	neural	_	
240-123	54865-54878	underpinnings	_	
240-124	54879-54881	of	_	
240-125	54882-54885	how	_	
240-126	54886-54892	reward	_	
240-127	54893-54905	associations	_	
240-128	54906-54909	can	_	
240-129	54910-54914	both	_	
240-130	54915-54920	guide	_	
240-131	54921-54924	and	_	
240-132	54925-54933	misguide	_	
240-133	54934-54943	attention	_	
240-134	54944-54955	Integrating	_	
240-135	54956-54963	rewards	_	
240-136	54964-54967	and	_	
240-137	54968-54977	cognition	_	
240-138	54978-54980	in	_	
240-139	54981-54984	the	_	
240-140	54985-54992	frontal	_	
240-141	54993-54999	cortex	_	
240-142	55000-55003	The	_	
240-143	55004-55010	neural	_	
240-144	55011-55017	system	_	
240-145	55018-55022	that	_	
240-146	55023-55030	bridges	_	
240-147	55031-55037	reward	_	
240-148	55038-55041	and	_	
240-149	55042-55051	cognition	_	
240-150	55052-55054	in	_	
240-151	55055-55061	humans	_	
240-152	55061-55062	:	_	
240-153	55063-55065	an	_	
240-154	55066-55070	fMRI	_	
240-155	55071-55076	study	_	
240-156	55077-55089	Dorsolateral	_	
240-157	55090-55100	prefrontal	_	
240-158	55101-55107	cortex	_	
240-159	55108-55117	modulates	_	
240-160	55118-55126	striatal	_	
240-161	55127-55133	reward	_	
240-162	55134-55142	encoding	_	
240-163	55143-55149	during	_	
240-164	55150-55161	reappraisal	_	
240-165	55162-55164	of	_	
240-166	55165-55171	reward	_	
240-167	55172-55184	anticipation	_	
240-168	55185-55191	Neural	_	
240-169	55192-55202	processing	_	
240-170	55203-55205	of	_	
240-171	55206-55212	reward	_	
240-172	55213-55222	magnitude	_	
240-173	55223-55228	under	_	
240-174	55229-55236	varying	_	
240-175	55237-55248	attentional	_	
240-176	55249-55256	demands	_	
240-177	55257-55273	Thalamo-cortical	_	
240-178	55274-55285	dysfunction	_	
240-179	55286-55288	in	_	
240-180	55289-55296	cocaine	_	
240-181	55297-55304	abusers	_	
240-182	55304-55305	:	_	
240-183	55306-55318	Implications	_	
240-184	55319-55321	in	_	
240-185	55322-55331	attention	_	
240-186	55332-55335	and	_	
240-187	55336-55346	perception	_	
240-188	55347-55355	Monetary	_	
240-189	55356-55366	incentives	_	
240-190	55367-55374	enhance	_	
240-191	55375-55385	processing	_	
240-192	55386-55388	in	_	
240-193	55389-55394	brain	_	
240-194	55395-55402	regions	_	
240-195	55403-55412	mediating	_	
240-196	55413-55421	top-down	_	
240-197	55422-55429	control	_	
240-198	55430-55432	of	_	
240-199	55433-55442	attention	_	
240-200	55443-55450	Effects	_	
240-201	55451-55453	of	_	
240-202	55454-55464	motivation	_	
240-203	55465-55467	on	_	
240-204	55468-55474	reward	_	
240-205	55475-55478	and	_	
240-206	55479-55490	attentional	_	
240-207	55491-55499	networks	_	
240-208	55499-55500	:	_	
240-209	55501-55503	An	_	
240-210	55504-55508	fMRI	_	
240-211	55509-55514	study	_	
240-212	55515-55524	Impulsive	_	
240-213	55525-55536	Personality	_	
240-214	55537-55545	Predicts	_	
240-215	55546-55564	Dopamine-Dependent	_	
240-216	55565-55572	Changes	_	
240-217	55573-55575	in	_	
240-218	55576-55590	Frontostriatal	_	
240-219	55591-55599	Activity	_	
240-220	55600-55606	during	_	
240-221	55607-55616	Component	_	
240-222	55617-55626	Processes	_	
240-223	55627-55629	of	_	
240-224	55630-55637	Working	_	
240-225	55638-55644	Memory	_	
240-226	55645-55651	Neural	_	
240-227	55652-55660	activity	_	
240-228	55661-55671	associated	_	
240-229	55672-55676	with	_	
240-230	55677-55691	stress-induced	_	
240-231	55692-55699	cocaine	_	
240-232	55700-55707	craving	_	
240-233	55707-55708	:	_	
240-234	55709-55710	A	_	
240-235	55711-55721	functional	_	
240-236	55722-55730	magnetic	_	
240-237	55731-55740	resonance	_	
240-238	55741-55748	imaging	_	
240-239	55749-55754	study	_	
240-240	55755-55756	A	_	
240-241	55757-55765	specific	_	
240-242	55766-55770	role	_	
240-243	55771-55774	for	_	
240-244	55775-55784	posterior	_	
240-245	55785-55797	dorsolateral	_	
240-246	55798-55806	striatum	_	
240-247	55807-55809	in	_	
240-248	55810-55815	human	_	
240-249	55816-55821	habit	_	
240-250	55822-55830	learning	_	
240-251	55831-55842	Optogenetic	_	
240-252	55843-55851	evidence	_	
240-253	55852-55856	that	_	
240-254	55857-55865	pallidal	_	
240-255	55866-55877	projections	_	
240-256	55877-55878	,	_	
240-257	55879-55882	not	_	
240-258	55883-55889	nigral	_	
240-259	55890-55901	projections	_	
240-260	55901-55902	,	_	
240-261	55903-55907	from	_	
240-262	55908-55911	the	_	
240-263	55912-55919	nucleus	_	
240-264	55920-55929	accumbens	_	
240-265	55930-55934	core	_	
240-266	55935-55938	are	_	
240-267	55939-55948	necessary	_	
240-268	55949-55952	for	_	
240-269	55953-55964	reinstating	_	
240-270	55965-55972	cocaine	_	
240-271	55973-55980	seeking	_	
240-272	55981-55985	Food	_	
240-273	55986-55989	and	_	
240-274	55990-55994	drug	_	
240-275	55995-55999	cues	_	
240-276	56000-56008	activate	_	
240-277	56009-56016	similar	_	
240-278	56017-56022	brain	_	
240-279	56023-56030	regions	_	
240-280	56030-56031	:	_	
240-281	56032-56033	a	_	
240-282	56034-56047	meta-analysis	_	
240-283	56048-56050	of	_	
240-284	56051-56061	functional	_	
240-285	56062-56065	MRI	_	
240-286	56066-56073	studies	_	
240-287	56074-56079	Rapid	_	
240-288	56080-56086	phasic	_	
240-289	56087-56095	activity	_	
240-290	56096-56098	of	_	
240-291	56099-56106	ventral	_	
240-292	56107-56115	pallidum	_	
240-293	56116-56123	neurons	_	
240-294	56124-56130	during	_	
240-295	56131-56138	cocaine	_	
240-296	56139-56157	self-adminstration	_	
240-297	56158-56161	The	_	
240-298	56162-56171	circuitry	_	
240-299	56172-56181	mediating	_	
240-300	56182-56197	cocaine-induced	_	
240-301	56198-56211	reinstatement	_	
240-302	56212-56214	of	_	
240-303	56215-56227	drug-seeking	_	
240-304	56228-56236	behavior	_	
